##DESCRIPTION=tumor_af=Mutant allele frequency in tumor (Sample SampleUID2_01).
##DESCRIPTION=tumor_dp=Tumor Depth (Sample SampleUID2_01).
##DESCRIPTION=filter=Filter criteria from vcf file.
##DESCRIPTION=snp_q=Quality parameters - SNP quality (QUAL).
##DESCRIPTION=strand_tumor=Strand information. Format: [mutation_plus]|[mutation_minus]|[mutation_unkown],[wildtype_plus]|[wildtype_minus]|[wildtype_unkown],[amplicons_plus]|[amplicons_minus].
##DESCRIPTION=gene=Affected gene list (comma-separated).
##DESCRIPTION=variant_type=Variant type.
##DESCRIPTION=coding_and_splicing=Coding and splicing details (Gene, NM number, type, impact, exon number, HGVS.c, HGVS.p).
##DESCRIPTION=interpro=Interpro domains.
##DESCRIPTION=RepeatMasker=RepeatMasker annotation.
##DESCRIPTION=dbSNP=Identifier in dbSNP database.
##DESCRIPTION=1000g=Allele frequency in all populations of 1000g project.
##DESCRIPTION=ExAC=Allele frequency in all populations of ExAC project.
##DESCRIPTION=Kaviar=Allele frequency in Kaviar database.
##DESCRIPTION=COSMIC=COSMIC somatic variant database anntotation.
##DESCRIPTION=OMIM=OMIM database annotation.
##DESCRIPTION=ClinVar=ClinVar database annotation.
##DESCRIPTION=HGMD=HGMD database annotation.
##DESCRIPTION=phyloP=phyloP (100way vertebrate) annotation. Deleterious threshold > 1.6.
##DESCRIPTION=MetaLR=MetaLR effect prediction: D=damaging, T=tolerated.
##DESCRIPTION=Sift=Sift effect prediction: D=damaging, T=tolerated.
##DESCRIPTION=PolyPhen2=Polyphen2 (HVAR) effect prediction: D=probably damaging, P=possibly damaging, B=benign.
##DESCRIPTION=FATHMM=FATHMM effect prediction: D=damaging, T=tolerated.
##DESCRIPTION=CADD=CADD pathogenicity prediction scores (scaled phred-like). Deleterious threshold > 15-20.
##DESCRIPTION=som_ihdb_c=Somatic variant count within NGSD.
##DESCRIPTION=som_ihdb_p=Projects with somatic variant in NGSD.
##DESCRIPTION=ihdb_allsys_hom=Homozygous variant counts in NGSD independent of the processing system.
##DESCRIPTION=ihdb_allsys_het=Heterozygous variant counts in NGSD independent of the processing system.
##DESCRIPTION=classification=Classification from the NGSD.
##DESCRIPTION=classification_comment=Classification comment from the NGSD.
##DESCRIPTION=validated=Validation information from the NGSD. Validation results of other samples are listed in brackets!
##DESCRIPTION=comment=Comments from the NGSD. Comments of other samples are listed in brackets!
##DESCRIPTION=gene_info=Gene information from NGSD (inheritance mode, ExAC pLI score).
##FILTER=fv.not_cod_spli=Not a coding or splicing variant (filter_vcf).
##FILTER=fv.som_all_freq_nor=Allele frequency normal too high (filter_vcf).
##FILTER=fv.som_all_freq_tum=Allele frequency tumor is 0.05 (filter_vcf).
##FILTER=fv.som_depth_nor=Sequencing depth normal is < 8 (filter_vcf).
##FILTER=fv.som_depth_tum=Sequencing depth tumor is < 8 (filter_vcf).
##FILTER=fv.som_lt_3_reads=Less than 3 supporting tumor reads (filter_vcf).
##FILTER=fv.som_tum_loh=Loss of heterozygosity within tumor tissue (filter_vcf).
#chr	start	end	ref	obs	tumor_af	tumor_dp	filter	snp_q	strand_tumor	gene	variant_type	coding_and_splicing	interpro	Pathway_KEGG_full	Function_description	Pathway_BioCarta_full	RepeatMasker	dbSNP	1000g	ExAC	Kaviar	COSMIC	OMIM	ClinVar	HGMD	phyloP	MetaLR	Sift	PolyPhen2	FATHMM	CADD	som_ihdb_c	som_ihdb_p	ihdb_allsys_hom	ihdb_allsys_het	classification	classification_comment	validated	comment	gene_info
chr1	11205058	11205058	C	T	1.0000	11		326.0	7|2|2,0|0|0,8|6	MTOR,MTOR-AS1	synonymous_variant,intron_variant	MTOR:NM_004958.3:synonymous_variant:LOW:exon33/58:c.4731G>A:p.Ala1577Ala,MTOR-AS1:NR_046600.1:intron_variant:MODIFIER:exon2/3:n.310+115C>T:		ErbB signaling pathway;mTOR signaling pathway;Insulin signaling pathway;Adipocytokine signaling pathway;Type II diabetes mellitus;Glioma;Prostate cancer;Acute myeloid leukemia	Serine/threonine protein kinase which is a central regulator of cellular metabolism, growth and survival in response to hormones, growth factors, nutrients, energy and stress signals. Functions as part of 2 structurally and functionally distinct signaling complexes mTORC1 and mTORC2 (mTOR complex 1 and 2). Activated mTORC1 up-regulates protein synthesis by phosphorylating key regulators of mRNA translation and ribosome synthesis. This includes phosphorylation of EIF4EBP1 and release of its inhibition toward the elongation initiation factor 4E (eiF4E). Moreover, phosphorylates and activates RPS6KB1 and RPS6KB2 that promote protein synthesis by modulating the activity of their downstream targets including ribosomal protein S6, eukaryotic translation initiation factor EIF4B and the inhibitor of translation initiation PDCD4. Regulates ribosome synthesis by activating RNA polymerase III-dependent transcription through phosphorylation and inhibition of MAF1 a RNA polymerase III-repressor. In parallel to protein synthesis, also regulates lipid synthesis through SREBF1/SREBP1 and LPIN1. To maintain energy homeostasis mTORC1 may also regulate mitochondrial biogenesis through regulation of PPARGC1A. mTORC1 also negatively regulates autophagy through phosphorylation of ULK1. Under nutrient sufficiency, phosphorylates ULK1 at 'Ser-758', disrupting the interaction with AMPK and preventing activation of ULK1. Also prevents autophagy through phosphorylation of the autophagy inhibitor DAP. mTORC1 exerts a feedback control on upstream growth factor signaling that includes phosphorylation and activation of GRB10 a INSR-dependent signaling suppressor. Among other potential targets mTORC1 may phosphorylate CLIP1 and regulate microtubules. As part of the mTORC2 complex MTOR may regulate other cellular processes including survival and organization of the cytoskeleton. Plays a critical role in the phosphorylation at 'Ser-473' of AKT1, a pro- survival effector of phosphoinositide 3-kinase, facilitating its activation by PDK1. mTORC2 may regulate the actin cytoskeleton, through phosphorylation of PRKCA, PXN and activation of the Rho- type guanine nucleotide exchange factors RHOA and RAC1A or RAC1B. mTORC2 also regulates the phosphorylation of SGK1 at 'Ser-422'	CTCF: First Multivalent Nuclear Factor;mTOR Signaling Pathway;Regulation of eIF4e and p70 S6 Kinase;Skeletal muscle hypertrophy is regulated via AKT/mTOR pathway;Stat3 Signaling Pathway		rs1057079	0.547524	0.67792184256483	0.6699956	COSM4142146	601231 [MTOR (provisional) Smith-Kingsmore syndrome,616638];									1	ERC_Mutaediting_NOQBIC,	449	378			n/a	n/a	MTOR (inh=n/a pLI=1.00), MTOR-AS1 (inh=n/a pLI=n/a)
chr1	11301714	11301714	A	G	1.0000	58		1836.0	19|36|3,0|0|0,7|6	MTOR	synonymous_variant	MTOR:NM_004958.3:synonymous_variant:LOW:exon10/58:c.1437T>C:p.Asp479Asp		ErbB signaling pathway;mTOR signaling pathway;Insulin signaling pathway;Adipocytokine signaling pathway;Type II diabetes mellitus;Glioma;Prostate cancer;Acute myeloid leukemia	Serine/threonine protein kinase which is a central regulator of cellular metabolism, growth and survival in response to hormones, growth factors, nutrients, energy and stress signals. Functions as part of 2 structurally and functionally distinct signaling complexes mTORC1 and mTORC2 (mTOR complex 1 and 2). Activated mTORC1 up-regulates protein synthesis by phosphorylating key regulators of mRNA translation and ribosome synthesis. This includes phosphorylation of EIF4EBP1 and release of its inhibition toward the elongation initiation factor 4E (eiF4E). Moreover, phosphorylates and activates RPS6KB1 and RPS6KB2 that promote protein synthesis by modulating the activity of their downstream targets including ribosomal protein S6, eukaryotic translation initiation factor EIF4B and the inhibitor of translation initiation PDCD4. Regulates ribosome synthesis by activating RNA polymerase III-dependent transcription through phosphorylation and inhibition of MAF1 a RNA polymerase III-repressor. In parallel to protein synthesis, also regulates lipid synthesis through SREBF1/SREBP1 and LPIN1. To maintain energy homeostasis mTORC1 may also regulate mitochondrial biogenesis through regulation of PPARGC1A. mTORC1 also negatively regulates autophagy through phosphorylation of ULK1. Under nutrient sufficiency, phosphorylates ULK1 at 'Ser-758', disrupting the interaction with AMPK and preventing activation of ULK1. Also prevents autophagy through phosphorylation of the autophagy inhibitor DAP. mTORC1 exerts a feedback control on upstream growth factor signaling that includes phosphorylation and activation of GRB10 a INSR-dependent signaling suppressor. Among other potential targets mTORC1 may phosphorylate CLIP1 and regulate microtubules. As part of the mTORC2 complex MTOR may regulate other cellular processes including survival and organization of the cytoskeleton. Plays a critical role in the phosphorylation at 'Ser-473' of AKT1, a pro- survival effector of phosphoinositide 3-kinase, facilitating its activation by PDK1. mTORC2 may regulate the actin cytoskeleton, through phosphorylation of PRKCA, PXN and activation of the Rho- type guanine nucleotide exchange factors RHOA and RAC1A or RAC1B. mTORC2 also regulates the phosphorylation of SGK1 at 'Ser-422'	CTCF: First Multivalent Nuclear Factor;mTOR Signaling Pathway;Regulation of eIF4e and p70 S6 Kinase;Skeletal muscle hypertrophy is regulated via AKT/mTOR pathway;Stat3 Signaling Pathway		rs1135172	0.639577	0.71697460155259	0.7115830	COSM4142157	601231 [MTOR (provisional) Smith-Kingsmore syndrome,616638];									4	ERC_Mutaediting_NOQBIC,TEST_SomaticAndTreatment,	489	354			n/a	n/a	MTOR (inh=n/a pLI=1.00)
chr1	16464673	16464673	G	A	0.3333	12		28.0	4|0|0,8|0|0,3|4	EPHA2	synonymous_variant	EPHA2:NM_004431.4:synonymous_variant:LOW:exon5/17:c.987C>T:p.Pro329Pro,EPHA2:NM_001329090.1:synonymous_variant:LOW:exon4/16:c.825C>T:p.Pro275Pro		Axon guidance	Receptor tyrosine kinase which binds promiscuously membrane-bound ephrin-A family ligands residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells. The signaling pathway downstream of the receptor is referred to as forward signaling while the signaling pathway downstream of the ephrin ligand is referred to as reverse signaling. Activated by the ligand ephrin-A1/EFNA1 regulates migration, integrin-mediated adhesion, proliferation and differentiation of cells. Regulates cell adhesion and differentiation through DSG1/desmoglein-1 and inhibition of the ERK1/ERK2 (MAPK3/MAPK1, respectively) signaling pathway. May also participate in UV radiation-induced apoptosis and have a ligand- independent stimulatory effect on chemotactic cell migration. During development, may function in distinctive aspects of pattern formation and subsequently in development of several fetal tissues. Involved for instance in angiogenesis, in early hindbrain development and epithelial proliferation and branching morphogenesis during mammary gland development. Engaged by the ligand ephrin-A5/EFNA5 may regulate lens fiber cells shape and interactions and be important for lens transparency development and maintenance. With ephrin-A2/EFNA2 may play a role in bone remodeling through regulation of osteoclastogenesis and osteoblastogenesis			rs2230597	0.349441	0.37870992247794	0.3666272	COSM3749009	176946 [EPHA2 (confirmed) Cataract 6,multiple types,116600];	RCV000247172.1 [benign]; RCV000281939.1 [benign]; 								0		235	593			n/a	n/a	EPHA2 (inh=AD pLI=0.74)
chr1	16475123	16475123	C	T	0.2243	107		309.0	2|8|14,6|12|65,6|9	EPHA2	synonymous_variant	EPHA2:NM_004431.4:synonymous_variant:LOW:exon3/17:c.573G>A:p.Leu191Leu,EPHA2:NM_001329090.1:synonymous_variant:LOW:exon2/16:c.411G>A:p.Leu137Leu		Axon guidance	Receptor tyrosine kinase which binds promiscuously membrane-bound ephrin-A family ligands residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells. The signaling pathway downstream of the receptor is referred to as forward signaling while the signaling pathway downstream of the ephrin ligand is referred to as reverse signaling. Activated by the ligand ephrin-A1/EFNA1 regulates migration, integrin-mediated adhesion, proliferation and differentiation of cells. Regulates cell adhesion and differentiation through DSG1/desmoglein-1 and inhibition of the ERK1/ERK2 (MAPK3/MAPK1, respectively) signaling pathway. May also participate in UV radiation-induced apoptosis and have a ligand- independent stimulatory effect on chemotactic cell migration. During development, may function in distinctive aspects of pattern formation and subsequently in development of several fetal tissues. Involved for instance in angiogenesis, in early hindbrain development and epithelial proliferation and branching morphogenesis during mammary gland development. Engaged by the ligand ephrin-A5/EFNA5 may regulate lens fiber cells shape and interactions and be important for lens transparency development and maintenance. With ephrin-A2/EFNA2 may play a role in bone remodeling through regulation of osteoclastogenesis and osteoblastogenesis			rs6678616	0.226438	0.28999072294745	0.2851695		176946 [EPHA2 (confirmed) Cataract 6,multiple types,116600];	RCV000253199.1 [benign]; RCV000309096.1 [benign]; 								0		164	595			n/a	n/a	EPHA2 (inh=AD pLI=0.74)
chr1	16475126	16475126	C	T	0.2243	107		309.0	2|8|14,6|12|65,6|9	EPHA2	synonymous_variant	EPHA2:NM_004431.4:synonymous_variant:LOW:exon3/17:c.570G>A:p.Ala190Ala,EPHA2:NM_001329090.1:synonymous_variant:LOW:exon2/16:c.408G>A:p.Ala136Ala		Axon guidance	Receptor tyrosine kinase which binds promiscuously membrane-bound ephrin-A family ligands residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells. The signaling pathway downstream of the receptor is referred to as forward signaling while the signaling pathway downstream of the ephrin ligand is referred to as reverse signaling. Activated by the ligand ephrin-A1/EFNA1 regulates migration, integrin-mediated adhesion, proliferation and differentiation of cells. Regulates cell adhesion and differentiation through DSG1/desmoglein-1 and inhibition of the ERK1/ERK2 (MAPK3/MAPK1, respectively) signaling pathway. May also participate in UV radiation-induced apoptosis and have a ligand- independent stimulatory effect on chemotactic cell migration. During development, may function in distinctive aspects of pattern formation and subsequently in development of several fetal tissues. Involved for instance in angiogenesis, in early hindbrain development and epithelial proliferation and branching morphogenesis during mammary gland development. Engaged by the ligand ephrin-A5/EFNA5 may regulate lens fiber cells shape and interactions and be important for lens transparency development and maintenance. With ephrin-A2/EFNA2 may play a role in bone remodeling through regulation of osteoclastogenesis and osteoblastogenesis			rs6678618	0.226637	0.29004225002071	0.2861084	COSM1178394	176946 [EPHA2 (confirmed) Cataract 6,multiple types,116600];	RCV000249831.1 [benign]; RCV000363768.1 [benign]; 								0		164	595			n/a	n/a	EPHA2 (inh=AD pLI=0.74)
chr1	22149935	22149935	T	C	0.6629	89		1563.0	10|18|31,6|4|20,6|7	HSPG2,LDLRAD2	synonymous_variant,3_prime_UTR_variant	HSPG2:NM_001291860.1:synonymous_variant:LOW:exon97/97:c.13053A>G:p.Ser4351Ser,HSPG2:NM_005529.6:synonymous_variant:LOW:exon97/97:c.13050A>G:p.Ser4350Ser,LDLRAD2:NM_001013693.2:3_prime_UTR_variant:MODIFIER:exon5/5:c.*1227T>C:		ECM-receptor interaction	The LG3 peptide has anti-angiogenic properties that require binding of calcium ions for full activity			rs897467	0.780351	0.82040563380282	0.7611508	COSM3750884	142461 [HSPG2 (confirmed) Schwartz-Jampel syndrome,type 1,255800|Dyssegmental dysplasia,Silverman-Handmaker type,224410];	RCV000302221.1 [benign]; RCV000359351.1 [benign]; 								0		957	359			n/a	n/a	HSPG2 (inh=AR pLI=0.00), LDLRAD2 (inh=n/a pLI=0.00)
chr1	22169325	22169325	C	T	0.8182	11		200.0	0|6|3,0|2|0,7|8	HSPG2	missense_variant	HSPG2:NM_001291860.1:missense_variant:MODERATE:exon67/97:c.8851G>A:p.Gly2951Arg,HSPG2:NM_005529.6:missense_variant:MODERATE:exon67/97:c.8848G>A:p.Gly2950Arg	Immunoglobulin_I-set__1_,Immunoglobulin_subtype_2__1_,Immunoglobulin-like__1_,Immunoglobulin-like_fold__1_	ECM-receptor interaction	The LG3 peptide has anti-angiogenic properties that require binding of calcium ions for full activity			rs41266007	0.0061901	0.013048077081991	0.0133308		142461 [HSPG2 (confirmed) Schwartz-Jampel syndrome,type 1,255800|Dyssegmental dysplasia,Silverman-Handmaker type,224410];	RCV000287678.1 [uncertain significance]; RCV000379542.1 [uncertain significance]; 		1.272000	T	D	B,B	T	33.00	0		0	40			n/a	n/a	HSPG2 (inh=AR pLI=0.00)
chr1	22191454	22191454	G	A	1.0000	20		570.0	0|12|8,0|0|0,2|3	HSPG2	missense_variant	HSPG2:NM_001291860.1:missense_variant:MODERATE:exon36/97:c.4511C>T:p.Ala1504Val,HSPG2:NM_005529.6:missense_variant:MODERATE:exon36/97:c.4508C>T:p.Ala1503Val	Laminin_B_type_IV__2_,Laminin_B__subgroup__1_	ECM-receptor interaction	The LG3 peptide has anti-angiogenic properties that require binding of calcium ions for full activity			rs897471	0.691494	0.74631226781951	0.6775581	COSM3750893	142461 [HSPG2 (confirmed) Schwartz-Jampel syndrome,type 1,255800|Dyssegmental dysplasia,Silverman-Handmaker type,224410];	RCV000274418.1 [benign]; RCV000299057.1 [benign]; RCV000371265.1 [benign]; 		2.260000	T	T	D	T	23.30	0		776	533			n/a	n/a	HSPG2 (inh=AR pLI=0.00)
chr1	22192224	22192224	C	T	0.2500	84		343.0	1|0|20,9|12|42,8|7	HSPG2	missense_variant	HSPG2:NM_001291860.1:missense_variant:MODERATE:exon34/97:c.4303G>A:p.Asp1435Asn,HSPG2:NM_005529.6:missense_variant:MODERATE:exon34/97:c.4300G>A:p.Asp1434Asn	Laminin_B_type_IV__2_,Laminin_B__subgroup__1_	ECM-receptor interaction	The LG3 peptide has anti-angiogenic properties that require binding of calcium ions for full activity			rs369941068	0.0000	4.9499232761892E-5	0.0000386		142461 [HSPG2 (confirmed) Schwartz-Jampel syndrome,type 1,255800|Dyssegmental dysplasia,Silverman-Handmaker type,224410];			5.859000	T	D	D	T	32.00	0		0	1			n/a	n/a	HSPG2 (inh=AR pLI=0.00)
chr1	22206942	22206942	G	A	1.0000	38		1175.0	26|12|0,0|0|0,4|6	HSPG2	synonymous_variant	HSPG2:NM_001291860.1:synonymous_variant:LOW:exon16/97:c.2112C>T:p.Ala704Ala,HSPG2:NM_005529.6:synonymous_variant:LOW:exon16/97:c.2109C>T:p.Ala703Ala		ECM-receptor interaction	The LG3 peptide has anti-angiogenic properties that require binding of calcium ions for full activity			rs1874793	0.929912	0.98118275126853	0.9258090	COSM4143367	142461 [HSPG2 (confirmed) Schwartz-Jampel syndrome,type 1,255800|Dyssegmental dysplasia,Silverman-Handmaker type,224410];	RCV000282418.1 [benign]; RCV000318734.1 [benign]; 								0		1422	7			n/a	n/a	HSPG2 (inh=AR pLI=0.00)
chr1	22207235	22207235	T	C	1.0000	28		818.0	14|10|4,0|0|0,8|8	HSPG2	missense_variant	HSPG2:NM_001291860.1:missense_variant:MODERATE:exon15/97:c.1915A>G:p.Met639Val,HSPG2:NM_005529.6:missense_variant:MODERATE:exon15/97:c.1912A>G:p.Met638Val	Laminin_B_type_IV__2_,Laminin_B__subgroup__1_	ECM-receptor interaction	The LG3 peptide has anti-angiogenic properties that require binding of calcium ions for full activity			rs1874792	0.973642	0.99312448304384	0.9216033		142461 [HSPG2 (confirmed) Schwartz-Jampel syndrome,type 1,255800|Dyssegmental dysplasia,Silverman-Handmaker type,224410];	RCV000260399.1 [benign]; RCV000296869.1 [benign]; 		1.555000	T	T	B	T	0.00	0		1427	1			n/a	n/a	HSPG2 (inh=AR pLI=0.00)
chr1	22216574	22216574	C	A	0.6923	52		798.0	34|2|0,16|0|0,5|6	HSPG2	synonymous_variant	HSPG2:NM_001291860.1:synonymous_variant:LOW:exon6/97:c.474G>T:p.Gly158Gly,HSPG2:NM_005529.6:synonymous_variant:LOW:exon6/97:c.474G>T:p.Gly158Gly		ECM-receptor interaction	The LG3 peptide has anti-angiogenic properties that require binding of calcium ions for full activity			rs2254358	0.444489	0.57693702007053	0.5726026		142461 [HSPG2 (confirmed) Schwartz-Jampel syndrome,type 1,255800|Dyssegmental dysplasia,Silverman-Handmaker type,224410];	RCV000282698.1 [benign]; RCV000374875.1 [benign]; 		-0.631000	T	T	B	T	12.00	1	ERC_Mutaediting_NOQBIC,	587	612			n/a	n/a	HSPG2 (inh=AR pLI=0.00)
chr1	22216604	22216604	C	G	0.6727	55		927.0	35|2|0,16|2|0,5|5	HSPG2	synonymous_variant	HSPG2:NM_001291860.1:synonymous_variant:LOW:exon6/97:c.444G>C:p.Leu148Leu,HSPG2:NM_005529.6:synonymous_variant:LOW:exon6/97:c.444G>C:p.Leu148Leu		ECM-receptor interaction	The LG3 peptide has anti-angiogenic properties that require binding of calcium ions for full activity			rs2254357	0.444489	0.57701624864045	0.5723647	COSM3997259, COSM3997260	142461 [HSPG2 (confirmed) Schwartz-Jampel syndrome,type 1,255800|Dyssegmental dysplasia,Silverman-Handmaker type,224410];	RCV000295447.1 [benign]; RCV000352676.1 [benign]; 		1.469000	T	T	P	T	12.14	1	ERC_Mutaediting_NOQBIC,	595	624			n/a	n/a	HSPG2 (inh=AR pLI=0.00)
chr1	22217108	22217108	G	A	1.0000	71		2056.0	5|12|54,0|0|0,6|5	HSPG2	synonymous_variant	HSPG2:NM_001291860.1:synonymous_variant:LOW:exon4/97:c.324C>T:p.Phe108Phe,HSPG2:NM_005529.6:synonymous_variant:LOW:exon4/97:c.324C>T:p.Phe108Phe		ECM-receptor interaction	The LG3 peptide has anti-angiogenic properties that require binding of calcium ions for full activity			rs2501260	0.948083	0.98608045333245	0.9229473		142461 [HSPG2 (confirmed) Schwartz-Jampel syndrome,type 1,255800|Dyssegmental dysplasia,Silverman-Handmaker type,224410];	RCV000289547.1 [benign]; RCV000406389.1 [benign]; 								0		1424	5			n/a	n/a	HSPG2 (inh=AR pLI=0.00)
chr1	27099438	27099438	C	A	0.2143	28		48.0	0|6|0,8|14|0,1|3	ARID1A	synonymous_variant	ARID1A:NM_006015.4:synonymous_variant:LOW:exon14/20:c.3675C>A:p.Ser1225Ser,ARID1A:NM_139135.2:synonymous_variant:LOW:exon14/20:c.3675C>A:p.Ser1225Ser			Involved in transcriptional activation and repression of select genes by chromatin remodeling (alteration of DNA-nucleosome topology). Binds DNA non-specifically. Also involved in vitamin D- coupled transcription regulation via its association with the WINAC complex, a chromatin-remodeling complex recruited by vitamin D receptor (VDR), which is required for the ligand-bound VDR- mediated transrepression of the CYP27B1 gene. Belongs to the neural progenitors-specific chromatin remodeling complex (npBAF complex) and the neuron-specific chromatin remodeling complex (nBAF complex). During neural development a switch from a stem/progenitor to a post-mitotic chromatin remodeling mechanism occurs as neurons exit the cell cycle and become committed to their adult state. The transition from proliferating neural stem/progenitor cells to post-mitotic neurons requires a switch in subunit composition of the npBAF and nBAF complexes. As neural progenitors exit mitosis and differentiate into neurons, npBAF complexes which contain ACTL6A/BAF53A and PHF10/BAF45A, are exchanged for homologous alternative ACTL6B/BAF53B and DPF1/BAF45B or DPF3/BAF45C subunits in neuron-specific complexes (nBAF). The npBAF complex is essential for the self-renewal/proliferative capacity of the multipotent neural stem cells. The nBAF complex along with CREST plays a role regulating the activity of genes essential for dendrite growth (By similarity)				0.0000	0.0000	0.0000		603024 [ARID1A (provisional) Coffin-Siris syndrome 2,614607];			0.285000	T				13.27	1	cfDNA_HNSCC,	0	0			n/a	n/a	ARID1A (inh=AD pLI=1.00)
chr1	27427041	27427041	T	C	1.0000	13		417.0	0|9|4,0|0|0,4|5	SLC9A1	synonymous_variant,non_coding_transcript_exon_variant	SLC9A1:NM_003047.4:synonymous_variant:LOW:exon12/12:c.2205A>G:p.Glu735Glu,SLC9A1:NR_046474.1:non_coding_transcript_exon_variant:MODIFIER:exon11/11:n.2540A>G:						rs4418629	0.989217	0.96942641584028	0.9389469		107310 [SLC9A1 (confirmed) Lichtenstein-Knorr syndrome,616291];									1	ERC_Mutaediting_NOQBIC,	1191	84			n/a	n/a	SLC9A1 (inh=AR pLI=0.95)
chr1	27428321	27428321	T	C	0.8710	31		672.0	0|0|27,0|0|4,3|2	SLC9A1	splice_region_variant&intron_variant	SLC9A1:NM_003047.4:splice_region_variant&intron_variant:LOW:exon9/11:c.1936-4A>G:,SLC9A1:NR_046474.1:splice_region_variant&intron_variant:LOW:exon8/10:n.2271-4A>G:						rs6598870	0.277157	0.32367868694515	0.3101335		107310 [SLC9A1 (confirmed) Lichtenstein-Knorr syndrome,616291];									1	cfDNA_HNSCC,	162	532			n/a	n/a	SLC9A1 (inh=AR pLI=0.95)
chr1	44035352	44035352	C	T	0.5618	89		1277.0	20|4|26,14|8|17,6|5	PTPRF	synonymous_variant,sequence_feature	PTPRF:NM_002840.4:synonymous_variant:LOW:exon6/34:c.471C>T:p.Ala157Ala,PTPRF:NM_001329137.1:synonymous_variant:LOW:exon7/35:c.471C>T:p.Ala157Ala,PTPRF:NM_001329138.1:synonymous_variant:LOW:exon7/37:c.471C>T:p.Ala157Ala,PTPRF:NM_001329139.1:synonymous_variant:LOW:exon6/33:c.471C>T:p.Ala157Ala,PTPRF:NM_001329140.1:synonymous_variant:LOW:exon6/31:c.471C>T:p.Ala157Ala,PTPRF:NM_130440.3:synonymous_variant:LOW:exon6/33:c.471C>T:p.Ala157Ala,PTPRF:NM_002840.4:sequence_feature:LOW:exon6/34:c.471C>T:,PTPRF:NM_130440.3:sequence_feature:LOW:exon6/33:c.471C>T:						rs1065771	0.222045	0.28203224262825	0.2797870	COSM3751223	179590 [PTPRF (provisional) Breasts and/or nipples,aplasia or hypoplasia of,2,616001];									1	cfDNA_HNSCC,	137	495			n/a	n/a	PTPRF (inh=n/a pLI=1.00)
chr1	44058265	44058265	C	A	0.4828	87		944.0	8|8|26,12|4|29,4|3	PTPRF	synonymous_variant	PTPRF:NM_002840.4:synonymous_variant:LOW:exon11/34:c.1806C>A:p.Ala602Ala,PTPRF:NM_001329137.1:synonymous_variant:LOW:exon13/35:c.1824C>A:p.Ala608Ala,PTPRF:NM_001329138.1:synonymous_variant:LOW:exon14/37:c.1836C>A:p.Ala612Ala,PTPRF:NM_001329139.1:synonymous_variant:LOW:exon11/33:c.1806C>A:p.Ala602Ala,PTPRF:NM_001329140.1:synonymous_variant:LOW:exon11/31:c.1806C>A:p.Ala602Ala,PTPRF:NM_130440.3:synonymous_variant:LOW:exon11/33:c.1806C>A:p.Ala602Ala						rs3828151	0.446486	0.41985196075079	0.4058738	COSM3751224, COSM3751225	179590 [PTPRF (provisional) Breasts and/or nipples,aplasia or hypoplasia of,2,616001];			-1.256000,-1.256000	T,T				18.32	1	cfDNA_HNSCC,	225	597			n/a	n/a	PTPRF (inh=n/a pLI=1.00)
chr1	44071221	44071221	G	A	0.9808	52		1669.0	18|12|21,0|0|1,7|4	PTPRF	synonymous_variant	PTPRF:NM_002840.4:synonymous_variant:LOW:exon19/34:c.3411G>A:p.Val1137Val,PTPRF:NM_001329137.1:synonymous_variant:LOW:exon19/35:c.2544G>A:p.Val848Val,PTPRF:NM_001329138.1:synonymous_variant:LOW:exon20/37:c.2556G>A:p.Val852Val,PTPRF:NM_001329139.1:synonymous_variant:LOW:exon17/33:c.2526G>A:p.Val842Val,PTPRF:NM_001329140.1:synonymous_variant:LOW:exon16/31:c.2499G>A:p.Val833Val,PTPRF:NM_130440.3:synonymous_variant:LOW:exon18/33:c.3384G>A:p.Val1128Val						rs631248	0.602436	0.69494367174337	0.6821239		179590 [PTPRF (provisional) Breasts and/or nipples,aplasia or hypoplasia of,2,616001];			0.308000,0.308000	T,T				10.84	1	ERC_Mutaediting_NOQBIC,	700	489			n/a	n/a	PTPRF (inh=n/a pLI=1.00)
chr1	44072018	44072018	C	T	1.0000	31		892.0	9|3|19,0|0|0,6|5	PTPRF	synonymous_variant	PTPRF:NM_002840.4:synonymous_variant:LOW:exon20/34:c.3591C>T:p.Thr1197Thr,PTPRF:NM_001329137.1:synonymous_variant:LOW:exon20/35:c.2724C>T:p.Thr908Thr,PTPRF:NM_001329138.1:synonymous_variant:LOW:exon21/37:c.2736C>T:p.Thr912Thr,PTPRF:NM_001329139.1:synonymous_variant:LOW:exon18/33:c.2706C>T:p.Thr902Thr,PTPRF:NM_001329140.1:synonymous_variant:LOW:exon17/31:c.2679C>T:p.Thr893Thr,PTPRF:NM_130440.3:synonymous_variant:LOW:exon19/33:c.3564C>T:p.Thr1188Thr						rs1065772	0.278155	0.32353086582512	0.3214065	COSM3751227, COSM3751226	179590 [PTPRF (provisional) Breasts and/or nipples,aplasia or hypoplasia of,2,616001];			0.196000,0.196000	T,T				8.19	1	cfDNA_HNSCC,	163	532			n/a	n/a	PTPRF (inh=n/a pLI=1.00)
chr1	44072066	44072066	C	T	1.0000	14		430.0	6|6|2,0|0|0,4|3	PTPRF	synonymous_variant	PTPRF:NM_002840.4:synonymous_variant:LOW:exon20/34:c.3639C>T:p.Pro1213Pro,PTPRF:NM_001329137.1:synonymous_variant:LOW:exon20/35:c.2772C>T:p.Pro924Pro,PTPRF:NM_001329138.1:synonymous_variant:LOW:exon21/37:c.2784C>T:p.Pro928Pro,PTPRF:NM_001329139.1:synonymous_variant:LOW:exon18/33:c.2754C>T:p.Pro918Pro,PTPRF:NM_001329140.1:synonymous_variant:LOW:exon17/31:c.2727C>T:p.Pro909Pro,PTPRF:NM_130440.3:synonymous_variant:LOW:exon19/33:c.3612C>T:p.Pro1204Pro						rs10890266	0.28115	0.33004828688673	0.3287504	COSM3751229, COSM3751228	179590 [PTPRF (provisional) Breasts and/or nipples,aplasia or hypoplasia of,2,616001];			-1.265000,-1.265000	T,T	T,T,T		T,T,T	17.52	1	cfDNA_HNSCC,	171	536			n/a	n/a	PTPRF (inh=n/a pLI=1.00)
chr1	44083507	44083507	T	C	1.0000	97		2932.0	6|31|60,0|0|0,6|7	PTPRF	synonymous_variant	PTPRF:NM_002840.4:synonymous_variant:LOW:exon25/34:c.4296T>C:p.Gly1432Gly,PTPRF:NM_001329137.1:synonymous_variant:LOW:exon26/35:c.3462T>C:p.Gly1154Gly,PTPRF:NM_001329138.1:synonymous_variant:LOW:exon28/37:c.3486T>C:p.Gly1162Gly,PTPRF:NM_001329139.1:synonymous_variant:LOW:exon24/33:c.3444T>C:p.Gly1148Gly,PTPRF:NM_001329140.1:synonymous_variant:LOW:exon22/31:c.3384T>C:p.Gly1128Gly,PTPRF:NM_130440.3:synonymous_variant:LOW:exon24/33:c.4269T>C:p.Gly1423Gly						rs641365	0.73722	0.71878198567042	0.7155186		179590 [PTPRF (provisional) Breasts and/or nipples,aplasia or hypoplasia of,2,616001];			-4.012000,-4.012000	T,				6.08	1	ERC_Mutaediting_NOQBIC,	695	494			n/a	n/a	PTPRF (inh=n/a pLI=1.00)
chr1	44083519	44083519	G	A	1.0000	119		3809.0	6|53|60,0|0|0,6|7	PTPRF	synonymous_variant	PTPRF:NM_002840.4:synonymous_variant:LOW:exon25/34:c.4308G>A:p.Arg1436Arg,PTPRF:NM_001329137.1:synonymous_variant:LOW:exon26/35:c.3474G>A:p.Arg1158Arg,PTPRF:NM_001329138.1:synonymous_variant:LOW:exon28/37:c.3498G>A:p.Arg1166Arg,PTPRF:NM_001329139.1:synonymous_variant:LOW:exon24/33:c.3456G>A:p.Arg1152Arg,PTPRF:NM_001329140.1:synonymous_variant:LOW:exon22/31:c.3396G>A:p.Arg1132Arg,PTPRF:NM_130440.3:synonymous_variant:LOW:exon24/33:c.4281G>A:p.Arg1427Arg						rs641351	0.73722	0.71853374952518	0.7143868		179590 [PTPRF (provisional) Breasts and/or nipples,aplasia or hypoplasia of,2,616001];			1.439000,1.439000	T,T				12.07	1	ERC_Mutaediting_NOQBIC,	695	494			n/a	n/a	PTPRF (inh=n/a pLI=1.00)
chr1	44084739	44084739	C	T	1.0000	19		564.0	3|4|12,0|0|0,7|4	PTPRF	synonymous_variant	PTPRF:NM_002840.4:synonymous_variant:LOW:exon27/34:c.4512C>T:p.Arg1504Arg,PTPRF:NM_001329137.1:synonymous_variant:LOW:exon28/35:c.3678C>T:p.Arg1226Arg,PTPRF:NM_001329138.1:synonymous_variant:LOW:exon30/37:c.3702C>T:p.Arg1234Arg,PTPRF:NM_001329139.1:synonymous_variant:LOW:exon26/33:c.3660C>T:p.Arg1220Arg,PTPRF:NM_001329140.1:synonymous_variant:LOW:exon24/31:c.3600C>T:p.Arg1200Arg,PTPRF:NM_130440.3:synonymous_variant:LOW:exon26/33:c.4485C>T:p.Arg1495Arg						rs1143701	0.73742	0.71918643956008	0.7065542		179590 [PTPRF (provisional) Breasts and/or nipples,aplasia or hypoplasia of,2,616001];			0.863000,0.863000	T,				15.41	1	ERC_Mutaediting_NOQBIC,	694	497			n/a	n/a	PTPRF (inh=n/a pLI=1.00)
chr1	44086831	44086831	C	T	1.0000	98		2844.0	47|35|16,0|0|0,7|7	PTPRF	synonymous_variant	PTPRF:NM_002840.4:synonymous_variant:LOW:exon33/34:c.5583C>T:p.Tyr1861Tyr,PTPRF:NM_001329137.1:synonymous_variant:LOW:exon34/35:c.4749C>T:p.Tyr1583Tyr,PTPRF:NM_001329138.1:synonymous_variant:LOW:exon36/37:c.4773C>T:p.Tyr1591Tyr,PTPRF:NM_001329139.1:synonymous_variant:LOW:exon32/33:c.4731C>T:p.Tyr1577Tyr,PTPRF:NM_001329140.1:synonymous_variant:LOW:exon30/31:c.4671C>T:p.Tyr1557Tyr,PTPRF:NM_130440.3:synonymous_variant:LOW:exon32/33:c.5556C>T:p.Tyr1852Tyr						rs1143702	0.570487	0.61317424807358	0.6108074	COSM3773501, COSM3773502	179590 [PTPRF (provisional) Breasts and/or nipples,aplasia or hypoplasia of,2,616001];			-2.838000,-2.838000	,T				11.47	1	ERC_Mutaediting_NOQBIC,	541	570			n/a	n/a	PTPRF (inh=n/a pLI=1.00)
chr1	65303659	65303659	C	T	0.7647	17		300.0	0|13|0,0|4|0,4|4	JAK1	synonymous_variant	JAK1:NM_001320923.1:synonymous_variant:LOW:exon23/26:c.3096G>A:p.Lys1032Lys,JAK1:NM_001321855.1:synonymous_variant:LOW:exon23/26:c.3096G>A:p.Lys1032Lys,JAK1:NM_001321857.1:synonymous_variant:LOW:exon22/25:c.3093G>A:p.Lys1031Lys,JAK1:NM_002227.3:synonymous_variant:LOW:exon22/25:c.3096G>A:p.Lys1032Lys,JAK1:NM_001321856.1:synonymous_variant:LOW:exon22/25:c.3096G>A:p.Lys1032Lys,JAK1:NM_001321852.1:synonymous_variant:LOW:exon22/25:c.3096G>A:p.Lys1032Lys,JAK1:NM_001321853.1:synonymous_variant:LOW:exon24/27:c.3096G>A:p.Lys1032Lys,JAK1:NM_001321854.1:synonymous_variant:LOW:exon23/26:c.3096G>A:p.Lys1032Lys		Jak-STAT signaling pathway;Adipocytokine signaling pathway;Pancreatic cancer	Tyrosine kinase of the non-receptor type, involved in the IFN-alpha/beta/gamma signal pathway. Kinase partner for the interleukin (IL)-2 receptor	EGF Signaling Pathway;IFN alpha signaling pathway;IFN gamma signaling pathway ;IL 2 signaling pathway;IL 4 signaling pathway;IL 6 signaling pathway;IL-10 Anti-inflammatory Signaling Pathway;IL-2 Receptor Beta Chain in T cell Activation;IL22 Soluble Receptor Signaling Pathway ;IL-7 Signal Transduction;PDGF Signaling Pathway;Stat3 Signaling Pathway		rs12129819	0.0385383	0.075744511507594	0.0758887											1	GT,	11	168			n/a	n/a	JAK1 (inh=n/a pLI=1.00)
chr1	65310489	65310489	T	C	0.4471	85		959.0	2|22|14,16|17|14,5|5	JAK1	synonymous_variant	JAK1:NM_001320923.1:synonymous_variant:LOW:exon17/26:c.2199A>G:p.Pro733Pro,JAK1:NM_001321855.1:synonymous_variant:LOW:exon17/26:c.2199A>G:p.Pro733Pro,JAK1:NM_001321857.1:synonymous_variant:LOW:exon16/25:c.2196A>G:p.Pro732Pro,JAK1:NM_002227.3:synonymous_variant:LOW:exon16/25:c.2199A>G:p.Pro733Pro,JAK1:NM_001321856.1:synonymous_variant:LOW:exon16/25:c.2199A>G:p.Pro733Pro,JAK1:NM_001321852.1:synonymous_variant:LOW:exon16/25:c.2199A>G:p.Pro733Pro,JAK1:NM_001321853.1:synonymous_variant:LOW:exon18/27:c.2199A>G:p.Pro733Pro,JAK1:NM_001321854.1:synonymous_variant:LOW:exon17/26:c.2199A>G:p.Pro733Pro		Jak-STAT signaling pathway;Adipocytokine signaling pathway;Pancreatic cancer	Tyrosine kinase of the non-receptor type, involved in the IFN-alpha/beta/gamma signal pathway. Kinase partner for the interleukin (IL)-2 receptor	EGF Signaling Pathway;IFN alpha signaling pathway;IFN gamma signaling pathway ;IL 2 signaling pathway;IL 4 signaling pathway;IL 6 signaling pathway;IL-10 Anti-inflammatory Signaling Pathway;IL-2 Receptor Beta Chain in T cell Activation;IL22 Soluble Receptor Signaling Pathway ;IL-7 Signal Transduction;PDGF Signaling Pathway;Stat3 Signaling Pathway		rs2230588	0.372604	0.29353625397667	0.2869637	COSM3751351										4	ERC_Mutaediting_NOQBIC,GT,Leuk,SomaticAndTreatment,	68	347			n/a	n/a	JAK1 (inh=n/a pLI=1.00)
chr1	65321388	65321388	G	A	0.4348	46		366.0	4|10|6,14|2|10,6|4	JAK1	splice_region_variant&intron_variant	JAK1:NM_001320923.1:splice_region_variant&intron_variant:LOW:exon11/25:c.1459-7C>T:,JAK1:NM_001321855.1:splice_region_variant&intron_variant:LOW:exon11/25:c.1459-7C>T:,JAK1:NM_001321857.1:splice_region_variant&intron_variant:LOW:exon10/24:c.1459-10C>T:,JAK1:NM_002227.3:splice_region_variant&intron_variant:LOW:exon10/24:c.1459-7C>T:,JAK1:NM_001321856.1:splice_region_variant&intron_variant:LOW:exon10/24:c.1459-7C>T:,JAK1:NM_001321852.1:splice_region_variant&intron_variant:LOW:exon10/24:c.1459-7C>T:,JAK1:NM_001321853.1:splice_region_variant&intron_variant:LOW:exon12/26:c.1459-7C>T:,JAK1:NM_001321854.1:splice_region_variant&intron_variant:LOW:exon11/25:c.1459-7C>T:		Jak-STAT signaling pathway;Adipocytokine signaling pathway;Pancreatic cancer	Tyrosine kinase of the non-receptor type, involved in the IFN-alpha/beta/gamma signal pathway. Kinase partner for the interleukin (IL)-2 receptor	EGF Signaling Pathway;IFN alpha signaling pathway;IFN gamma signaling pathway ;IL 2 signaling pathway;IL 4 signaling pathway;IL 6 signaling pathway;IL-10 Anti-inflammatory Signaling Pathway;IL-2 Receptor Beta Chain in T cell Activation;IL22 Soluble Receptor Signaling Pathway ;IL-7 Signal Transduction;PDGF Signaling Pathway;Stat3 Signaling Pathway		rs310229	0.402556	0.35736439392648	0.3424092											3	ERC_Mutaediting_NOQBIC,Leuk,SomaticAndTreatment,	96	391			n/a	n/a	JAK1 (inh=n/a pLI=1.00)
chr1	65335062	65335062	A	G	0.6400	25		352.0	0|16|0,8|1|0,2|2	JAK1	synonymous_variant	JAK1:NM_001320923.1:synonymous_variant:LOW:exon7/26:c.579T>C:p.Ala193Ala,JAK1:NM_001321855.1:synonymous_variant:LOW:exon7/26:c.579T>C:p.Ala193Ala,JAK1:NM_001321857.1:synonymous_variant:LOW:exon6/25:c.579T>C:p.Ala193Ala,JAK1:NM_002227.3:synonymous_variant:LOW:exon6/25:c.579T>C:p.Ala193Ala,JAK1:NM_001321856.1:synonymous_variant:LOW:exon6/25:c.579T>C:p.Ala193Ala,JAK1:NM_001321852.1:synonymous_variant:LOW:exon6/25:c.579T>C:p.Ala193Ala,JAK1:NM_001321853.1:synonymous_variant:LOW:exon8/27:c.579T>C:p.Ala193Ala,JAK1:NM_001321854.1:synonymous_variant:LOW:exon7/26:c.579T>C:p.Ala193Ala		Jak-STAT signaling pathway;Adipocytokine signaling pathway;Pancreatic cancer	Tyrosine kinase of the non-receptor type, involved in the IFN-alpha/beta/gamma signal pathway. Kinase partner for the interleukin (IL)-2 receptor	EGF Signaling Pathway;IFN alpha signaling pathway;IFN gamma signaling pathway ;IL 2 signaling pathway;IL 4 signaling pathway;IL 6 signaling pathway;IL-10 Anti-inflammatory Signaling Pathway;IL-2 Receptor Beta Chain in T cell Activation;IL22 Soluble Receptor Signaling Pathway ;IL-7 Signal Transduction;PDGF Signaling Pathway;Stat3 Signaling Pathway		rs45598436	0.0391374	0.076438342552416	0.0766283											1	GT,	12	167			n/a	n/a	JAK1 (inh=n/a pLI=1.00)
chr1	91781413	91781413	T	G	1.0000	11		345.0	5|6|0,0|0|0,8|6	HFM1	synonymous_variant	HFM1:NM_001017975.4:synonymous_variant:LOW:exon28/39:c.3099A>C:p.Ile1033Ile						rs281992	0.762979	0.70587212479507	0.6971975		615684 [HFM1 (provisional) Premature ovarian failure 9,615724];			1.237000					11.20	1	ERC_Mutaediting_NOQBIC,	525	416			n/a	n/a	HFM1 (inh=AR pLI=0.00)
chr1	103354138	103354138	A	G	1.0000	8		242.0	0|0|8,0|0|0,5|5	COL11A1	missense_variant,non_coding_transcript_exon_variant	COL11A1:NM_080629.2:missense_variant:MODERATE:exon62/67:c.4639T>C:p.Ser1547Pro,COL11A1:NM_001190709.1:missense_variant:MODERATE:exon61/66:c.4486T>C:p.Ser1496Pro,COL11A1:NM_001854.3:missense_variant:MODERATE:exon62/67:c.4603T>C:p.Ser1535Pro,COL11A1:NM_080630.3:missense_variant:MODERATE:exon60/65:c.4255T>C:p.Ser1419Pro,COL11A1:NR_134980.1:non_coding_transcript_exon_variant:MODIFIER:exon63/68:n.4937T>C:						rs1676486	0.782947	0.79415508207019	0.7853302		120280 [COL11A1 (confirmed) Stickler syndrome,type II,604841|Marshall syndrome,154780|Lumbar disc herniation,susceptibility to,603932|Fibrochondrogenesis 1,228520];	RCV000018675.5 [other]; RCV000252849.1 [benign]; RCV000292881.1 [benign]; RCV000332848.1 [benign]; RCV000387237.1 [benign]; 	CM074756 [CLASS=DFP MUT=REF PHEN="Lumbar disc herniation association with" GENE=COL11A1]; 	6.349000	T	T,T,T,T,T	B,B,B,B,B	D,D,D,D	22.00	0		813	408			n/a	n/a	COL11A1 (inh=AR+AD pLI=1.00)
chr1	103405892	103405892	G	A	0.6842	19		313.0	13|0|0,4|0|2,4|2	COL11A1	synonymous_variant,non_coding_transcript_exon_variant	COL11A1:NM_080629.2:synonymous_variant:LOW:exon43/67:c.3411C>T:p.Asp1137Asp,COL11A1:NM_001190709.1:synonymous_variant:LOW:exon42/66:c.3258C>T:p.Asp1086Asp,COL11A1:NM_001854.3:synonymous_variant:LOW:exon43/67:c.3375C>T:p.Asp1125Asp,COL11A1:NM_080630.3:synonymous_variant:LOW:exon41/65:c.3027C>T:p.Asp1009Asp,COL11A1:NR_134980.1:non_coding_transcript_exon_variant:MODIFIER:exon44/68:n.3709C>T:						rs17127270	0.122604	0.14701985658215	0.1436297		120280 [COL11A1 (confirmed) Stickler syndrome,type II,604841|Marshall syndrome,154780|Lumbar disc herniation,susceptibility to,603932|Fibrochondrogenesis 1,228520];	RCV000246941.1 [benign]; RCV000311798.1 [benign]; RCV000368939.1 [benign]; RCV000393379.1 [benign]; 								0		37	333			n/a	n/a	COL11A1 (inh=AR+AD pLI=1.00)
chr1	110210780	110210780	C	G	1.0000	18		525.0	2|8|8,0|0|0,4|5	GSTM2	splice_region_variant&intron_variant	GSTM2:NM_000848.3:splice_region_variant&intron_variant:LOW:exon1/7:c.36+7C>G:,GSTM2:NM_001142368.1:splice_region_variant&intron_variant:LOW:exon1/8:c.36+7C>G:		Glutathione metabolism;Metabolism of xenobiotics by cytochrome P450;Drug metabolism - cytochrome P450	Conjugation of reduced glutathione to a wide number of exogenous and endogenous hydrophobic electrophiles			rs530021	0.904752	0.90914066776136	0.8782347											1	ERC_Mutaediting_NOQBIC,	705	138			n/a	n/a	GSTM2 (inh=n/a pLI=0.01)
chr1	120468135	120468135	C	T	0.2286	35		48.0	0|0|8,0|8|19,4|5	NOTCH2	missense_variant	NOTCH2:NM_024408.3:missense_variant:MODERATE:exon25/34:c.4304G>A:p.Arg1435Gln	Notch_domain__4_	Notch signaling pathway	Functions as a receptor for membrane-bound ligands Jagged1, Jagged2 and Delta1 to regulate cell-fate determination. Upon ligand activation through the released notch intracellular domain (NICD) it forms a transcriptional activator complex with RBPJ/RBPSUH and activates genes of the enhancer of split locus. Affects the implementation of differentiation, proliferation and apoptotic programs (By similarity). Involved in bone remodeling and homeostasis. In collaboration with RELA/p65 enhances NFATc1 promoter activity and positively regulates RANKL-induced osteoclast differentiation			rs747190078	0.0000	1.6523463317911E-5	0.0000129	COSM1320073	600275 [NOTCH2 (provisional) Alagille syndrome 2,610205|Hajdu-Cheney syndrome,102500];			0.419000	D	D	P	D	25.30	0		0	0			n/a	n/a	NOTCH2 (inh=n/a pLI=1.00)
chr1	120611964	120611964	G	C	0.4848	66		645.0	31|1|0,32|2|0,5|3	NOTCH2	missense_variant	NOTCH2:NM_024408.3:missense_variant:MODERATE:exon1/34:c.57C>G:p.Cys19Trp,NOTCH2:NM_001200001.1:missense_variant:MODERATE:exon1/22:c.57C>G:p.Cys19Trp		Notch signaling pathway	Functions as a receptor for membrane-bound ligands Jagged1, Jagged2 and Delta1 to regulate cell-fate determination. Upon ligand activation through the released notch intracellular domain (NICD) it forms a transcriptional activator complex with RBPJ/RBPSUH and activates genes of the enhancer of split locus. Affects the implementation of differentiation, proliferation and apoptotic programs (By similarity). Involved in bone remodeling and homeostasis. In collaboration with RELA/p65 enhances NFATc1 promoter activity and positively regulates RANKL-induced osteoclast differentiation			rs11810554	0.0000	0.44931652582348	0.0209770	COSM132738	600275 [NOTCH2 (provisional) Alagille syndrome 2,610205|Hajdu-Cheney syndrome,102500];			0.766000,0.766000	T,T	,T	,B,B	,T	17.56	2	GT,SomaticAndTreatment,	6	2466			n/a	n/a	NOTCH2 (inh=n/a pLI=1.00)
chr1	120612006	120612006	G	A	0.4706	85		674.0	32|1|7,32|2|11,5|3	NOTCH2	synonymous_variant	NOTCH2:NM_024408.3:synonymous_variant:LOW:exon1/34:c.15C>T:p.Arg5Arg,NOTCH2:NM_001200001.1:synonymous_variant:LOW:exon1/22:c.15C>T:p.Arg5Arg		Notch signaling pathway	Functions as a receptor for membrane-bound ligands Jagged1, Jagged2 and Delta1 to regulate cell-fate determination. Upon ligand activation through the released notch intracellular domain (NICD) it forms a transcriptional activator complex with RBPJ/RBPSUH and activates genes of the enhancer of split locus. Affects the implementation of differentiation, proliferation and apoptotic programs (By similarity). Involved in bone remodeling and homeostasis. In collaboration with RELA/p65 enhances NFATc1 promoter activity and positively regulates RANKL-induced osteoclast differentiation			rs4021006	0.39397	0.46375621218107	0.0256585	COSM1320072	600275 [NOTCH2 (provisional) Alagille syndrome 2,610205|Hajdu-Cheney syndrome,102500];	RCV000173523.1 [uncertain significance]; 		1.074000					8.96	2	GT,SomaticAndTreatment,	7	2465			n/a	n/a	NOTCH2 (inh=n/a pLI=1.00)
chr1	146714392	146714392	G	C	1.0000	26		766.0	10|14|2,0|0|0,2|2	CHD1L	synonymous_variant,5_prime_UTR_variant,non_coding_transcript_exon_variant	CHD1L:NM_004284.4:synonymous_variant:LOW:exon1/23:c.39G>C:p.Ala13Ala,CHD1L:NM_001256338.1:synonymous_variant:LOW:exon1/17:c.39G>C:p.Ala13Ala,CHD1L:NM_001256336.1:5_prime_UTR_variant:MODIFIER:exon1/22:c.-155G>C:,CHD1L:NM_001256337.1:5_prime_UTR_variant:MODIFIER:exon1/18:c.-275G>C:,CHD1L:NM_024568.2:5_prime_UTR_variant:MODIFIER:exon1/23:c.-273G>C:,CHD1L:NR_046070.1:non_coding_transcript_exon_variant:MODIFIER:exon1/21:n.102G>C:						rs1890042	0.535343	0.56159734827559	0.3724149	COSM4142543										0		395	414			n/a	n/a	CHD1L (inh=n/a pLI=0.00)
chr1	146751782	146751782	A	C	1.0000	50		1669.0	20|8|22,0|0|0,7|3	CHD1L	synonymous_variant,non_coding_transcript_exon_variant	CHD1L:NM_004284.4:synonymous_variant:LOW:exon15/23:c.1623A>C:p.Ile541Ile,CHD1L:NM_001256336.1:synonymous_variant:LOW:exon14/22:c.1323A>C:p.Ile441Ile,CHD1L:NM_001256337.1:synonymous_variant:LOW:exon10/18:c.780A>C:p.Ile260Ile,CHD1L:NM_001256338.1:synonymous_variant:LOW:exon9/17:c.1011A>C:p.Ile337Ile,CHD1L:NM_024568.2:synonymous_variant:LOW:exon15/23:c.1284A>C:p.Ile428Ile,CHD1L:NR_046070.1:non_coding_transcript_exon_variant:MODIFIER:exon13/21:n.1501A>C:						rs7547279	0.967851	0.96580105126135	0.9440529											0		1198	81			n/a	n/a	CHD1L (inh=n/a pLI=0.00)
chr1	146767149	146767149	G	T	1.0000	26		795.0	4|22|0,0|0|0,4|4	CHD1L	missense_variant,non_coding_transcript_exon_variant	CHD1L:NM_004284.4:missense_variant:MODERATE:exon23/23:c.2653G>T:p.Ala885Ser,CHD1L:NM_001256336.1:missense_variant:MODERATE:exon22/22:c.2353G>T:p.Ala785Ser,CHD1L:NM_001256337.1:missense_variant:MODERATE:exon18/18:c.1810G>T:p.Ala604Ser,CHD1L:NM_001256338.1:missense_variant:MODERATE:exon17/17:c.2041G>T:p.Ala681Ser,CHD1L:NM_024568.2:missense_variant:MODERATE:exon23/23:c.2314G>T:p.Ala772Ser,CHD1L:NR_046070.1:non_coding_transcript_exon_variant:MODIFIER:exon21/21:n.2531G>T:	Appr-1-p_processing__1_					rs4950394	0.968051	0.96659631998945	0.9442715					0.498000	T	T,T,T,T	B,B,B	D,T,D,T	0.02	0		1198	78			n/a	n/a	CHD1L (inh=n/a pLI=0.00)
chr1	147092112	147092112	G	A	0.6250	16		236.0	10|0|0,4|2|0,4|2	BCL9	synonymous_variant	BCL9:NM_004326.3:synonymous_variant:LOW:exon8/10:c.2151G>A:p.Lys717Lys						rs61754125	0.0181709	0.027059134107709	0.0267710	COSM3750343										0		8	88			n/a	n/a	BCL9 (inh=n/a pLI=0.83)
chr1	152057478	152057478	C	A	0.2963	54		265.0	0|16|0,2|36|0,2|4	TCHHL1	missense_variant	TCHHL1:NM_001008536.1:missense_variant:MODERATE:exon3/3:c.2680G>T:p.Val894Leu							0.0000	0.0000	0.0000					-0.066000	T	T	B	T	11.07	1	cfDNA_HNSCC,	0	0			n/a	n/a	TCHHL1 (inh=n/a pLI=0.00)
chr1	152276671	152276671	C	A	0.5882	17		176.0	0|6|4,0|6|1,4|4	FLG	missense_variant	FLG:NM_002016.1:missense_variant:MODERATE:exon3/3:c.10691G>T:p.Arg3564Leu			Aggregates keratin intermediate filaments and promotes disulfide-bond formation among the intermediate filaments during terminal differentiation of mammalian epidermis			rs7518080	0.0163738	0.033925372629871	0.0029453		135940 [FLG (confirmed) Ichthyosis vulgaris,146700|Dermatitis,atopic,susceptibility to,2,605803];			-1.306000	T	D	P	T	7.93	0		4	78			n/a	n/a	FLG (inh=AD pLI=n/a)
chr1	152281621	152281621	T	C	0.3214	28		90.0	4|0|5,8|0|11,5|2	FLG	missense_variant	FLG:NM_002016.1:missense_variant:MODERATE:exon3/3:c.5741A>G:p.Gln1914Arg			Aggregates keratin intermediate filaments and promotes disulfide-bond formation among the intermediate filaments during terminal differentiation of mammalian epidermis			rs34806697	0.0369409	0.066914865577227	0.0630402		135940 [FLG (confirmed) Ichthyosis vulgaris,146700|Dermatitis,atopic,susceptibility to,2,605803];			-3.196000	T	T,T	B	T	0.00	0		12	147			n/a	n/a	FLG (inh=AD pLI=n/a)
chr1	158324425	158324425	A	G	0.8333	36		693.0	22|8|0,6|0|0,6|4	CD1E	missense_variant,intron_variant	CD1E:NM_030893.3:missense_variant:MODERATE:exon2/6:c.317A>G:p.Gln106Arg,CD1E:NM_001042583.2:missense_variant:MODERATE:exon2/6:c.317A>G:p.Gln106Arg,CD1E:NM_001042584.2:missense_variant:MODERATE:exon2/6:c.317A>G:p.Gln106Arg,CD1E:NM_001042585.2:missense_variant:MODERATE:exon2/6:c.317A>G:p.Gln106Arg,CD1E:NM_001185107.1:missense_variant:MODERATE:exon2/5:c.317A>G:p.Gln106Arg,CD1E:NM_001185108.1:missense_variant:MODERATE:exon2/5:c.317A>G:p.Gln106Arg,CD1E:NM_001185115.1:missense_variant:MODERATE:exon2/5:c.317A>G:p.Gln106Arg,CD1E:NM_001042586.2:intron_variant:MODIFIER:exon1/3:c.58+589A>G:,CD1E:NM_001042587.2:intron_variant:MODIFIER:exon1/3:c.58+589A>G:,CD1E:NM_001185110.1:intron_variant:MODIFIER:exon1/3:c.58+589A>G:,CD1E:NM_001185112.1:intron_variant:MODIFIER:exon1/3:c.58+589A>G:,CD1E:NM_001185113.1:intron_variant:MODIFIER:exon1/3:c.58+589A>G:,CD1E:NM_001185114.1:intron_variant:MODIFIER:exon1/4:c.58+589A>G:	MHC_classes_I/II-like_antigen_recognition_protein__1_,MHC_class_I-like_antigen_recognition__1_					rs1065457	0.616414	0.45011910116103	0.4406961				CM067657 [CLASS=DP MUT=ALT PHEN="Guillain-Barre syndrome reduced risk association with" GENE=CD1E]; 	-4.010000	T	T,T,T,T,T,T,T,T	B,B,B,B,B,B,B,B	T,T,T,T,T,T,T,T	0.00	0		209	613			n/a	n/a	CD1E (inh=n/a pLI=0.00)
chr1	169510233	169510233	G	A	1.0000	24		695.0	10|14|0,0|0|0,3|3	F5	synonymous_variant	F5:NM_000130.4:synonymous_variant:LOW:exon13/25:c.4095C>T:p.Thr1365Thr		Complement and coagulation cascades	Central regulator of hemostasis. It serves as a critical cofactor for the prothrombinase activity of factor Xa that results in the activation of prothrombin to thrombin	Extrinsic Prothrombin Activation Pathway;Intrinsic Prothrombin Activation Pathway		rs9332607	0.182109	0.29581561686278	0.2797163	COSM4143007	612309 [F5 (confirmed) Factor V deficiency,227400|Thrombophilia,susceptibility to,due to factor V Leiden,188055|Stroke,ischemic,susceptibility to,601367|Budd-Chiari syndrome,600880|Thrombophilia due to activated protein C resistance,188055|Pregnancy loss,recurrent,susceptibility to,1,614389];	RCV000243401.1 [benign]; RCV000268268.1 [likely benign]; RCV000298910.1 [likely benign]; RCV000302299.1 [likely benign]; RCV000360723.1 [likely benign]; 								4	GT,Mesotheliomstudie,TEST_SomaticAndTreatment,	121	625			n/a	n/a	F5 (inh=AR+AD pLI=0.00)
chr1	169580885	169580885	C	T	0.5000	16		170.0	0|8|0,0|4|4,6|8	SELP	missense_variant	SELP:NM_003005.3:missense_variant:MODERATE:exon7/17:c.992G>A:p.Ser331Asn	Complement_control_module__2_,Sushi/SCR/CCP__2_					rs6131	0.239018	0.20580326949407	0.2011910	COSM3750567, COSM3750568	173610 [SELP (confirmed) Atopy,susceptibility to,147050];		CM055538 [CLASS=DP MUT=ALT PHEN="Myocardial infarction lower risk association" GENE=SELP]; 	-2.365000	T	T,T,T,T,T,T	B,B,B	T,T,T	0.03	0		55	419			n/a	n/a	SELP (inh=n/a pLI=0.00)
chr1	196227526	196227526	A	G	1.0000	47		1438.0	0|47|0,0|0|0,3|3	KCNT2	synonymous_variant	KCNT2:NM_198503.3:synonymous_variant:LOW:exon26/28:c.3009T>C:p.Asp1003Asp,KCNT2:NM_001287819.1:synonymous_variant:LOW:exon25/27:c.2937T>C:p.Asp979Asp,KCNT2:NM_001287820.1:synonymous_variant:LOW:exon25/27:c.2808T>C:p.Asp936Asp						rs977157	0.98722	0.99613552841911	0.9323618											0		856	3			n/a	n/a	KCNT2 (inh=n/a pLI=0.67)
chr1	197009798	197009798	A	G	1.0000	28		896.0	22|6|0,0|0|0,5|5	F13B	synonymous_variant	F13B:NM_001994.2:synonymous_variant:LOW:exon11/12:c.1806T>C:p.Asn602Asn		Complement and coagulation cascades	The B chain of factor XIII is not catalytically active, but is thought to stabilize the A subunits and regulate the rate of transglutaminase formation by thrombin			rs5998	0.52496	0.52701192561087	0.5193628		134580 [F13B (confirmed) Factor XIIIB deficiency,613235];	RCV000248564.1 [benign]; RCV000307541.1 [benign]; 								0		309	590			n/a	n/a	F13B (inh=AR pLI=0.00)
chr1	202705455	202705455	G	C	1.0000	50		1552.0	2|42|6,0|0|0,3|5	KDM5B	synonymous_variant	KDM5B:NM_001314042.1:synonymous_variant:LOW:exon22/28:c.3258C>G:p.Pro1086Pro,KDM5B:NM_006618.4:synonymous_variant:LOW:exon21/27:c.3150C>G:p.Pro1050Pro			Histone demethylase that demethylates 'Lys-4' of histone H3, thereby playing a central role in histone code. Does not demethylate histone H3 'Lys-9' or H3 'Lys-27'. Demethylates trimethylated, dimethylated and monomethylated H3 'Lys-4'. Acts as a transcriptional corepressor for FOXG1B and PAX9. Favors the proliferation of breast cancer cells by repressing tumor suppressor genes such as BRCA1 and HOXA5. In contrast, may act as a tumor suppressor for melanoma			rs1141109	0.639577	0.73936477064825	0.7321098											0		518	299			n/a	n/a	KDM5B (inh=n/a pLI=0.00)
chr1	202715284	202715284	G	A	1.0000	15		453.0	8|6|1,0|0|0,4|2	KDM5B	synonymous_variant	KDM5B:NM_001314042.1:synonymous_variant:LOW:exon16/28:c.2292C>T:p.Tyr764Tyr,KDM5B:NM_006618.4:synonymous_variant:LOW:exon15/27:c.2184C>T:p.Tyr728Tyr			Histone demethylase that demethylates 'Lys-4' of histone H3, thereby playing a central role in histone code. Does not demethylate histone H3 'Lys-9' or H3 'Lys-27'. Demethylates trimethylated, dimethylated and monomethylated H3 'Lys-4'. Acts as a transcriptional corepressor for FOXG1B and PAX9. Favors the proliferation of breast cancer cells by repressing tumor suppressor genes such as BRCA1 and HOXA5. In contrast, may act as a tumor suppressor for melanoma			rs1141108	0.639177	0.740036635477	0.7340004											0		519	297			n/a	n/a	KDM5B (inh=n/a pLI=0.00)
chr1	202718202	202718202	G	A	1.0000	33		1011.0	0|0|33,0|0|0,4|4	KDM5B	synonymous_variant,sequence_feature	KDM5B:NM_001314042.1:synonymous_variant:LOW:exon15/28:c.1995C>T:p.His665His,KDM5B:NM_006618.4:synonymous_variant:LOW:exon14/27:c.1887C>T:p.His629His,KDM5B:NM_006618.4:sequence_feature:LOW:exon14/27:c.1887C>T:			Histone demethylase that demethylates 'Lys-4' of histone H3, thereby playing a central role in histone code. Does not demethylate histone H3 'Lys-9' or H3 'Lys-27'. Demethylates trimethylated, dimethylated and monomethylated H3 'Lys-4'. Acts as a transcriptional corepressor for FOXG1B and PAX9. Favors the proliferation of breast cancer cells by repressing tumor suppressor genes such as BRCA1 and HOXA5. In contrast, may act as a tumor suppressor for melanoma			rs1892164	0.520168	0.66909777162447	0.6647675											0		482	320			n/a	n/a	KDM5B (inh=n/a pLI=0.00)
chr1	248020556	248020556	G	C	1.0000	87		2795.0	34|49|4,0|0|0,7|6	TRIM58	missense_variant	TRIM58:NM_015431.3:missense_variant:MODERATE:exon1/6:c.8G>C:p.Trp3Ser						rs11204523	0.680112	0.76596947427925	0.4811966	COSM425890				0.548000	T	T	B	T	0.07	0		490	296			n/a	n/a	TRIM58 (inh=n/a pLI=0.00)
chr1	248059423	248059423	C	T	1.0000	36		1154.0	7|13|16,0|0|0,4|4	OR2W3	missense_variant	OR2W3:NM_001001957.2:missense_variant:MODERATE:exon1/1:c.535C>T:p.Arg179Cys	GPCR__rhodopsin-like_superfamily__1_	Olfactory transduction	Odorant receptor (Potential)			rs10888267	0.388978	0.4774757697633	0.4749781	COSM3751095				3.535000	T	T,T	B	T,T	17.71	1	I16R041,	244	418			n/a	n/a	OR2W3 (inh=n/a pLI=0.08)
chr1	248059456	248059456	G	A	1.0000	30		874.0	14|16|0,0|0|0,2|2	OR2W3	missense_variant	OR2W3:NM_001001957.2:missense_variant:MODERATE:exon1/1:c.568G>A:p.Val190Ile	GPCR__rhodopsin-like_superfamily__1_	Olfactory transduction	Odorant receptor (Potential)			rs12135078	0.363618	0.46126841810331	0.4597374	COSM1600163				-1.678000	T	T,T	B	T,T	0.74	1	I16R041,	247	430			n/a	n/a	OR2W3 (inh=n/a pLI=0.08)
chr1	248059476	248059476	A	C	1.0000	55		1743.0	14|16|25,0|0|0,4|4	OR2W3	missense_variant,sequence_feature	OR2W3:NM_001001957.2:missense_variant:MODERATE:exon1/1:c.588A>C:p.Glu196Asp,OR2W3:NM_001001957.2:sequence_feature:LOW:exon1/1:c.588A>C:	GPCR__rhodopsin-like_superfamily__1_	Olfactory transduction	Odorant receptor (Potential)			rs12139390	0.576078	0.71546893027856	0.7099496	COSM3997394				-0.407000	T	D,D	D	T,T	17.23	0		544	280			n/a	n/a	OR2W3 (inh=n/a pLI=0.08)
chr1	248059703	248059703	T	A	1.0000	25		770.0	1|4|20,0|0|0,3|4	OR2W3	missense_variant	OR2W3:NM_001001957.2:missense_variant:MODERATE:exon1/1:c.815T>A:p.Met272Lys	GPCR__rhodopsin-like_superfamily__1_	Olfactory transduction	Odorant receptor (Potential)			rs11204545	0.478035	0.57470658050903	0.5712715	COSM4143640				0.366000	T	T,T	B	T,T	4.34	1	I16R041,	369	379			n/a	n/a	OR2W3 (inh=n/a pLI=0.08)
chr1	248059712	248059712	T	C	1.0000	25		762.0	1|4|20,0|0|0,3|4	OR2W3	missense_variant	OR2W3:NM_001001957.2:missense_variant:MODERATE:exon1/1:c.824T>C:p.Met275Thr	GPCR__rhodopsin-like_superfamily__1_	Olfactory transduction	Odorant receptor (Potential)			rs11204546	0.479832	0.57986053872276	0.5758694	COSM4143641				0.343000	T	T,T	B	T,T	0.10	1	I16R041,	372	380			n/a	n/a	OR2W3 (inh=n/a pLI=0.08)
chr1	248343543	248343543	C	T	0.7500	8		107.0	1|5|0,0|2|0,2|3	OR2M2	synonymous_variant	OR2M2:NM_001004688.1:synonymous_variant:LOW:exon1/1:c.256C>T:p.Leu86Leu		Olfactory transduction	Odorant receptor (Potential)			rs9435919	0.578474	0.61308288021091	0.5457673											0		349	390			n/a	n/a	OR2M2 (inh=n/a pLI=0.00)
chr1	248343945	248343945	C	G	0.7143	14		223.0	4|6|0,0|4|0,3|4	OR2M2	missense_variant,sequence_feature	OR2M2:NM_001004688.1:missense_variant:MODERATE:exon1/1:c.658C>G:p.Arg220Gly,OR2M2:NM_001004688.1:sequence_feature:LOW:exon1/1:c.658C>G:	GPCR__rhodopsin-like_superfamily__1_	Olfactory transduction	Odorant receptor (Potential)			rs4244171	0.574681	0.61092789314065	0.5443397	COSM1178407				-0.965000	T	T	P	T	4.11	0		339	347			n/a	n/a	OR2M2 (inh=n/a pLI=0.00)
chr1	248458876	248458876	T	-	0.6923	26		343.0	0|18|0,0|8|0,0|1	OR2T12	frameshift_variant	OR2T12:NM_001004692.1:frameshift_variant:HIGH:exon1/1:c.5delA:p.Glu2fs		Olfactory transduction	Odorant receptor (Potential)			rs11339452	0.214657	0.20346534653465	0.1674877	COSM327981										0		29	242			n/a	n/a	OR2T12 (inh=n/a pLI=0.02)
chr2	1418192	1418192	C	G	1.0000	32		1045.0	13|19|0,0|0|0,5|5	TPO	synonymous_variant	TPO:NM_000547.5:synonymous_variant:LOW:exon2/17:c.12C>G:p.Leu4Leu,TPO:NM_001206744.1:synonymous_variant:LOW:exon2/17:c.12C>G:p.Leu4Leu,TPO:NM_001206745.1:synonymous_variant:LOW:exon2/16:c.12C>G:p.Leu4Leu,TPO:NM_175719.3:synonymous_variant:LOW:exon2/16:c.12C>G:p.Leu4Leu,TPO:NM_175721.3:synonymous_variant:LOW:exon1/15:c.12C>G:p.Leu4Leu,TPO:NM_175722.3:synonymous_variant:LOW:exon1/15:c.12C>G:p.Leu4Leu						rs9678281	0.311701	0.36911191631914	0.3562995	COSM1399678	606765 [TPO (confirmed) Thyroid dyshormonogenesis 2A,274500];	RCV000247664.1 [benign]; RCV000327723.1 [likely benign]; RCV000377691.1 [uncertain significance]; 								0		220	654			n/a	n/a	TPO (inh=AR pLI=0.00)
chr2	1457577	1457577	C	T	0.2500	24		57.0	6|0|0,11|6|1,5|4	TPO	synonymous_variant	TPO:NM_000547.5:synonymous_variant:LOW:exon6/17:c.594C>T:p.Asn198Asn,TPO:NM_001206744.1:synonymous_variant:LOW:exon6/17:c.594C>T:p.Asn198Asn,TPO:NM_001206745.1:synonymous_variant:LOW:exon6/16:c.594C>T:p.Asn198Asn,TPO:NM_175719.3:synonymous_variant:LOW:exon6/16:c.594C>T:p.Asn198Asn,TPO:NM_175721.3:synonymous_variant:LOW:exon5/15:c.594C>T:p.Asn198Asn,TPO:NM_175722.3:synonymous_variant:LOW:exon5/15:c.594C>T:p.Asn198Asn						rs375152400	0.0000	2.4882224139075E-5	0.0000193	COSM1399784	606765 [TPO (confirmed) Thyroid dyshormonogenesis 2A,274500];									1	cfDNA_HNSCC,	0	0			n/a	n/a	TPO (inh=AR pLI=0.00)
chr2	1481231	1481231	G	C	1.0000	104		3148.0	24|16|64,0|0|0,9|9	TPO	missense_variant,intron_variant	TPO:NM_000547.5:missense_variant:MODERATE:exon8/17:c.1193G>C:p.Ser398Thr,TPO:NM_001206744.1:missense_variant:MODERATE:exon8/17:c.1193G>C:p.Ser398Thr,TPO:NM_001206745.1:missense_variant:MODERATE:exon8/16:c.1193G>C:p.Ser398Thr,TPO:NM_175719.3:missense_variant:MODERATE:exon8/16:c.1193G>C:p.Ser398Thr,TPO:NM_175721.3:missense_variant:MODERATE:exon7/15:c.1193G>C:p.Ser398Thr,TPO:NM_175722.3:intron_variant:MODIFIER:exon6/14:c.820-7137G>C:						rs2175977	0.710264	0.64004437049362	0.2582441	COSM1579950, COSM3749599	606765 [TPO (confirmed) Thyroid dyshormonogenesis 2A,274500];	RCV000242879.1 [benign]; RCV000311144.1 [benign]; 		1.297000,1.297000	T,T	T,T,T,T,T,T,T	,D,D,D	,T,T,T,T,T,T	23.50	0		524	619			n/a	n/a	TPO (inh=AR pLI=0.00)
chr2	21225753	21225753	C	T	0.3000	20		89.0	3|3|0,8|6|0,11|13	APOB	missense_variant	APOB:NM_000384.2:missense_variant:MODERATE:exon29/29:c.12541G>A:p.Glu4181Lys			Apolipoprotein B is a major protein constituent of chylomicrons (apo B-48), LDL (apo B-100) and VLDL (apo B-100). Apo B-100 functions as a recognition signal for the cellular binding and internalization of LDL particles by the apoB/E receptor			rs1042031	0.127796	0.15301378249144	0.1508836	COSM3746534	107730 [APOB (confirmed) Hypobetalipoproteinemia,615558|Hypercholesterolemia,due to ligand-defective apo B,144010];	RCV000116381.3 [other]; RCV000256314.2 [other]; RCV000268700.1 [likely benign]; 	CM068651 [CLASS=DP MUT=ALT PHEN="Ischaemic stroke association with" GENE=APOB]; 	-0.080000	T	T,T	B	T	1.71	0		39	370			n/a	n/a	APOB (inh=AR+AD pLI=0.00)
chr2	21228827	21228827	C	T	0.3077	13		45.0	2|2|0,4|5|0,3|10	APOB	missense_variant	APOB:NM_000384.2:missense_variant:MODERATE:exon26/29:c.10913G>A:p.Arg3638Gln			Apolipoprotein B is a major protein constituent of chylomicrons (apo B-48), LDL (apo B-100) and VLDL (apo B-100). Apo B-100 functions as a recognition signal for the cellular binding and internalization of LDL particles by the apoB/E receptor			rs1801701	0.0385383	0.068873447320851	0.0693551	COSM3757925	107730 [APOB (confirmed) Hypobetalipoproteinemia,615558|Hypercholesterolemia,due to ligand-defective apo B,144010];	RCV000116380.4 [other]; RCV000256270.2 [other]; RCV000331169.1 [likely benign]; 		3.086000	T	T,T	B	T	8.45	0		12	173			n/a	n/a	APOB (inh=AR+AD pLI=0.00)
chr2	21232195	21232195	G	A	0.4889	45		431.0	2|0|20,1|0|22,9|5	APOB	synonymous_variant	APOB:NM_000384.2:synonymous_variant:LOW:exon26/29:c.7545C>T:p.Thr2515Thr			Apolipoprotein B is a major protein constituent of chylomicrons (apo B-48), LDL (apo B-100) and VLDL (apo B-100). Apo B-100 functions as a recognition signal for the cellular binding and internalization of LDL particles by the apoB/E receptor			rs693	0.250998	0.38993503281338	0.3889353	COSM4133426	107730 [APOB (confirmed) Hypobetalipoproteinemia,615558|Hypercholesterolemia,due to ligand-defective apo B,144010];	RCV000116389.3 [other]; RCV000274903.1 [likely benign]; RCV000388049.1 [likely benign]; 								0		263	633			n/a	n/a	APOB (inh=AR+AD pLI=0.00)
chr2	21232803	21232803	T	C	0.4286	14		346.0	4|8|2,0|0|0,3|4	APOB	missense_variant	APOB:NM_000384.2:missense_variant:MODERATE:exon26/29:c.6937A>G:p.Ile2313Val			Apolipoprotein B is a major protein constituent of chylomicrons (apo B-48), LDL (apo B-100) and VLDL (apo B-100). Apo B-100 functions as a recognition signal for the cellular binding and internalization of LDL particles by the apoB/E receptor			rs584542	0.986222	0.99503204864143	0.9416285		107730 [APOB (confirmed) Hypobetalipoproteinemia,615558|Hypercholesterolemia,due to ligand-defective apo B,144010];			-0.205000	T	T,T	B	T	0.00	0		1324	6			n/a	n/a	APOB (inh=AR+AD pLI=0.00)
chr2	21232804	21232804	G	A	0.4286	14		346.0	2|4|0,2|4|2,3|4	APOB	synonymous_variant	APOB:NM_000384.2:synonymous_variant:LOW:exon26/29:c.6936C>T:p.Asp2312Asp			Apolipoprotein B is a major protein constituent of chylomicrons (apo B-48), LDL (apo B-100) and VLDL (apo B-100). Apo B-100 functions as a recognition signal for the cellular binding and internalization of LDL particles by the apoB/E receptor			rs1041968	0.249201	0.38914161392405	0.3651546	COSM3933524	107730 [APOB (confirmed) Hypobetalipoproteinemia,615558|Hypercholesterolemia,due to ligand-defective apo B,144010];	RCV000116388.3 [other]; RCV000283635.1 [likely benign]; RCV000392137.1 [likely benign]; 								0		266	624			n/a	n/a	APOB (inh=AR+AD pLI=0.00)
chr2	21235475	21235475	T	C	1.0000	20		611.0	20|0|0,0|0|0,7|8	APOB	missense_variant	APOB:NM_000384.2:missense_variant:MODERATE:exon26/29:c.4265A>G:p.Tyr1422Cys			Apolipoprotein B is a major protein constituent of chylomicrons (apo B-48), LDL (apo B-100) and VLDL (apo B-100). Apo B-100 functions as a recognition signal for the cellular binding and internalization of LDL particles by the apoB/E receptor			rs568413	1	0.99985124458696	0.9443165		107730 [APOB (confirmed) Hypobetalipoproteinemia,615558|Hypercholesterolemia,due to ligand-defective apo B,144010];			0.573000	T	T,T	B	T	0.04	0		1329	1			n/a	n/a	APOB (inh=AR+AD pLI=0.00)
chr2	21263900	21263900	G	A	0.8000	10		183.0	2|6|0,2|0|0,7|2	APOB	missense_variant	APOB:NM_000384.2:missense_variant:MODERATE:exon4/29:c.293C>T:p.Thr98Ile	Lipid_transport_protein__beta-sheet_shell__1_,Lipid_transport_protein__N-terminal__3_,Vitellinogen__beta-sheet_N-terminal__1_		Apolipoprotein B is a major protein constituent of chylomicrons (apo B-48), LDL (apo B-100) and VLDL (apo B-100). Apo B-100 functions as a recognition signal for the cellular binding and internalization of LDL particles by the apoB/E receptor			rs1367117	0.169329	0.26191078932712	0.2574725	COSM148808	107730 [APOB (confirmed) Hypobetalipoproteinemia,615558|Hypercholesterolemia,due to ligand-defective apo B,144010];	RCV000116386.3 [likely benign]; RCV000256320.2 [other]; RCV000324495.1 [likely benign]; 	CM020623 [CLASS=FP MUT=ALT PHEN="Increased cholesterol levels" GENE=APOB]; 	2.809000	T	T,T,T	B	T,T	23.00	0		108	490			n/a	n/a	APOB (inh=AR+AD pLI=0.00)
chr2	21266775	21266783	GCAGCGCCA	-	0.3571	14		50.0	4|0|1,6|0|3,5|7	APOB	disruptive_inframe_deletion	APOB:NM_000384.2:disruptive_inframe_deletion:MODERATE:exon1/29:c.35_43delTGGCGCTGC:p.Leu12_Leu14del			Apolipoprotein B is a major protein constituent of chylomicrons (apo B-48), LDL (apo B-100) and VLDL (apo B-100). Apo B-100 functions as a recognition signal for the cellular binding and internalization of LDL particles by the apoB/E receptor			rs17240441	0.221246	0.083021806853583	0.0376774		107730 [APOB (confirmed) Hypobetalipoproteinemia,615558|Hypercholesterolemia,due to ligand-defective apo B,144010];	RCV000251913.1 [likely benign]; RCV000256231.2 [other]; 	CD068106 [CLASS=DP MUT=ALT PHEN="Oligoasthenoteratozoospermia association with" GENE=APOB]; 							0		73	336			n/a	n/a	APOB (inh=AR+AD pLI=0.00)
chr2	25469913	25469913	C	T	0.4872	117		1435.0	6|1|50,0|0|60,6|6	DNMT3A	splice_region_variant&intron_variant	DNMT3A:NM_022552.4:splice_region_variant&intron_variant:LOW:exon9/22:c.1122+7G>A:,DNMT3A:NM_001320893.1:splice_region_variant&intron_variant:LOW:exon4/17:c.666+7G>A:,DNMT3A:NM_153759.3:splice_region_variant&intron_variant:LOW:exon5/18:c.555+7G>A:,DNMT3A:NM_175629.2:splice_region_variant&intron_variant:LOW:exon9/22:c.1122+7G>A:,DNMT3A:NR_135490.1:splice_region_variant&intron_variant:LOW:exon9/23:n.1460+7G>A:		Methionine metabolism	Required for genome-wide de novo methylation and is essential for the establishment of DNA methylation patterns during development. DNA methylation is coordinated with methylation of histones. It modifies DNA in a non-processive manner and also methylates non-CpG sites. May preferentially methylate DNA linker between 2 nucleosomal cores and is inhibited by histone H1. Plays a role in paternal and maternal imprinting. Required for methylation of most imprinted loci in germ cells. Acts as a transcriptional corepressor for ZBTB18. Recruited to trimethylated 'Lys-36' of histone H3 (H3K36me3) sites. Can actively repress transcription through the recruitment of HDAC activity			rs2276599	0.614018	0.71670177703782	0.6895835		602769 [DNMT3A (provisional) Tatton-Brown-Rahman syndrome,615879];									1	I16R041,	737	495			n/a	n/a	DNMT3A (inh=AD pLI=0.00)
chr2	29416366	29416366	G	C	0.5200	100		1276.0	8|0|44,0|0|48,7|5	ALK	missense_variant	ALK:NM_004304.4:missense_variant:MODERATE:exon29/29:c.4587C>G:p.Asp1529Glu			Neuronal orphan receptor tyrosine kinase that is essentially and transiently expressed in specific regions of the central and peripheral nervous systems and plays an important role in the genesis and differentiation of the nervous system. Transduces signals from ligands at the cell surface, through specific activation of the mitogen-activated protein kinase (MAPK) pathway. Phosphorylates almost exclusively at the first tyrosine of the Y-x-x-x-Y-Y motif. Following activation by ligand, ALK induces tyrosine phosphorylation of CBL, FRS2, IRS1 and SHC1, as well as of the MAP kinases MAPK1/ERK2 and MAPK3/ERK1. Acts as a receptor for ligands pleiotrophin (PTN), a secreted growth factor, and midkine (MDK), a PTN-related factor, thus participating in PTN and MDK signal transduction. PTN-binding induces MAPK pathway activation, which is important for the anti-apoptotic signaling of PTN and regulation of cell proliferation. MDK-binding induces phosphorylation of the ALK target insulin receptor substrate (IRS1), activates mitogen-activated protein kinases (MAPKs) and PI3-kinase, resulting also in cell proliferation induction. Drives NF-kappa-B activation, probably through IRS1 and the activation of the AKT serine/threonine kinase. Recruitment of IRS1 to activated ALK and the activation of NF-kappa-B are essential for the autocrine growth and survival signaling of MDK			rs1881421	0.572883	0.46001977587343	0.4412748	COSM3758201	105590 [ALK (confirmed) Neuroblastoma,susceptibility to,3,613014];	RCV000119980.2 [benign]; RCV000316289.1 [benign]; 		-0.022000	T	T,T	B	T,T	0.00	2	SomaticAndTreatment,	183	643			n/a	n/a	ALK (inh=n/a pLI=0.52)
chr2	29416481	29416481	T	C	0.6667	18		250.0	0|0|12,0|0|6,5|5	ALK	missense_variant	ALK:NM_004304.4:missense_variant:MODERATE:exon29/29:c.4472A>G:p.Lys1491Arg			Neuronal orphan receptor tyrosine kinase that is essentially and transiently expressed in specific regions of the central and peripheral nervous systems and plays an important role in the genesis and differentiation of the nervous system. Transduces signals from ligands at the cell surface, through specific activation of the mitogen-activated protein kinase (MAPK) pathway. Phosphorylates almost exclusively at the first tyrosine of the Y-x-x-x-Y-Y motif. Following activation by ligand, ALK induces tyrosine phosphorylation of CBL, FRS2, IRS1 and SHC1, as well as of the MAP kinases MAPK1/ERK2 and MAPK3/ERK1. Acts as a receptor for ligands pleiotrophin (PTN), a secreted growth factor, and midkine (MDK), a PTN-related factor, thus participating in PTN and MDK signal transduction. PTN-binding induces MAPK pathway activation, which is important for the anti-apoptotic signaling of PTN and regulation of cell proliferation. MDK-binding induces phosphorylation of the ALK target insulin receptor substrate (IRS1), activates mitogen-activated protein kinases (MAPKs) and PI3-kinase, resulting also in cell proliferation induction. Drives NF-kappa-B activation, probably through IRS1 and the activation of the AKT serine/threonine kinase. Recruitment of IRS1 to activated ALK and the activation of NF-kappa-B are essential for the autocrine growth and survival signaling of MDK			rs1881420	0.415136	0.33181758270726	0.3267890	COSM1130802	105590 [ALK (confirmed) Neuroblastoma,susceptibility to,3,613014];	RCV000119978.2 [benign]; RCV000286120.1 [benign]; 		2.447000	T	T,T	B	T,T	13.96	0		73	474			n/a	n/a	ALK (inh=n/a pLI=0.52)
chr2	29416572	29416572	T	C	1.0000	55		1706.0	0|3|52,0|0|0,6|6	ALK	missense_variant	ALK:NM_004304.4:missense_variant:MODERATE:exon29/29:c.4381A>G:p.Ile1461Val			Neuronal orphan receptor tyrosine kinase that is essentially and transiently expressed in specific regions of the central and peripheral nervous systems and plays an important role in the genesis and differentiation of the nervous system. Transduces signals from ligands at the cell surface, through specific activation of the mitogen-activated protein kinase (MAPK) pathway. Phosphorylates almost exclusively at the first tyrosine of the Y-x-x-x-Y-Y motif. Following activation by ligand, ALK induces tyrosine phosphorylation of CBL, FRS2, IRS1 and SHC1, as well as of the MAP kinases MAPK1/ERK2 and MAPK3/ERK1. Acts as a receptor for ligands pleiotrophin (PTN), a secreted growth factor, and midkine (MDK), a PTN-related factor, thus participating in PTN and MDK signal transduction. PTN-binding induces MAPK pathway activation, which is important for the anti-apoptotic signaling of PTN and regulation of cell proliferation. MDK-binding induces phosphorylation of the ALK target insulin receptor substrate (IRS1), activates mitogen-activated protein kinases (MAPKs) and PI3-kinase, resulting also in cell proliferation induction. Drives NF-kappa-B activation, probably through IRS1 and the activation of the AKT serine/threonine kinase. Recruitment of IRS1 to activated ALK and the activation of NF-kappa-B are essential for the autocrine growth and survival signaling of MDK			rs1670283	0.992212	0.99716344805977	0.9337059		105590 [ALK (confirmed) Neuroblastoma,susceptibility to,3,613014];	RCV000119976.3 [benign]; RCV000390907.1 [benign]; 		-0.728000	T	T,T	B	T,T	0.00	0		1384	1			n/a	n/a	ALK (inh=n/a pLI=0.52)
chr2	29445458	29445458	G	T	1.0000	47		1186.0	0|44|3,0|0|0,10|12	ALK	synonymous_variant	ALK:NM_004304.4:synonymous_variant:LOW:exon21/29:c.3375C>A:p.Gly1125Gly			Neuronal orphan receptor tyrosine kinase that is essentially and transiently expressed in specific regions of the central and peripheral nervous systems and plays an important role in the genesis and differentiation of the nervous system. Transduces signals from ligands at the cell surface, through specific activation of the mitogen-activated protein kinase (MAPK) pathway. Phosphorylates almost exclusively at the first tyrosine of the Y-x-x-x-Y-Y motif. Following activation by ligand, ALK induces tyrosine phosphorylation of CBL, FRS2, IRS1 and SHC1, as well as of the MAP kinases MAPK1/ERK2 and MAPK3/ERK1. Acts as a receptor for ligands pleiotrophin (PTN), a secreted growth factor, and midkine (MDK), a PTN-related factor, thus participating in PTN and MDK signal transduction. PTN-binding induces MAPK pathway activation, which is important for the anti-apoptotic signaling of PTN and regulation of cell proliferation. MDK-binding induces phosphorylation of the ALK target insulin receptor substrate (IRS1), activates mitogen-activated protein kinases (MAPKs) and PI3-kinase, resulting also in cell proliferation induction. Drives NF-kappa-B activation, probably through IRS1 and the activation of the AKT serine/threonine kinase. Recruitment of IRS1 to activated ALK and the activation of NF-kappa-B are essential for the autocrine growth and survival signaling of MDK			rs3795850	0.415935	0.32714881361041	0.3174002		105590 [ALK (confirmed) Neuroblastoma,susceptibility to,3,613014];	RCV000284362.1 [benign]; 								0		78	450			n/a	n/a	ALK (inh=n/a pLI=0.52)
chr2	29455267	29455267	A	G	0.4333	30		287.0	0|10|3,5|5|7,7|9	ALK	synonymous_variant	ALK:NM_004304.4:synonymous_variant:LOW:exon15/29:c.2535T>C:p.Gly845Gly			Neuronal orphan receptor tyrosine kinase that is essentially and transiently expressed in specific regions of the central and peripheral nervous systems and plays an important role in the genesis and differentiation of the nervous system. Transduces signals from ligands at the cell surface, through specific activation of the mitogen-activated protein kinase (MAPK) pathway. Phosphorylates almost exclusively at the first tyrosine of the Y-x-x-x-Y-Y motif. Following activation by ligand, ALK induces tyrosine phosphorylation of CBL, FRS2, IRS1 and SHC1, as well as of the MAP kinases MAPK1/ERK2 and MAPK3/ERK1. Acts as a receptor for ligands pleiotrophin (PTN), a secreted growth factor, and midkine (MDK), a PTN-related factor, thus participating in PTN and MDK signal transduction. PTN-binding induces MAPK pathway activation, which is important for the anti-apoptotic signaling of PTN and regulation of cell proliferation. MDK-binding induces phosphorylation of the ALK target insulin receptor substrate (IRS1), activates mitogen-activated protein kinases (MAPKs) and PI3-kinase, resulting also in cell proliferation induction. Drives NF-kappa-B activation, probably through IRS1 and the activation of the AKT serine/threonine kinase. Recruitment of IRS1 to activated ALK and the activation of NF-kappa-B are essential for the autocrine growth and survival signaling of MDK			rs2256740	0.5	0.61210122825818	0.5881971	COSM148825	105590 [ALK (confirmed) Neuroblastoma,susceptibility to,3,613014];	RCV000247134.1 [benign]; RCV000296991.1 [benign]; 								0		711	544			n/a	n/a	ALK (inh=n/a pLI=0.52)
chr2	29543663	29543663	T	C	1.0000	29		845.0	23|6|0,0|0|0,3|2	ALK	synonymous_variant	ALK:NM_004304.4:synonymous_variant:LOW:exon7/29:c.1500A>G:p.Gln500Gln			Neuronal orphan receptor tyrosine kinase that is essentially and transiently expressed in specific regions of the central and peripheral nervous systems and plays an important role in the genesis and differentiation of the nervous system. Transduces signals from ligands at the cell surface, through specific activation of the mitogen-activated protein kinase (MAPK) pathway. Phosphorylates almost exclusively at the first tyrosine of the Y-x-x-x-Y-Y motif. Following activation by ligand, ALK induces tyrosine phosphorylation of CBL, FRS2, IRS1 and SHC1, as well as of the MAP kinases MAPK1/ERK2 and MAPK3/ERK1. Acts as a receptor for ligands pleiotrophin (PTN), a secreted growth factor, and midkine (MDK), a PTN-related factor, thus participating in PTN and MDK signal transduction. PTN-binding induces MAPK pathway activation, which is important for the anti-apoptotic signaling of PTN and regulation of cell proliferation. MDK-binding induces phosphorylation of the ALK target insulin receptor substrate (IRS1), activates mitogen-activated protein kinases (MAPKs) and PI3-kinase, resulting also in cell proliferation induction. Drives NF-kappa-B activation, probably through IRS1 and the activation of the AKT serine/threonine kinase. Recruitment of IRS1 to activated ALK and the activation of NF-kappa-B are essential for the autocrine growth and survival signaling of MDK			rs2293564	0.776558	0.87163308676958	0.8579072	COSM4133810	105590 [ALK (confirmed) Neuroblastoma,susceptibility to,3,613014];	RCV000244976.1 [benign]; RCV000281550.1 [benign]; 								0		1161	214			n/a	n/a	ALK (inh=n/a pLI=0.52)
chr2	29940529	29940529	A	T	1.0000	12		325.0	1|6|5,0|0|0,5|5	ALK	synonymous_variant	ALK:NM_004304.4:synonymous_variant:LOW:exon2/29:c.702T>A:p.Pro234Pro			Neuronal orphan receptor tyrosine kinase that is essentially and transiently expressed in specific regions of the central and peripheral nervous systems and plays an important role in the genesis and differentiation of the nervous system. Transduces signals from ligands at the cell surface, through specific activation of the mitogen-activated protein kinase (MAPK) pathway. Phosphorylates almost exclusively at the first tyrosine of the Y-x-x-x-Y-Y motif. Following activation by ligand, ALK induces tyrosine phosphorylation of CBL, FRS2, IRS1 and SHC1, as well as of the MAP kinases MAPK1/ERK2 and MAPK3/ERK1. Acts as a receptor for ligands pleiotrophin (PTN), a secreted growth factor, and midkine (MDK), a PTN-related factor, thus participating in PTN and MDK signal transduction. PTN-binding induces MAPK pathway activation, which is important for the anti-apoptotic signaling of PTN and regulation of cell proliferation. MDK-binding induces phosphorylation of the ALK target insulin receptor substrate (IRS1), activates mitogen-activated protein kinases (MAPKs) and PI3-kinase, resulting also in cell proliferation induction. Drives NF-kappa-B activation, probably through IRS1 and the activation of the AKT serine/threonine kinase. Recruitment of IRS1 to activated ALK and the activation of NF-kappa-B are essential for the autocrine growth and survival signaling of MDK			rs2246745	0.589257	0.73346678529063	0.7300134		105590 [ALK (confirmed) Neuroblastoma,susceptibility to,3,613014];	RCV000226929.1 [likely benign]; RCV000249360.1 [benign]; RCV000302546.1 [benign]; 								1	SomaticAndTreatment,	899	438			n/a	n/a	ALK (inh=n/a pLI=0.52)
chr2	30143420	30143420	G	A	0.3077	26		119.0	4|4|0,12|6|0,4|7	ALK	missense_variant	ALK:NM_004304.4:missense_variant:MODERATE:exon1/29:c.106C>T:p.Pro36Ser			Neuronal orphan receptor tyrosine kinase that is essentially and transiently expressed in specific regions of the central and peripheral nervous systems and plays an important role in the genesis and differentiation of the nervous system. Transduces signals from ligands at the cell surface, through specific activation of the mitogen-activated protein kinase (MAPK) pathway. Phosphorylates almost exclusively at the first tyrosine of the Y-x-x-x-Y-Y motif. Following activation by ligand, ALK induces tyrosine phosphorylation of CBL, FRS2, IRS1 and SHC1, as well as of the MAP kinases MAPK1/ERK2 and MAPK3/ERK1. Acts as a receptor for ligands pleiotrophin (PTN), a secreted growth factor, and midkine (MDK), a PTN-related factor, thus participating in PTN and MDK signal transduction. PTN-binding induces MAPK pathway activation, which is important for the anti-apoptotic signaling of PTN and regulation of cell proliferation. MDK-binding induces phosphorylation of the ALK target insulin receptor substrate (IRS1), activates mitogen-activated protein kinases (MAPKs) and PI3-kinase, resulting also in cell proliferation induction. Drives NF-kappa-B activation, probably through IRS1 and the activation of the AKT serine/threonine kinase. Recruitment of IRS1 to activated ALK and the activation of NF-kappa-B are essential for the autocrine growth and survival signaling of MDK			rs201490095	0.0000	0.001012446340344	0.0005402		105590 [ALK (confirmed) Neuroblastoma,susceptibility to,3,613014];	RCV000119961.1 [not provided]; RCV000318132.1 [likely benign]; 		1.803000	T	D,D	B	T,T	13.35	0		0	3			n/a	n/a	ALK (inh=n/a pLI=0.52)
chr2	30143499	30143499	G	C	1.0000	52		1709.0	14|5|33,0|0|0,5|6	ALK	synonymous_variant	ALK:NM_004304.4:synonymous_variant:LOW:exon1/29:c.27C>G:p.Leu9Leu			Neuronal orphan receptor tyrosine kinase that is essentially and transiently expressed in specific regions of the central and peripheral nervous systems and plays an important role in the genesis and differentiation of the nervous system. Transduces signals from ligands at the cell surface, through specific activation of the mitogen-activated protein kinase (MAPK) pathway. Phosphorylates almost exclusively at the first tyrosine of the Y-x-x-x-Y-Y motif. Following activation by ligand, ALK induces tyrosine phosphorylation of CBL, FRS2, IRS1 and SHC1, as well as of the MAP kinases MAPK1/ERK2 and MAPK3/ERK1. Acts as a receptor for ligands pleiotrophin (PTN), a secreted growth factor, and midkine (MDK), a PTN-related factor, thus participating in PTN and MDK signal transduction. PTN-binding induces MAPK pathway activation, which is important for the anti-apoptotic signaling of PTN and regulation of cell proliferation. MDK-binding induces phosphorylation of the ALK target insulin receptor substrate (IRS1), activates mitogen-activated protein kinases (MAPKs) and PI3-kinase, resulting also in cell proliferation induction. Drives NF-kappa-B activation, probably through IRS1 and the activation of the AKT serine/threonine kinase. Recruitment of IRS1 to activated ALK and the activation of NF-kappa-B are essential for the autocrine growth and survival signaling of MDK			rs4358080	0.89377	0.89494904740806	0.6579960	COSM3749653	105590 [ALK (confirmed) Neuroblastoma,susceptibility to,3,613014];	RCV000250274.1 [benign]; RCV000324219.1 [benign]; 								0		1091	249			n/a	n/a	ALK (inh=n/a pLI=0.52)
chr2	32690189	32690189	A	G	0.5625	32		409.0	0|0|18,0|0|13,2|2	BIRC6	synonymous_variant	BIRC6:NM_016252.3:synonymous_variant:LOW:exon26/74:c.5313A>G:p.Gln1771Gln		Ubiquitin mediated proteolysis	Anti-apoptotic protein which can regulate cell death by controlling caspases and by acting as an E3 ubiquitin-protein ligase. Has an unusual ubiquitin conjugation system in that it could combine in a single polypeptide, ubiquitin conjugating (E2) with ubiquitin ligase (E3) activity, forming a chimeric E2/E3 ubiquitin ligase. Its tragets include CASP9 and DIABLO/SMAC. Acts as an inhibitor of CASP3, CASP7 and CASP9. Important regulator for the final stages of cytokinesis. Crucial for normal vesicle targeting to the site of abscission, but also for the integrity of the midbody and the midbody ring, and its striking ubiquitin modification			rs35682129	0.0678914	0.091157674174961	0.0737987	COSM1407805, COSM1407804										0		12	125			n/a	n/a	BIRC6 (inh=n/a pLI=1.00)
chr2	32800422	32800422	C	G	0.7273	22		342.0	2|14|0,6|0|0,6|4	BIRC6	synonymous_variant	BIRC6:NM_016252.3:synonymous_variant:LOW:exon66/74:c.13344C>G:p.Thr4448Thr		Ubiquitin mediated proteolysis	Anti-apoptotic protein which can regulate cell death by controlling caspases and by acting as an E3 ubiquitin-protein ligase. Has an unusual ubiquitin conjugation system in that it could combine in a single polypeptide, ubiquitin conjugating (E2) with ubiquitin ligase (E3) activity, forming a chimeric E2/E3 ubiquitin ligase. Its tragets include CASP9 and DIABLO/SMAC. Acts as an inhibitor of CASP3, CASP7 and CASP9. Important regulator for the final stages of cytokinesis. Crucial for normal vesicle targeting to the site of abscission, but also for the integrity of the midbody and the midbody ring, and its striking ubiquitin modification			rs35286811	0.0940495	0.11204410237817	0.1093477											0		20	195			n/a	n/a	BIRC6 (inh=n/a pLI=1.00)
chr2	33412077	33412077	G	A	0.4600	50		501.0	8|15|0,16|11|0,5|6	LTBP1	synonymous_variant	LTBP1:NM_206943.2:synonymous_variant:LOW:exon6/34:c.1356G>A:p.Ala452Ala,LTBP1:NM_000627.3:synonymous_variant:LOW:exon2/30:c.378G>A:p.Ala126Ala,LTBP1:NM_001166264.1:synonymous_variant:LOW:exon2/29:c.378G>A:p.Ala126Ala,LTBP1:NM_001166265.1:synonymous_variant:LOW:exon2/30:c.378G>A:p.Ala126Ala,LTBP1:NM_001166266.1:synonymous_variant:LOW:exon2/29:c.378G>A:p.Ala126Ala						rs1065324	0.367812	0.45920471038396	0.4553323	COSM4001652, COSM4001651										0		300	602			n/a	n/a	LTBP1 (inh=n/a pLI=0.53)
chr2	33447202	33447202	C	T	0.3636	22		141.0	0|4|4,4|8|2,4|6	LTBP1	sequence_feature,synonymous_variant	LTBP1:NM_206943.2:sequence_feature:MODERATE:exon9/34:c.1860C>T:,LTBP1:NM_000627.3:sequence_feature:MODERATE:exon5/30:c.882C>T:,LTBP1:NM_001166265.1:sequence_feature:MODERATE:exon5/30:c.882C>T:,LTBP1:NM_206943.2:synonymous_variant:LOW:exon9/34:c.1860C>T:p.Asn620Asn,LTBP1:NM_000627.3:synonymous_variant:LOW:exon5/30:c.882C>T:p.Asn294Asn,LTBP1:NM_001166264.1:synonymous_variant:LOW:exon5/29:c.882C>T:p.Asn294Asn,LTBP1:NM_001166265.1:synonymous_variant:LOW:exon5/30:c.882C>T:p.Asn294Asn,LTBP1:NM_001166266.1:synonymous_variant:LOW:exon5/29:c.882C>T:p.Asn294Asn						rs2290448	0.332668	0.43122741001139	0.4289086	COSM4001656, COSM4001655										0		284	604			n/a	n/a	LTBP1 (inh=n/a pLI=0.53)
chr2	33540248	33540248	G	A	0.6364	11		136.0	5|2|0,0|4|0,5|4	LTBP1	synonymous_variant	LTBP1:NM_206943.2:synonymous_variant:LOW:exon24/34:c.3642G>A:p.Pro1214Pro,LTBP1:NM_000627.3:synonymous_variant:LOW:exon20/30:c.2664G>A:p.Pro888Pro,LTBP1:NM_001166264.1:synonymous_variant:LOW:exon20/29:c.2664G>A:p.Pro888Pro,LTBP1:NM_001166265.1:synonymous_variant:LOW:exon20/30:c.2505G>A:p.Pro835Pro,LTBP1:NM_001166266.1:synonymous_variant:LOW:exon20/29:c.2505G>A:p.Pro835Pro						rs1058840	0.460264	0.60032986970147	0.5885765	COSM4001659, COSM4001660				-0.419000	T				13.60	0		543	551			n/a	n/a	LTBP1 (inh=n/a pLI=0.53)
chr2	33585796	33585796	T	C	1.0000	43		1243.0	4|5|34,0|0|0,3|3	LTBP1	missense_variant,sequence_feature	LTBP1:NM_206943.2:missense_variant:MODERATE:exon27/34:c.4133T>C:p.Val1378Ala,LTBP1:NM_000627.3:missense_variant:MODERATE:exon23/30:c.3155T>C:p.Val1052Ala,LTBP1:NM_001166264.1:missense_variant:MODERATE:exon22/29:c.3029T>C:p.Val1010Ala,LTBP1:NM_001166265.1:missense_variant:MODERATE:exon23/30:c.2996T>C:p.Val999Ala,LTBP1:NM_001166266.1:missense_variant:MODERATE:exon22/29:c.2870T>C:p.Val957Ala,LTBP1:NM_206943.2:sequence_feature:LOW:exon27/34:c.4133T>C:,LTBP1:NM_000627.3:sequence_feature:LOW:exon23/30:c.3155T>C:,LTBP1:NM_001166265.1:sequence_feature:LOW:exon23/30:c.2996T>C:	Matrix_fibril-associated__3_,TGF-beta_binding__1_					rs4422143	1	0.99991762632004	0.9445223					3.902000	T	T,T,T,T,T,T,T,T,T	B,B,B,B,B,B,B	D,D,D,D,D,D,D,D,D	5.45	0		1282	0			n/a	n/a	LTBP1 (inh=n/a pLI=0.53)
chr2	46603671	46603671	C	G	0.6316	19		282.0	6|6|0,0|6|1,6|7	EPAS1	splice_region_variant&intron_variant	EPAS1:NM_001430.4:splice_region_variant&intron_variant:LOW:exon8/15:c.1035-7C>G:		Renal cell carcinoma	Transcription factor involved in the induction of oxygen regulated genes. Binds to core DNA sequence 5'-[AG]CGTG-3' within the hypoxia response element (HRE) of target gene promoters. Regulates the vascular endothelial growth factor (VEGF) expression and seems to be implicated in the development of blood vessels and the tubular system of lung. May also play a role in the formation of the endothelium that gives rise to the blood brain barrier. Potent activator of the Tie-2 tyrosine kinase expression. Activation seems to require recruitment of transcriptional coactivators such as CREBPB and probably EP300. Interaction with redox regulatory protein APEX seems to activate CTAD			rs7557402	0.3125	0.41038419717289	0.3904723	COSM4001689	603349 [EPAS1 (confirmed) Erythrocytosis,familial,4,611783];	RCV000329925.1 [benign]; 								0		339	702			n/a	n/a	EPAS1 (inh=AD pLI=1.00)
chr2	54858296	54858296	G	A	0.1875	32		28.0	0|0|6,16|8|2,6|6	SPTBN1	missense_variant	SPTBN1:NM_003128.2:missense_variant:MODERATE:exon16/36:c.3112G>A:p.Ala1038Thr,SPTBN1:NM_178313.2:missense_variant:MODERATE:exon15/31:c.3073G>A:p.Ala1025Thr							0.0000	0.0000	0.0000					6.550000	T	T,T	B,B	T,T	19.94	1	cfDNA_HNSCC,	0	0			n/a	n/a	SPTBN1 (inh=n/a pLI=1.00)
chr2	54858511	54858511	C	T	1.0000	8		173.0	0|0|8,0|0|0,7|8	SPTBN1	synonymous_variant	SPTBN1:NM_003128.2:synonymous_variant:LOW:exon16/36:c.3327C>T:p.Asn1109Asn,SPTBN1:NM_178313.2:synonymous_variant:LOW:exon15/31:c.3288C>T:p.Asn1096Asn						rs1052788	0.240415	0.30896078625375	0.3046996	COSM148857										0		87	335			n/a	n/a	SPTBN1 (inh=n/a pLI=1.00)
chr2	54886347	54886347	G	A	1.0000	8		234.0	0|5|3,0|0|0,4|5	SPTBN1	synonymous_variant	SPTBN1:NM_003128.2:synonymous_variant:LOW:exon31/36:c.6300G>A:p.Pro2100Pro,SPTBN1:NM_178313.2:synonymous_variant:LOW:exon30/31:c.6261G>A:p.Pro2087Pro						rs1052820	0.278155	0.3275731355583	0.3200432	COSM148858										0		108	331			n/a	n/a	SPTBN1 (inh=n/a pLI=1.00)
chr2	58388696	58388696	A	G	0.7500	12		199.0	8|1|0,0|3|0,4|5	FANCL	synonymous_variant,sequence_feature	FANCL:NM_001114636.1:synonymous_variant:LOW:exon12/14:c.996T>C:p.Ser332Ser,FANCL:NM_018062.3:synonymous_variant:LOW:exon12/14:c.981T>C:p.Ser327Ser,FANCL:NM_001114636.1:sequence_feature:LOW:exon12/14:c.996T>C:,FANCL:NM_018062.3:sequence_feature:LOW:exon12/14:c.981T>C:						rs848291	0.70647	0.6486633843307	0.6370576	COSM4001713	608111 [FANCL (provisional) Fanconi anemia,complementation group L,614083];	RCV000253562.1 [benign]; RCV000282580.1 [benign]; 								2	TEST_SomaticAndTreatment,	687	972			n/a	n/a	FANCL (inh=AR pLI=0.00)
chr2	60687959	60687959	A	G	0.3214	56		279.0	0|0|18,0|16|22,2|2	BCL11A	synonymous_variant,intron_variant	BCL11A:NM_022893.3:synonymous_variant:LOW:exon4/4:c.2088T>C:p.Ser696Ser,BCL11A:NM_018014.3:synonymous_variant:LOW:exon4/5:c.2088T>C:p.Ser696Ser,BCL11A:NM_138559.1:intron_variant:MODIFIER:exon4/4:c.630+1458T>C:						rs7569946	0.830072	0.69774986310008	0.6786706	COSM3758292, COSM3758293	606557 [BCL11A (provisional) Dias-Logan syndrome,617101];									0		437	612			n/a	n/a	BCL11A (inh=n/a pLI=0.83)
chr2	116497479	116497479	A	G	1.0000	26		854.0	12|14|0,0|0|0,6|6	DPP10	splice_region_variant&intron_variant	DPP10:NM_001321905.1:splice_region_variant&intron_variant:LOW:exon10/26:c.903+10A>G:,DPP10:NM_001321907.1:splice_region_variant&intron_variant:LOW:exon9/24:c.852+10A>G:,DPP10:NM_001321910.1:splice_region_variant&intron_variant:LOW:exon10/26:c.702+10A>G:,DPP10:NM_020868.4:splice_region_variant&intron_variant:LOW:exon9/25:c.852+10A>G:,DPP10:NM_001178036.1:splice_region_variant&intron_variant:LOW:exon10/26:c.702+10A>G:,DPP10:NM_001321908.1:splice_region_variant&intron_variant:LOW:exon9/25:c.762+10A>G:,DPP10:NM_001321911.1:splice_region_variant&intron_variant:LOW:exon9/25:c.702+10A>G:,DPP10:NM_001321912.1:splice_region_variant&intron_variant:LOW:exon10/25:c.702+10A>G:,DPP10:NM_001178037.1:splice_region_variant&intron_variant:LOW:exon9/25:c.840+10A>G:,DPP10:NM_001321906.1:splice_region_variant&intron_variant:LOW:exon10/26:c.831+10A>G:,DPP10:NM_001321914.1:splice_region_variant&intron_variant:LOW:exon9/25:c.90+10A>G:,DPP10:NM_001178034.1:splice_region_variant&intron_variant:LOW:exon9/25:c.864+10A>G:,DPP10:NM_001004360.3:splice_region_variant&intron_variant:LOW:exon9/25:c.831+10A>G:,DPP10:NM_001321909.1:splice_region_variant&intron_variant:LOW:exon8/24:c.735+10A>G:,DPP10:NM_001321913.1:splice_region_variant&intron_variant:LOW:exon7/23:c.90+10A>G:			Has no dipeptidyl aminopeptidase activity. May modulate cell surface expression and activity of the potassium channels KCND1 and KCND2			rs1550854	0.954872	0.98793114818967	0.9185680											0		1274	6			n/a	n/a	DPP10 (inh=n/a pLI=1.00)
chr2	116525960	116525960	G	A	1.0000	19		559.0	19|0|0,0|0|0,6|3	DPP10	missense_variant	DPP10:NM_001321905.1:missense_variant:MODERATE:exon14/27:c.1252G>A:p.Val418Ile,DPP10:NM_001321907.1:missense_variant:MODERATE:exon12/25:c.1162G>A:p.Val388Ile,DPP10:NM_001321910.1:missense_variant:MODERATE:exon14/27:c.1051G>A:p.Val351Ile,DPP10:NM_020868.4:missense_variant:MODERATE:exon13/26:c.1201G>A:p.Val401Ile,DPP10:NM_001178036.1:missense_variant:MODERATE:exon14/27:c.1051G>A:p.Val351Ile,DPP10:NM_001321908.1:missense_variant:MODERATE:exon13/26:c.1111G>A:p.Val371Ile,DPP10:NM_001321911.1:missense_variant:MODERATE:exon13/26:c.1051G>A:p.Val351Ile,DPP10:NM_001321912.1:missense_variant:MODERATE:exon14/26:c.1051G>A:p.Val351Ile,DPP10:NM_001178037.1:missense_variant:MODERATE:exon13/26:c.1189G>A:p.Val397Ile,DPP10:NM_001321906.1:missense_variant:MODERATE:exon14/27:c.1180G>A:p.Val394Ile,DPP10:NM_001321914.1:missense_variant:MODERATE:exon13/26:c.439G>A:p.Val147Ile,DPP10:NM_001178034.1:missense_variant:MODERATE:exon13/26:c.1213G>A:p.Val405Ile,DPP10:NM_001004360.3:missense_variant:MODERATE:exon13/26:c.1180G>A:p.Val394Ile,DPP10:NM_001321909.1:missense_variant:MODERATE:exon12/25:c.1084G>A:p.Val362Ile,DPP10:NM_001321913.1:missense_variant:MODERATE:exon11/24:c.439G>A:p.Val147Ile	Peptidase_S9B__dipeptidylpeptidase_IV_N-terminal__1_		Has no dipeptidyl aminopeptidase activity. May modulate cell surface expression and activity of the potassium channels KCND1 and KCND2			rs1446495	0.96905	0.99169991098216	0.9366190					6.278000	T	T,T,T,T,T	B,B	T,T,T,T	16.91	0		1278	4			n/a	n/a	DPP10 (inh=n/a pLI=1.00)
chr2	125192068	125192068	T	C	0.6667	24		376.0	2|0|14,0|0|8,8|6	CNTNAP5	synonymous_variant	CNTNAP5:NM_130773.3:synonymous_variant:LOW:exon5/24:c.537T>C:p.Asp179Asp			May play a role in the correct development and proper functioning of the peripheral and central nervous system and be involved in cell adhesion and intercellular communication			rs1425745	0.824281	0.90177255031889	0.8830641	COSM4001161										0		1120	157			n/a	n/a	CNTNAP5 (inh=n/a pLI=0.10)
chr2	125281910	125281910	C	T	0.2258	31		55.0	6|1|0,18|2|4,6|4	CNTNAP5	missense_variant	CNTNAP5:NM_130773.3:missense_variant:MODERATE:exon9/24:c.1355C>T:p.Ser452Leu	Concanavalin_A-like_lectin/glucanase__1_,Concanavalin_A-like_lectin/glucanase__subgroup__1_,Laminin_G_domain__2_,Laminin_G__subdomain_2__1_		May play a role in the correct development and proper functioning of the peripheral and central nervous system and be involved in cell adhesion and intercellular communication			rs17727261	0.0179712	0.034026637474913	0.0329702					1.421000	T	D	B	T	23.10	0		3	90			n/a	n/a	CNTNAP5 (inh=n/a pLI=0.10)
chr2	141032088	141032088	C	T	0.6098	41		615.0	21|0|4,4|0|12,5|3	LRP1B	synonymous_variant	LRP1B:NM_018557.2:synonymous_variant:LOW:exon85/91:c.13047G>A:p.Thr4349Thr			Potential cell surface proteins that bind and internalize ligands in the process of receptor-mediated endocytosis			rs1386356	0.486222	0.60372340425532	0.6033672					0.285000	T				20.40	1	GT,	362	429			n/a	n/a	LRP1B (inh=n/a pLI=1.00)
chr2	141260668	141260668	A	G	0.4074	27		189.0	6|5|0,2|14|0,4|6	LRP1B	synonymous_variant	LRP1B:NM_018557.2:synonymous_variant:LOW:exon54/91:c.8526T>C:p.Tyr2842Tyr			Potential cell surface proteins that bind and internalize ligands in the process of receptor-mediated endocytosis			rs4444457	0.543131	0.54898548333883	0.5472592	COSM3757652										1	GT,	235	443			n/a	n/a	LRP1B (inh=n/a pLI=1.00)
chr2	141457985	141457985	T	A	0.4000	15		94.0	0|6|0,0|6|3,6|6	LRP1B	synonymous_variant	LRP1B:NM_018557.2:synonymous_variant:LOW:exon41/91:c.6633A>T:p.Pro2211Pro			Potential cell surface proteins that bind and internalize ligands in the process of receptor-mediated endocytosis			rs13431727	0.245008	0.1950738509778	0.1890305											1	SomaticAndTreatment,	34	223			n/a	n/a	LRP1B (inh=n/a pLI=1.00)
chr2	141533662	141533662	T	C	1.0000	22		660.0	0|0|22,0|0|0,5|7	LRP1B	splice_region_variant&intron_variant,sequence_feature	LRP1B:NM_018557.2:splice_region_variant&intron_variant:LOW:exon33/90:c.5500+5A>G:,LRP1B:NM_018557.2:sequence_feature:LOW::c.5500+5A>G:			Potential cell surface proteins that bind and internalize ligands in the process of receptor-mediated endocytosis			rs996361	0.855232	0.87318930142878	0.8531162											0		653	241			n/a	n/a	LRP1B (inh=n/a pLI=1.00)
chr2	141571329	141571329	T	C	0.4545	22		209.0	4|6|0,6|6|0,4|6	LRP1B	synonymous_variant	LRP1B:NM_018557.2:synonymous_variant:LOW:exon32/91:c.5256A>G:p.Ser1752Ser			Potential cell surface proteins that bind and internalize ligands in the process of receptor-mediated endocytosis			rs3749010	0.845248	0.87075306768703	0.8518109	COSM4133144										0		692	214			n/a	n/a	LRP1B (inh=n/a pLI=1.00)
chr2	141709419	141709419	T	G	0.4146	41		396.0	9|0|8,10|4|10,3|2	LRP1B	splice_region_variant&intron_variant	LRP1B:NM_018557.2:splice_region_variant&intron_variant:LOW:exon19/90:c.2968+10A>C:			Potential cell surface proteins that bind and internalize ligands in the process of receptor-mediated endocytosis			rs1429348	0.536542	0.64645621113904	0.6393791											3	GT,TEST_SomaticAndTreatment,	373	418			n/a	n/a	LRP1B (inh=n/a pLI=1.00)
chr2	178096529	178096529	C	T	0.5000	14		137.0	5|1|1,3|2|2,4|6	NFE2L2	missense_variant	NFE2L2:NM_006164.4:missense_variant:MODERATE:exon5/5:c.802G>A:p.Val268Met,NFE2L2:NM_001145412.3:missense_variant:MODERATE:exon5/5:c.754G>A:p.Val252Met,NFE2L2:NM_001145413.3:missense_variant:MODERATE:exon5/5:c.733G>A:p.Val245Met,NFE2L2:NM_001313900.1:missense_variant:MODERATE:exon5/5:c.754G>A:p.Val252Met,NFE2L2:NM_001313901.1:missense_variant:MODERATE:exon5/5:c.754G>A:p.Val252Met,NFE2L2:NM_001313904.1:missense_variant:MODERATE:exon5/5:c.502G>A:p.Val168Met,NFE2L2:NM_001313902.1:missense_variant:MODERATE:exon4/4:c.712G>A:p.Val238Met,NFE2L2:NM_001313903.1:missense_variant:MODERATE:exon5/5:c.583G>A:p.Val195Met						rs34154613	0.000798722	0.002401576759362	0.0026559	COSM3694999		RCV000121656.1 [not provided]; 		0.640000	T	T,T,T,T,T	B,B	T,T,T,T,T	10.72	0		0	8			n/a	n/a	NFE2L2 (inh=n/a pLI=0.69)
chr2	202122995	202122995	A	G	1.0000	60		1978.0	14|26|20,0|0|0,5|4	CASP8	missense_variant,intron_variant,non_coding_transcript_exon_variant	CASP8:NM_001080125.1:missense_variant:MODERATE:exon1/9:c.41A>G:p.Lys14Arg,CASP8:NM_033358.3:intron_variant:MODIFIER:exon2/7:c.-26-8189A>G:,CASP8:NM_001080124.1:intron_variant:MODIFIER:exon2/8:c.-26-8189A>G:,CASP8:NM_001228.4:intron_variant:MODIFIER:exon2/9:c.-26-8189A>G:,CASP8:NM_033355.3:intron_variant:MODIFIER:exon2/9:c.1-8215A>G:,CASP8:NR_111983.1:non_coding_transcript_exon_variant:MODIFIER:exon1/9:n.242A>G:						rs3769823	0.646366	0.66729899435047	0.6610698	COSM4133375	601763 [CASP8 (confirmed) Autoimmune lymphoproliferative syndrome,type IIB,607271|Hepatocellular carcinoma,somatic,114550|Breast cancer,protection against,114480|Lung cancer,protection against,211980];			1.746000	T	T	B	T	0.06	1	Leuk,	620	532			n/a	n/a	CASP8 (inh=AR+AD pLI=0.00)
chr2	216229692	216229692	A	G	0.4266	143		1555.0	49|8|4,45|4|33,8|5	FN1	synonymous_variant	FN1:NM_212482.2:synonymous_variant:LOW:exon44/46:c.7161T>C:p.Tyr2387Tyr,FN1:NM_002026.3:synonymous_variant:LOW:exon44/46:c.6795T>C:p.Tyr2265Tyr,FN1:NM_212474.2:synonymous_variant:LOW:exon42/44:c.6258T>C:p.Tyr2086Tyr,FN1:NM_212476.2:synonymous_variant:LOW:exon42/44:c.6618T>C:p.Tyr2206Tyr,FN1:NM_212478.2:synonymous_variant:LOW:exon44/46:c.6720T>C:p.Tyr2240Tyr,FN1:NM_001306129.1:synonymous_variant:LOW:exon45/47:c.7068T>C:p.Tyr2356Tyr,FN1:NM_001306130.1:synonymous_variant:LOW:exon43/45:c.6531T>C:p.Tyr2177Tyr,FN1:NM_001306131.1:synonymous_variant:LOW:exon43/45:c.6525T>C:p.Tyr2175Tyr,FN1:NM_001306132.1:synonymous_variant:LOW:exon43/45:c.6450T>C:p.Tyr2150Tyr						rs11651	0.282748	0.40786582079031	0.2773755	COSM442286, COSM1482745	135600 [FN1 (confirmed) Glomerulopathy with fibronectin deposits 2,601894|Plasma fibronectin deficiency,614101];									0		157	569			n/a	n/a	FN1 (inh=AD pLI=0.06)
chr2	216249587	216249587	C	T	1.0000	29		878.0	5|24|0,0|0|0,2|3	FN1	synonymous_variant	FN1:NM_212482.2:synonymous_variant:LOW:exon29/46:c.4725G>A:p.Glu1575Glu,FN1:NM_002026.3:synonymous_variant:LOW:exon28/46:c.4452G>A:p.Glu1484Glu,FN1:NM_212474.2:synonymous_variant:LOW:exon28/44:c.4452G>A:p.Glu1484Glu,FN1:NM_212476.2:synonymous_variant:LOW:exon28/44:c.4452G>A:p.Glu1484Glu,FN1:NM_212478.2:synonymous_variant:LOW:exon28/46:c.4452G>A:p.Glu1484Glu,FN1:NM_001306129.1:synonymous_variant:LOW:exon29/47:c.4725G>A:p.Glu1575Glu,FN1:NM_001306130.1:synonymous_variant:LOW:exon29/45:c.4725G>A:p.Glu1575Glu,FN1:NM_001306131.1:synonymous_variant:LOW:exon28/45:c.4452G>A:p.Glu1484Glu,FN1:NM_001306132.1:synonymous_variant:LOW:exon28/45:c.4452G>A:p.Glu1484Glu						rs13652	0.86861	0.87515657964135	0.8546468		135600 [FN1 (confirmed) Glomerulopathy with fibronectin deposits 2,601894|Plasma fibronectin deficiency,614101];									0		934	309			n/a	n/a	FN1 (inh=AD pLI=0.06)
chr2	216269209	216269209	T	G	1.0000	52		1595.0	34|18|0,0|0|0,6|7	FN1	synonymous_variant	FN1:NM_212482.2:synonymous_variant:LOW:exon20/46:c.3156A>C:p.Pro1052Pro,FN1:NM_002026.3:synonymous_variant:LOW:exon20/46:c.3156A>C:p.Pro1052Pro,FN1:NM_212474.2:synonymous_variant:LOW:exon20/44:c.3156A>C:p.Pro1052Pro,FN1:NM_212476.2:synonymous_variant:LOW:exon20/44:c.3156A>C:p.Pro1052Pro,FN1:NM_212478.2:synonymous_variant:LOW:exon20/46:c.3156A>C:p.Pro1052Pro,FN1:NM_001306129.1:synonymous_variant:LOW:exon20/47:c.3156A>C:p.Pro1052Pro,FN1:NM_001306130.1:synonymous_variant:LOW:exon20/45:c.3156A>C:p.Pro1052Pro,FN1:NM_001306131.1:synonymous_variant:LOW:exon20/45:c.3156A>C:p.Pro1052Pro,FN1:NM_001306132.1:synonymous_variant:LOW:exon20/45:c.3156A>C:p.Pro1052Pro						rs1053238	0.286741	0.36425358008009	0.3554056		135600 [FN1 (confirmed) Glomerulopathy with fibronectin deposits 2,601894|Plasma fibronectin deficiency,614101];									1	Leuk,	201	583			n/a	n/a	FN1 (inh=AD pLI=0.06)
chr2	216269254	216269254	T	G	1.0000	86		2564.0	52|34|0,0|0|0,4|5	FN1	synonymous_variant	FN1:NM_212482.2:synonymous_variant:LOW:exon20/46:c.3111A>C:p.Gly1037Gly,FN1:NM_002026.3:synonymous_variant:LOW:exon20/46:c.3111A>C:p.Gly1037Gly,FN1:NM_212474.2:synonymous_variant:LOW:exon20/44:c.3111A>C:p.Gly1037Gly,FN1:NM_212476.2:synonymous_variant:LOW:exon20/44:c.3111A>C:p.Gly1037Gly,FN1:NM_212478.2:synonymous_variant:LOW:exon20/46:c.3111A>C:p.Gly1037Gly,FN1:NM_001306129.1:synonymous_variant:LOW:exon20/47:c.3111A>C:p.Gly1037Gly,FN1:NM_001306130.1:synonymous_variant:LOW:exon20/45:c.3111A>C:p.Gly1037Gly,FN1:NM_001306131.1:synonymous_variant:LOW:exon20/45:c.3111A>C:p.Gly1037Gly,FN1:NM_001306132.1:synonymous_variant:LOW:exon20/45:c.3111A>C:p.Gly1037Gly						rs7589580	0.286941	0.36439141755381	0.3520424		135600 [FN1 (confirmed) Glomerulopathy with fibronectin deposits 2,601894|Plasma fibronectin deficiency,614101];									1	Leuk,	201	582			n/a	n/a	FN1 (inh=AD pLI=0.06)
chr2	216272900	216272900	T	G	1.0000	24		734.0	4|20|0,0|0|0,6|2	FN1	missense_variant	FN1:NM_212482.2:missense_variant:MODERATE:exon17/46:c.2449A>C:p.Thr817Pro,FN1:NM_002026.3:missense_variant:MODERATE:exon17/46:c.2449A>C:p.Thr817Pro,FN1:NM_212474.2:missense_variant:MODERATE:exon17/44:c.2449A>C:p.Thr817Pro,FN1:NM_212476.2:missense_variant:MODERATE:exon17/44:c.2449A>C:p.Thr817Pro,FN1:NM_212478.2:missense_variant:MODERATE:exon17/46:c.2449A>C:p.Thr817Pro,FN1:NM_001306129.1:missense_variant:MODERATE:exon17/47:c.2449A>C:p.Thr817Pro,FN1:NM_001306130.1:missense_variant:MODERATE:exon17/45:c.2449A>C:p.Thr817Pro,FN1:NM_001306131.1:missense_variant:MODERATE:exon17/45:c.2449A>C:p.Thr817Pro,FN1:NM_001306132.1:missense_variant:MODERATE:exon17/45:c.2449A>C:p.Thr817Pro						rs2577301	0.9998	0.99999176331049	0.9362589		135600 [FN1 (confirmed) Glomerulopathy with fibronectin deposits 2,601894|Plasma fibronectin deficiency,614101];			4.979000	T	T,T,T,T,T,T,T,T,T,T,T,T,T,T	B,B,B,B,B,B,B,B,B,B	T,T,T,T,T,T,T,T,T,T,T,T,T	14.00	0		1282	0			n/a	n/a	FN1 (inh=AD pLI=0.06)
chr2	216300482	216300482	T	A	0.3667	30		200.0	0|10|1,6|6|7,4|4	FN1	missense_variant	FN1:NM_212482.2:missense_variant:MODERATE:exon1/46:c.44A>T:p.Gln15Leu,FN1:NM_002026.3:missense_variant:MODERATE:exon1/46:c.44A>T:p.Gln15Leu,FN1:NM_212474.2:missense_variant:MODERATE:exon1/44:c.44A>T:p.Gln15Leu,FN1:NM_212476.2:missense_variant:MODERATE:exon1/44:c.44A>T:p.Gln15Leu,FN1:NM_212478.2:missense_variant:MODERATE:exon1/46:c.44A>T:p.Gln15Leu,FN1:NM_001306129.1:missense_variant:MODERATE:exon1/47:c.44A>T:p.Gln15Leu,FN1:NM_001306130.1:missense_variant:MODERATE:exon1/45:c.44A>T:p.Gln15Leu,FN1:NM_001306131.1:missense_variant:MODERATE:exon1/45:c.44A>T:p.Gln15Leu,FN1:NM_001306132.1:missense_variant:MODERATE:exon1/45:c.44A>T:p.Gln15Leu,FN1:NM_054034.2:missense_variant:MODERATE:exon1/13:c.44A>T:p.Gln15Leu						rs1250259	0.795128	0.7690655571798	0.6993582	COSM3757940, COSM3757941, COSM3757942	135600 [FN1 (confirmed) Glomerulopathy with fibronectin deposits 2,601894|Plasma fibronectin deficiency,614101];			3.387000	T	T,T,T,T,T,T,T,T,T,T,T,T,T,T,T	B,B,B,B,B,B,B,B,B,B,B	T,T,T,T,T,T,T,T,T,T,T,T,T,T	13.69	0		712	463			n/a	n/a	FN1 (inh=AD pLI=0.06)
chr2	234054873	234054873	G	A	0.7500	20		342.0	0|8|7,0|4|1,3|5	INPP5D	synonymous_variant	INPP5D:NM_001017915.2:synonymous_variant:LOW:exon6/26:c.732G>A:p.Ser244Ser,INPP5D:NM_005541.4:synonymous_variant:LOW:exon6/26:c.729G>A:p.Ser243Ser						rs1135173	0.20028	0.32346973283734	0.1052256											0		146	378			n/a	n/a	INPP5D (inh=n/a pLI=0.17)
chr2	234055004	234055004	T	C	0.3448	58		385.0	0|0|20,0|6|31,4|6	INPP5D	splice_region_variant&intron_variant	INPP5D:NM_001017915.2:splice_region_variant&intron_variant:LOW:exon6/25:c.748-9T>C:,INPP5D:NM_005541.4:splice_region_variant&intron_variant:LOW:exon6/25:c.745-9T>C:						rs36189208	0.707268	0.62858433054866	0.1702014											0		305	394			n/a	n/a	INPP5D (inh=n/a pLI=0.17)
chr2	234078057	234078057	C	-	0.6818	22		370.0	10|3|2,3|4|0,4|4	INPP5D	splice_region_variant&intron_variant	INPP5D:NM_001017915.2:splice_region_variant&intron_variant:LOW:exon13/25:c.1565+10delC:,INPP5D:NM_005541.4:splice_region_variant&intron_variant:LOW:exon13/25:c.1562+10delC:						rs868506689	0.190096	0.42330001459215	0.2998122											0		132	370			n/a	n/a	INPP5D (inh=n/a pLI=0.17)
chr2	234113301	234113301	C	T	0.1923	52		48.0	4|0|6,6|6|30,8|6	INPP5D	missense_variant	INPP5D:NM_001017915.2:missense_variant:MODERATE:exon25/26:c.3418C>T:p.His1140Tyr,INPP5D:NM_005541.4:missense_variant:MODERATE:exon25/26:c.3415C>T:p.His1139Tyr						rs9247	0.240016	0.34569691946401	0.1789279					2.300000	T	T,T,T,T,T,T	B,B	D,D,D,D,D,D	14.44	0		50	246			n/a	n/a	INPP5D (inh=n/a pLI=0.17)
chr3	10088266	10088266	G	T	0.5714	21		268.0	0|0|12,3|0|6,5|4	FANCD2	splice_region_variant&synonymous_variant	FANCD2:NM_033084.4:splice_region_variant&synonymous_variant:LOW:exon15/43:c.1137G>T:p.Val379Val,FANCD2:NM_001018115.2:splice_region_variant&synonymous_variant:LOW:exon15/44:c.1137G>T:p.Val379Val,FANCD2:NM_001319984.1:splice_region_variant&synonymous_variant:LOW:exon15/44:c.1137G>T:p.Val379Val		Homologous recombination;Pancreatic cancer	Required for maintenance of chromosomal stability. Promotes accurate and efficient pairing of homologs during meiosis. Involved in the repair of DNA double-strand breaks, both by homologous recombination and single-strand annealing. May participate in S phase and G2 phase checkpoint activation upon DNA damage. Plays a role in preventing breakage and loss of missegregating chromatin at the end of cell division, particularly after replication stress. Required for the targeting, or stabilization, of BLM to non-centromeric abnormal structures induced by replicative stress. Promotes BRCA2/FANCD1 loading onto damaged chromatin. May also be involved in B-cell immunoglobulin isotype switching	BRCA1-dependent Ub-ligase activity;Role of BRCA1,  BRCA2 and ATR in Cancer Susceptibility		rs72492997	0.0000	0.37449561322326	0.0029774	COSM4157095, COSM4157094	613984 [FANCD2 (provisional) Fanconi anemia,complementation group D2,227646];	RCV000347785.1 [benign]; 								0		1	1277			n/a	n/a	FANCD2 (inh=AR pLI=0.00)
chr3	10088299	10088299	C	T	0.6316	19		255.0	0|0|12,1|0|6,6|3	FANCD2	synonymous_variant	FANCD2:NM_033084.4:synonymous_variant:LOW:exon15/43:c.1170C>T:p.Ser390Ser,FANCD2:NM_001018115.2:synonymous_variant:LOW:exon15/44:c.1170C>T:p.Ser390Ser,FANCD2:NM_001319984.1:synonymous_variant:LOW:exon15/44:c.1170C>T:p.Ser390Ser		Homologous recombination;Pancreatic cancer	Required for maintenance of chromosomal stability. Promotes accurate and efficient pairing of homologs during meiosis. Involved in the repair of DNA double-strand breaks, both by homologous recombination and single-strand annealing. May participate in S phase and G2 phase checkpoint activation upon DNA damage. Plays a role in preventing breakage and loss of missegregating chromatin at the end of cell division, particularly after replication stress. Required for the targeting, or stabilization, of BLM to non-centromeric abnormal structures induced by replicative stress. Promotes BRCA2/FANCD1 loading onto damaged chromatin. May also be involved in B-cell immunoglobulin isotype switching	BRCA1-dependent Ub-ligase activity;Role of BRCA1,  BRCA2 and ATR in Cancer Susceptibility		rs112887807	0.0000	0.43038387555407	0.0032346		613984 [FANCD2 (provisional) Fanconi anemia,complementation group D2,227646];	RCV000400148.1 [benign]; 								1	GT,	1	1779	1	[1] Ilnaz Sepahi 29-03-2016 batch import	n/a	n/a	FANCD2 (inh=AR pLI=0.00)
chr3	10088308	10088308	T	C	0.6667	18		236.0	0|0|12,0|0|6,6|3	FANCD2	synonymous_variant	FANCD2:NM_033084.4:synonymous_variant:LOW:exon15/43:c.1179T>C:p.Thr393Thr,FANCD2:NM_001018115.2:synonymous_variant:LOW:exon15/44:c.1179T>C:p.Thr393Thr,FANCD2:NM_001319984.1:synonymous_variant:LOW:exon15/44:c.1179T>C:p.Thr393Thr		Homologous recombination;Pancreatic cancer	Required for maintenance of chromosomal stability. Promotes accurate and efficient pairing of homologs during meiosis. Involved in the repair of DNA double-strand breaks, both by homologous recombination and single-strand annealing. May participate in S phase and G2 phase checkpoint activation upon DNA damage. Plays a role in preventing breakage and loss of missegregating chromatin at the end of cell division, particularly after replication stress. Required for the targeting, or stabilization, of BLM to non-centromeric abnormal structures induced by replicative stress. Promotes BRCA2/FANCD1 loading onto damaged chromatin. May also be involved in B-cell immunoglobulin isotype switching	BRCA1-dependent Ub-ligase activity;Role of BRCA1,  BRCA2 and ATR in Cancer Susceptibility		rs72492998	0.0000	0.4331435270474	0.0035176	COSM4152592, COSM4152593	613984 [FANCD2 (provisional) Fanconi anemia,complementation group D2,227646];	RCV000289250.1 [benign]; 								1	GT,	0	1888	1	[1] Ilnaz Sepahi 29-03-2016 batch import	n/a	n/a	FANCD2 (inh=AR pLI=0.00)
chr3	10088343	10088343	A	G	0.6667	9		100.0	0|0|6,2|0|3,8|5	FANCD2	missense_variant	FANCD2:NM_033084.4:missense_variant:MODERATE:exon15/43:c.1214A>G:p.Asn405Ser,FANCD2:NM_001018115.2:missense_variant:MODERATE:exon15/44:c.1214A>G:p.Asn405Ser,FANCD2:NM_001319984.1:missense_variant:MODERATE:exon15/44:c.1214A>G:p.Asn405Ser		Homologous recombination;Pancreatic cancer	Required for maintenance of chromosomal stability. Promotes accurate and efficient pairing of homologs during meiosis. Involved in the repair of DNA double-strand breaks, both by homologous recombination and single-strand annealing. May participate in S phase and G2 phase checkpoint activation upon DNA damage. Plays a role in preventing breakage and loss of missegregating chromatin at the end of cell division, particularly after replication stress. Required for the targeting, or stabilization, of BLM to non-centromeric abnormal structures induced by replicative stress. Promotes BRCA2/FANCD1 loading onto damaged chromatin. May also be involved in B-cell immunoglobulin isotype switching	BRCA1-dependent Ub-ligase activity;Role of BRCA1,  BRCA2 and ATR in Cancer Susceptibility		rs73126218	0.0000	0.42006511309116	0.0069387	COSM4152595, COSM4152594	613984 [FANCD2 (provisional) Fanconi anemia,complementation group D2,227646];	RCV000352188.1 [benign]; 		0.211000	T	T,T,T,T	B,B	T,T,T,T	3.37	2	GT,Ringversuch_EMQN,	0	1932	1	[1] Ilnaz Sepahi 29-03-2016 batch import	n/a	n/a	FANCD2 (inh=AR pLI=0.00)
chr3	10132044	10132044	C	A	0.3636	11		40.0	0|4|0,2|4|1,3|5	FANCD2,FANCD2OS	missense_variant,intron_variant	FANCD2:NM_033084.4:missense_variant:MODERATE:exon37/43:c.3752C>A:p.Pro1251His,FANCD2:NM_001018115.2:missense_variant:MODERATE:exon37/44:c.3752C>A:p.Pro1251His,FANCD2:NM_001319984.1:missense_variant:MODERATE:exon37/44:c.3752C>A:p.Pro1251His,FANCD2OS:NM_173472.1:intron_variant:MODIFIER:exon2/2:c.*44-8829G>T:		Homologous recombination;Pancreatic cancer	Required for maintenance of chromosomal stability. Promotes accurate and efficient pairing of homologs during meiosis. Involved in the repair of DNA double-strand breaks, both by homologous recombination and single-strand annealing. May participate in S phase and G2 phase checkpoint activation upon DNA damage. Plays a role in preventing breakage and loss of missegregating chromatin at the end of cell division, particularly after replication stress. Required for the targeting, or stabilization, of BLM to non-centromeric abnormal structures induced by replicative stress. Promotes BRCA2/FANCD1 loading onto damaged chromatin. May also be involved in B-cell immunoglobulin isotype switching	BRCA1-dependent Ub-ligase activity;Role of BRCA1,  BRCA2 and ATR in Cancer Susceptibility			0.0000	0.0000	0.0000		613984 [FANCD2 (provisional) Fanconi anemia,complementation group D2,227646];			2.824000	T	T,T,T	B,P	T,T,T	25.30	0		0	0			n/a	n/a	FANCD2 (inh=AR pLI=0.00), FANCD2OS (inh=n/a pLI=0.05)
chr3	50144951	50144951	T	C	0.4286	42		357.0	0|18|0,10|14|0,5|4	RBM5	synonymous_variant,non_coding_transcript_exon_variant	RBM5:NM_005778.3:synonymous_variant:LOW:exon12/25:c.990T>C:p.Ala330Ala,RBM5:NR_036627.2:non_coding_transcript_exon_variant:MODIFIER:exon11/24:n.1091T>C:			Component of the spliceosome A complex. Regulates alternative splicing of a number of mRNAs. May modulate splice site pairing after recruitment of the U1 and U2 snRNPs to the 5' and 3' splice sites of the intron. May both positively and negatively regulate aopotosis by regulating the alternative splicing of several genes involved in this process, including FAS and CASP2/caspase-2. In the case of FAS, promotes exclusion of exon 6 thereby producing a soluble form of FAS that inhibits apoptosis. In the case of CASP2/caspase-2, promotes exclusion of exon 9 thereby producing a catalytically active form of CASP2/Caspase-2 that induces apoptosis			rs1061474	0.747404	0.67154884096413	0.6590892	COSM4158173										0		358	369			n/a	n/a	RBM5 (inh=n/a pLI=1.00)
chr3	50153356	50153356	T	C	0.5882	17		220.0	2|8|0,4|3|0,2|6	RBM5	synonymous_variant,non_coding_transcript_exon_variant	RBM5:NM_005778.3:synonymous_variant:LOW:exon22/25:c.2037T>C:p.Tyr679Tyr,RBM5:NR_036627.2:non_coding_transcript_exon_variant:MODIFIER:exon21/24:n.2138T>C:			Component of the spliceosome A complex. Regulates alternative splicing of a number of mRNAs. May modulate splice site pairing after recruitment of the U1 and U2 snRNPs to the 5' and 3' splice sites of the intron. May both positively and negatively regulate aopotosis by regulating the alternative splicing of several genes involved in this process, including FAS and CASP2/caspase-2. In the case of FAS, promotes exclusion of exon 6 thereby producing a soluble form of FAS that inhibits apoptosis. In the case of CASP2/caspase-2, promotes exclusion of exon 9 thereby producing a catalytically active form of CASP2/Caspase-2 that induces apoptosis			rs1138536	0.747404	0.67181938035597	0.6601631											0		358	370			n/a	n/a	RBM5 (inh=n/a pLI=1.00)
chr3	52584787	52584787	T	C	0.2400	25		72.0	0|4|2,2|10|7,5|6	PBRM1	synonymous_variant	PBRM1:NM_018313.4:synonymous_variant:LOW:exon28/30:c.4335A>G:p.Pro1445Pro						rs2251219	0.323083	0.38222526656323	0.3820288	COSM4002743, COSM4002745, COSM4002744										3	TEST_SomaticAndTreatment,	266	707			n/a	n/a	PBRM1 (inh=n/a pLI=1.00)
chr3	52610651	52610651	T	A	0.2778	36		146.0	0|0|10,8|4|14,7|5	PBRM1	synonymous_variant	PBRM1:NM_018313.4:synonymous_variant:LOW:exon23/30:c.3522A>T:p.Pro1174Pro						rs17264436	0.316094	0.37524527181889	0.3753987	COSM4002746, COSM4002748, COSM4002747										2	TEST_SomaticAndTreatment,	260	705			n/a	n/a	PBRM1 (inh=n/a pLI=1.00)
chr3	89521693	89521693	T	C	0.6667	12		152.0	0|8|0,0|4|0,2|7	EPHA3	missense_variant	EPHA3:NM_005233.5:missense_variant:MODERATE:exon16/17:c.2770T>C:p.Trp924Arg	Sterile_alpha_motif_domain__2_,Sterile_alpha_motif/pointed_domain__2_,Sterile_alpha_motif__type_2__1_					rs35124509	0.391174	0.37585269401878	0.3702606	COSM4002834				1.947000	T	T	B	D	18.10	3	Leuk,SomaticAndTreatment,TEST_SomaticAndTreatment,	189	618			n/a	n/a	EPHA3 (inh=n/a pLI=0.02)
chr3	89521725	89521725	T	C	0.6000	15		190.0	0|8|1,0|4|2,3|8	EPHA3	synonymous_variant	EPHA3:NM_005233.5:synonymous_variant:LOW:exon16/17:c.2802T>C:p.Gly934Gly						rs1054750	0.129593	0.19977588451461	0.1970367											0		73	426			n/a	n/a	EPHA3 (inh=n/a pLI=0.02)
chr3	109052732	109052732	T	C	0.3111	45		242.0	4|10|0,12|19|0,8|8	DPPA4	missense_variant	DPPA4:NM_018189.3:missense_variant:MODERATE:exon2/7:c.163A>G:p.Ile55Val			May be involved in the maintenance of active epigenetic status of target genes (By similarity). May inhibit differentiation of embryonic cells into a primitive ectoderm lineage (By similarity)			rs3762648	0.484026	0.49335914970751	0.4888685	COSM3736301				-1.085000	T	T,	B	T,T	0.00	0		205	427			n/a	n/a	DPPA4 (inh=n/a pLI=0.00)
chr3	125826059	125826059	T	C	0.3077	78		398.0	4|4|16,24|12|18,3|5	ALDH1L1,ALDH1L1-AS1	missense_variant,intron_variant,non_coding_transcript_exon_variant	ALDH1L1:NM_001270364.1:missense_variant:MODERATE:exon21/23:c.2408A>G:p.Asp803Gly,ALDH1L1:NM_001270365.1:missense_variant:MODERATE:exon19/21:c.2075A>G:p.Asp692Gly,ALDH1L1:NM_012190.3:missense_variant:MODERATE:exon21/23:c.2378A>G:p.Asp793Gly,ALDH1L1-AS1:NR_046602.1:intron_variant:MODIFIER:exon3/3:n.252-668T>C:,ALDH1L1:NR_072979.1:non_coding_transcript_exon_variant:MODIFIER:exon19/21:n.2477A>G:	Aldehyde_dehydrogenase_domain__1_,Aldehyde_dehydrogenase__C-terminal__1_,Aldehyde/histidinol_dehydrogenase__1_	One carbon pool by folate				rs1127717	0.198083	0.18864471883809	0.1864582	COSM3759700				3.804000	T	T,T,T,T	B,B,B	T,T,T,T	20.30	0		51	270			n/a	n/a	ALDH1L1 (inh=n/a pLI=0.00), ALDH1L1-AS1 (inh=n/a pLI=n/a)
chr3	142222284	142222284	A	G	0.6667	12		169.0	8|0|0,4|0|0,2|0	ATR	synonymous_variant	ATR:NM_001184.3:synonymous_variant:LOW:exon30/47:c.5208T>C:p.Tyr1736Tyr		Cell cycle;p53 signaling pathway	Serine/threonine protein kinase which activates checkpoint signaling upon genotoxic stresses such as ionizing radiation (IR), ultraviolet light (UV), or DNA replication stalling, thereby acting as a DNA damage sensor. Recognizes the substrate consensus sequence [ST]-Q. Phosphorylates BRCA1, CHEK1, MCM2, RAD17, RPA2, SMC1 and p53/TP53, which collectively inhibit DNA replication and mitosis and promote DNA repair, recombination and apoptosis. Phosphorylates 'Ser-139' of histone variant H2AX/H2AFX at sites of DNA damage, thereby regulating DNA damage response mechanism. Required for FANCD2 ubiquitination. Critical for maintenance of fragile site stability and efficient regulation of centrosome duplication	Cell Cycle: G1/S Check Point ;Cell Cycle: G2/M Checkpoint;Regulation of cell cycle progression by Plk3;Role of BRCA1,  BRCA2 and ATR in Cancer Susceptibility		rs2227931	0.3125	0.36398252503102	0.3554249	COSM4002479	601215 [ATR (confirmed) Seckel syndrome 1,210600|Cutaneous telangiectasia and cancer syndrome,familial,614564];	RCV000145318.1 [likely benign]; RCV000271882.1 [benign]; 								3	TEST_SomaticAndTreatment,	494	1459	1	[1] Ilnaz Sepahi 29-03-2016 batch import	n/a	n/a	ATR (inh=AR pLI=0.70)
chr3	142277536	142277536	A	G	0.7538	65		1339.0	17|12|20,4|6|6,7|5	ATR	synonymous_variant	ATR:NM_001184.3:synonymous_variant:LOW:exon8/47:c.1815T>C:p.Asp605Asp		Cell cycle;p53 signaling pathway	Serine/threonine protein kinase which activates checkpoint signaling upon genotoxic stresses such as ionizing radiation (IR), ultraviolet light (UV), or DNA replication stalling, thereby acting as a DNA damage sensor. Recognizes the substrate consensus sequence [ST]-Q. Phosphorylates BRCA1, CHEK1, MCM2, RAD17, RPA2, SMC1 and p53/TP53, which collectively inhibit DNA replication and mitosis and promote DNA repair, recombination and apoptosis. Phosphorylates 'Ser-139' of histone variant H2AX/H2AFX at sites of DNA damage, thereby regulating DNA damage response mechanism. Required for FANCD2 ubiquitination. Critical for maintenance of fragile site stability and efficient regulation of centrosome duplication	Cell Cycle: G1/S Check Point ;Cell Cycle: G2/M Checkpoint;Regulation of cell cycle progression by Plk3;Role of BRCA1,  BRCA2 and ATR in Cancer Susceptibility		rs2227929	0.310703	0.35160163459003	0.3409108	COSM4002481	601215 [ATR (confirmed) Seckel syndrome 1,210600|Cutaneous telangiectasia and cancer syndrome,familial,614564];	RCV000145292.4 [benign]; RCV000350591.1 [benign]; 								4	TEST_SomaticAndTreatment,cfDNA_HNSCC,	478	1467	1	[1] Ilnaz Sepahi 29-03-2016 batch import	n/a	n/a	ATR (inh=AR pLI=0.70)
chr3	142277575	142277575	A	T	1.0000	44		1408.0	26|18|0,0|0|0,7|4	ATR	synonymous_variant	ATR:NM_001184.3:synonymous_variant:LOW:exon8/47:c.1776T>A:p.Gly592Gly		Cell cycle;p53 signaling pathway	Serine/threonine protein kinase which activates checkpoint signaling upon genotoxic stresses such as ionizing radiation (IR), ultraviolet light (UV), or DNA replication stalling, thereby acting as a DNA damage sensor. Recognizes the substrate consensus sequence [ST]-Q. Phosphorylates BRCA1, CHEK1, MCM2, RAD17, RPA2, SMC1 and p53/TP53, which collectively inhibit DNA replication and mitosis and promote DNA repair, recombination and apoptosis. Phosphorylates 'Ser-139' of histone variant H2AX/H2AFX at sites of DNA damage, thereby regulating DNA damage response mechanism. Required for FANCD2 ubiquitination. Critical for maintenance of fragile site stability and efficient regulation of centrosome duplication	Cell Cycle: G1/S Check Point ;Cell Cycle: G2/M Checkpoint;Regulation of cell cycle progression by Plk3;Role of BRCA1,  BRCA2 and ATR in Cancer Susceptibility		rs2227930	0.598043	0.55292469929148	0.5329187	COSM149486	601215 [ATR (confirmed) Seckel syndrome 1,210600|Cutaneous telangiectasia and cancer syndrome,familial,614564];	RCV000145291.5 [other]; RCV000306424.1 [benign]; 								4	TEST_SomaticAndTreatment,cfDNA_HNSCC,	1031	1430	1	[1] Ilnaz Sepahi 29-03-2016 batch import	n/a	n/a	ATR (inh=AR pLI=0.70)
chr3	145917761	145917761	T	C	1.0000	48		1459.0	38|10|0,0|0|0,4|4	PLSCR4	missense_variant,intron_variant	PLSCR4:NM_001128304.1:missense_variant:MODERATE:exon8/11:c.463A>G:p.Ile155Val,PLSCR4:NM_001128305.1:missense_variant:MODERATE:exon6/9:c.463A>G:p.Ile155Val,PLSCR4:NM_020353.2:missense_variant:MODERATE:exon6/9:c.463A>G:p.Ile155Val,PLSCR4:NM_001128306.1:intron_variant:MODIFIER:exon4/6:c.355-3181A>G:,PLSCR4:NM_001177304.1:intron_variant:MODIFIER:exon3/5:c.310-3181A>G:			May mediate accelerated ATP-independent bidirectional transbilayer migration of phospholipids upon binding calcium ions that results in a loss of phospholipid asymmetry in the plasma membrane. May play a central role in the initiation of fibrin clot formation, in the activation of mast cells and in the recognition of apoptotic and injured cells by the reticuloendothelial system			rs1061409	0.240216	0.32149382141908	0.3153102	COSM3759810				-1.353000	T	T,T,T,T,T	B	T,T,T,T,T	1.60	0		88	380			n/a	n/a	PLSCR4 (inh=n/a pLI=0.00)
chr3	148459395	148459395	C	T	1.0000	50		1599.0	0|16|34,0|0|0,4|4	AGTR1	synonymous_variant,sequence_feature	AGTR1:NM_004835.4:synonymous_variant:LOW:exon3/3:c.678C>T:p.Leu226Leu,AGTR1:NM_000685.4:synonymous_variant:LOW:exon3/3:c.573C>T:p.Leu191Leu,AGTR1:NM_009585.3:synonymous_variant:LOW:exon2/2:c.573C>T:p.Leu191Leu,AGTR1:NM_031850.3:synonymous_variant:LOW:exon4/4:c.678C>T:p.Leu226Leu,AGTR1:NM_032049.3:synonymous_variant:LOW:exon3/3:c.660C>T:p.Leu220Leu,AGTR1:NM_009585.3:sequence_feature:LOW:exon2/2:c.573C>T:		Calcium signaling pathway;Neuroactive ligand-receptor interaction;Renin-angiotensin system	Receptor for angiotensin II. Mediates its action by association with G proteins that activate a phosphatidylinositol- calcium second messenger system	Angiotensin II mediated activation of JNK Pathway via Pyk2 dependent signaling;Angiotensin-converting enzyme 2 regulates heart function;Role of EGF Receptor Transactivation by GPCRs in Cardiac Hypertrophy		rs5182	0.458067	0.48370591157476	0.4781935	COSM4157351	106165 [AGTR1 (confirmed) Hypertension,essential,145500|Renal tubular dysgenesis,267430];	RCV000248373.1 [benign]; RCV000392743.1 [benign]; 								0		293	586			n/a	n/a	AGTR1 (inh=AR pLI=0.01)
chr3	184037533	184037533	A	G	1.0000	55		1669.0	46|6|3,0|0|0,3|4	EIF4G1	missense_variant,5_prime_UTR_variant	EIF4G1:NM_001194946.1:missense_variant:MODERATE:exon8/34:c.502A>G:p.Thr168Ala,EIF4G1:NM_001194947.1:missense_variant:MODERATE:exon7/33:c.502A>G:p.Thr168Ala,EIF4G1:NM_198241.2:missense_variant:MODERATE:exon7/33:c.481A>G:p.Thr161Ala,EIF4G1:NM_198244.2:missense_variant:MODERATE:exon4/30:c.220A>G:p.Thr74Ala,EIF4G1:NM_001291157.1:missense_variant:MODERATE:exon7/33:c.361A>G:p.Thr121Ala,EIF4G1:NM_182917.4:missense_variant:MODERATE:exon6/32:c.481A>G:p.Thr161Ala,EIF4G1:NM_198242.2:5_prime_UTR_variant:MODIFIER:exon3/29:c.-12A>G:						rs13319149	0.999201	0.99808040366369	0.9354229		600495 [EIF4G1 (confirmed) Parkinson disease 18,614251];			0.706000	T	T,T,T,T,T,T,T,T,T,T,T,T,T,T,T	B,B,B	T,T,T,T,T,T,T,T,T,T,T,T,T,T,T	1.88	0		1566	4			n/a	n/a	EIF4G1 (inh=AD pLI=1.00)
chr3	184039666	184039666	A	G	0.3846	26		204.0	4|2|4,4|0|12,5|3	EIF4G1	missense_variant	EIF4G1:NM_001194946.1:missense_variant:MODERATE:exon11/34:c.1315A>G:p.Met439Val,EIF4G1:NM_001194947.1:missense_variant:MODERATE:exon10/33:c.1315A>G:p.Met439Val,EIF4G1:NM_198241.2:missense_variant:MODERATE:exon10/33:c.1294A>G:p.Met432Val,EIF4G1:NM_198242.2:missense_variant:MODERATE:exon6/29:c.802A>G:p.Met268Val,EIF4G1:NM_198244.2:missense_variant:MODERATE:exon7/30:c.1033A>G:p.Met345Val,EIF4G1:NM_001291157.1:missense_variant:MODERATE:exon10/33:c.1174A>G:p.Met392Val,EIF4G1:NM_182917.4:missense_variant:MODERATE:exon9/32:c.1294A>G:p.Met432Val,EIF4G1:NM_004953.4:missense_variant:MODERATE:exon3/26:c.706A>G:p.Met236Val						rs2178403	0.782348	0.7553898137465	0.7472734		600495 [EIF4G1 (confirmed) Parkinson disease 18,614251];			0.724000	T	T,T,T,T,T,T,T,T,T,T,T,T,T,T,T,T,T,T,T	B,B,B,B	T,T,T,T,T,T,T,T,T,T,T,T,T,T,T,T,T,T,T	0.00	0		948	538			n/a	n/a	EIF4G1 (inh=AD pLI=1.00)
chr3	184045799	184045799	A	G	0.3725	51		394.0	5|14|0,6|26|0,6|4	EIF4G1	splice_region_variant&intron_variant	EIF4G1:NM_001194946.1:splice_region_variant&intron_variant:LOW:exon27/33:c.3974+9A>G:,EIF4G1:NM_001194947.1:splice_region_variant&intron_variant:LOW:exon26/32:c.3974+9A>G:,EIF4G1:NM_198241.2:splice_region_variant&intron_variant:LOW:exon26/32:c.3953+9A>G:,EIF4G1:NM_198242.2:splice_region_variant&intron_variant:LOW:exon22/28:c.3461+9A>G:,EIF4G1:NM_198244.2:splice_region_variant&intron_variant:LOW:exon23/29:c.3692+9A>G:,EIF4G1:NM_001291157.1:splice_region_variant&intron_variant:LOW:exon26/32:c.3833+9A>G:,EIF4G1:NM_182917.4:splice_region_variant&intron_variant:LOW:exon25/31:c.3956+9A>G:,EIF4G1:NM_004953.4:splice_region_variant&intron_variant:LOW:exon19/25:c.3368+9A>G:						rs939317	0.786941	0.7582122105123	0.7505016		600495 [EIF4G1 (confirmed) Parkinson disease 18,614251];									0		941	544			n/a	n/a	EIF4G1 (inh=AD pLI=1.00)
chr3	184046470	184046470	C	T	0.4419	86		890.0	17|16|5,10|34|4,7|8	EIF4G1	synonymous_variant	EIF4G1:NM_001194946.1:synonymous_variant:LOW:exon28/34:c.4026C>T:p.His1342His,EIF4G1:NM_001194947.1:synonymous_variant:LOW:exon27/33:c.4026C>T:p.His1342His,EIF4G1:NM_198241.2:synonymous_variant:LOW:exon27/33:c.4005C>T:p.His1335His,EIF4G1:NM_198242.2:synonymous_variant:LOW:exon23/29:c.3513C>T:p.His1171His,EIF4G1:NM_198244.2:synonymous_variant:LOW:exon24/30:c.3744C>T:p.His1248His,EIF4G1:NM_001291157.1:synonymous_variant:LOW:exon27/33:c.3885C>T:p.His1295His,EIF4G1:NM_182917.4:synonymous_variant:LOW:exon26/32:c.4008C>T:p.His1336His,EIF4G1:NM_004953.4:synonymous_variant:LOW:exon20/26:c.3420C>T:p.His1140His						rs2230571	0.134185	0.20545157995321	0.2021234	COSM1179814	600495 [EIF4G1 (confirmed) Parkinson disease 18,614251];									0		105	597			n/a	n/a	EIF4G1 (inh=AD pLI=1.00)
chr4	1801511	1801511	C	T	0.6531	49		773.0	0|13|19,3|9|5,5|6	FGFR3	synonymous_variant	FGFR3:NM_001163213.1:synonymous_variant:LOW:exon4/18:c.417C>T:p.Asp139Asp,FGFR3:NM_000142.4:synonymous_variant:LOW:exon4/18:c.417C>T:p.Asp139Asp,FGFR3:NM_022965.3:synonymous_variant:LOW:exon4/16:c.417C>T:p.Asp139Asp						rs3135867	0.0201677	0.039415464424365	0.0373817		134934 [FGFR3 (confirmed) Achondroplasia,100800|Hypochondroplasia,146000|Thanatophoric dysplasia,type I,187600|Crouzon syndrome with acanthosis nigricans,612247|Muenke syndrome,602849|Bladder cancer,somatic,109800|Colorectal cancer,somatic,114500|Cervical cancer,somatic,603956|LADD syndrome,149730|CATSHL syndrome,610474|Nevus,epidermal,somatic,162900|Thanatophoric dysplasia,type II,187601|Spermatocytic seminoma,somatic,273300|SADDAN,616482];	RCV000252545.1 [benign]; 								2	Leuk,SomaticAndTreatment,	2	149			n/a	n/a	FGFR3 (inh=AR+AD pLI=0.00)
chr4	1803704	1803704	T	C	0.4796	98		1188.0	13|4|30,11|8|32,7|6	FGFR3	sequence_feature,synonymous_variant	FGFR3:NM_001163213.1:sequence_feature:MODERATE:exon7/18:c.882T>C:,FGFR3:NM_000142.4:sequence_feature:MODERATE:exon7/18:c.882T>C:,FGFR3:NM_022965.3:sequence_feature:MODERATE:exon7/16:c.882T>C:,FGFR3:NM_001163213.1:synonymous_variant:LOW:exon7/18:c.882T>C:p.Asn294Asn,FGFR3:NM_000142.4:synonymous_variant:LOW:exon7/18:c.882T>C:p.Asn294Asn,FGFR3:NM_022965.3:synonymous_variant:LOW:exon7/16:c.882T>C:p.Asn294Asn						rs2234909	0.207468	0.16919760029996	0.1614942	COSM1428695, COSM1428696	134934 [FGFR3 (confirmed) Achondroplasia,100800|Hypochondroplasia,146000|Thanatophoric dysplasia,type I,187600|Crouzon syndrome with acanthosis nigricans,612247|Muenke syndrome,602849|Bladder cancer,somatic,109800|Colorectal cancer,somatic,114500|Cervical cancer,somatic,603956|LADD syndrome,149730|CATSHL syndrome,610474|Nevus,epidermal,somatic,162900|Thanatophoric dysplasia,type II,187601|Spermatocytic seminoma,somatic,273300|SADDAN,616482];	RCV000253435.1 [benign]; 								2	GT,SomaticAndTreatment,	58	404			n/a	n/a	FGFR3 (inh=AR+AD pLI=0.00)
chr4	1807894	1807894	G	A	1.0000	36		1144.0	8|0|28,0|0|0,6|3	FGFR3	synonymous_variant	FGFR3:NM_001163213.1:synonymous_variant:LOW:exon14/18:c.1959G>A:p.Thr653Thr,FGFR3:NM_000142.4:synonymous_variant:LOW:exon14/18:c.1953G>A:p.Thr651Thr,FGFR3:NM_022965.3:synonymous_variant:LOW:exon12/16:c.1617G>A:p.Thr539Thr						rs7688609	0.95607	0.98730637193335	0.9484065		134934 [FGFR3 (confirmed) Achondroplasia,100800|Hypochondroplasia,146000|Thanatophoric dysplasia,type I,187600|Crouzon syndrome with acanthosis nigricans,612247|Muenke syndrome,602849|Bladder cancer,somatic,109800|Colorectal cancer,somatic,114500|Cervical cancer,somatic,603956|LADD syndrome,149730|CATSHL syndrome,610474|Nevus,epidermal,somatic,162900|Thanatophoric dysplasia,type II,187601|Spermatocytic seminoma,somatic,273300|SADDAN,616482];									0		1481	8			n/a	n/a	FGFR3 (inh=AR+AD pLI=0.00)
chr4	55133726	55133726	T	G	0.6250	24		364.0	8|6|1,0|7|2,5|6	PDGFRA	synonymous_variant	PDGFRA:NM_006206.4:synonymous_variant:LOW:exon7/23:c.939T>G:p.Gly313Gly		MAPK signaling pathway;Calcium signaling pathway;Cytokine-cytokine receptor interaction;Focal adhesion;Gap junction;Regulation of actin cytoskeleton;Colorectal cancer;Glioma;Prostate cancer;Melanoma	Tyrosine-protein kinase that acts as a cell-surface receptor for PDGFA, PDGFB and PDGFC and plays an essential role in the regulation of embryonic development, cell proliferation, survival and chemotaxis. Depending on the context, promotes or inhibits cell proliferation and cell migration. Plays an important role in the differentiation of bone marrow-derived mesenchymal stem cells. Required for normal skeleton development and cephalic closure during embryonic development. Required for normal development of the mucosa lining the gastrointestinal tract, and for recruitment of mesenchymal cells and normal development of intestinal villi. Plays a role in cell migration and chemotaxis in wound healing. Plays a role in platelet activation, secretion of agonists from platelet granules, and in thrombin-induced platelet aggregation. Binding of its cognate ligands - homodimeric PDGFA, homodimeric PDGFB, heterodimers formed by PDGFA and PDGFB or homodimeric PDGFC -leads to the activation of several signaling cascades; the response depends on the nature of the bound ligand and is modulated by the formation of heterodimers between PDGFRA and PDGFRB. Phosphorylates PIK3R1, PLCG1, and PTPN11. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate, mobilization of cytosolic Ca(2+) and the activation of protein kinase C. Phosphorylates PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, and thereby mediates activation of the AKT1 signaling pathway. Mediates activation of HRAS and of the MAP kinases MAPK1/ERK2 and/or MAPK3/ERK1. Promotes activation of STAT family members STAT1, STAT3 and STAT5A and/or STAT5B. Receptor signaling is down-regulated by protein phosphatases that dephosphorylate the receptor and its down-stream effectors, and by rapid internalization of the activated receptor	CBL mediated ligand-induced downregulation of EGF receptors;Erk1/Erk2 Mapk Signaling pathway;PDGF Signaling Pathway;Phospholipids as signalling intermediaries;Rac 1 cell motility signaling pathway;Role of PI3K subunit p85 in regulation of Actin Organization and Cell Migration		rs4358459	0.234225	0.17747519039926	0.1737319	COSM1666925	173490 [PDGFRA (confirmed) Gastrointestinal stromal tumor,somatic,606764|Hypereosinophilic syndrome,idiopathic,resistant to imatinib,607685];	RCV000244224.1 [benign]; RCV000322335.1 [benign]; RCV000377030.1 [benign]; 								1	MIPs_Etablierung,	18	259			n/a	n/a	PDGFRA (inh=AD pLI=1.00)
chr4	55139771	55139771	T	C	0.5179	56		616.0	5|0|24,9|0|18,8|5	PDGFRA	missense_variant	PDGFRA:NM_006206.4:missense_variant:MODERATE:exon10/23:c.1432T>C:p.Ser478Pro	Immunoglobulin-like_fold__1_	MAPK signaling pathway;Calcium signaling pathway;Cytokine-cytokine receptor interaction;Focal adhesion;Gap junction;Regulation of actin cytoskeleton;Colorectal cancer;Glioma;Prostate cancer;Melanoma	Tyrosine-protein kinase that acts as a cell-surface receptor for PDGFA, PDGFB and PDGFC and plays an essential role in the regulation of embryonic development, cell proliferation, survival and chemotaxis. Depending on the context, promotes or inhibits cell proliferation and cell migration. Plays an important role in the differentiation of bone marrow-derived mesenchymal stem cells. Required for normal skeleton development and cephalic closure during embryonic development. Required for normal development of the mucosa lining the gastrointestinal tract, and for recruitment of mesenchymal cells and normal development of intestinal villi. Plays a role in cell migration and chemotaxis in wound healing. Plays a role in platelet activation, secretion of agonists from platelet granules, and in thrombin-induced platelet aggregation. Binding of its cognate ligands - homodimeric PDGFA, homodimeric PDGFB, heterodimers formed by PDGFA and PDGFB or homodimeric PDGFC -leads to the activation of several signaling cascades; the response depends on the nature of the bound ligand and is modulated by the formation of heterodimers between PDGFRA and PDGFRB. Phosphorylates PIK3R1, PLCG1, and PTPN11. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate, mobilization of cytosolic Ca(2+) and the activation of protein kinase C. Phosphorylates PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, and thereby mediates activation of the AKT1 signaling pathway. Mediates activation of HRAS and of the MAP kinases MAPK1/ERK2 and/or MAPK3/ERK1. Promotes activation of STAT family members STAT1, STAT3 and STAT5A and/or STAT5B. Receptor signaling is down-regulated by protein phosphatases that dephosphorylate the receptor and its down-stream effectors, and by rapid internalization of the activated receptor	CBL mediated ligand-induced downregulation of EGF receptors;Erk1/Erk2 Mapk Signaling pathway;PDGF Signaling Pathway;Phospholipids as signalling intermediaries;Rac 1 cell motility signaling pathway;Role of PI3K subunit p85 in regulation of Actin Organization and Cell Migration		rs35597368	0.199281	0.15155809699586	0.1473596		173490 [PDGFRA (confirmed) Gastrointestinal stromal tumor,somatic,606764|Hypereosinophilic syndrome,idiopathic,resistant to imatinib,607685];	RCV000034716.1 [benign]; RCV000121780.2 [benign]; RCV000326887.1 [benign]; RCV000381487.1 [benign]; 		-1.239000	T	T	B,B	T	0.14	0		16	243			n/a	n/a	PDGFRA (inh=AD pLI=1.00)
chr4	55141055	55141055	A	G	1.0000	37		1155.0	6|3|28,0|0|0,3|4	PDGFRA	synonymous_variant	PDGFRA:NM_006206.4:synonymous_variant:LOW:exon12/23:c.1701A>G:p.Pro567Pro		MAPK signaling pathway;Calcium signaling pathway;Cytokine-cytokine receptor interaction;Focal adhesion;Gap junction;Regulation of actin cytoskeleton;Colorectal cancer;Glioma;Prostate cancer;Melanoma	Tyrosine-protein kinase that acts as a cell-surface receptor for PDGFA, PDGFB and PDGFC and plays an essential role in the regulation of embryonic development, cell proliferation, survival and chemotaxis. Depending on the context, promotes or inhibits cell proliferation and cell migration. Plays an important role in the differentiation of bone marrow-derived mesenchymal stem cells. Required for normal skeleton development and cephalic closure during embryonic development. Required for normal development of the mucosa lining the gastrointestinal tract, and for recruitment of mesenchymal cells and normal development of intestinal villi. Plays a role in cell migration and chemotaxis in wound healing. Plays a role in platelet activation, secretion of agonists from platelet granules, and in thrombin-induced platelet aggregation. Binding of its cognate ligands - homodimeric PDGFA, homodimeric PDGFB, heterodimers formed by PDGFA and PDGFB or homodimeric PDGFC -leads to the activation of several signaling cascades; the response depends on the nature of the bound ligand and is modulated by the formation of heterodimers between PDGFRA and PDGFRB. Phosphorylates PIK3R1, PLCG1, and PTPN11. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate, mobilization of cytosolic Ca(2+) and the activation of protein kinase C. Phosphorylates PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, and thereby mediates activation of the AKT1 signaling pathway. Mediates activation of HRAS and of the MAP kinases MAPK1/ERK2 and/or MAPK3/ERK1. Promotes activation of STAT family members STAT1, STAT3 and STAT5A and/or STAT5B. Receptor signaling is down-regulated by protein phosphatases that dephosphorylate the receptor and its down-stream effectors, and by rapid internalization of the activated receptor	CBL mediated ligand-induced downregulation of EGF receptors;Erk1/Erk2 Mapk Signaling pathway;PDGF Signaling Pathway;Phospholipids as signalling intermediaries;Rac 1 cell motility signaling pathway;Role of PI3K subunit p85 in regulation of Actin Organization and Cell Migration		rs1873778	0.957668	0.9880399327864	0.9661038	COSM1430082	173490 [PDGFRA (confirmed) Gastrointestinal stromal tumor,somatic,606764|Hypereosinophilic syndrome,idiopathic,resistant to imatinib,607685];	RCV000250036.1 [benign]; RCV000281727.1 [benign]; RCV000385643.1 [benign]; 								0		1364	16			n/a	n/a	PDGFRA (inh=AD pLI=1.00)
chr4	55143577	55143577	G	A	0.5000	24		254.0	9|3|0,2|10|0,3|3	PDGFRA	synonymous_variant	PDGFRA:NM_006206.4:synonymous_variant:LOW:exon13/23:c.1809G>A:p.Ala603Ala		MAPK signaling pathway;Calcium signaling pathway;Cytokine-cytokine receptor interaction;Focal adhesion;Gap junction;Regulation of actin cytoskeleton;Colorectal cancer;Glioma;Prostate cancer;Melanoma	Tyrosine-protein kinase that acts as a cell-surface receptor for PDGFA, PDGFB and PDGFC and plays an essential role in the regulation of embryonic development, cell proliferation, survival and chemotaxis. Depending on the context, promotes or inhibits cell proliferation and cell migration. Plays an important role in the differentiation of bone marrow-derived mesenchymal stem cells. Required for normal skeleton development and cephalic closure during embryonic development. Required for normal development of the mucosa lining the gastrointestinal tract, and for recruitment of mesenchymal cells and normal development of intestinal villi. Plays a role in cell migration and chemotaxis in wound healing. Plays a role in platelet activation, secretion of agonists from platelet granules, and in thrombin-induced platelet aggregation. Binding of its cognate ligands - homodimeric PDGFA, homodimeric PDGFB, heterodimers formed by PDGFA and PDGFB or homodimeric PDGFC -leads to the activation of several signaling cascades; the response depends on the nature of the bound ligand and is modulated by the formation of heterodimers between PDGFRA and PDGFRB. Phosphorylates PIK3R1, PLCG1, and PTPN11. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate, mobilization of cytosolic Ca(2+) and the activation of protein kinase C. Phosphorylates PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, and thereby mediates activation of the AKT1 signaling pathway. Mediates activation of HRAS and of the MAP kinases MAPK1/ERK2 and/or MAPK3/ERK1. Promotes activation of STAT family members STAT1, STAT3 and STAT5A and/or STAT5B. Receptor signaling is down-regulated by protein phosphatases that dephosphorylate the receptor and its down-stream effectors, and by rapid internalization of the activated receptor	CBL mediated ligand-induced downregulation of EGF receptors;Erk1/Erk2 Mapk Signaling pathway;PDGF Signaling Pathway;Phospholipids as signalling intermediaries;Rac 1 cell motility signaling pathway;Role of PI3K subunit p85 in regulation of Actin Organization and Cell Migration		rs10028020	0.228035	0.15829667342198	0.1535202		173490 [PDGFRA (confirmed) Gastrointestinal stromal tumor,somatic,606764|Hypereosinophilic syndrome,idiopathic,resistant to imatinib,607685];	RCV000242800.1 [benign]; RCV000278036.1 [benign]; RCV000342427.1 [benign]; 								0		17	243			n/a	n/a	PDGFRA (inh=AD pLI=1.00)
chr4	55152040	55152040	C	T	1.0000	46		1460.0	0|0|46,0|0|0,3|3	PDGFRA	synonymous_variant	PDGFRA:NM_006206.4:synonymous_variant:LOW:exon18/23:c.2472C>T:p.Val824Val		MAPK signaling pathway;Calcium signaling pathway;Cytokine-cytokine receptor interaction;Focal adhesion;Gap junction;Regulation of actin cytoskeleton;Colorectal cancer;Glioma;Prostate cancer;Melanoma	Tyrosine-protein kinase that acts as a cell-surface receptor for PDGFA, PDGFB and PDGFC and plays an essential role in the regulation of embryonic development, cell proliferation, survival and chemotaxis. Depending on the context, promotes or inhibits cell proliferation and cell migration. Plays an important role in the differentiation of bone marrow-derived mesenchymal stem cells. Required for normal skeleton development and cephalic closure during embryonic development. Required for normal development of the mucosa lining the gastrointestinal tract, and for recruitment of mesenchymal cells and normal development of intestinal villi. Plays a role in cell migration and chemotaxis in wound healing. Plays a role in platelet activation, secretion of agonists from platelet granules, and in thrombin-induced platelet aggregation. Binding of its cognate ligands - homodimeric PDGFA, homodimeric PDGFB, heterodimers formed by PDGFA and PDGFB or homodimeric PDGFC -leads to the activation of several signaling cascades; the response depends on the nature of the bound ligand and is modulated by the formation of heterodimers between PDGFRA and PDGFRB. Phosphorylates PIK3R1, PLCG1, and PTPN11. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate, mobilization of cytosolic Ca(2+) and the activation of protein kinase C. Phosphorylates PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, and thereby mediates activation of the AKT1 signaling pathway. Mediates activation of HRAS and of the MAP kinases MAPK1/ERK2 and/or MAPK3/ERK1. Promotes activation of STAT family members STAT1, STAT3 and STAT5A and/or STAT5B. Receptor signaling is down-regulated by protein phosphatases that dephosphorylate the receptor and its down-stream effectors, and by rapid internalization of the activated receptor	CBL mediated ligand-induced downregulation of EGF receptors;Erk1/Erk2 Mapk Signaling pathway;PDGF Signaling Pathway;Phospholipids as signalling intermediaries;Rac 1 cell motility signaling pathway;Role of PI3K subunit p85 in regulation of Actin Organization and Cell Migration		rs2228230	0.240415	0.18201440034271	0.1787157	COSM22413	173490 [PDGFRA (confirmed) Gastrointestinal stromal tumor,somatic,606764|Hypereosinophilic syndrome,idiopathic,resistant to imatinib,607685];	RCV000247800.1 [benign]; RCV000275201.1 [benign]; RCV000369832.1 [benign]; 								0		28	316			n/a	n/a	PDGFRA (inh=AD pLI=1.00)
chr4	55161391	55161391	T	C	1.0000	22		654.0	8|4|10,0|0|0,2|2	PDGFRA	synonymous_variant	PDGFRA:NM_006206.4:synonymous_variant:LOW:exon23/23:c.3222T>C:p.Asp1074Asp		MAPK signaling pathway;Calcium signaling pathway;Cytokine-cytokine receptor interaction;Focal adhesion;Gap junction;Regulation of actin cytoskeleton;Colorectal cancer;Glioma;Prostate cancer;Melanoma	Tyrosine-protein kinase that acts as a cell-surface receptor for PDGFA, PDGFB and PDGFC and plays an essential role in the regulation of embryonic development, cell proliferation, survival and chemotaxis. Depending on the context, promotes or inhibits cell proliferation and cell migration. Plays an important role in the differentiation of bone marrow-derived mesenchymal stem cells. Required for normal skeleton development and cephalic closure during embryonic development. Required for normal development of the mucosa lining the gastrointestinal tract, and for recruitment of mesenchymal cells and normal development of intestinal villi. Plays a role in cell migration and chemotaxis in wound healing. Plays a role in platelet activation, secretion of agonists from platelet granules, and in thrombin-induced platelet aggregation. Binding of its cognate ligands - homodimeric PDGFA, homodimeric PDGFB, heterodimers formed by PDGFA and PDGFB or homodimeric PDGFC -leads to the activation of several signaling cascades; the response depends on the nature of the bound ligand and is modulated by the formation of heterodimers between PDGFRA and PDGFRB. Phosphorylates PIK3R1, PLCG1, and PTPN11. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate, mobilization of cytosolic Ca(2+) and the activation of protein kinase C. Phosphorylates PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, and thereby mediates activation of the AKT1 signaling pathway. Mediates activation of HRAS and of the MAP kinases MAPK1/ERK2 and/or MAPK3/ERK1. Promotes activation of STAT family members STAT1, STAT3 and STAT5A and/or STAT5B. Receptor signaling is down-regulated by protein phosphatases that dephosphorylate the receptor and its down-stream effectors, and by rapid internalization of the activated receptor	CBL mediated ligand-induced downregulation of EGF receptors;Erk1/Erk2 Mapk Signaling pathway;PDGF Signaling Pathway;Phospholipids as signalling intermediaries;Rac 1 cell motility signaling pathway;Role of PI3K subunit p85 in regulation of Actin Organization and Cell Migration		rs7685117	0.997204	0.99898690387942	0.9354293		173490 [PDGFRA (confirmed) Gastrointestinal stromal tumor,somatic,606764|Hypereosinophilic syndrome,idiopathic,resistant to imatinib,607685];	RCV000243112.1 [benign]; RCV000344752.1 [benign]; RCV000403157.1 [benign]; 								0		1353	0			n/a	n/a	PDGFRA (inh=AD pLI=1.00)
chr4	69964271	69964271	A	G	0.4000	10		45.0	0|4|0,0|6|0,1|2	UGT2B7	synonymous_variant	UGT2B7:NM_001074.2:synonymous_variant:LOW:exon2/6:c.735A>G:p.Thr245Thr		Pentose and glucuronate interconversions;Androgen and estrogen metabolism;Starch and sucrose metabolism;Retinol metabolism;Porphyrin and chlorophyll metabolism;Metabolism of xenobiotics by cytochrome P450;Drug metabolism - cytochrome P450;Drug metabolism - other enzymes	UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds			rs28365062	0.148562	0.16655392027455	0.1550763				CS086286 [CLASS=FP MUT=ALT PHEN="Altered mRNA expression" GENE=UGT2B7]; 							0		35	291			n/a	n/a	UGT2B7 (inh=n/a pLI=0.00)
chr4	187516880	187516880	A	G	0.3846	39		285.0	0|0|15,0|0|24,7|6	FAT1	synonymous_variant	FAT1:NM_005245.3:synonymous_variant:LOW:exon26/27:c.13101T>C:p.Ser4367Ser			Plays an essential role for cellular polarization, directed cell migration and modulating cell-cell contact (By similarity)	Mechanism of Gene Regulation by Peroxisome Proliferators via PPARa(alpha)		rs1298865	0.491813	0.42117732823036	0.4152240	COSM4158951, COSM4158952				-0.504000	T	D,D			9.49	3	I16R041,Leuk,cfDNA_HNSCC,	138	378			n/a	n/a	FAT1 (inh=n/a pLI=0.00)
chr4	187531022	187531022	A	G	0.4762	21		212.0	6|4|0,2|9|0,4|6	FAT1	missense_variant	FAT1:NM_005245.3:missense_variant:MODERATE:exon15/27:c.10001T>C:p.Val3334Ala	Cadherin__2_,Cadherin-like__1_		Plays an essential role for cellular polarization, directed cell migration and modulating cell-cell contact (By similarity)	Mechanism of Gene Regulation by Peroxisome Proliferators via PPARa(alpha)		rs28647489	0.192492	0.14965822742808	0.1484078	COSM1131159, COSM1131161				3.445000	T	T,T	B	T	4.14	2	Leuk,cfDNA_HNSCC,	23	216			n/a	n/a	FAT1 (inh=n/a pLI=0.00)
chr4	187534363	187534363	G	A	0.4746	59		601.0	0|0|28,0|0|31,6|6	FAT1	synonymous_variant	FAT1:NM_005245.3:synonymous_variant:LOW:exon13/27:c.9363C>T:p.Asn3121Asn			Plays an essential role for cellular polarization, directed cell migration and modulating cell-cell contact (By similarity)	Mechanism of Gene Regulation by Peroxisome Proliferators via PPARa(alpha)		rs2249916	0.611422	0.5912856882467	0.5840943											2	I16R041,cfDNA_HNSCC,	297	418			n/a	n/a	FAT1 (inh=n/a pLI=0.00)
chr4	187538942	187538942	T	G	0.1724	29		7.0	4|0|1,24|0|0,4|3	FAT1	missense_variant	FAT1:NM_005245.3:missense_variant:MODERATE:exon10/27:c.8798A>C:p.Gln2933Pro	Cadherin__3_,Cadherin-like__1_		Plays an essential role for cellular polarization, directed cell migration and modulating cell-cell contact (By similarity)	Mechanism of Gene Regulation by Peroxisome Proliferators via PPARa(alpha)		rs1280098	0.592053	0.5553823187925	0.5300828	COSM4005727, COSM4005726				5.993000	T	T,T	B	T	0.01	1	I16R041,	266	409			n/a	n/a	FAT1 (inh=n/a pLI=0.00)
chr4	187557893	187557893	T	C	0.4412	102		1046.0	6|21|18,9|22|26,5|4	FAT1	missense_variant	FAT1:NM_005245.3:missense_variant:MODERATE:exon5/27:c.3818A>G:p.His1273Arg	Cadherin__3_,Cadherin-like__1_		Plays an essential role for cellular polarization, directed cell migration and modulating cell-cell contact (By similarity)	Mechanism of Gene Regulation by Peroxisome Proliferators via PPARa(alpha)		rs328418	0.645767	0.5876117919841	0.5611045					5.940000	T	T,T	B	T	0.01	1	I16R041,	276	425			n/a	n/a	FAT1 (inh=n/a pLI=0.00)
chr4	187628398	187628398	C	G	1.0000	64		1898.0	26|36|2,0|0|0,4|4	FAT1	missense_variant	FAT1:NM_005245.3:missense_variant:MODERATE:exon2/27:c.2584G>C:p.Val862Leu	Cadherin__4_,Cadherin-like__1_		Plays an essential role for cellular polarization, directed cell migration and modulating cell-cell contact (By similarity)	Mechanism of Gene Regulation by Peroxisome Proliferators via PPARa(alpha)		rs1877731	0.689097	0.74600109400123	0.7279620	COSM4003036, COSM4003037				1.610000	T	T,T	B	T	0.00	1	cfDNA_HNSCC,	544	289			n/a	n/a	FAT1 (inh=n/a pLI=0.00)
chr4	187629140	187629140	G	C	1.0000	9		226.0	6|3|0,0|0|0,7|7	FAT1	missense_variant	FAT1:NM_005245.3:missense_variant:MODERATE:exon2/27:c.1842C>G:p.Phe614Leu	Cadherin__3_,Cadherin-like__1_		Plays an essential role for cellular polarization, directed cell migration and modulating cell-cell contact (By similarity)	Mechanism of Gene Regulation by Peroxisome Proliferators via PPARa(alpha)		rs367863	0.690495	0.74757104486521	0.7266115	COSM4003038, COSM4003039				1.447000	T	T,T	B	T	0.07	1	cfDNA_HNSCC,	542	290			n/a	n/a	FAT1 (inh=n/a pLI=0.00)
chr4	187629497	187629497	G	A	1.0000	36		1103.0	11|20|5,0|0|0,4|4	FAT1	synonymous_variant	FAT1:NM_005245.3:synonymous_variant:LOW:exon2/27:c.1485C>T:p.Asn495Asn			Plays an essential role for cellular polarization, directed cell migration and modulating cell-cell contact (By similarity)	Mechanism of Gene Regulation by Peroxisome Proliferators via PPARa(alpha)		rs458021	0.421925	0.56435873221002	0.5557799	COSM4003041, COSM4003040										0		340	400			n/a	n/a	FAT1 (inh=n/a pLI=0.00)
chr4	187629538	187629538	C	T	0.1900	100		137.0	2|13|4,60|20|1,5|6	FAT1	missense_variant	FAT1:NM_005245.3:missense_variant:MODERATE:exon2/27:c.1444G>A:p.Val482Ile	Cadherin__4_,Cadherin-like__1_		Plays an essential role for cellular polarization, directed cell migration and modulating cell-cell contact (By similarity)	Mechanism of Gene Regulation by Peroxisome Proliferators via PPARa(alpha)		rs3733413	0.338858	0.48646387328727	0.4785407					3.947000	T	T,T,T	B	T,T	8.01	0		268	403			n/a	n/a	FAT1 (inh=n/a pLI=0.00)
chr5	224633	224633	A	G	0.2889	45		196.0	12|1|0,12|20|0,4|5	SDHA	synonymous_variant	SDHA:NM_004168.3:synonymous_variant:LOW:exon3/15:c.309A>G:p.Ala103Ala,SDHA:NM_001294332.1:synonymous_variant:LOW:exon3/14:c.309A>G:p.Ala103Ala						rs1139424	0.240016	0.1529025969735	0.1467293	COSM3761191	600857 [SDHA (confirmed) Leigh syndrome,256000|Mitochondrial respiratory chain complex II deficiency,252011|Cardiomyopathy,dilated,1GG,613642|Paragangliomas 5,614165];	RCV000118318.3 [other]; RCV000162942.1 [benign]; RCV000261547.1 [likely benign]; RCV000319629.1 [likely benign]; RCV000385778.1 [likely benign]; 								1	cfDNA_HNSCC,	25	312			n/a	n/a	SDHA (inh=AR+AD pLI=0.00)
chr5	233734	233734	C	G	0.4737	57		596.0	6|17|4,12|17|1,4|5	SDHA	synonymous_variant	SDHA:NM_004168.3:synonymous_variant:LOW:exon8/15:c.1038C>G:p.Ser346Ser,SDHA:NM_001294332.1:synonymous_variant:LOW:exon7/14:c.894C>G:p.Ser298Ser						rs1041949	0.257788	0.15974235635213	0.1554365	COSM3761193	600857 [SDHA (confirmed) Leigh syndrome,256000|Mitochondrial respiratory chain complex II deficiency,252011|Cardiomyopathy,dilated,1GG,613642|Paragangliomas 5,614165];	RCV000118311.3 [other]; RCV000162943.1 [benign]; RCV000274141.1 [likely benign]; RCV000319420.1 [likely benign]; RCV000368680.1 [likely benign]; 								1	cfDNA_HNSCC,	25	319			n/a	n/a	SDHA (inh=AR+AD pLI=0.00)
chr5	251541	251541	A	G	0.9333	15		344.0	1|1|12,0|0|1,3|4	SDHA	synonymous_variant	SDHA:NM_004168.3:synonymous_variant:LOW:exon13/15:c.1752A>G:p.Ala584Ala,SDHA:NM_001294332.1:synonymous_variant:LOW:exon12/14:c.1608A>G:p.Ala536Ala						rs13070	0.248403	0.15593792954971	0.1500733		600857 [SDHA (confirmed) Leigh syndrome,256000|Mitochondrial respiratory chain complex II deficiency,252011|Cardiomyopathy,dilated,1GG,613642|Paragangliomas 5,614165];	RCV000118315.3 [other]; RCV000162485.1 [benign]; RCV000268103.1 [likely benign]; RCV000323384.1 [likely benign]; RCV000359489.1 [likely benign]; 								0		25	318			n/a	n/a	SDHA (inh=AR+AD pLI=0.00)
chr5	254599	254599	A	T	0.3421	38		181.0	2|0|11,2|0|23,4|4	SDHA	missense_variant	SDHA:NM_004168.3:missense_variant:MODERATE:exon14/15:c.1886A>T:p.Tyr629Phe,SDHA:NM_001294332.1:missense_variant:MODERATE:exon13/14:c.1742A>T:p.Tyr581Phe	,Fumarate_reductase/succinate_dehydrogenase_flavoprotein-like__C-terminal__1_,Fumarate_reductase/succinate_dehydrogenase_flavoprotein__C-terminal__1_					rs6960	0.0000	0.15153080044264	0.0731621	COSM1666612	600857 [SDHA (confirmed) Leigh syndrome,256000|Mitochondrial respiratory chain complex II deficiency,252011|Cardiomyopathy,dilated,1GG,613642|Paragangliomas 5,614165];	RCV000210491.1 [benign]; RCV000210491.1 [benign]; RCV000243534.1 [benign]; RCV000270762.1 [likely benign]; RCV000325852.1 [likely benign]; RCV000389777.1 [likely benign]; 		4.002000,4.002000	T,T	D,T,T,T,T	,B,B,B,B	D,T,T,T	7.45	0		16	248			n/a	n/a	SDHA (inh=AR+AD pLI=0.00)
chr5	7743787	7743787	C	T	1.0000	31		965.0	9|18|4,0|0|0,3|3	ADCY2	synonymous_variant	ADCY2:NM_020546.2:synonymous_variant:LOW:exon15/25:c.1878C>T:p.Ser626Ser		Purine metabolism;Calcium signaling pathway;Gap junction;GnRH signaling pathway;Melanogenesis	This is a membrane-bound, calmodulin-insensitive adenylyl cyclase			rs62342477	0.323682	0.4689981875103	0.4491589	COSM4159997, COSM4159996										1	Leuk,	242	409			n/a	n/a	ADCY2 (inh=n/a pLI=1.00)
chr5	9044587	9044587	G	A	0.1905	42		19.0	0|8|0,20|14|0,7|4	SEMA5A	synonymous_variant	SEMA5A:NM_003966.2:synonymous_variant:LOW:exon22/23:c.3003C>T:p.His1001His		Axon guidance	Bifunctional axonal guidance cue regulated by sulfated proteoglycans; attractive effects result from interactions with heparan sulfate proteoglycans (HSPGs), while the inhibitory effects depend on interactions with chondroitin sulfate proteoglycans (CSPGs) (By similarity). Ligand for receptor PLXNB3. In glioma cells, SEMA5A stimulation of PLXNB3 results in the disassembly of F-actin stress fibers, disruption of focal adhesions and cellular collapse as well as inhibition of cell migration and invasion through ARHGDIA-mediated inactivation of RAC1. May promote angiogenesis by increasing endothelial cell proliferation and migration and inhibiting apoptosis			rs147519596	0.00319489	0.0026110305745915	0.0024501											1	cfDNA_HNSCC,	0	6			n/a	n/a	SEMA5A (inh=n/a pLI=0.00)
chr5	9154659	9154659	G	C	0.5397	63		849.0	0|10|24,0|3|26,4|5	SEMA5A	synonymous_variant	SEMA5A:NM_003966.2:synonymous_variant:LOW:exon12/23:c.1422C>G:p.Gly474Gly		Axon guidance	Bifunctional axonal guidance cue regulated by sulfated proteoglycans; attractive effects result from interactions with heparan sulfate proteoglycans (HSPGs), while the inhibitory effects depend on interactions with chondroitin sulfate proteoglycans (CSPGs) (By similarity). Ligand for receptor PLXNB3. In glioma cells, SEMA5A stimulation of PLXNB3 results in the disassembly of F-actin stress fibers, disruption of focal adhesions and cellular collapse as well as inhibition of cell migration and invasion through ARHGDIA-mediated inactivation of RAC1. May promote angiogenesis by increasing endothelial cell proliferation and migration and inhibiting apoptosis			rs1806151	0.273962	0.42241820251786	0.4204715	COSM4003627										0		228	380			n/a	n/a	SEMA5A (inh=n/a pLI=0.00)
chr5	55251931	55251931	G	C	0.6053	38		552.0	13|10|0,0|12|3,4|4	IL6ST	missense_variant,3_prime_UTR_variant,non_coding_transcript_exon_variant	IL6ST:NM_002184.3:missense_variant:MODERATE:exon10/17:c.1189C>G:p.Leu397Val,IL6ST:NM_001190981.1:missense_variant:MODERATE:exon10/16:c.1189C>G:p.Leu397Val,IL6ST:NM_175767.2:3_prime_UTR_variant:MODIFIER:exon9/16:c.*116C>G:,IL6ST:NR_120480.1:non_coding_transcript_exon_variant:MODIFIER:exon11/18:n.1548C>G:	Fibronectin__type_III__3_					rs2228043	0.159744	0.12261726279717	0.1205821					-0.097000	T	T,T,T	B,B	T,T,T	0.01	0		22	182			n/a	n/a	IL6ST (inh=n/a pLI=1.00)
chr5	55264153	55264153	C	G	0.4444	18		174.0	0|8|0,0|10|0,1|3	IL6ST	missense_variant,non_coding_transcript_exon_variant	IL6ST:NM_002184.3:missense_variant:MODERATE:exon5/17:c.442G>C:p.Gly148Arg,IL6ST:NM_001190981.1:missense_variant:MODERATE:exon5/16:c.442G>C:p.Gly148Arg,IL6ST:NM_175767.2:missense_variant:MODERATE:exon5/16:c.442G>C:p.Gly148Arg,IL6ST:NR_120480.1:non_coding_transcript_exon_variant:MODIFIER:exon5/18:n.755G>C:	Interleukin-6_receptor_alpha_chain__binding__1_,Fibronectin__type_III__3_,Immunoglobulin-like_fold__1_					rs2228044	0.196286	0.13222159970998	0.1285305				CM1613074 [CLASS=DFP MUT=ALT PHEN="Thiopurine intolerance" GENE=IL6ST]; 	4.663000	T	T,T,T,T,T,T,T	B,B,B	T,T,T,T,T,T	23.40	0		21	186			n/a	n/a	IL6ST (inh=n/a pLI=1.00)
chr5	67522722	67522722	C	T	0.5000	54		700.0	16|6|5,6|14|7,6|5	PIK3R1	synonymous_variant	PIK3R1:NM_181523.2:synonymous_variant:LOW:exon2/16:c.219C>T:p.Tyr73Tyr						rs706713	0.419329	0.31293659990068	0.3113489		171833 [PIK3R1 (provisional) Agammaglobulinemia 7,autosomal recessive,615214|SHORT syndrome,269880|Immunodeficiency 36,616005];	RCV000147276.1 [likely benign]; 								1	GT,	70	494			n/a	n/a	PIK3R1 (inh=AR+AD pLI=1.00)
chr5	82833145	82833145	G	A	0.5000	36		431.0	0|2|16,0|0|18,6|3	VCAN,LOC105379054	synonymous_variant,intron_variant	VCAN:NM_004385.4:synonymous_variant:LOW:exon8/15:c.4323G>A:p.Gln1441Gln,VCAN:NM_001164097.1:synonymous_variant:LOW:exon7/14:c.1362G>A:p.Gln454Gln,LOC105379054:NR_136215.1:intron_variant:MODIFIER:exon1/2:n.285-3153C>T:,VCAN:NM_001126336.2:intron_variant:MODIFIER:exon6/12:c.1043-8211G>A:,VCAN:NM_001164098.1:intron_variant:MODIFIER:exon7/13:c.4004-8211G>A:		Cell adhesion molecules (CAMs)	May play a role in intercellular signaling and in connecting cells with the extracellular matrix. May take part in the regulation of cell motility, growth and differentiation. Binds hyaluronic acid			rs2548541	0.0000	0.64775520979425	0.6166787		118661 [VCAN (confirmed) Wagner syndrome 1,143200];	RCV000180254.2 [benign]; RCV000267291.1 [benign]; RCV000297799.1 [benign]; 								0		516	580			n/a	n/a	VCAN (inh=AD pLI=1.00), LOC105379054 (inh=n/a pLI=n/a)
chr5	82833369	82833369	A	G	0.4167	12		87.0	2|1|2,1|4|2,4|3	VCAN,LOC105379054	missense_variant,intron_variant	VCAN:NM_004385.4:missense_variant:MODERATE:exon8/15:c.4547A>G:p.Lys1516Arg,VCAN:NM_001164097.1:missense_variant:MODERATE:exon7/14:c.1586A>G:p.Lys529Arg,LOC105379054:NR_136215.1:intron_variant:MODIFIER:exon1/2:n.285-3377T>C:,VCAN:NM_001126336.2:intron_variant:MODIFIER:exon6/12:c.1043-7987A>G:,VCAN:NM_001164098.1:intron_variant:MODIFIER:exon7/13:c.4004-7987A>G:		Cell adhesion molecules (CAMs)	May play a role in intercellular signaling and in connecting cells with the extracellular matrix. May take part in the regulation of cell motility, growth and differentiation. Binds hyaluronic acid			rs309559	0.471046	0.48399489956448	0.4794668		118661 [VCAN (confirmed) Wagner syndrome 1,143200];	RCV000154116.4 [benign]; RCV000288593.1 [benign]; RCV000328381.1 [benign]; 		0.289000	T	T,T,D	B,B	D,D,T	0.04	0		304	629			n/a	n/a	VCAN (inh=AD pLI=1.00), LOC105379054 (inh=n/a pLI=n/a)
chr5	82834948	82834948	C	T	0.2500	16		34.0	0|0|4,0|0|12,2|2	VCAN,LOC105379054	synonymous_variant,intron_variant	VCAN:NM_004385.4:synonymous_variant:LOW:exon8/15:c.6126C>T:p.Asp2042Asp,VCAN:NM_001164097.1:synonymous_variant:LOW:exon7/14:c.3165C>T:p.Asp1055Asp,LOC105379054:NR_136215.1:intron_variant:MODIFIER:exon1/2:n.285-4956G>A:,VCAN:NM_001126336.2:intron_variant:MODIFIER:exon6/12:c.1043-6408C>T:,VCAN:NM_001164098.1:intron_variant:MODIFIER:exon7/13:c.4004-6408C>T:		Cell adhesion molecules (CAMs)	May play a role in intercellular signaling and in connecting cells with the extracellular matrix. May take part in the regulation of cell motility, growth and differentiation. Binds hyaluronic acid			rs138910265	0.00319489	0.0011000645150618	0.0009775		118661 [VCAN (confirmed) Wagner syndrome 1,143200];									1	cfDNA_HNSCC,	0	1			n/a	n/a	VCAN (inh=AD pLI=1.00), LOC105379054 (inh=n/a pLI=n/a)
chr5	82837631	82837631	G	T	0.5172	29		352.0	13|2|0,11|2|1,5|3	VCAN,LOC105379054	missense_variant,intron_variant	VCAN:NM_004385.4:missense_variant:MODERATE:exon8/15:c.8809G>T:p.Asp2937Tyr,VCAN:NM_001164097.1:missense_variant:MODERATE:exon7/14:c.5848G>T:p.Asp1950Tyr,LOC105379054:NR_136215.1:intron_variant:MODIFIER:exon1/2:n.285-7639C>A:,VCAN:NM_001126336.2:intron_variant:MODIFIER:exon6/12:c.1043-3725G>T:,VCAN:NM_001164098.1:intron_variant:MODIFIER:exon7/13:c.4004-3725G>T:		Cell adhesion molecules (CAMs)	May play a role in intercellular signaling and in connecting cells with the extracellular matrix. May take part in the regulation of cell motility, growth and differentiation. Binds hyaluronic acid			rs160277	0.360623	0.38118697496328	0.3797973		118661 [VCAN (confirmed) Wagner syndrome 1,143200];	RCV000180253.2 [benign]; RCV000277745.1 [benign]; RCV000316409.1 [benign]; 	CM100489 [CLASS=DP MUT=ALT PHEN="Gastric cancer association with" GENE=VCAN]; 	0.638000	T	D,D	P,P	T,T	23.30	0		194	596			n/a	n/a	VCAN (inh=AD pLI=1.00), LOC105379054 (inh=n/a pLI=n/a)
chr5	82875800	82875800	C	T	1.0000	11		322.0	4|7|0,0|0|0,6|5	VCAN	splice_region_variant&synonymous_variant,sequence_feature	VCAN:NM_004385.4:splice_region_variant&synonymous_variant:LOW:exon14/15:c.9882C>T:p.Val3294Val,VCAN:NM_001126336.2:splice_region_variant&synonymous_variant:LOW:exon12/13:c.1659C>T:p.Val553Val,VCAN:NM_001164097.1:splice_region_variant&synonymous_variant:LOW:exon13/14:c.6921C>T:p.Val2307Val,VCAN:NM_001164098.1:splice_region_variant&synonymous_variant:LOW:exon13/14:c.4620C>T:p.Val1540Val,VCAN:NM_004385.4:sequence_feature:LOW:exon14/15:c.9882C>T:,VCAN:NM_001126336.2:sequence_feature:LOW:exon12/13:c.1659C>T:,VCAN:NM_001164097.1:sequence_feature:LOW:exon13/14:c.6921C>T:		Cell adhesion molecules (CAMs)	May play a role in intercellular signaling and in connecting cells with the extracellular matrix. May take part in the regulation of cell motility, growth and differentiation. Binds hyaluronic acid			rs308365	0.992013	0.97550401397887	0.9472039		118661 [VCAN (confirmed) Wagner syndrome 1,143200];	RCV000245890.1 [benign]; RCV000269869.1 [benign]; RCV000308582.1 [benign]; 								0		1196	81			n/a	n/a	VCAN (inh=AD pLI=1.00)
chr5	86564564	86564564	C	T	0.4444	18		166.0	5|0|3,3|0|7,5|3	RASA1	missense_variant	RASA1:NM_002890.2:missense_variant:MODERATE:exon1/25:c.296C>T:p.Ala99Val						rs111840875	0.0125799	0.020004639791566	0.0192664		139150 [RASA1 (confirmed) Parkes Weber syndrome,608355|Capillary malformation-arteriovenous malformation,608354|Basal cell carcinoma,somatic,605462];	RCV000199589.2 [benign]; RCV000279612.1 [likely benign]; RCV000351057.1 [likely benign]; 		2.605000	T	T,T	B,B	T	11.81	0		1	53			n/a	n/a	RASA1 (inh=AD pLI=1.00)
chr5	112175770	112175770	G	A	0.4118	34		292.0	4|10|0,14|6|0,5|8	APC	synonymous_variant	APC:NM_000038.5:synonymous_variant:LOW:exon16/16:c.4479G>A:p.Thr1493Thr,APC:NM_001127511.2:synonymous_variant:LOW:exon14/14:c.4425G>A:p.Thr1475Thr,APC:NM_001127510.2:synonymous_variant:LOW:exon17/17:c.4479G>A:p.Thr1493Thr						rs41115	0.665535	0.6485700596428	0.6435269	COSM3760869	611731 [APC (confirmed) Adenomatous polyposis coli,175100|Gastric cancer,somatic,613659|Adenoma,periampullary,somatic|Hepatoblastoma,somatic,114550|Desmoid disease,hereditary,135290|Colorectal cancer,somatic,114500|Brain tumor-polyposis syndrome 2,175100|Gardner syndrome,175100];	RCV000035071.9 [benign]; RCV000074234.1 [other]; RCV000162372.1 [benign]; RCV000383485.1 [benign]; 								2	Leuk,SomaticAndTreatment,	1097	1330	1	[1] old entry - no details available	n/a	n/a	APC (inh=AD pLI=1.00)
chr5	112176325	112176325	G	A	0.3571	28		182.0	0|10|0,16|2|0,4|4	APC	synonymous_variant	APC:NM_000038.5:synonymous_variant:LOW:exon16/16:c.5034G>A:p.Gly1678Gly,APC:NM_001127511.2:synonymous_variant:LOW:exon14/14:c.4980G>A:p.Gly1660Gly,APC:NM_001127510.2:synonymous_variant:LOW:exon17/17:c.5034G>A:p.Gly1678Gly						rs42427	0.666733	0.65139551052841	0.6443950	COSM3760870	611731 [APC (confirmed) Adenomatous polyposis coli,175100|Gastric cancer,somatic,613659|Adenoma,periampullary,somatic|Hepatoblastoma,somatic,114550|Desmoid disease,hereditary,135290|Colorectal cancer,somatic,114500|Brain tumor-polyposis syndrome 2,175100|Gardner syndrome,175100];	RCV000035074.9 [benign]; RCV000074235.1 [other]; RCV000162373.1 [benign]; RCV000390083.1 [benign]; 								2	Leuk,SomaticAndTreatment,	1107	1314	1	[1] old entry - no details available	n/a	n/a	APC (inh=AD pLI=1.00)
chr5	112176756	112176756	T	A	0.6364	11		157.0	6|1|0,3|1|0,6|9	APC	missense_variant	APC:NM_000038.5:missense_variant:MODERATE:exon16/16:c.5465T>A:p.Val1822Asp,APC:NM_001127511.2:missense_variant:MODERATE:exon14/14:c.5411T>A:p.Val1804Asp,APC:NM_001127510.2:missense_variant:MODERATE:exon17/17:c.5465T>A:p.Val1822Asp						rs459552	0.865415	0.79810490805662	0.7913816	COSM3760871	611731 [APC (confirmed) Adenomatous polyposis coli,175100|Gastric cancer,somatic,613659|Adenoma,periampullary,somatic|Hepatoblastoma,somatic,114550|Desmoid disease,hereditary,135290|Colorectal cancer,somatic,114500|Brain tumor-polyposis syndrome 2,175100|Gardner syndrome,175100];	RCV000020089.2 [benign]; RCV000034393.1 [benign]; RCV000035078.10 [benign]; RCV000074239.1 [other]; RCV000132160.2 [benign]; RCV000358689.1 [benign]; RCV000216852.1 [uncertain significance]; 	CM990164 [CLASS=DP MUT=REF PHEN="Adenomatous polyposis coli association with" GENE=APC]; 	3.653000	T	T,T,T	B,B	D,D,D	13.24	0		1696	1012	1	[1] old entry - no details available	n/a	n/a	APC (inh=AD pLI=1.00)
chr5	176636882	176636882	C	T	1.0000	62		1973.0	22|40|0,0|0|0,7|8	NSD1	synonymous_variant	NSD1:NM_022455.4:synonymous_variant:LOW:exon5/23:c.1482C>T:p.Cys494Cys,NSD1:NM_172349.2:synonymous_variant:LOW:exon6/24:c.675C>T:p.Cys225Cys						rs1363405	0.468051	0.29990591575333	0.2926227		606681 [NSD1 (confirmed) Sotos syndrome 1,117550|Leukemia,acute myeloid,601626|Beckwith-Wiedemann syndrome,130650];	RCV000082100.6 [benign]; RCV000319604.1 [benign]; RCV000371717.1 [benign]; 								2	GT,SomaticAndTreatment,	97	539			n/a	n/a	NSD1 (inh=AD pLI=1.00)
chr5	176637149	176637149	G	A	1.0000	15		474.0	5|10|0,0|0|0,6|8	NSD1	synonymous_variant	NSD1:NM_022455.4:synonymous_variant:LOW:exon5/23:c.1749G>A:p.Glu583Glu,NSD1:NM_172349.2:synonymous_variant:LOW:exon6/24:c.942G>A:p.Glu314Glu						rs3733874	0.0000	0.17646373531272	0.1644588		606681 [NSD1 (confirmed) Sotos syndrome 1,117550|Leukemia,acute myeloid,601626|Beckwith-Wiedemann syndrome,130650];	RCV000082103.6 [benign]; RCV000283379.1 [benign]; RCV000379961.1 [benign]; 								2	GT,SomaticAndTreatment,	34	331			n/a	n/a	NSD1 (inh=AD pLI=1.00)
chr5	176637240	176637240	G	T	1.0000	9		277.0	8|1|0,0|0|0,6|5	NSD1	missense_variant	NSD1:NM_022455.4:missense_variant:MODERATE:exon5/23:c.1840G>T:p.Val614Leu,NSD1:NM_172349.2:missense_variant:MODERATE:exon6/24:c.1033G>T:p.Val345Leu						rs3733875	0.228634	0.17623767391598	0.1710245		606681 [NSD1 (confirmed) Sotos syndrome 1,117550|Leukemia,acute myeloid,601626|Beckwith-Wiedemann syndrome,130650];	RCV000082107.6 [benign]; RCV000291627.1 [benign]; RCV000344352.1 [benign]; 		-0.301000	T	T,T,T,T,T	B,B,B	D,D,D,D	0.00	2	GT,SomaticAndTreatment,	34	330			n/a	n/a	NSD1 (inh=AD pLI=1.00)
chr5	176694565	176694565	G	T	0.4000	10		63.0	0|0|4,0|0|6,3|3	NSD1	missense_variant&splice_region_variant	NSD1:NM_022455.4:missense_variant&splice_region_variant:MODERATE:exon15/23:c.5149G>T:p.Gly1717Cys,NSD1:NM_172349.2:missense_variant&splice_region_variant:MODERATE:exon16/24:c.4342G>T:p.Gly1448Cys	Zinc_finger__PHD-finger__2_,Zinc_finger__RING/FYVE/PHD-type__1_,Zinc_finger__PHD-type__conserved_site__1_,Zinc_finger__PHD-type__1_,Zinc_finger__FYVE/PHD-type__1_						0.0000	0.0000	0.0000		606681 [NSD1 (confirmed) Sotos syndrome 1,117550|Leukemia,acute myeloid,601626|Beckwith-Wiedemann syndrome,130650];			9.864000	D	D,D,D,D	D,D,D	D,D,D,D	33.00	1	cfDNA_HNSCC,	0	0			n/a	n/a	NSD1 (inh=AD pLI=1.00)
chr6	7572262	7572262	A	G	1.0000	23		766.0	19|4|0,0|0|0,5|4	DSP	synonymous_variant	DSP:NM_004415.3:synonymous_variant:LOW:exon15/24:c.2091A>G:p.Gly697Gly,DSP:NM_001008844.2:synonymous_variant:LOW:exon15/24:c.2091A>G:p.Gly697Gly,DSP:NM_001319034.1:synonymous_variant:LOW:exon15/24:c.2091A>G:p.Gly697Gly						rs2076304	0.774361	0.76143710007256	0.7531060		125647 [DSP (confirmed) Keratosis palmoplantaris striata II,612908|Cardiomyopathy,dilated,with woolly hair and keratoderma,605676|Arrhythmogenic right ventricular dysplasia 8,607450|Skin fragility-woolly hair syndrome,607655|Epidermolysis bullosa,lethal acantholytic,609638|Dilated cardiomyopathy with woolly hair,keratoderma,and tooth agenesis,615821];	RCV000154389.1 [benign]; RCV000206052.1 [benign]; RCV000206052.1 [benign]; RCV000038004.2 [benign]; 								0		911	542			n/a	n/a	DSP (inh=AR+AD pLI=1.00)
chr6	7585967	7585967	G	C	1.0000	13		394.0	13|0|0,0|0|0,3|5	DSP	synonymous_variant,sequence_feature	DSP:NM_004415.3:synonymous_variant:LOW:exon24/24:c.8472G>C:p.Gly2824Gly,DSP:NM_001008844.2:synonymous_variant:LOW:exon24/24:c.6675G>C:p.Gly2225Gly,DSP:NM_001319034.1:synonymous_variant:LOW:exon24/24:c.7143G>C:p.Gly2381Gly,DSP:NM_004415.3:sequence_feature:LOW:exon24/24:c.8472G>C:,DSP:NM_001008844.2:sequence_feature:LOW:exon24/24:c.6675G>C:						rs2744380	0.709465	0.7116652312177	0.6998662		125647 [DSP (confirmed) Keratosis palmoplantaris striata II,612908|Cardiomyopathy,dilated,with woolly hair and keratoderma,605676|Arrhythmogenic right ventricular dysplasia 8,607450|Skin fragility-woolly hair syndrome,607655|Epidermolysis bullosa,lethal acantholytic,609638|Dilated cardiomyopathy with woolly hair,keratoderma,and tooth agenesis,615821];	RCV000154391.1 [benign]; RCV000038104.4 [benign]; RCV000241982.1 [benign]; RCV000273141.1 [benign]; RCV000304085.1 [benign]; RCV000328251.1 [benign]; RCV000363396.1 [benign]; 								0		768	598			n/a	n/a	DSP (inh=AR+AD pLI=1.00)
chr6	29141743	29141743	A	G	1.0000	29		935.0	11|0|18,0|0|0,4|2	OR2J2	missense_variant	OR2J2:NM_030905.2:missense_variant:MODERATE:exon1/1:c.331A>G:p.Thr111Ala		Olfactory transduction	Odorant receptor (Potential)			rs3129157	0.941494	0.96632227299821	0.9027356	COSM4160486			CM141886 [CLASS=FP MUT=ALT PHEN="Altered receptor function" GENE=OR2J2]; 	-0.824000	T	T		T	5.09	0		819	43			n/a	n/a	OR2J2 (inh=n/a pLI=0.01)
chr6	29141772	29141772	A	G	1.0000	30		951.0	12|0|18,0|0|0,4|2	OR2J2	synonymous_variant	OR2J2:NM_030905.2:synonymous_variant:LOW:exon1/1:c.360A>G:p.Ser120Ser		Olfactory transduction	Odorant receptor (Potential)			rs3129158	0.749201	0.8189897952422	0.7706490											0		614	213			n/a	n/a	OR2J2 (inh=n/a pLI=0.01)
chr6	35434083	35434083	G	A	0.5000	12		114.0	6|0|0,4|2|0,3|3	FANCE	synonymous_variant,sequence_feature	FANCE:NM_021922.2:synonymous_variant:LOW:exon10/10:c.1572G>A:p.Arg524Arg,FANCE:NM_021922.2:sequence_feature:LOW:exon10/10:c.1572G>A:			As part of the Fanconi anemia (FA) complex functions in DNA cross-links repair. Required for the nuclear accumulation of FANCC and provides a critical bridge between the FA complex and FANCD2	BRCA1-dependent Ub-ligase activity;Role of BRCA1,  BRCA2 and ATR in Cancer Susceptibility		rs115195341	0.00199681	0.003690036900369	0.0039420		613976 [FANCE (provisional) Fanconi anemia,complementation group E,600901];	RCV000204051.2 [benign]; RCV000297095.1 [uncertain significance]; 								0		0	40			n/a	n/a	FANCE (inh=AR pLI=0.00)
chr6	57244780	57244780	G	A	0.5000	16		166.0	8|0|0,8|0|0,3|1	PRIM2	missense_variant	PRIM2:NM_000947.4:missense_variant:MODERATE:exon6/15:c.541G>A:p.Glu181Lys						rs5011403	0.0000	0.50001556032739	0.0364171											0		0	865			n/a	n/a	PRIM2 (inh=n/a pLI=0.00)
chr6	57246847	57246847	C	T	0.5000	20		222.0	1|9|0,0|10|0,4|6	PRIM2	synonymous_variant	PRIM2:NM_000947.4:synonymous_variant:LOW:exon7/15:c.574C>T:p.Leu192Leu						rs2230042	0.0521166	0.066106030461605	0.0615675											0		0	94			n/a	n/a	PRIM2 (inh=n/a pLI=0.00)
chr6	57246969	57246969	G	A	0.4000	15		86.0	6|0|0,8|1|0,5|3	PRIM2	splice_region_variant&intron_variant	PRIM2:NM_000947.4:splice_region_variant&intron_variant:LOW:exon7/14:c.693+3G>A:						rs4256440	0.0000	0.49980100492513	0.0364814											0		0	866			n/a	n/a	PRIM2 (inh=n/a pLI=0.00)
chr6	57372361	57372361	C	A	0.3889	36		299.0	0|2|22,2|0|10,3|7	PRIM2	splice_region_variant&intron_variant	PRIM2:NM_000947.4:splice_region_variant&intron_variant:LOW:exon8/14:c.761+6C>A:						rs9382770	0.0000	0.5000165831979	0.0325458											0		24	837			n/a	n/a	PRIM2 (inh=n/a pLI=0.00)
chr6	57372365	57372365	A	G	0.3889	36		299.0	0|0|14,2|6|18,3|7	PRIM2	splice_region_variant&intron_variant	PRIM2:NM_000947.4:splice_region_variant&intron_variant:LOW:exon8/14:c.761+10A>G:						rs9396315	0.0000	0.35794828536014	0.0131829											0		0	122			n/a	n/a	PRIM2 (inh=n/a pLI=0.00)
chr6	57398154	57398154	T	C	0.3750	16		85.0	0|6|0,2|8|0,5|2	PRIM2	missense_variant	PRIM2:NM_000947.4:missense_variant:MODERATE:exon10/15:c.857T>C:p.Leu286Pro						rs80081867	0.0000	0.49937131169528	0.0202889											0		1	865			n/a	n/a	PRIM2 (inh=n/a pLI=0.00)
chr6	57398157	57398157	A	G	0.3750	16		85.0	0|6|0,2|8|0,5|2	PRIM2	missense_variant	PRIM2:NM_000947.4:missense_variant:MODERATE:exon10/15:c.860A>G:p.Tyr287Cys						rs9476080	0.0000	0.49937131169528	0.0201088											0		1	865			n/a	n/a	PRIM2 (inh=n/a pLI=0.00)
chr6	57398163	57398163	A	G	0.3333	18		88.0	0|6|0,4|8|0,5|2	PRIM2	missense_variant	PRIM2:NM_000947.4:missense_variant:MODERATE:exon10/15:c.866A>G:p.His289Arg						rs9476081	0.0000	0.49937970460527	0.0201795											0		1	865			n/a	n/a	PRIM2 (inh=n/a pLI=0.00)
chr6	57398186	57398186	-	A	0.3125	16		54.0	0|6|0,2|8|0,5|2	PRIM2	frameshift_variant	PRIM2:NM_000947.4:frameshift_variant:HIGH:exon10/15:c.893dupA:p.Asn298fs						rs386407218	0.0000	0.18679016942841	0.0252019	COSM1745432										0		0	832			n/a	n/a	PRIM2 (inh=n/a pLI=0.00)
chr6	57398201	57398201	T	C	0.3333	15		73.0	0|5|0,2|8|0,5|2	PRIM2	missense_variant	PRIM2:NM_000947.4:missense_variant:MODERATE:exon10/15:c.904T>C:p.Cys302Arg						rs62398997	0.0000	0.49807917635082	0.0356068											0		1	866			n/a	n/a	PRIM2 (inh=n/a pLI=0.00)
chr6	57467084	57467084	A	G	0.3333	12		54.0	4|0|0,0|0|8,3|3	PRIM2	missense_variant	PRIM2:NM_000947.4:missense_variant:MODERATE:exon11/15:c.1025A>G:p.Asp342Gly						rs9885913	0.0000	0.4994111109268	0.0187905	COSM150112										0		0	840			n/a	n/a	PRIM2 (inh=n/a pLI=0.00)
chr6	57467093	57467093	A	G	0.3333	12		55.0	4|0|0,0|0|8,3|3	PRIM2	missense_variant	PRIM2:NM_000947.4:missense_variant:MODERATE:exon11/15:c.1034A>G:p.Tyr345Cys						rs9885916	0.0000	0.49944425089998	0.0187905	COSM150113										0		0	847			n/a	n/a	PRIM2 (inh=n/a pLI=0.00)
chr6	57467100	57467100	G	C	0.5000	12		120.0	4|0|2,0|0|6,3|3	PRIM2	stop_lost	PRIM2:NM_000947.4:stop_lost:HIGH:exon11/15:c.1041G>C:p.Ter347Tyrext*?						rs4535533	0.0000	0.5	0.0253884											0		0	869			n/a	n/a	PRIM2 (inh=n/a pLI=0.00)
chr6	57467107	57467107	C	T	0.3333	12		55.0	4|0|0,0|0|8,3|3	PRIM2	missense_variant	PRIM2:NM_000947.4:missense_variant:MODERATE:exon11/15:c.1048C>T:p.Arg350Cys						rs9885751	0.0000	0.49936165273909	0.0218901	COSM150114										0		0	847			n/a	n/a	PRIM2 (inh=n/a pLI=0.00)
chr6	57467175	57467175	A	G	0.2000	20		16.0	0|0|4,2|0|14,2|2	PRIM2	synonymous_variant	PRIM2:NM_000947.4:synonymous_variant:LOW:exon11/15:c.1116A>G:p.Leu372Leu						rs4406234	0.0000	0.5	0.0310024											0		0	866			n/a	n/a	PRIM2 (inh=n/a pLI=0.00)
chr6	57499042	57499042	-	T	0.3636	11		55.0	0|0|4,0|0|7,2|3	PRIM2	splice_region_variant&intron_variant	PRIM2:NM_000947.4:splice_region_variant&intron_variant:LOW:exon13/14:c.1299+14dupT:						rs397693584	0.0000	0.49331783846601	0.0246682											0		0	820			n/a	n/a	PRIM2 (inh=n/a pLI=0.00)
chr6	57512476	57512476	G	A	0.6522	23		273.0	11|4|0,8|0|0,5|2	PRIM2	missense_variant	PRIM2:NM_000947.4:missense_variant:MODERATE:exon14/15:c.1304G>A:p.Gly435Asp						rs4307164	0.0000	0.50027365453188	0.0310153											0		4	850			n/a	n/a	PRIM2 (inh=n/a pLI=0.00)
chr6	57512510	57512510	T	G	0.8750	32		758.0	24|4|0,4|0|0,5|2	PRIM2	missense_variant	PRIM2:NM_000947.4:missense_variant:MODERATE:exon14/15:c.1338T>G:p.His446Gln						rs4294007	0.629193	0.69874393566824	0.0732200											0		329	535			n/a	n/a	PRIM2 (inh=n/a pLI=0.00)
chr6	57512529	57512529	C	A	0.1739	46		15.0	8|0|0,30|8|0,5|2	PRIM2	missense_variant	PRIM2:NM_000947.4:missense_variant:MODERATE:exon14/15:c.1357C>A:p.Arg453Ser						rs5001076	0.0000	0.49922073184886	0.0185847											0		0	830			n/a	n/a	PRIM2 (inh=n/a pLI=0.00)
chr6	57512565	57512565	T	C	0.6522	46		743.0	22|8|0,16|0|0,5|2	PRIM2	missense_variant	PRIM2:NM_000947.4:missense_variant:MODERATE:exon14/15:c.1393T>C:p.Ser465Pro						rs4294008	0.0000	0.50024844720497	0.0364299											0		0	863			n/a	n/a	PRIM2 (inh=n/a pLI=0.00)
chr6	57512678	57512678	G	A	0.2857	14		46.0	0|4|0,4|6|0,3|2	PRIM2	synonymous_variant	PRIM2:NM_000947.4:synonymous_variant:LOW:exon14/15:c.1506G>A:p.Glu502Glu						rs4398719	0.0000	0.50017389000215	0.0337419											0		2	855			n/a	n/a	PRIM2 (inh=n/a pLI=0.00)
chr6	105526518	105526518	C	A	0.2857	14		38.0	0|0|4,2|2|6,5|4	LIN28B	missense_variant	LIN28B:NM_001004317.3:missense_variant:MODERATE:exon4/4:c.613C>A:p.Pro205Thr			Acts as a suppressor of microRNA (miRNA) biogenesis by specifically binding the precursor let-7 (pre-let-7), a miRNA precursor. Acts by binding pre-let-7 and recruiting ZCCHC11/TUT4 uridylyltransferase, leading to the terminal uridylation of pre- let-7. Uridylated pre-let-7 miRNAs fail to be processed by Dicer and undergo degradation. Specifically recognizes the 5'-GGAG-3' motif in the terminal loop of pre-let-7. Also recognizes and binds non pre-let-7 pre-miRNAs that contain the 5'-GGAG-3' motif in the terminal loop, leading to their terminal uridylation and subsequent degradation. Mediates MYC-mediated let-7 repression. Isoform 1, when overexpressed, stimulates growth of the breast adenocarcinoma cell line MCF-7. Isoform 2 has no effect on cell growth				0.0000	0.0000	0.0000					0.959000	T	T	B		4.83	2	cfDNA_HNSCC,	0	1			n/a	n/a	LIN28B (inh=n/a pLI=0.72)
chr6	112435273	112435273	A	C	0.2857	14		46.0	4|0|0,6|4|0,2|3	LAMA4	splice_region_variant&intron_variant	LAMA4:NM_001105206.2:splice_region_variant&intron_variant:LOW:exon38/38:c.5326+6T>G:,LAMA4:NM_001105207.2:splice_region_variant&intron_variant:LOW:exon38/38:c.5305+6T>G:,LAMA4:NM_002290.4:splice_region_variant&intron_variant:LOW:exon38/38:c.5305+6T>G:						rs3734289	0.240016	0.23923373923374	0.2422960		600133 [LAMA4 (provisional) Cardiomyopathy,dilated,1JJ,615235];	RCV000037394.5 [benign]; 								1	cfDNA_HNSCC,	100	495			n/a	n/a	LAMA4 (inh=AD pLI=0.00)
chr6	112435912	112435912	A	T	0.5789	19		261.0	1|10|0,0|8|0,9|8	LAMA4	synonymous_variant	LAMA4:NM_001105206.2:synonymous_variant:LOW:exon37/39:c.5160T>A:p.Val1720Val,LAMA4:NM_001105207.2:synonymous_variant:LOW:exon37/39:c.5139T>A:p.Val1713Val,LAMA4:NM_002290.4:synonymous_variant:LOW:exon37/39:c.5139T>A:p.Val1713Val						rs1050353	0.281749	0.26712532171847	0.2689191		600133 [LAMA4 (provisional) Cardiomyopathy,dilated,1JJ,615235];	RCV000037389.5 [benign]; 								0		112	533			n/a	n/a	LAMA4 (inh=AD pLI=0.00)
chr6	112457383	112457383	G	C	0.7333	15		247.0	8|0|3,2|2|0,3|6	LAMA4	missense_variant	LAMA4:NM_001105206.2:missense_variant:MODERATE:exon25/39:c.3356C>G:p.Pro1119Arg,LAMA4:NM_001105207.2:missense_variant:MODERATE:exon25/39:c.3335C>G:p.Pro1112Arg,LAMA4:NM_002290.4:missense_variant:MODERATE:exon25/39:c.3335C>G:p.Pro1112Arg	Concanavalin_A-like_lectin/glucanase__1_,Concanavalin_A-like_lectin/glucanase__subgroup__1_,Laminin_G_domain__2_,Laminin_G__subdomain_2__1_					rs1050349	0.210463	0.2249026145517	0.2245280		600133 [LAMA4 (provisional) Cardiomyopathy,dilated,1JJ,615235];	RCV000037365.6 [benign]; 		9.026000	D	T,D,D,D	D,D	T,T,T,T	23.70	1	I16R041,	91	489			n/a	n/a	LAMA4 (inh=AD pLI=0.00)
chr6	112457390	112457390	C	T	0.7333	15		247.0	8|0|3,2|2|0,5|8	LAMA4	missense_variant	LAMA4:NM_001105206.2:missense_variant:MODERATE:exon25/39:c.3349G>A:p.Gly1117Ser,LAMA4:NM_001105207.2:missense_variant:MODERATE:exon25/39:c.3328G>A:p.Gly1110Ser,LAMA4:NM_002290.4:missense_variant:MODERATE:exon25/39:c.3328G>A:p.Gly1110Ser	Concanavalin_A-like_lectin/glucanase__1_,Concanavalin_A-like_lectin/glucanase__subgroup__1_,Laminin_G_domain__2_,Laminin_G__subdomain_2__1_					rs2032567	0.839856	0.76914509182714	0.7190232		600133 [LAMA4 (provisional) Cardiomyopathy,dilated,1JJ,615235];	RCV000037364.6 [benign]; 		3.709000	T	T,T,T,T	B,B	T,T,T,T	18.04	0		714	540			n/a	n/a	LAMA4 (inh=AD pLI=0.00)
chr6	112493872	112493872	A	G	0.4138	29		229.0	0|0|12,0|0|17,6|5	LAMA4	missense_variant	LAMA4:NM_001105206.2:missense_variant:MODERATE:exon12/39:c.1492T>C:p.Tyr498His,LAMA4:NM_001105207.2:missense_variant:MODERATE:exon12/39:c.1471T>C:p.Tyr491His,LAMA4:NM_002290.4:missense_variant:MODERATE:exon12/39:c.1471T>C:p.Tyr491His	Laminin_I__1_					rs1050348	0.758387	0.66491939471862	0.6621502	COSM3761440	600133 [LAMA4 (provisional) Cardiomyopathy,dilated,1JJ,615235];	RCV000037336.6 [benign]; 		2.174000	T	T,T,T,T	B,B	T,T,T,T	2.21	0		553	658			n/a	n/a	LAMA4 (inh=AD pLI=0.00)
chr6	112508769	112508769	T	G	1.0000	38		1081.0	0|2|36,0|0|0,5|5	LAMA4	synonymous_variant	LAMA4:NM_001105206.2:synonymous_variant:LOW:exon8/39:c.849A>C:p.Ala283Ala,LAMA4:NM_001105207.2:synonymous_variant:LOW:exon8/39:c.828A>C:p.Ala276Ala,LAMA4:NM_002290.4:synonymous_variant:LOW:exon8/39:c.828A>C:p.Ala276Ala						rs9387061	1	0.99998351222568	0.9092499		600133 [LAMA4 (provisional) Cardiomyopathy,dilated,1JJ,615235];	RCV000154630.3 [benign]; 		4.759000,4.759000	T,T				9.71	0		1381	0			n/a	n/a	LAMA4 (inh=AD pLI=0.00)
chr6	112508770	112508770	G	T	1.0000	38		1081.0	0|2|36,0|0|0,5|5	LAMA4	missense_variant	LAMA4:NM_001105206.2:missense_variant:MODERATE:exon8/39:c.848C>A:p.Ala283Glu,LAMA4:NM_001105207.2:missense_variant:MODERATE:exon8/39:c.827C>A:p.Ala276Glu,LAMA4:NM_002290.4:missense_variant:MODERATE:exon8/39:c.827C>A:p.Ala276Glu						rs9400522	1	0.99999175597692	0.9086647		600133 [LAMA4 (provisional) Cardiomyopathy,dilated,1JJ,615235];	RCV000172753.3 [benign]; 		4.601000,4.601000,4.601000	T,,T	D,D,D,D,D,D,D,,	B,B,,	T,T,T,T,T,,	23.70	0		1381	0			n/a	n/a	LAMA4 (inh=AD pLI=0.00)
chr6	117678083	117678083	A	G	1.0000	8		254.0	6|2|0,0|0|0,3|4	ROS1	splice_region_variant&intron_variant	ROS1:NM_002944.2:splice_region_variant&intron_variant:LOW:exon24/42:c.3855-5T>C:			Orphan receptor tyrosine kinase (RTK) that plays a role in epithelial cell differentiation and regionalization of the proximal epididymal epithelium. May activate several downstream signaling pathways related to cell differentiation, proliferation, growth and survival including the PI3 kinase-mTOR signaling pathway. Mediates the phosphorylation of PTPN11, an activator of this pathway. May also phosphorylate and activate the transcription factor STAT3 to control anchorage-independent cell growth. Mediates the phosphorylation and the activation of VAV3, a guanine nucleotide exchange factor regulating cell morphology. May activate other downstream signaling proteins including AKT1, MAPK1, MAPK3, IRS1 and PLCG2			rs2243384	0.394569	0.46566651739066	0.4609528											3	TEST_SomaticAndTreatment,	329	670			n/a	n/a	ROS1 (inh=n/a pLI=0.00)
chr6	117724379	117724379	C	T	0.5484	31		375.0	2|2|13,6|0|8,7|4	ROS1	missense_variant	ROS1:NM_002944.2:missense_variant:MODERATE:exon6/43:c.500G>A:p.Arg167Gln			Orphan receptor tyrosine kinase (RTK) that plays a role in epithelial cell differentiation and regionalization of the proximal epididymal epithelium. May activate several downstream signaling pathways related to cell differentiation, proliferation, growth and survival including the PI3 kinase-mTOR signaling pathway. Mediates the phosphorylation of PTPN11, an activator of this pathway. May also phosphorylate and activate the transcription factor STAT3 to control anchorage-independent cell growth. Mediates the phosphorylation and the activation of VAV3, a guanine nucleotide exchange factor regulating cell morphology. May activate other downstream signaling proteins including AKT1, MAPK1, MAPK3, IRS1 and PLCG2			rs2243380	0.0501198	0.071045952004219	0.0709628					2.643000	T	D,D	B	T,T	28.30	3	TEST_SomaticAndTreatment,cfDNA_HNSCC,	9	206			n/a	n/a	ROS1 (inh=n/a pLI=0.00)
chr6	129635800	129635800	G	A	0.4286	56		449.0	16|4|4,12|18|2,6|5	LAMA2	missense_variant&splice_region_variant	LAMA2:NM_000426.3:missense_variant&splice_region_variant:MODERATE:exon24/65:c.3412G>A:p.Val1138Met,LAMA2:NM_001079823.1:missense_variant&splice_region_variant:MODERATE:exon24/64:c.3412G>A:p.Val1138Met	EGF-like__laminin__3_	Cell Communication;Focal adhesion;ECM-receptor interaction;Small cell lung cancer	Binding to cells via a high affinity receptor, laminin is thought to mediate the attachment, migration and organization of cells into tissues during embryonic development by interacting with other extracellular matrix components	Agrin in Postsynaptic Differentiation		rs2306942	0.120008	0.068732770862919	0.0674452		156225 [LAMA2 (confirmed) Muscular dystrophy,congenital merosin-deficient,607855|Muscular dystrophy,congenital,due to partial LAMA2 deficiency,607855];	RCV000078762.7 [benign]; RCV000327660.1 [likely benign]; 	CM087682 [CLASS=DM? MUT=ALT PHEN="Muscular dystrophy merosin deficient" GENE=LAMA2]; 	3.073000	T	T,T,T	B,B	T	20.90	0		6	147	2	[2] old entry - no details available	n/a	n/a	LAMA2 (inh=AR pLI=0.00)
chr6	129722389	129722389	A	G	1.0000	42		1345.0	3|3|36,0|0|0,6|7	LAMA2	synonymous_variant	LAMA2:NM_000426.3:synonymous_variant:LOW:exon38/65:c.5466A>G:p.Glu1822Glu,LAMA2:NM_001079823.1:synonymous_variant:LOW:exon38/64:c.5466A>G:p.Glu1822Glu		Cell Communication;Focal adhesion;ECM-receptor interaction;Small cell lung cancer	Binding to cells via a high affinity receptor, laminin is thought to mediate the attachment, migration and organization of cells into tissues during embryonic development by interacting with other extracellular matrix components	Agrin in Postsynaptic Differentiation		rs3749877	0.544529	0.49784870015331	0.4910292		156225 [LAMA2 (confirmed) Muscular dystrophy,congenital merosin-deficient,607855|Muscular dystrophy,congenital,due to partial LAMA2 deficiency,607855];	RCV000078777.6 [benign]; RCV000387332.1 [benign]; 								1	Leuk,	356	704			n/a	n/a	LAMA2 (inh=AR pLI=0.00)
chr6	129722425	129722425	G	A	1.0000	34		1049.0	1|0|33,0|0|0,7|8	LAMA2	synonymous_variant	LAMA2:NM_000426.3:synonymous_variant:LOW:exon38/65:c.5502G>A:p.Glu1834Glu,LAMA2:NM_001079823.1:synonymous_variant:LOW:exon38/64:c.5502G>A:p.Glu1834Glu		Cell Communication;Focal adhesion;ECM-receptor interaction;Small cell lung cancer	Binding to cells via a high affinity receptor, laminin is thought to mediate the attachment, migration and organization of cells into tissues during embryonic development by interacting with other extracellular matrix components	Agrin in Postsynaptic Differentiation		rs3749878	0.543331	0.49628022829996	0.4884440	COSM4160174	156225 [LAMA2 (confirmed) Muscular dystrophy,congenital merosin-deficient,607855|Muscular dystrophy,congenital,due to partial LAMA2 deficiency,607855];	RCV000078778.6 [benign]; RCV000338699.1 [benign]; 								1	Leuk,	356	703			n/a	n/a	LAMA2 (inh=AR pLI=0.00)
chr6	129807629	129807629	C	T	1.0000	13		379.0	0|13|0,0|0|0,3|5	LAMA2	missense_variant	LAMA2:NM_000426.3:missense_variant:MODERATE:exon56/65:c.7760C>T:p.Ala2587Val,LAMA2:NM_001079823.1:missense_variant:MODERATE:exon55/64:c.7748C>T:p.Ala2583Val	Concanavalin_A-like_lectin/glucanase__1_,Concanavalin_A-like_lectin/glucanase__subgroup__1_,Laminin_G_domain__2_,Laminin_G__subdomain_1__1_	Cell Communication;Focal adhesion;ECM-receptor interaction;Small cell lung cancer	Binding to cells via a high affinity receptor, laminin is thought to mediate the attachment, migration and organization of cells into tissues during embryonic development by interacting with other extracellular matrix components	Agrin in Postsynaptic Differentiation		rs2229848	0.583866	0.66784215916223	0.6644524	COSM1440401	156225 [LAMA2 (confirmed) Muscular dystrophy,congenital merosin-deficient,607855|Muscular dystrophy,congenital,due to partial LAMA2 deficiency,607855];	RCV000153440.2 [benign]; 	CM023406 [CLASS=DP MUT=REF PHEN="Tuberculoid leprosy association with" GENE=LAMA2]; 	4.499000	D	T,T,T,T	D,D	T	34.00	0		723	605			n/a	n/a	LAMA2 (inh=AR pLI=0.00)
chr6	137540381	137540381	T	C	0.1899	79		106.0	12|3|0,34|30|0,9|10	IFNGR1	splice_region_variant&synonymous_variant	IFNGR1:NM_000416.2:splice_region_variant&synonymous_variant:LOW:exon1/7:c.84A>G:p.Ser28Ser						rs201996266	0.0000	8.7854162090929E-5	0.0000579		107470 [IFNGR1 (confirmed) Immunodeficiency 27A,mycobacteriosis,AR,209950|H. pylori infection,susceptibility to,600263|Tuberculosis,susceptibility to,607948|Immunodeficiency 27B,mycobacteriosis,AD,615978|Tuberculosis infection,protection against,607948|Hepatitis B virus infection,susceptibility to,610424];	RCV000323766.1 [uncertain significance]; 								0		0	2			n/a	n/a	IFNGR1 (inh=AR+AD pLI=0.33)
chr6	146720360	146720360	C	A	0.2174	23		14.0	4|1|0,8|6|4,5|6	GRM1	missense_variant	GRM1:NM_001278064.1:missense_variant:MODERATE:exon7/8:c.2185C>A:p.Pro729Thr,GRM1:NM_001278065.1:missense_variant:MODERATE:exon8/10:c.2185C>A:p.Pro729Thr,GRM1:NM_001278066.1:missense_variant:MODERATE:exon7/9:c.2185C>A:p.Pro729Thr,GRM1:NM_001278067.1:missense_variant:MODERATE:exon7/8:c.2185C>A:p.Pro729Thr	GPCR__family_3__C-terminal__2_					rs41305288	0.0103834	0.017206444385872	0.0160446		604473 [GRM1 (confirmed) Spinocerebellar ataxia,autosomal recessive 13,614831];		CM1414797 [CLASS=FP MUT=ALT PHEN="Diminished calcium response" GENE=GRM1]; 	5.920000	D	D,D,D,D,D,D	D,D,P	D,D,D,D,D,D	24.40	0		3	87			n/a	n/a	GRM1 (inh=AR pLI=0.99)
chr6	151627034	151627034	A	G	0.6333	30		439.0	11|8|0,3|8|0,2|1	AKAP12	synonymous_variant	AKAP12:NM_005100.3:synonymous_variant:LOW:exon3/5:c.315A>G:p.Thr105Thr			Anchoring protein that mediates the subcellular compartmentation of protein kinase A (PKA) and protein kinase C (PKC)			rs2294792	0.23103	0.38291321301485	0.3295864	COSM3761551										1	cfDNA_HNSCC,	144	373			n/a	n/a	AKAP12 (inh=n/a pLI=0.37)
chr6	151670172	151670172	A	C	0.7317	41		704.0	24|6|0,4|7|0,4|3	AKAP12	missense_variant	AKAP12:NM_005100.3:missense_variant:MODERATE:exon4/5:c.646A>C:p.Lys216Gln,AKAP12:NM_144497.2:missense_variant:MODERATE:exon2/3:c.352A>C:p.Lys118Gln			Anchoring protein that mediates the subcellular compartmentation of protein kinase A (PKA) and protein kinase C (PKC)			rs3734799	0.54393	0.67285286972617	0.6680149					0.834000	T	T,T,T,T	B,B,B	T,T,T,T	0.14	0		403	367			n/a	n/a	AKAP12 (inh=n/a pLI=0.37)
chr6	151670897	151670897	T	C	0.2667	15		12.0	0|4|0,4|7|0,2|3	AKAP12	synonymous_variant	AKAP12:NM_005100.3:synonymous_variant:LOW:exon4/5:c.1371T>C:p.Ala457Ala,AKAP12:NM_144497.2:synonymous_variant:LOW:exon2/3:c.1077T>C:p.Ala359Ala			Anchoring protein that mediates the subcellular compartmentation of protein kinase A (PKA) and protein kinase C (PKC)			rs900654	0.711062	0.75245142471036	0.7397816											0		503	302			n/a	n/a	AKAP12 (inh=n/a pLI=0.37)
chr6	152443744	152443744	G	T	0.4167	24		188.0	2|8|0,8|1|5,6|6	SYNE1,ESR1	missense_variant,intron_variant	SYNE1:NM_182961.3:missense_variant:MODERATE:exon146/146:c.26221C>A:p.Leu8741Met,SYNE1:NM_033071.3:missense_variant:MODERATE:exon146/146:c.26077C>A:p.Leu8693Met,ESR1:NM_001328100.1:intron_variant:MODIFIER:exon6/6:c.851-2657G>T:	Klarsicht/ANC-1/syne-1_homology__2_		Multi-isomeric modular protein which forms a linking network between organelles and the actin cytoskeleton to maintain the subcellular spatial organization. Component of SUN-protein- containing multivariate complexes also called LINC complexes which link the nucleoskeleton and cytoskeleton by providing versatile outer nuclear membrane attachment sites for cytoskeletal filaments. May be involved in the maintenance of nuclear organization and structural integrity. Connects nuclei to the cytoskeleton by interacting with the nuclear envelope and with F- actin in the cytoplasm. May be required for centrosome migration to the apical cell surface during early ciliogenesis			rs2295190	0.076877	0.11816428783334	0.1177526	COSM3761559, COSM3761560, COSM3761561, COSM3761557, COSM3761558	608441 [SYNE1 (confirmed) Spinocerebellar ataxia,autosomal recessive 8,610743|Emery-Dreifuss muscular dystrophy 4,autosomal dominant,612998];	RCV000118476.3 [other]; RCV000325739.1 [benign]; RCV000384879.1 [benign]; 		1.590000	T	D,D,D,D,D,D,D,,D,D	D,D,D	T,T,T,T,T,T,T,T	24.50	0		38	648	1	[1] Julia Bickmann 18.09.2014	n/a	n/a	SYNE1 (inh=AR+AD pLI=0.00), ESR1 (inh=AR pLI=0.99)
chr6	152464839	152464839	A	G	1.0000	28		854.0	10|13|5,0|0|0,6|7	SYNE1	synonymous_variant	SYNE1:NM_182961.3:synonymous_variant:LOW:exon138/146:c.25038T>C:p.Arg8346Arg,SYNE1:NM_033071.3:synonymous_variant:LOW:exon138/146:c.24894T>C:p.Arg8298Arg			Multi-isomeric modular protein which forms a linking network between organelles and the actin cytoskeleton to maintain the subcellular spatial organization. Component of SUN-protein- containing multivariate complexes also called LINC complexes which link the nucleoskeleton and cytoskeleton by providing versatile outer nuclear membrane attachment sites for cytoskeletal filaments. May be involved in the maintenance of nuclear organization and structural integrity. Connects nuclei to the cytoskeleton by interacting with the nuclear envelope and with F- actin in the cytoplasm. May be required for centrosome migration to the apical cell surface during early ciliogenesis			rs2256135	0.689696	0.61089506986554	0.6053606		608441 [SYNE1 (confirmed) Spinocerebellar ataxia,autosomal recessive 8,610743|Emery-Dreifuss muscular dystrophy 4,autosomal dominant,612998];	RCV000118470.3 [other]; RCV000313035.1 [benign]; RCV000367836.1 [benign]; 								1	Leuk,	882	1347			n/a	n/a	SYNE1 (inh=AR+AD pLI=0.00)
chr6	152614804	152614804	C	T	0.1935	31		28.0	0|0|6,3|0|22,7|6	SYNE1	synonymous_variant	SYNE1:NM_182961.3:synonymous_variant:LOW:exon95/146:c.17931G>A:p.Thr5977Thr,SYNE1:NM_033071.3:synonymous_variant:LOW:exon94/146:c.17718G>A:p.Thr5906Thr			Multi-isomeric modular protein which forms a linking network between organelles and the actin cytoskeleton to maintain the subcellular spatial organization. Component of SUN-protein- containing multivariate complexes also called LINC complexes which link the nucleoskeleton and cytoskeleton by providing versatile outer nuclear membrane attachment sites for cytoskeletal filaments. May be involved in the maintenance of nuclear organization and structural integrity. Connects nuclei to the cytoskeleton by interacting with the nuclear envelope and with F- actin in the cytoplasm. May be required for centrosome migration to the apical cell surface during early ciliogenesis			rs761522466	0.0000	2.4712918266142E-5	0.0000193		608441 [SYNE1 (confirmed) Spinocerebellar ataxia,autosomal recessive 8,610743|Emery-Dreifuss muscular dystrophy 4,autosomal dominant,612998];									1	cfDNA_HNSCC,	0	0			n/a	n/a	SYNE1 (inh=AR+AD pLI=0.00)
chr6	152629617	152629617	C	T	0.4839	31		314.0	0|0|15,2|0|14,8|5	SYNE1	splice_region_variant&intron_variant	SYNE1:NM_182961.3:splice_region_variant&intron_variant:LOW:exon91/145:c.17346+7G>A:,SYNE1:NM_033071.3:splice_region_variant&intron_variant:LOW:exon90/145:c.17133+7G>A:			Multi-isomeric modular protein which forms a linking network between organelles and the actin cytoskeleton to maintain the subcellular spatial organization. Component of SUN-protein- containing multivariate complexes also called LINC complexes which link the nucleoskeleton and cytoskeleton by providing versatile outer nuclear membrane attachment sites for cytoskeletal filaments. May be involved in the maintenance of nuclear organization and structural integrity. Connects nuclei to the cytoskeleton by interacting with the nuclear envelope and with F- actin in the cytoplasm. May be required for centrosome migration to the apical cell surface during early ciliogenesis			rs9383985	0.304313	0.32362923421642	0.3152138		608441 [SYNE1 (confirmed) Spinocerebellar ataxia,autosomal recessive 8,610743|Emery-Dreifuss muscular dystrophy 4,autosomal dominant,612998];	RCV000118452.3 [other]; RCV000336490.1 [benign]; RCV000394440.1 [benign]; 								1	cfDNA_HNSCC,	340	1256	1	[1] Julia Bickmann 18.09.2014	n/a	n/a	SYNE1 (inh=AR+AD pLI=0.00)
chr6	152647681	152647681	A	T	0.2174	46		101.0	8|2|0,18|18|0,5|5	SYNE1	missense_variant	SYNE1:NM_182961.3:missense_variant:MODERATE:exon79/146:c.15043T>A:p.Leu5015Met,SYNE1:NM_033071.3:missense_variant:MODERATE:exon78/146:c.14830T>A:p.Leu4944Met			Multi-isomeric modular protein which forms a linking network between organelles and the actin cytoskeleton to maintain the subcellular spatial organization. Component of SUN-protein- containing multivariate complexes also called LINC complexes which link the nucleoskeleton and cytoskeleton by providing versatile outer nuclear membrane attachment sites for cytoskeletal filaments. May be involved in the maintenance of nuclear organization and structural integrity. Connects nuclei to the cytoskeleton by interacting with the nuclear envelope and with F- actin in the cytoplasm. May be required for centrosome migration to the apical cell surface during early ciliogenesis			rs2306916	0.814696	0.77974120168136	0.7736971		608441 [SYNE1 (confirmed) Spinocerebellar ataxia,autosomal recessive 8,610743|Emery-Dreifuss muscular dystrophy 4,autosomal dominant,612998];	RCV000118448.3 [other]; RCV000296846.1 [benign]; RCV000335569.1 [benign]; 		2.934000	T	T,T,T,T,T	B,B,B,B	T,T,T,T,T	16.07	1	Leuk,	1514	1082			n/a	n/a	SYNE1 (inh=AR+AD pLI=0.00)
chr6	152652034	152652034	A	T	0.6190	21		315.0	0|3|10,2|1|5,6|10	SYNE1	missense_variant	SYNE1:NM_182961.3:missense_variant:MODERATE:exon78/146:c.13786T>A:p.Ser4596Thr,SYNE1:NM_033071.3:missense_variant:MODERATE:exon77/146:c.13573T>A:p.Ser4525Thr			Multi-isomeric modular protein which forms a linking network between organelles and the actin cytoskeleton to maintain the subcellular spatial organization. Component of SUN-protein- containing multivariate complexes also called LINC complexes which link the nucleoskeleton and cytoskeleton by providing versatile outer nuclear membrane attachment sites for cytoskeletal filaments. May be involved in the maintenance of nuclear organization and structural integrity. Connects nuclei to the cytoskeleton by interacting with the nuclear envelope and with F- actin in the cytoplasm. May be required for centrosome migration to the apical cell surface during early ciliogenesis			rs6911096	0.803315	0.77597145776342	0.7705397	COSM450728, COSM450729, COSM1487365	608441 [SYNE1 (confirmed) Spinocerebellar ataxia,autosomal recessive 8,610743|Emery-Dreifuss muscular dystrophy 4,autosomal dominant,612998];	RCV000118444.3 [other]; RCV000290438.1 [benign]; RCV000387036.1 [benign]; 		-2.513000	T	T,T,T,T,T	B,B,B,B	T,T,T,T,T	0.00	1	Leuk,	1512	1087			n/a	n/a	SYNE1 (inh=AR+AD pLI=0.00)
chr6	152658142	152658142	T	C	0.6667	18		279.0	6|0|6,0|0|6,4|2	SYNE1	missense_variant	SYNE1:NM_182961.3:missense_variant:MODERATE:exon76/146:c.12362A>G:p.Lys4121Arg,SYNE1:NM_033071.3:missense_variant:MODERATE:exon75/146:c.12149A>G:p.Lys4050Arg			Multi-isomeric modular protein which forms a linking network between organelles and the actin cytoskeleton to maintain the subcellular spatial organization. Component of SUN-protein- containing multivariate complexes also called LINC complexes which link the nucleoskeleton and cytoskeleton by providing versatile outer nuclear membrane attachment sites for cytoskeletal filaments. May be involved in the maintenance of nuclear organization and structural integrity. Connects nuclei to the cytoskeleton by interacting with the nuclear envelope and with F- actin in the cytoplasm. May be required for centrosome migration to the apical cell surface during early ciliogenesis			rs9479297	0.793131	0.75468099283691	0.7259813		608441 [SYNE1 (confirmed) Spinocerebellar ataxia,autosomal recessive 8,610743|Emery-Dreifuss muscular dystrophy 4,autosomal dominant,612998];	RCV000118439.4 [other]; RCV000267635.1 [benign]; RCV000317782.1 [benign]; 		1.431000	T	T,T,T,T,T	B,B,B,B	T,T,T,T,T	6.36	1	Leuk,	1468	1103			n/a	n/a	SYNE1 (inh=AR+AD pLI=0.00)
chr6	152665261	152665261	C	A	1.0000	61		1961.0	31|30|0,0|0|0,4|3	SYNE1	missense_variant	SYNE1:NM_182961.3:missense_variant:MODERATE:exon74/146:c.12180G>T:p.Glu4060Asp,SYNE1:NM_033071.3:missense_variant:MODERATE:exon73/146:c.11967G>T:p.Glu3989Asp			Multi-isomeric modular protein which forms a linking network between organelles and the actin cytoskeleton to maintain the subcellular spatial organization. Component of SUN-protein- containing multivariate complexes also called LINC complexes which link the nucleoskeleton and cytoskeleton by providing versatile outer nuclear membrane attachment sites for cytoskeletal filaments. May be involved in the maintenance of nuclear organization and structural integrity. Connects nuclei to the cytoskeleton by interacting with the nuclear envelope and with F- actin in the cytoplasm. May be required for centrosome migration to the apical cell surface during early ciliogenesis			rs4645434	0.545527	0.57614928324271	0.5765640	COSM1441465, COSM3748319, COSM42924, COSM136573, COSM3748318	608441 [SYNE1 (confirmed) Spinocerebellar ataxia,autosomal recessive 8,610743|Emery-Dreifuss muscular dystrophy 4,autosomal dominant,612998];	RCV000118437.3 [other]; RCV000307999.1 [benign]; RCV000393801.1 [benign]; 		0.426000	T	T,T,T,T,D	B,B,B,B	T,T,T,T,T	5.05	1	Leuk,	1036	1289			n/a	n/a	SYNE1 (inh=AR+AD pLI=0.00)
chr6	152671475	152671475	A	C	1.0000	20		572.0	10|4|6,0|0|0,5|5	SYNE1	splice_region_variant&intron_variant,intron_variant	SYNE1:NM_182961.3:splice_region_variant&intron_variant:LOW:exon71/145:c.11734-5T>G:,SYNE1:NM_033071.3:intron_variant:MODIFIER:exon71/145:c.11688+278T>G:			Multi-isomeric modular protein which forms a linking network between organelles and the actin cytoskeleton to maintain the subcellular spatial organization. Component of SUN-protein- containing multivariate complexes also called LINC complexes which link the nucleoskeleton and cytoskeleton by providing versatile outer nuclear membrane attachment sites for cytoskeletal filaments. May be involved in the maintenance of nuclear organization and structural integrity. Connects nuclei to the cytoskeleton by interacting with the nuclear envelope and with F- actin in the cytoplasm. May be required for centrosome migration to the apical cell surface during early ciliogenesis			rs9478320	0.58746	0.58461918892186	0.5799143		608441 [SYNE1 (confirmed) Spinocerebellar ataxia,autosomal recessive 8,610743|Emery-Dreifuss muscular dystrophy 4,autosomal dominant,612998];	RCV000243119.1 [benign]; 								1	Leuk,	1024	1305	1	[1] Julia Bickmann 18.09.2014	n/a	n/a	SYNE1 (inh=AR+AD pLI=0.00)
chr6	152675854	152675854	A	G	1.0000	22		655.0	12|10|0,0|0|0,5|5	SYNE1	splice_region_variant&intron_variant,synonymous_variant	SYNE1:NM_033071.3:splice_region_variant&intron_variant:LOW:exon67/145:c.10881+6T>C:,SYNE1:NM_182961.3:synonymous_variant:LOW:exon67/146:c.10866T>C:p.Ser3622Ser			Multi-isomeric modular protein which forms a linking network between organelles and the actin cytoskeleton to maintain the subcellular spatial organization. Component of SUN-protein- containing multivariate complexes also called LINC complexes which link the nucleoskeleton and cytoskeleton by providing versatile outer nuclear membrane attachment sites for cytoskeletal filaments. May be involved in the maintenance of nuclear organization and structural integrity. Connects nuclei to the cytoskeleton by interacting with the nuclear envelope and with F- actin in the cytoplasm. May be required for centrosome migration to the apical cell surface during early ciliogenesis			rs9397102	0.568291	0.57994365640291	0.5808017		608441 [SYNE1 (confirmed) Spinocerebellar ataxia,autosomal recessive 8,610743|Emery-Dreifuss muscular dystrophy 4,autosomal dominant,612998];	RCV000118433.3 [other]; RCV000269796.1 [benign]; RCV000364406.1 [benign]; 								1	Leuk,	1026	1301			n/a	n/a	SYNE1 (inh=AR+AD pLI=0.00)
chr6	152708310	152708310	G	A	0.5333	30		408.0	6|10|0,6|8|0,2|5	SYNE1	missense_variant	SYNE1:NM_182961.3:missense_variant:MODERATE:exon54/146:c.8384C>T:p.Ala2795Val,SYNE1:NM_033071.3:missense_variant:MODERATE:exon54/146:c.8405C>T:p.Ala2802Val			Multi-isomeric modular protein which forms a linking network between organelles and the actin cytoskeleton to maintain the subcellular spatial organization. Component of SUN-protein- containing multivariate complexes also called LINC complexes which link the nucleoskeleton and cytoskeleton by providing versatile outer nuclear membrane attachment sites for cytoskeletal filaments. May be involved in the maintenance of nuclear organization and structural integrity. Connects nuclei to the cytoskeleton by interacting with the nuclear envelope and with F- actin in the cytoplasm. May be required for centrosome migration to the apical cell surface during early ciliogenesis			rs214950	0.249002	0.23728534229869	0.2357881	COSM3761573, COSM3761575, COSM3761576, COSM3761574, COSM3761572	608441 [SYNE1 (confirmed) Spinocerebellar ataxia,autosomal recessive 8,610743|Emery-Dreifuss muscular dystrophy 4,autosomal dominant,612998];	RCV000118492.3 [other]; RCV000261819.1 [benign]; RCV000354335.1 [benign]; 		4.552000	T	D,T,D,T,T	B,B,B,B	T,T,T,T,T	7.32	0		171	966	1	[1] Julia Bickmann 05.12.2014	n/a	n/a	SYNE1 (inh=AR+AD pLI=0.00)
chr7	6431546	6431546	A	G	0.5238	21		188.0	4|5|2,6|3|1,7|7	RAC1	splice_region_variant&intron_variant	RAC1:NM_018890.3:splice_region_variant&intron_variant:LOW:exon2/6:c.108-9A>G:,RAC1:NM_006908.4:splice_region_variant&intron_variant:LOW:exon2/5:c.108-9A>G:						rs371132934	0.0000	4.1196341764851E-5	0.0000322											0		0	1			n/a	n/a	RAC1 (inh=n/a pLI=0.57)
chr7	20198440	20198440	G	A	0.6364	44		669.0	6|10|12,6|2|8,3|4	MACC1	missense_variant,sequence_feature	MACC1:NM_182762.3:missense_variant:MODERATE:exon5/7:c.1544C>T:p.Ser515Leu,MACC1:NM_182762.3:sequence_feature:MODERATE:exon5/7:c.1544C>T:			Acts as a transcription activator for MET and as a key regulator of HGF-MET signaling. Promotes cell motility, proliferation and hepatocyte growth factor (HGF)-dependent scattering in vitro and tumor growth and metastasis in vivo			rs975263	0.425519	0.33885477534581	0.3328082	COSM3762560				2.152000	T	T,T	B	T,T	10.56	0		76	354			n/a	n/a	MACC1 (inh=n/a pLI=0.00)
chr7	53103382	53103382	G	T	0.4000	60		505.0	0|0|24,0|0|36,8|7	POM121L12	synonymous_variant	POM121L12:NM_182595.3:synonymous_variant:LOW:exon1/1:c.18G>T:p.Pro6Pro						rs72598685	0.302915	0.42857964347326	0.2541864											0		83	329			n/a	n/a	POM121L12 (inh=n/a pLI=0.00)
chr7	53103554	53103554	C	G	0.4783	23		190.0	2|1|8,2|3|7,8|8	POM121L12	missense_variant	POM121L12:NM_182595.3:missense_variant:MODERATE:exon1/1:c.190C>G:p.Gln64Glu						rs11238247	0.335463	0.44146570089476	0.4318667	COSM3762745				0.130000	T	D	B	T	6.09	0		190	417			n/a	n/a	POM121L12 (inh=n/a pLI=0.00)
chr7	53103571	53103571	G	A	0.3077	13		25.0	2|1|1,2|3|4,8|8	POM121L12	synonymous_variant	POM121L12:NM_182595.3:synonymous_variant:LOW:exon1/1:c.207G>A:p.Gly69Gly						rs11238248	0.328674	0.43925852082295	0.4275195	COSM3762746										0		189	416			n/a	n/a	POM121L12 (inh=n/a pLI=0.00)
chr7	53103673	53103673	C	A	0.3684	19		122.0	4|0|3,1|0|11,7|6	POM121L12	synonymous_variant	POM121L12:NM_182595.3:synonymous_variant:LOW:exon1/1:c.309C>A:p.Pro103Pro						rs1184320	0.485823	0.42444506443007	0.4060860	COSM3762747										0		156	399			n/a	n/a	POM121L12 (inh=n/a pLI=0.00)
chr7	53103946	53103946	G	C	0.5823	79		1095.0	16|30|0,21|12|0,5|6	POM121L12	synonymous_variant	POM121L12:NM_182595.3:synonymous_variant:LOW:exon1/1:c.582G>C:p.Gly194Gly						rs12113170	0.328874	0.43798759086448	0.4322782	COSM4162293										0		189	423			n/a	n/a	POM121L12 (inh=n/a pLI=0.00)
chr7	55233089	55233089	C	T	0.5556	18		235.0	10|0|0,8|0|0,6|3	EGFR	synonymous_variant	EGFR:NM_005228.3:synonymous_variant:LOW:exon15/28:c.1839C>T:p.Ala613Ala,EGFR:NM_201282.1:synonymous_variant:LOW:exon15/16:c.1839C>T:p.Ala613Ala,EGFR:NM_201284.1:synonymous_variant:LOW:exon15/16:c.1839C>T:p.Ala613Ala						rs17290169	0.0421326	0.051241032407026	0.0500630		131550 [EGFR (confirmed) Nonsmall cell lung cancer,response to tyrosine kinase inhibitor in,211980|Adenocarcinoma of lung,response to tyrosine kinase inhibitor in,211980|Nonsmall cell lung cancer,susceptibility to,211980|Inflammatory skin and bowel disease,neonatal,2,616069];	RCV000394040.1 [likely benign]; 								2	TEST_SomaticAndTreatment,	10	195			n/a	n/a	EGFR (inh=AR pLI=1.00)
chr7	55238087	55238087	C	T	0.3704	27		203.0	0|10|0,6|9|2,2|6	EGFR	synonymous_variant,intron_variant	EGFR:NM_201284.1:synonymous_variant:LOW:exon16/16:c.1968C>T:p.His656His,EGFR:NM_005228.3:intron_variant:MODIFIER:exon15/27:c.1881-781C>T:						rs10258429	0.11242	0.08298173907311	0.0809883	COSM3762771	131550 [EGFR (confirmed) Nonsmall cell lung cancer,response to tyrosine kinase inhibitor in,211980|Adenocarcinoma of lung,response to tyrosine kinase inhibitor in,211980|Nonsmall cell lung cancer,susceptibility to,211980|Inflammatory skin and bowel disease,neonatal,2,616069];									1	GT,	7	181			n/a	n/a	EGFR (inh=AR pLI=1.00)
chr7	55266417	55266417	T	C	1.0000	29		772.0	0|29|0,0|0|0,4|5	EGFR	synonymous_variant	EGFR:NM_005228.3:synonymous_variant:LOW:exon23/28:c.2709T>C:p.Thr903Thr						rs1140475	0.916733	0.89567409066948	0.8867425		131550 [EGFR (confirmed) Nonsmall cell lung cancer,response to tyrosine kinase inhibitor in,211980|Adenocarcinoma of lung,response to tyrosine kinase inhibitor in,211980|Nonsmall cell lung cancer,susceptibility to,211980|Inflammatory skin and bowel disease,neonatal,2,616069];	RCV000038451.2 [benign]; 								0		1090	273			n/a	n/a	EGFR (inh=AR pLI=1.00)
chr7	88965993	88965993	G	T	0.1818	22		10.0	0|0|4,0|2|15,5|3	ZNF804B	missense_variant	ZNF804B:NM_181646.3:missense_variant:MODERATE:exon4/4:c.3697G>T:p.Ala1233Ser							0.0000	0.0000	0.0000					0.837000	T	T	P	T	21.90	0		0	0			n/a	n/a	ZNF804B (inh=n/a pLI=0.00)
chr7	94039032	94039032	C	T	0.4643	28		289.0	0|13|0,1|14|0,4|5	COL1A2	splice_region_variant&intron_variant	COL1A2:NM_000089.3:splice_region_variant&intron_variant:LOW:exon18/51:c.937-3C>T:		Cell Communication;Focal adhesion;ECM-receptor interaction	Type I collagen is a member of group I collagen (fibrillar forming collagen)			rs42519	0.824281	0.77422198059276	0.7588101		120160 [COL1A2 (confirmed) Ehlers-Danlos syndrome,type VIIB,130060|Osteogenesis imperfecta,type IV,166220|Osteogenesis imperfecta,type III,259420|Osteogenesis imperfecta,type II,166210|Osteoporosis,postmenopausal,166710|Ehlers-Danlos syndrome,cardiac valvular form,225320];	RCV000253006.2 [benign]; RCV000274743.1 [benign]; RCV000329587.1 [benign]; 	CS151749 [CLASS=R MUT=ALT PHEN="Osteogenesis imperfecta" GENE=COL1A2]; 							0		764	530	2	[2] Ute Grasshoff 24.11.2015	n/a	n/a	COL1A2 (inh=AR+AD pLI=1.00)
chr7	97488569	97488569	A	T	1.0000	14		420.0	2|12|0,0|0|0,3|3	ASNS	missense_variant	ASNS:NM_001673.4:missense_variant:MODERATE:exon5/13:c.629T>A:p.Val210Glu,ASNS:NM_001178077.1:missense_variant:MODERATE:exon3/11:c.380T>A:p.Val127Glu,ASNS:NM_133436.3:missense_variant:MODERATE:exon5/13:c.629T>A:p.Val210Glu,ASNS:NM_001178075.1:missense_variant:MODERATE:exon5/13:c.566T>A:p.Val189Glu,ASNS:NM_001178076.1:missense_variant:MODERATE:exon3/11:c.380T>A:p.Val127Glu,ASNS:NM_183356.3:missense_variant:MODERATE:exon6/14:c.629T>A:p.Val210Glu						rs1049674	0.875998	0.7947767342231	0.7807001		108370 [ASNS (confirmed) Asparagine synthetase deficiency,615574];			4.408000	T	T,T,T,T,T,T,T,T	B	T,T,T,T,T,T,T,T	7.64	1	Leuk,	764	439			n/a	n/a	ASNS (inh=AR pLI=0.00)
chr7	98558880	98558880	G	C	1.0000	57		1812.0	11|16|30,0|0|0,6|5	TRRAP	splice_region_variant&intron_variant	TRRAP:NM_001244580.1:splice_region_variant&intron_variant:LOW:exon44/71:c.6469-4G>C:,TRRAP:NM_003496.3:splice_region_variant&intron_variant:LOW:exon43/70:c.6415-4G>C:						rs160384	0.886981	0.90073153853758	0.8909803											0		1027	237			n/a	n/a	TRRAP (inh=n/a pLI=1.00)
chr7	101755060	101755060	A	G	0.3833	60		486.0	2|8|13,10|12|15,4|6	CUX1	splice_region_variant&intron_variant	CUX1:NM_001202543.1:splice_region_variant&intron_variant:LOW:exon7/23:c.640+6A>G:,CUX1:NM_001202544.2:splice_region_variant&intron_variant:LOW:exon6/21:c.592+6A>G:,CUX1:NM_001202545.2:splice_region_variant&intron_variant:LOW:exon6/21:c.502+6A>G:,CUX1:NM_001913.4:splice_region_variant&intron_variant:LOW:exon7/22:c.640+6A>G:,CUX1:NM_181500.3:splice_region_variant&intron_variant:LOW:exon7/22:c.640+6A>G:,CUX1:NM_001202546.2:splice_region_variant&intron_variant:LOW:exon6/21:c.529+6A>G:,CUX1:NM_181552.3:splice_region_variant&intron_variant:LOW:exon7/23:c.607+6A>G:						rs9655774	0.157348	0.24255419336394	0.2366692											5	SomaticAndTreatment,TEST_SomaticAndTreatment,	56	355			n/a	n/a	CUX1 (inh=n/a pLI=1.00)
chr7	101844851	101844851	A	G	0.7333	30		503.0	18|4|0,4|4|0,3|3	CUX1	synonymous_variant,intron_variant	CUX1:NM_001202543.1:synonymous_variant:LOW:exon18/24:c.2307A>G:p.Pro769Pro,CUX1:NM_181552.3:synonymous_variant:LOW:exon18/24:c.2274A>G:p.Pro758Pro,CUX1:NM_001202544.2:intron_variant:MODIFIER:exon13/21:c.1207+5968A>G:,CUX1:NM_001202545.2:intron_variant:MODIFIER:exon13/21:c.1117+5968A>G:,CUX1:NM_001913.4:intron_variant:MODIFIER:exon14/22:c.1255+5968A>G:,CUX1:NM_181500.3:intron_variant:MODIFIER:exon14/22:c.1249+5968A>G:,CUX1:NM_001202546.2:intron_variant:MODIFIER:exon13/21:c.1138+5968A>G:						rs60987662	0.316693	0.35703339979238	0.3367888	COSM4161680										3	GT,SomaticAndTreatment,	155	445			n/a	n/a	CUX1 (inh=n/a pLI=1.00)
chr7	101892121	101892121	G	A	0.5385	78		943.0	0|0|42,0|0|36,7|6	CUX1	synonymous_variant,intron_variant	CUX1:NM_001202543.1:synonymous_variant:LOW:exon24/24:c.4350G>A:p.Pro1450Pro,CUX1:NM_181552.3:synonymous_variant:LOW:exon24/24:c.4317G>A:p.Pro1439Pro,CUX1:NM_001202544.2:intron_variant:MODIFIER:exon13/21:c.1208-24516G>A:,CUX1:NM_001202545.2:intron_variant:MODIFIER:exon13/21:c.1118-24516G>A:,CUX1:NM_001913.4:intron_variant:MODIFIER:exon14/22:c.1256-24516G>A:,CUX1:NM_181500.3:intron_variant:MODIFIER:exon14/22:c.1250-24516G>A:,CUX1:NM_001202546.2:intron_variant:MODIFIER:exon13/21:c.1139-24516G>A:						rs410825	0.544529	0.7	0.1623302	COSM4161681										2	TEST_SomaticAndTreatment,	184	371			n/a	n/a	CUX1 (inh=n/a pLI=1.00)
chr7	101916647	101916647	A	G	0.4792	48		476.0	1|22|0,8|17|0,2|2	CUX1	synonymous_variant	CUX1:NM_001202544.2:synonymous_variant:LOW:exon14/22:c.1218A>G:p.Ala406Ala,CUX1:NM_001202545.2:synonymous_variant:LOW:exon14/22:c.1128A>G:p.Ala376Ala,CUX1:NM_001913.4:synonymous_variant:LOW:exon15/23:c.1266A>G:p.Ala422Ala,CUX1:NM_181500.3:synonymous_variant:LOW:exon15/23:c.1260A>G:p.Ala420Ala,CUX1:NM_001202546.2:synonymous_variant:LOW:exon14/22:c.1149A>G:p.Ala383Ala						rs813000	0.733626	0.72957181477283	0.7185410	COSM3721378										3	SomaticAndTreatment,TEST_SomaticAndTreatment,	496	343			n/a	n/a	CUX1 (inh=n/a pLI=1.00)
chr7	101917521	101917521	G	A	0.6290	124		2182.0	30|24|24,16|16|14,8|8	CUX1	missense_variant	CUX1:NM_001202544.2:missense_variant:MODERATE:exon15/22:c.1342G>A:p.Ala448Thr,CUX1:NM_001202545.2:missense_variant:MODERATE:exon15/22:c.1252G>A:p.Ala418Thr,CUX1:NM_001913.4:missense_variant:MODERATE:exon16/23:c.1390G>A:p.Ala464Thr,CUX1:NM_181500.3:missense_variant:MODERATE:exon16/23:c.1384G>A:p.Ala462Thr,CUX1:NM_001202546.2:missense_variant:MODERATE:exon15/22:c.1273G>A:p.Ala425Thr	CASP__C-terminal__1_					rs803064	0.559105	0.56850275495727	0.5601528	COSM1755000				2.486000	T	T,T,T,T	B,B,B,B	T,T,T,T	5.82	2	SomaticAndTreatment,TEST_SomaticAndTreatment,	263	457			n/a	n/a	CUX1 (inh=n/a pLI=1.00)
chr7	103123368	103123368	T	C	0.4000	25		192.0	8|2|0,13|2|0,3|2	RELN,LOC101927870	missense_variant,sequence_feature,intron_variant	RELN:NM_005045.3:missense_variant:MODERATE:exon63/65:c.10232A>G:p.Asn3411Ser,RELN:NM_173054.2:missense_variant:MODERATE:exon63/64:c.10232A>G:p.Asn3411Ser,RELN:NM_005045.3:sequence_feature:MODERATE:exon63/65:c.10232A>G:,RELN:NM_173054.2:sequence_feature:MODERATE:exon63/64:c.10232A>G:,LOC101927870:NR_110141.1:intron_variant:MODIFIER:exon2/3:n.1366-21483T>C:		Cell Communication;Focal adhesion;ECM-receptor interaction	Extracellular matrix serine protease that plays a role in layering of neurons in the cerebral cortex and cerebellum. Regulates microtubule function in neurons and neuronal migration. Affects migration of sympathetic preganglionic neurons in the spinal cord, where it seems to act as a barrier to neuronal migration. Enzymatic activity is important for the modulation of cell adhesion. Binding to the extracellular domains of lipoprotein receptors VLDLR and LRP8/APOER2 induces tyrosine phosphorylation of DAB1 and modulation of TAU phosphorylation (By similarity)	Lissencephaly gene (LIS1) in neuronal migration and development;Reelin Signaling Pathway		rs747044548	0.0000	3.2955444239388E-5	0.0000257		600514 [RELN (confirmed) Lissencephaly 2 (Norman-Roberts type),257320|Epilepsy,familial temporal lobe,7,616436];			3.888000,3.888000	T,T	,T,T,T,T,T	,B,P	,T,T,T	15.34	0		0	1			n/a	n/a	RELN (inh=AR+AD pLI=1.00), LOC101927870 (inh=n/a pLI=n/a)
chr7	103185709	103185709	C	T	0.2727	11		25.0	0|0|3,6|0|2,2|2	RELN	missense_variant	RELN:NM_005045.3:missense_variant:MODERATE:exon42/65:c.6385G>A:p.Gly2129Ser,RELN:NM_173054.2:missense_variant:MODERATE:exon42/64:c.6385G>A:p.Gly2129Ser	Neuraminidase__1_,Epidermal_growth_factor-like__type_3__1_	Cell Communication;Focal adhesion;ECM-receptor interaction	Extracellular matrix serine protease that plays a role in layering of neurons in the cerebral cortex and cerebellum. Regulates microtubule function in neurons and neuronal migration. Affects migration of sympathetic preganglionic neurons in the spinal cord, where it seems to act as a barrier to neuronal migration. Enzymatic activity is important for the modulation of cell adhesion. Binding to the extracellular domains of lipoprotein receptors VLDLR and LRP8/APOER2 induces tyrosine phosphorylation of DAB1 and modulation of TAU phosphorylation (By similarity)	Lissencephaly gene (LIS1) in neuronal migration and development;Reelin Signaling Pathway			0.0000	0.0000	0.0000		600514 [RELN (confirmed) Lissencephaly 2 (Norman-Roberts type),257320|Epilepsy,familial temporal lobe,7,616436];			7.219000	T	T,T,T,T	P,D	T,T,T	24.00	1	cfDNA_HNSCC,	0	0			n/a	n/a	RELN (inh=AR+AD pLI=1.00)
chr7	106508978	106508978	A	G	1.0000	32		967.0	8|6|18,0|0|0,6|5	PIK3CG	synonymous_variant	PIK3CG:NM_001282426.1:synonymous_variant:LOW:exon2/11:c.972A>G:p.Pro324Pro,PIK3CG:NM_001282427.1:synonymous_variant:LOW:exon2/11:c.972A>G:p.Pro324Pro,PIK3CG:NM_002649.3:synonymous_variant:LOW:exon2/11:c.972A>G:p.Pro324Pro						rs849389	0.939497	0.94901142064959	0.9268572											2	TEST_SomaticAndTreatment,	1192	143			n/a	n/a	PIK3CG (inh=n/a pLI=0.56)
chr7	106508987	106508987	T	C	1.0000	33		930.0	9|6|18,0|0|0,6|5	PIK3CG	synonymous_variant	PIK3CG:NM_001282426.1:synonymous_variant:LOW:exon2/11:c.981T>C:p.Asp327Asp,PIK3CG:NM_001282427.1:synonymous_variant:LOW:exon2/11:c.981T>C:p.Asp327Asp,PIK3CG:NM_002649.3:synonymous_variant:LOW:exon2/11:c.981T>C:p.Asp327Asp						rs849390	0.940895	0.95017250202215	0.9027421											2	TEST_SomaticAndTreatment,	1199	136			n/a	n/a	PIK3CG (inh=n/a pLI=0.56)
chr7	128846328	128846328	G	C	0.5354	127		1491.0	18|34|16,32|16|10,4|3	SMO	synonymous_variant	SMO:NM_005631.4:synonymous_variant:LOW:exon6/12:c.1164G>C:p.Gly388Gly		Hedgehog signaling pathway;Basal cell carcinoma	G protein-coupled receptor that probably associates with the patched protein (PTCH) to transduce the hedgehog's proteins signal. Binding of sonic hedgehog (SHH) to its receptor patched is thought to prevent normal inhibition by patched of smoothened (SMO). Required for the accumulation of KIF7 and GLI3 in the cilia	Sonic Hedgehog (Shh) Pathway		rs2228617	0.75619	0.79748587244839	0.7921725	COSM4004294	601500 [SMO (provisional) Basal cell carcinoma,somatic,605462|Curry-Jones syndrome,somatic mosaic,601707];									0		1749	547			n/a	n/a	SMO (inh=n/a pLI=0.06)
chr7	142460313	142460313	T	C	1.0000	9		216.0	0|0|9,0|0|0,2|2	PRSS1	synonymous_variant	PRSS1:NM_002769.4:synonymous_variant:LOW:exon4/5:c.486T>C:p.Asp162Asp		Neuroactive ligand-receptor interaction	Has activity against the synthetic substrates Boc-Phe- Ser-Arg-Mec, Boc-Leu-Thr-Arg-Mec, Boc-Gln-Ala-Arg-Mec and Boc-Val- Pro-Arg-Mec. The single-chain form is more active than the two- chain form against all of these substrates			rs6666	0.396565	0.36925434116445	0.0368286	COSM4161889	276000 [PRSS1 (confirmed) Pancreatitis,hereditary,167800|Trypsinogen deficiency,614044];	RCV000231064.1 [likely benign]; RCV000244488.1 [benign]; 	CM086253 [CLASS=DP MUT=REF PHEN="Pancreatitis chronic association with" GENE=PRSS1]; 							1	Leuk,	326	1886	1	[1] Ilnaz Sepahi 29-03-2016 batch import	n/a	n/a	PRSS1 (inh=AR+AD pLI=0.00)
chr7	142460865	142460865	T	C	1.0000	14		413.0	14|0|0,0|0|0,4|3	PRSS1	synonymous_variant	PRSS1:NM_002769.4:synonymous_variant:LOW:exon5/5:c.738T>C:p.Asn246Asn		Neuroactive ligand-receptor interaction	Has activity against the synthetic substrates Boc-Phe- Ser-Arg-Mec, Boc-Leu-Thr-Arg-Mec, Boc-Gln-Ala-Arg-Mec and Boc-Val- Pro-Arg-Mec. The single-chain form is more active than the two- chain form against all of these substrates			rs6667	0.39377	0.5040651747283	0.4946368		276000 [PRSS1 (confirmed) Pancreatitis,hereditary,167800|Trypsinogen deficiency,614044];	RCV000248971.1 [benign]; 								0		903	1355	1	[1] Ilnaz Sepahi 29-03-2016 batch import	n/a	n/a	PRSS1 (inh=AR+AD pLI=0.00)
chr7	151932908	151932908	T	C	0.8485	33		179.0	41|0|0,4|0|1,7|3	KMT2C	synonymous_variant	KMT2C:NM_170606.2:synonymous_variant:LOW:exon16/59:c.2763A>G:p.Leu921Leu						rs112326730	0.0000	0.47900233402048	0.0033568	COSM4161995, COSM4161996				0.193000	T				1.79	0		0	740			n/a	n/a	KMT2C (inh=n/a pLI=1.00)
chr7	151932965	151932965	C	T	0.4809	183		1352.0	0|0|88,0|0|95,8|6	KMT2C	synonymous_variant	KMT2C:NM_170606.2:synonymous_variant:LOW:exon16/59:c.2706G>A:p.Ser902Ser						rs78472109	0.0000	0.32112475422335	0.0004501	COSM4161999, COSM4162000				-1.881000	T				20.30	0		0	376			n/a	n/a	KMT2C (inh=n/a pLI=1.00)
chr7	151932990	151932990	C	T	0.2637	182		390.0	0|0|48,0|0|134,6|6	KMT2C	missense_variant	KMT2C:NM_170606.2:missense_variant:MODERATE:exon16/59:c.2681G>A:p.Arg894Gln						rs76844681	0.0000	0.009881312283059	0.0000514					7.268000	D	D,D	D	D,D	35.00	0		0	20			n/a	n/a	KMT2C (inh=n/a pLI=1.00)
chr7	151945071	151945071	-	T	0.2941	34		111.0	0|0|10,5|4|15,7|7	KMT2C	frameshift_variant&stop_gained	KMT2C:NM_170606.2:frameshift_variant&stop_gained:HIGH:exon14/59:c.2447dupA:p.Tyr816fs						rs150073007	0.0000	0.49007207942336	0.0057555	COSM289942, COSM289943			CI134413 [CLASS=DM MUT=ALT PHEN="Colorectal cancer and acute myeloid leukaemia" GENE=KMT2C]; 							0		1	699			n/a	n/a	KMT2C (inh=n/a pLI=1.00)
chr7	151962176	151962176	T	A	0.1875	224		405.0	6|2|34,18|12|152,6|5	KMT2C	synonymous_variant	KMT2C:NM_170606.2:synonymous_variant:LOW:exon8/59:c.1131A>T:p.Pro377Pro						rs62478356	0.0000	0.45537207001262	0.0046751	COSM4162022, COSM4162021										0		0	815			n/a	n/a	KMT2C (inh=n/a pLI=1.00)
chr8	31024638	31024638	C	T	0.4000	10		42.0	0|4|0,6|0|0,5|5	WRN	synonymous_variant	WRN:NM_000553.4:synonymous_variant:LOW:exon34/35:c.4083C>T:p.Ser1361Ser			Multifunctional enzyme that has both magnesium and ATP- dependent DNA-helicase activity and 3'->5' exonuclease activity towards double-stranded DNA with a 5'-overhang. Has no nuclease activity towards single-stranded DNA or blunt-ended double- stranded DNA. Binds preferentially to DNA substrates containing alternate secondary structures, such as replication forks and Holliday junctions. May play an important role in the dissociation of joint DNA molecules that can arise as products of homologous recombination, at stalled replication forks or during DNA repair. Alleviates stalling of DNA polymerases at the site of DNA lesions. Important for genomic integrity. Plays a role in the formation of DNA replication focal centers; stably associates with foci elements generating binding sites for RP-A (By similarity). Plays a role in double-strand break repair after gamma-irradiation			rs1801196	0.273562	0.29890612865381	0.2944362	COSM3763320	604611 [WRN (confirmed) Werner syndrome,277700];	RCV000118879.3 [other]; RCV000368541.1 [likely benign]; 								0		152	634			n/a	n/a	WRN (inh=AR pLI=0.00)
chr8	31024654	31024654	T	C	0.6000	10		86.0	6|0|0,0|4|0,5|5	WRN	missense_variant	WRN:NM_000553.4:missense_variant:MODERATE:exon34/35:c.4099T>C:p.Cys1367Arg			Multifunctional enzyme that has both magnesium and ATP- dependent DNA-helicase activity and 3'->5' exonuclease activity towards double-stranded DNA with a 5'-overhang. Has no nuclease activity towards single-stranded DNA or blunt-ended double- stranded DNA. Binds preferentially to DNA substrates containing alternate secondary structures, such as replication forks and Holliday junctions. May play an important role in the dissociation of joint DNA molecules that can arise as products of homologous recombination, at stalled replication forks or during DNA repair. Alleviates stalling of DNA polymerases at the site of DNA lesions. Important for genomic integrity. Plays a role in the formation of DNA replication focal centers; stably associates with foci elements generating binding sites for RP-A (By similarity). Plays a role in double-strand break repair after gamma-irradiation			rs1346044	0.192692	0.24163897568153	0.2349907		604611 [WRN (confirmed) Werner syndrome,277700];	RCV000118880.5 [other]; RCV000273969.1 [likely benign]; 	CM971591 [CLASS=DFP MUT=ALT PHEN="Thromboembolic disease association with" GENE=WRN]; 	0.579000	T	D	B	T	11.91	0		103	575			n/a	n/a	WRN (inh=AR pLI=0.00)
chr8	72111599	72111599	A	G	0.4262	61		600.0	8|12|6,13|0|22,5|2	EYA1	synonymous_variant	EYA1:NM_000503.5:synonymous_variant:LOW:exon18/18:c.1755T>C:p.His585His,EYA1:NM_172059.3:synonymous_variant:LOW:exon16/16:c.1650T>C:p.His550His,EYA1:NM_172058.3:synonymous_variant:LOW:exon17/17:c.1755T>C:p.His585His,EYA1:NM_172060.3:synonymous_variant:LOW:exon16/16:c.1656T>C:p.His552His,EYA1:NM_001288574.1:synonymous_variant:LOW:exon18/18:c.1737T>C:p.His579His,EYA1:NM_001288575.1:synonymous_variant:LOW:exon18/18:c.1389T>C:p.His463His						rs10103397	0.476637	0.39577554571611	0.3828262		601653 [EYA1 (confirmed) Branchiootorenal syndrome 1,with or without cataracts,113650|Anterior segment anomalies with or without cataract,602588|Branchiootic syndrome 1,602588|Otofaciocervical syndrome,166780];	RCV000041393.3 [benign]; RCV000329591.1 [benign]; RCV000370365.1 [benign]; 								0		131	576			n/a	n/a	EYA1 (inh=AD pLI=0.96)
chr8	72129009	72129009	G	A	0.4878	41		413.0	6|14|0,12|9|0,4|6	EYA1	synonymous_variant	EYA1:NM_000503.5:synonymous_variant:LOW:exon14/18:c.1278C>T:p.Gly426Gly,EYA1:NM_172059.3:synonymous_variant:LOW:exon12/16:c.1173C>T:p.Gly391Gly,EYA1:NM_172058.3:synonymous_variant:LOW:exon13/17:c.1278C>T:p.Gly426Gly,EYA1:NM_172060.3:synonymous_variant:LOW:exon12/16:c.1179C>T:p.Gly393Gly,EYA1:NM_001288574.1:synonymous_variant:LOW:exon14/18:c.1260C>T:p.Gly420Gly,EYA1:NM_001288575.1:synonymous_variant:LOW:exon14/18:c.912C>T:p.Gly304Gly						rs4738118	0.29373	0.21273491592483	0.2104705	COSM3763394, COSM3763395	601653 [EYA1 (confirmed) Branchiootorenal syndrome 1,with or without cataracts,113650|Anterior segment anomalies with or without cataract,602588|Branchiootic syndrome 1,602588|Otofaciocervical syndrome,166780];	RCV000041387.3 [benign]; RCV000344172.1 [benign]; RCV000391012.1 [benign]; 								0		31	297			n/a	n/a	EYA1 (inh=AD pLI=0.96)
chr8	103311772	103311772	C	A	0.2667	15		41.0	0|4|0,0|11|0,1|2	UBR5	missense_variant	UBR5:NM_015902.5:missense_variant:MODERATE:exon24/59:c.3110G>T:p.Gly1037Val,UBR5:NM_001282873.1:missense_variant:MODERATE:exon24/59:c.3110G>T:p.Gly1037Val							0.0000	0.0000	0.0000					7.361000,7.361000	T,T	D,D,D,	D,D,	T,T,T,	31.00	0		0	0			n/a	n/a	UBR5 (inh=n/a pLI=1.00)
chr8	114186003	114186003	T	C	0.4839	62		722.0	16|14|0,14|18|0,7|8	CSMD3	missense_variant	CSMD3:NM_198123.1:missense_variant:MODERATE:exon4/71:c.657A>G:p.Ile219Met,CSMD3:NM_198124.1:missense_variant:MODERATE:exon5/72:c.537A>G:p.Ile179Met,CSMD3:NM_052900.2:missense_variant:MODERATE:exon4/69:c.657A>G:p.Ile219Met	Complement_control_module__2_,Sushi/SCR/CCP__3_					rs2219898	0.466054	0.36704382391265	0.3637141					0.054000	T	T,T,T,T	B,B,P,P	T,T,T,T	16.16	2	I16R041,cfDNA_HNSCC,	95	481			n/a	n/a	CSMD3 (inh=n/a pLI=1.00)
chr8	131124559	131124559	T	C	0.3529	17		97.0	6|0|0,4|0|6,3|4	ASAP1	missense_variant	ASAP1:NM_018482.3:missense_variant:MODERATE:exon24/30:c.2182A>G:p.Ile728Val,ASAP1:NM_001247996.1:missense_variant:MODERATE:exon25/31:c.2161A>G:p.Ile721Val						rs966185	0.474441	0.47593538543187	0.4705088	COSM150541				0.633000,0.633000	T,T	T,T,T,,	B,B,B,	T,T,	1.90	0		228	403			n/a	n/a	ASAP1 (inh=n/a pLI=1.00)
chr8	133900252	133900252	T	G	0.3689	103		759.0	0|0|38,0|0|65,6|8	TG	missense_variant	TG:NM_003235.4:missense_variant:MODERATE:exon10/48:c.2200T>G:p.Ser734Ala	Thyroglobulin_type-1__1_					rs180223	0.676318	0.58699941476465	0.5723711	COSM4162675	188450 [TG (confirmed) Thyroid dyshormonogenesis 3,274700|Autoimmune thyroid disease,susceptibility to,3,608175];	RCV000013534.3 [other]; RCV000253912.1 [benign]; RCV000309189.1 [likely benign]; 		6.076000	T	T,T,	B	T,T	6.49	0		454	690			n/a	n/a	TG (inh=AR pLI=0.00)
chr8	133900386	133900386	T	C	0.5957	47		688.0	22|4|2,2|16|1,4|5	TG	synonymous_variant	TG:NM_003235.4:synonymous_variant:LOW:exon10/48:c.2334T>C:p.Pro778Pro						rs2069550	0.672724	0.58294181123931	0.5768469		188450 [TG (confirmed) Thyroid dyshormonogenesis 3,274700|Autoimmune thyroid disease,susceptibility to,3,608175];	RCV000246346.1 [benign]; RCV000331886.1 [likely benign]; 								0		456	691			n/a	n/a	TG (inh=AR pLI=0.00)
chr8	133909974	133909974	A	G	0.4640	125		1344.0	18|6|34,13|16|38,6|13	TG	missense_variant	TG:NM_003235.4:missense_variant:MODERATE:exon12/48:c.3082A>G:p.Met1028Val	Thyroglobulin_type-1__6_					rs853326	0.67492	0.58416698254693	0.5782295	COSM4162676	188450 [TG (confirmed) Thyroid dyshormonogenesis 3,274700|Autoimmune thyroid disease,susceptibility to,3,608175];	RCV000013535.3 [other]; RCV000254213.1 [benign]; RCV000368266.1 [likely benign]; 		-0.453000	T	T,T	B	T,T	0.00	0		458	692			n/a	n/a	TG (inh=AR pLI=0.00)
chr8	133920518	133920518	A	G	0.8947	38		936.0	0|4|30,0|0|4,4|5	TG	missense_variant	TG:NM_003235.4:missense_variant:MODERATE:exon18/48:c.3935A>G:p.Asp1312Gly						rs2069556	0.398762	0.56972315201082	0.5543716	COSM1454960	188450 [TG (confirmed) Thyroid dyshormonogenesis 3,274700|Autoimmune thyroid disease,susceptibility to,3,608175];	RCV000241944.1 [benign]; RCV000280505.1 [likely benign]; 		4.289000	T	T,T,T	B	T,T	0.75	0		525	648			n/a	n/a	TG (inh=AR pLI=0.00)
chr8	133931748	133931748	T	C	1.0000	17		473.0	0|2|15,0|0|0,9|5	TG	synonymous_variant	TG:NM_003235.4:synonymous_variant:LOW:exon21/48:c.4506T>C:p.Ala1502Ala						rs853304	0.473842	0.59147386461011	0.5819593	COSM150549	188450 [TG (confirmed) Thyroid dyshormonogenesis 3,274700|Autoimmune thyroid disease,susceptibility to,3,608175];	RCV000244917.1 [benign]; RCV000267031.1 [likely benign]; 		-0.618000	T				0.02	0		527	639			n/a	n/a	TG (inh=AR pLI=0.00)
chr8	133975283	133975283	G	A	0.2222	18		26.0	4|0|0,5|9|0,4|4	TG	missense_variant	TG:NM_003235.4:missense_variant:MODERATE:exon29/48:c.5512G>A:p.Asp1838Asn						rs2069561	0.346845	0.48460385192019	0.4654157	COSM150550	188450 [TG (confirmed) Thyroid dyshormonogenesis 3,274700|Autoimmune thyroid disease,susceptibility to,3,608175];	RCV000242253.1 [benign]; RCV000305066.1 [likely benign]; 		0.528000,0.528000	T,T	T,T,D,T,	B,B,	T,T,T,	3.74	1	I16R041,	369	650			n/a	n/a	TG (inh=AR pLI=0.00)
chr8	133984058	133984058	C	T	1.0000	33		1051.0	15|1|17,0|0|0,5|3	TG	missense_variant	TG:NM_003235.4:missense_variant:MODERATE:exon33/48:c.5995C>T:p.Arg1999Trp						rs2076740	0.332468	0.32261655424906	0.3198246	COSM3982409	188450 [TG (confirmed) Thyroid dyshormonogenesis 3,274700|Autoimmune thyroid disease,susceptibility to,3,608175];	RCV000013533.3 [other]; RCV000251808.1 [benign]; RCV000277644.1 [likely benign]; 	CM035973 [CLASS=DP MUT=ALT PHEN="Autoimmune thyroid disease association with" GENE=TG]; 	0.050000,0.050000	T,T	T,T,T,T,T,	B,B,B,	T,T,T,T,	17.87	1	cfDNA_HNSCC,	197	635			n/a	n/a	TG (inh=AR pLI=0.00)
chr8	134024278	134024278	C	T	0.5000	16		154.0	2|4|2,6|0|2,6|6	TG	missense_variant&splice_region_variant	TG:NM_003235.4:missense_variant&splice_region_variant:MODERATE:exon36/48:c.6395C>T:p.Ser2132Leu						rs61741457	0.0261581	0.045951156812339	0.0456130		188450 [TG (confirmed) Thyroid dyshormonogenesis 3,274700|Autoimmune thyroid disease,susceptibility to,3,608175];	RCV000247563.1 [benign]; 		0.174000	T	T,T,T,T,T	B,B,B	T,T,T,T	0.22	0		6	182			n/a	n/a	TG (inh=AR pLI=0.00)
chr8	134108453	134108453	C	T	0.4000	10		62.0	4|0|0,6|0|0,8|7	TG,SLA	synonymous_variant,intron_variant	TG:NM_003235.4:synonymous_variant:LOW:exon43/48:c.7408C>T:p.Leu2470Leu,SLA:NM_001045556.2:intron_variant:MODIFIER:exon1/8:c.-319+6344G>A:,SLA:NM_001045557.2:intron_variant:MODIFIER:exon1/7:c.11+6344G>A:,SLA:NM_001282964.1:intron_variant:MODIFIER:exon1/6:c.11+6344G>A:,SLA:NM_001282965.1:intron_variant:MODIFIER:exon1/6:c.-264+6344G>A:						rs2069568	0.344649	0.43471166999028	0.4286835		188450 [TG (confirmed) Thyroid dyshormonogenesis 3,274700|Autoimmune thyroid disease,susceptibility to,3,608175];	RCV000252113.1 [benign]; RCV000299677.1 [likely benign]; 		1.553000	T				13.97	0		296	737			n/a	n/a	TG (inh=AR pLI=0.00), SLA (inh=n/a pLI=0.72)
chr8	134125682	134125682	G	A	0.2174	46		97.0	10|0|0,24|12|0,10|7	TG	missense_variant	TG:NM_003235.4:missense_variant:MODERATE:exon44/48:c.7589G>A:p.Arg2530Gln	Carboxylesterase__type_B__1_					rs1133076	0.53734	0.49758960558683	0.4876338	COSM4162677	188450 [TG (confirmed) Thyroid dyshormonogenesis 3,274700|Autoimmune thyroid disease,susceptibility to,3,608175];	RCV000249422.1 [benign]; RCV000329782.1 [benign]; 	CM045980 [CLASS=DP MUT=REF PHEN="Thyroid cancer increased risk association with" GENE=TG]; 	5.139000	T	T,T,T,T,T	B,B,B	T,T,T,T	19.72	0		325	735			n/a	n/a	TG (inh=AR pLI=0.00)
chr8	134144113	134144113	C	T	0.4167	12		83.0	1|4|0,1|6|0,3|3	TG	synonymous_variant	TG:NM_003235.4:synonymous_variant:LOW:exon46/48:c.7920C>T:p.Tyr2640Tyr						rs2294024	0.405351	0.43354153962787	0.4305356	COSM150551	188450 [TG (confirmed) Thyroid dyshormonogenesis 3,274700|Autoimmune thyroid disease,susceptibility to,3,608175];	RCV000252575.1 [benign]; RCV000342038.1 [likely benign]; 		-0.075000					13.75	1	I16R041,	332	713			n/a	n/a	TG (inh=AR pLI=0.00)
chr8	144990528	144990528	A	G	0.3846	13		67.0	0|2|3,3|0|5,6|6	PLEC	synonymous_variant	PLEC:NM_201380.3:synonymous_variant:LOW:exon32/32:c.13872T>C:p.Ala4624Ala,PLEC:NM_201384.2:synonymous_variant:LOW:exon32/32:c.13461T>C:p.Ala4487Ala,PLEC:NM_201383.2:synonymous_variant:LOW:exon32/32:c.13473T>C:p.Ala4491Ala,PLEC:NM_201382.3:synonymous_variant:LOW:exon32/32:c.13461T>C:p.Ala4487Ala,PLEC:NM_201381.2:synonymous_variant:LOW:exon32/32:c.13365T>C:p.Ala4455Ala,PLEC:NM_201379.2:synonymous_variant:LOW:exon32/32:c.13395T>C:p.Ala4465Ala,PLEC:NM_201378.3:synonymous_variant:LOW:exon32/32:c.13419T>C:p.Ala4473Ala,PLEC:NM_000445.4:synonymous_variant:LOW:exon33/33:c.13542T>C:p.Ala4514Ala						rs7014582	0.477037	0.41913398192125	0.3776945	COSM3763110, COSM3763107, COSM3763112, COSM3763109, COSM3763111, COSM3763108	601282 [PLEC (confirmed) Epidermolysis bullosa simplex with muscular dystrophy,226670|Epidermolysis bullosa simplex,Ogna type,131950|Epidermolysis bullosa simplex with pyloric atresia,612138|Muscular dystrophy,limb-girdle,type 2Q,613723|Epidermolysis bullosa simplex with nail dystrophy,616487];	RCV000078848.10 [other]; 								0		239	666			n/a	n/a	PLEC (inh=AR+AD pLI=0.02)
chr8	144992103	144992103	T	C	0.5172	29		318.0	5|0|10,4|1|9,8|7	PLEC	synonymous_variant	PLEC:NM_201380.3:synonymous_variant:LOW:exon32/32:c.12297A>G:p.Thr4099Thr,PLEC:NM_201384.2:synonymous_variant:LOW:exon32/32:c.11886A>G:p.Thr3962Thr,PLEC:NM_201383.2:synonymous_variant:LOW:exon32/32:c.11898A>G:p.Thr3966Thr,PLEC:NM_201382.3:synonymous_variant:LOW:exon32/32:c.11886A>G:p.Thr3962Thr,PLEC:NM_201381.2:synonymous_variant:LOW:exon32/32:c.11790A>G:p.Thr3930Thr,PLEC:NM_201379.2:synonymous_variant:LOW:exon32/32:c.11820A>G:p.Thr3940Thr,PLEC:NM_201378.3:synonymous_variant:LOW:exon32/32:c.11844A>G:p.Thr3948Thr,PLEC:NM_000445.4:synonymous_variant:LOW:exon33/33:c.11967A>G:p.Thr3989Thr						rs6558406	0.490415	0.43431630889042	0.4262462	COSM3763120, COSM454175, COSM1489094, COSM3763121, COSM3763119, COSM454174	601282 [PLEC (confirmed) Epidermolysis bullosa simplex with muscular dystrophy,226670|Epidermolysis bullosa simplex,Ogna type,131950|Epidermolysis bullosa simplex with pyloric atresia,612138|Muscular dystrophy,limb-girdle,type 2Q,613723|Epidermolysis bullosa simplex with nail dystrophy,616487];	RCV000078840.9 [other]; 								0		266	686			n/a	n/a	PLEC (inh=AR+AD pLI=0.02)
chr8	144993069	144993069	G	A	0.4000	10		51.0	0|4|0,1|5|0,5|6	PLEC	synonymous_variant	PLEC:NM_201380.3:synonymous_variant:LOW:exon32/32:c.11331C>T:p.Tyr3777Tyr,PLEC:NM_201384.2:synonymous_variant:LOW:exon32/32:c.10920C>T:p.Tyr3640Tyr,PLEC:NM_201383.2:synonymous_variant:LOW:exon32/32:c.10932C>T:p.Tyr3644Tyr,PLEC:NM_201382.3:synonymous_variant:LOW:exon32/32:c.10920C>T:p.Tyr3640Tyr,PLEC:NM_201381.2:synonymous_variant:LOW:exon32/32:c.10824C>T:p.Tyr3608Tyr,PLEC:NM_201379.2:synonymous_variant:LOW:exon32/32:c.10854C>T:p.Tyr3618Tyr,PLEC:NM_201378.3:synonymous_variant:LOW:exon32/32:c.10878C>T:p.Tyr3626Tyr,PLEC:NM_000445.4:synonymous_variant:LOW:exon33/33:c.11001C>T:p.Tyr3667Tyr						rs28455570	0.0333466	0.068103883005547	0.0684420		601282 [PLEC (confirmed) Epidermolysis bullosa simplex with muscular dystrophy,226670|Epidermolysis bullosa simplex,Ogna type,131950|Epidermolysis bullosa simplex with pyloric atresia,612138|Muscular dystrophy,limb-girdle,type 2Q,613723|Epidermolysis bullosa simplex with nail dystrophy,616487];	RCV000117943.4 [other]; 								1	Leuk,	6	172			n/a	n/a	PLEC (inh=AR+AD pLI=0.02)
chr8	144993377	144993377	A	G	0.3387	62		414.0	7|14|0,9|32|0,4|4	PLEC	synonymous_variant	PLEC:NM_201380.3:synonymous_variant:LOW:exon32/32:c.11023T>C:p.Leu3675Leu,PLEC:NM_201384.2:synonymous_variant:LOW:exon32/32:c.10612T>C:p.Leu3538Leu,PLEC:NM_201383.2:synonymous_variant:LOW:exon32/32:c.10624T>C:p.Leu3542Leu,PLEC:NM_201382.3:synonymous_variant:LOW:exon32/32:c.10612T>C:p.Leu3538Leu,PLEC:NM_201381.2:synonymous_variant:LOW:exon32/32:c.10516T>C:p.Leu3506Leu,PLEC:NM_201379.2:synonymous_variant:LOW:exon32/32:c.10546T>C:p.Leu3516Leu,PLEC:NM_201378.3:synonymous_variant:LOW:exon32/32:c.10570T>C:p.Leu3524Leu,PLEC:NM_000445.4:synonymous_variant:LOW:exon33/33:c.10693T>C:p.Leu3565Leu						rs6992333	0.471845	0.41480669589478	0.4033594	COSM3723094, COSM3723091, COSM3723095, COSM3723090, COSM3723093, COSM3723092	601282 [PLEC (confirmed) Epidermolysis bullosa simplex with muscular dystrophy,226670|Epidermolysis bullosa simplex,Ogna type,131950|Epidermolysis bullosa simplex with pyloric atresia,612138|Muscular dystrophy,limb-girdle,type 2Q,613723|Epidermolysis bullosa simplex with nail dystrophy,616487];	RCV000078833.9 [other]; 								1	cfDNA_HNSCC,	253	672			n/a	n/a	PLEC (inh=AR+AD pLI=0.02)
chr8	144995494	144995494	C	T	0.4516	62		594.0	14|4|10,13|14|7,9|10	PLEC	missense_variant	PLEC:NM_201380.3:missense_variant:MODERATE:exon32/32:c.8906G>A:p.Arg2969His,PLEC:NM_201384.2:missense_variant:MODERATE:exon32/32:c.8495G>A:p.Arg2832His,PLEC:NM_201383.2:missense_variant:MODERATE:exon32/32:c.8507G>A:p.Arg2836His,PLEC:NM_201382.3:missense_variant:MODERATE:exon32/32:c.8495G>A:p.Arg2832His,PLEC:NM_201381.2:missense_variant:MODERATE:exon32/32:c.8399G>A:p.Arg2800His,PLEC:NM_201379.2:missense_variant:MODERATE:exon32/32:c.8429G>A:p.Arg2810His,PLEC:NM_201378.3:missense_variant:MODERATE:exon32/32:c.8453G>A:p.Arg2818His,PLEC:NM_000445.4:missense_variant:MODERATE:exon33/33:c.8576G>A:p.Arg2859His						rs6558407	0.230631	0.34437080578822	0.3331490	COSM3763129, COSM3763130, COSM3763126, COSM3763127, COSM3763125, COSM3763128	601282 [PLEC (confirmed) Epidermolysis bullosa simplex with muscular dystrophy,226670|Epidermolysis bullosa simplex,Ogna type,131950|Epidermolysis bullosa simplex with pyloric atresia,612138|Muscular dystrophy,limb-girdle,type 2Q,613723|Epidermolysis bullosa simplex with nail dystrophy,616487];	RCV000078902.9 [other]; 		2.910000	T	D,D,D,D,D,D,D,D,D	B,B,B,B,B,B,B,B	T,T,T,T,T,T,T,T,T	23.80	0		240	658			n/a	n/a	PLEC (inh=AR+AD pLI=0.02)
chr8	144995736	144995736	G	A	0.7067	150		2562.0	0|2|104,0|0|44,8|10	PLEC	synonymous_variant	PLEC:NM_201380.3:synonymous_variant:LOW:exon32/32:c.8664C>T:p.Asn2888Asn,PLEC:NM_201384.2:synonymous_variant:LOW:exon32/32:c.8253C>T:p.Asn2751Asn,PLEC:NM_201383.2:synonymous_variant:LOW:exon32/32:c.8265C>T:p.Asn2755Asn,PLEC:NM_201382.3:synonymous_variant:LOW:exon32/32:c.8253C>T:p.Asn2751Asn,PLEC:NM_201381.2:synonymous_variant:LOW:exon32/32:c.8157C>T:p.Asn2719Asn,PLEC:NM_201379.2:synonymous_variant:LOW:exon32/32:c.8187C>T:p.Asn2729Asn,PLEC:NM_201378.3:synonymous_variant:LOW:exon32/32:c.8211C>T:p.Asn2737Asn,PLEC:NM_000445.4:synonymous_variant:LOW:exon33/33:c.8334C>T:p.Asn2778Asn						rs11777402	0.230232	0.34463310078171	0.3347952	COSM3763135, COSM3763132, COSM3763134, COSM3763131, COSM3763136, COSM3763133	601282 [PLEC (confirmed) Epidermolysis bullosa simplex with muscular dystrophy,226670|Epidermolysis bullosa simplex,Ogna type,131950|Epidermolysis bullosa simplex with pyloric atresia,612138|Muscular dystrophy,limb-girdle,type 2Q,613723|Epidermolysis bullosa simplex with nail dystrophy,616487];	RCV000078899.9 [other]; 								1	cfDNA_HNSCC,	243	651			n/a	n/a	PLEC (inh=AR+AD pLI=0.02)
chr8	144995939	144995939	G	A	0.2500	44		137.0	2|0|9,17|6|10,7|9	PLEC	missense_variant	PLEC:NM_201380.3:missense_variant:MODERATE:exon32/32:c.8461C>T:p.Arg2821Trp,PLEC:NM_201384.2:missense_variant:MODERATE:exon32/32:c.8050C>T:p.Arg2684Trp,PLEC:NM_201383.2:missense_variant:MODERATE:exon32/32:c.8062C>T:p.Arg2688Trp,PLEC:NM_201382.3:missense_variant:MODERATE:exon32/32:c.8050C>T:p.Arg2684Trp,PLEC:NM_201381.2:missense_variant:MODERATE:exon32/32:c.7954C>T:p.Arg2652Trp,PLEC:NM_201379.2:missense_variant:MODERATE:exon32/32:c.7984C>T:p.Arg2662Trp,PLEC:NM_201378.3:missense_variant:MODERATE:exon32/32:c.8008C>T:p.Arg2670Trp,PLEC:NM_000445.4:missense_variant:MODERATE:exon33/33:c.8131C>T:p.Arg2711Trp						rs35723243	0.0101837	0.024123033495129	0.0232663	COSM1489101, COSM454184, COSM454185	601282 [PLEC (confirmed) Epidermolysis bullosa simplex with muscular dystrophy,226670|Epidermolysis bullosa simplex,Ogna type,131950|Epidermolysis bullosa simplex with pyloric atresia,612138|Muscular dystrophy,limb-girdle,type 2Q,613723|Epidermolysis bullosa simplex with nail dystrophy,616487];	RCV000117979.2 [likely benign]; 		0.951000	T	D,D,D,D,D,D,D,D,D	B,B,B,B,B,B,B,B	T,T,T,T,T,T,T,T,T	23.70	0		0	76			n/a	n/a	PLEC (inh=AR+AD pLI=0.02)
chr8	144996029	144996029	A	G	0.6667	39		612.0	0|0|26,1|0|12,5|7	PLEC	missense_variant,sequence_feature	PLEC:NM_201380.3:missense_variant:MODERATE:exon32/32:c.8371T>C:p.Ser2791Pro,PLEC:NM_201384.2:missense_variant:MODERATE:exon32/32:c.7960T>C:p.Ser2654Pro,PLEC:NM_201383.2:missense_variant:MODERATE:exon32/32:c.7972T>C:p.Ser2658Pro,PLEC:NM_201382.3:missense_variant:MODERATE:exon32/32:c.7960T>C:p.Ser2654Pro,PLEC:NM_201381.2:missense_variant:MODERATE:exon32/32:c.7864T>C:p.Ser2622Pro,PLEC:NM_201379.2:missense_variant:MODERATE:exon32/32:c.7894T>C:p.Ser2632Pro,PLEC:NM_201378.3:missense_variant:MODERATE:exon32/32:c.7918T>C:p.Ser2640Pro,PLEC:NM_000445.4:missense_variant:MODERATE:exon33/33:c.8041T>C:p.Ser2681Pro,PLEC:NM_201380.3:sequence_feature:MODERATE:exon32/32:c.8371T>C:,PLEC:NM_201384.2:sequence_feature:MODERATE:exon32/32:c.7960T>C:,PLEC:NM_201383.2:sequence_feature:MODERATE:exon32/32:c.7972T>C:,PLEC:NM_201382.3:sequence_feature:MODERATE:exon32/32:c.7960T>C:,PLEC:NM_201381.2:sequence_feature:MODERATE:exon32/32:c.7864T>C:,PLEC:NM_201379.2:sequence_feature:MODERATE:exon32/32:c.7894T>C:,PLEC:NM_201378.3:sequence_feature:MODERATE:exon32/32:c.7918T>C:,PLEC:NM_000445.4:sequence_feature:MODERATE:exon33/33:c.8041T>C:						rs7833924	0.466653	0.40851021658438	0.3929545	COSM3750079, COSM454186, COSM3750080, COSM1489102, COSM454187, COSM3750078	601282 [PLEC (confirmed) Epidermolysis bullosa simplex with muscular dystrophy,226670|Epidermolysis bullosa simplex,Ogna type,131950|Epidermolysis bullosa simplex with pyloric atresia,612138|Muscular dystrophy,limb-girdle,type 2Q,613723|Epidermolysis bullosa simplex with nail dystrophy,616487];	RCV000078898.9 [other]; 		0.441000	T	T,T,T,T,T,T,T,T,T	B,B,B,B,B,B,B,B	T,T,T,T,T,T,T,T,T	3.09	1	cfDNA_HNSCC,	254	673			n/a	n/a	PLEC (inh=AR+AD pLI=0.02)
chr8	144997656	144997656	C	T	0.2807	57		261.0	13|2|1,39|2|0,9|7	PLEC	synonymous_variant	PLEC:NM_201380.3:synonymous_variant:LOW:exon31/32:c.6852G>A:p.Ala2284Ala,PLEC:NM_201384.2:synonymous_variant:LOW:exon31/32:c.6441G>A:p.Ala2147Ala,PLEC:NM_201383.2:synonymous_variant:LOW:exon31/32:c.6453G>A:p.Ala2151Ala,PLEC:NM_201382.3:synonymous_variant:LOW:exon31/32:c.6441G>A:p.Ala2147Ala,PLEC:NM_201381.2:synonymous_variant:LOW:exon31/32:c.6345G>A:p.Ala2115Ala,PLEC:NM_201379.2:synonymous_variant:LOW:exon31/32:c.6375G>A:p.Ala2125Ala,PLEC:NM_201378.3:synonymous_variant:LOW:exon31/32:c.6399G>A:p.Ala2133Ala,PLEC:NM_000445.4:synonymous_variant:LOW:exon32/33:c.6522G>A:p.Ala2174Ala						rs7016416	0.230232	0.35354734184846	0.3147829	COSM454190, COSM1489104, COSM454191, COSM3763150, COSM3763151, COSM3763149	601282 [PLEC (confirmed) Epidermolysis bullosa simplex with muscular dystrophy,226670|Epidermolysis bullosa simplex,Ogna type,131950|Epidermolysis bullosa simplex with pyloric atresia,612138|Muscular dystrophy,limb-girdle,type 2Q,613723|Epidermolysis bullosa simplex with nail dystrophy,616487];	RCV000078888.9 [other]; 								1	cfDNA_HNSCC,	237	650			n/a	n/a	PLEC (inh=AR+AD pLI=0.02)
chr8	144997927	144997927	G	A	0.4091	44		410.0	6|2|10,0|12|14,6|6	PLEC	missense_variant	PLEC:NM_201380.3:missense_variant:MODERATE:exon31/32:c.6581C>T:p.Ala2194Val,PLEC:NM_201384.2:missense_variant:MODERATE:exon31/32:c.6170C>T:p.Ala2057Val,PLEC:NM_201383.2:missense_variant:MODERATE:exon31/32:c.6182C>T:p.Ala2061Val,PLEC:NM_201382.3:missense_variant:MODERATE:exon31/32:c.6170C>T:p.Ala2057Val,PLEC:NM_201381.2:missense_variant:MODERATE:exon31/32:c.6074C>T:p.Ala2025Val,PLEC:NM_201379.2:missense_variant:MODERATE:exon31/32:c.6104C>T:p.Ala2035Val,PLEC:NM_201378.3:missense_variant:MODERATE:exon31/32:c.6128C>T:p.Ala2043Val,PLEC:NM_000445.4:missense_variant:MODERATE:exon32/33:c.6251C>T:p.Ala2084Val						rs7002002	0.230631	0.46514867074426	0.2696329	COSM3750084, COSM3750082, COSM3750081, COSM3750085, COSM3750083, COSM3750086	601282 [PLEC (confirmed) Epidermolysis bullosa simplex with muscular dystrophy,226670|Epidermolysis bullosa simplex,Ogna type,131950|Epidermolysis bullosa simplex with pyloric atresia,612138|Muscular dystrophy,limb-girdle,type 2Q,613723|Epidermolysis bullosa simplex with nail dystrophy,616487];	RCV000078886.9 [other]; 		2.047000	T	T,T,T,T,T,T,T,T,T	B,B,B,B,B,B,B,B	T,T,T,T,T,T,T,T,T	12.02	1	cfDNA_HNSCC,	238	629			n/a	n/a	PLEC (inh=AR+AD pLI=0.02)
chr8	144998169	144998169	C	T	1.0000	8		215.0	0|3|5,0|0|0,3|3	PLEC	synonymous_variant	PLEC:NM_201380.3:synonymous_variant:LOW:exon31/32:c.6339G>A:p.Ala2113Ala,PLEC:NM_201384.2:synonymous_variant:LOW:exon31/32:c.5928G>A:p.Ala1976Ala,PLEC:NM_201383.2:synonymous_variant:LOW:exon31/32:c.5940G>A:p.Ala1980Ala,PLEC:NM_201382.3:synonymous_variant:LOW:exon31/32:c.5928G>A:p.Ala1976Ala,PLEC:NM_201381.2:synonymous_variant:LOW:exon31/32:c.5832G>A:p.Ala1944Ala,PLEC:NM_201379.2:synonymous_variant:LOW:exon31/32:c.5862G>A:p.Ala1954Ala,PLEC:NM_201378.3:synonymous_variant:LOW:exon31/32:c.5886G>A:p.Ala1962Ala,PLEC:NM_000445.4:synonymous_variant:LOW:exon32/33:c.6009G>A:p.Ala2003Ala						rs1140522	0.230831	0.36315135905809	0.3002559	COSM3750089, COSM3750090, COSM3750092, COSM3750091, COSM3750088, COSM3750087	601282 [PLEC (confirmed) Epidermolysis bullosa simplex with muscular dystrophy,226670|Epidermolysis bullosa simplex,Ogna type,131950|Epidermolysis bullosa simplex with pyloric atresia,612138|Muscular dystrophy,limb-girdle,type 2Q,613723|Epidermolysis bullosa simplex with nail dystrophy,616487];	RCV000078883.9 [other]; 								0		238	647			n/a	n/a	PLEC (inh=AR+AD pLI=0.02)
chr8	144999417	144999417	C	T	0.4375	64		689.0	8|8|12,8|8|20,7|7	PLEC	synonymous_variant	PLEC:NM_201380.3:synonymous_variant:LOW:exon31/32:c.5091G>A:p.Ala1697Ala,PLEC:NM_201384.2:synonymous_variant:LOW:exon31/32:c.4680G>A:p.Ala1560Ala,PLEC:NM_201383.2:synonymous_variant:LOW:exon31/32:c.4692G>A:p.Ala1564Ala,PLEC:NM_201382.3:synonymous_variant:LOW:exon31/32:c.4680G>A:p.Ala1560Ala,PLEC:NM_201381.2:synonymous_variant:LOW:exon31/32:c.4584G>A:p.Ala1528Ala,PLEC:NM_201379.2:synonymous_variant:LOW:exon31/32:c.4614G>A:p.Ala1538Ala,PLEC:NM_201378.3:synonymous_variant:LOW:exon31/32:c.4638G>A:p.Ala1546Ala,PLEC:NM_000445.4:synonymous_variant:LOW:exon32/33:c.4761G>A:p.Ala1587Ala						rs55836855	0.230831	0.37586189973744	0.2891630	COSM3750102, COSM3750103, COSM3750101, COSM3750099, COSM3750104, COSM3750100	601282 [PLEC (confirmed) Epidermolysis bullosa simplex with muscular dystrophy,226670|Epidermolysis bullosa simplex,Ogna type,131950|Epidermolysis bullosa simplex with pyloric atresia,612138|Muscular dystrophy,limb-girdle,type 2Q,613723|Epidermolysis bullosa simplex with nail dystrophy,616487];	RCV000078871.9 [other]; 								1	cfDNA_HNSCC,	238	627			n/a	n/a	PLEC (inh=AR+AD pLI=0.02)
chr8	144999621	144999621	C	T	0.3810	42		317.0	0|0|16,8|0|18,4|3	PLEC	synonymous_variant	PLEC:NM_201380.3:synonymous_variant:LOW:exon31/32:c.4887G>A:p.Ala1629Ala,PLEC:NM_201384.2:synonymous_variant:LOW:exon31/32:c.4476G>A:p.Ala1492Ala,PLEC:NM_201383.2:synonymous_variant:LOW:exon31/32:c.4488G>A:p.Ala1496Ala,PLEC:NM_201382.3:synonymous_variant:LOW:exon31/32:c.4476G>A:p.Ala1492Ala,PLEC:NM_201381.2:synonymous_variant:LOW:exon31/32:c.4380G>A:p.Ala1460Ala,PLEC:NM_201379.2:synonymous_variant:LOW:exon31/32:c.4410G>A:p.Ala1470Ala,PLEC:NM_201378.3:synonymous_variant:LOW:exon31/32:c.4434G>A:p.Ala1478Ala,PLEC:NM_000445.4:synonymous_variant:LOW:exon32/33:c.4557G>A:p.Ala1519Ala						rs55646585	0.22484	0.32949762257386	0.2950663	COSM3750107, COSM3750109, COSM3750110, COSM3750106, COSM3750105, COSM3750108	601282 [PLEC (confirmed) Epidermolysis bullosa simplex with muscular dystrophy,226670|Epidermolysis bullosa simplex,Ogna type,131950|Epidermolysis bullosa simplex with pyloric atresia,612138|Muscular dystrophy,limb-girdle,type 2Q,613723|Epidermolysis bullosa simplex with nail dystrophy,616487];	RCV000078867.9 [other]; 								2	Leuk,cfDNA_HNSCC,	228	620			n/a	n/a	PLEC (inh=AR+AD pLI=0.02)
chr8	144999642	144999642	A	C	0.4000	40		300.0	0|0|16,6|0|18,4|3	PLEC	synonymous_variant	PLEC:NM_201380.3:synonymous_variant:LOW:exon31/32:c.4866T>G:p.Ala1622Ala,PLEC:NM_201384.2:synonymous_variant:LOW:exon31/32:c.4455T>G:p.Ala1485Ala,PLEC:NM_201383.2:synonymous_variant:LOW:exon31/32:c.4467T>G:p.Ala1489Ala,PLEC:NM_201382.3:synonymous_variant:LOW:exon31/32:c.4455T>G:p.Ala1485Ala,PLEC:NM_201381.2:synonymous_variant:LOW:exon31/32:c.4359T>G:p.Ala1453Ala,PLEC:NM_201379.2:synonymous_variant:LOW:exon31/32:c.4389T>G:p.Ala1463Ala,PLEC:NM_201378.3:synonymous_variant:LOW:exon31/32:c.4413T>G:p.Ala1471Ala,PLEC:NM_000445.4:synonymous_variant:LOW:exon32/33:c.4536T>G:p.Ala1512Ala						rs56117011	0.232628	0.3356962367147	0.3028347	COSM4162796, COSM4162799, COSM4162795, COSM4162794, COSM4162798, COSM4162797	601282 [PLEC (confirmed) Epidermolysis bullosa simplex with muscular dystrophy,226670|Epidermolysis bullosa simplex,Ogna type,131950|Epidermolysis bullosa simplex with pyloric atresia,612138|Muscular dystrophy,limb-girdle,type 2Q,613723|Epidermolysis bullosa simplex with nail dystrophy,616487];	RCV000078866.9 [other]; 								1	cfDNA_HNSCC,	229	636			n/a	n/a	PLEC (inh=AR+AD pLI=0.02)
chr8	144999684	144999684	A	G	0.6471	17		194.0	0|4|7,0|3|3,2|3	PLEC	synonymous_variant	PLEC:NM_201380.3:synonymous_variant:LOW:exon31/32:c.4824T>C:p.Ala1608Ala,PLEC:NM_201384.2:synonymous_variant:LOW:exon31/32:c.4413T>C:p.Ala1471Ala,PLEC:NM_201383.2:synonymous_variant:LOW:exon31/32:c.4425T>C:p.Ala1475Ala,PLEC:NM_201382.3:synonymous_variant:LOW:exon31/32:c.4413T>C:p.Ala1471Ala,PLEC:NM_201381.2:synonymous_variant:LOW:exon31/32:c.4317T>C:p.Ala1439Ala,PLEC:NM_201379.2:synonymous_variant:LOW:exon31/32:c.4347T>C:p.Ala1449Ala,PLEC:NM_201378.3:synonymous_variant:LOW:exon31/32:c.4371T>C:p.Ala1457Ala,PLEC:NM_000445.4:synonymous_variant:LOW:exon32/33:c.4494T>C:p.Ala1498Ala						rs35916068	0.232628	0.33564805359258	0.2908800	COSM3763159, COSM3763161, COSM3763162, COSM3763163, COSM3763158, COSM3763160	601282 [PLEC (confirmed) Epidermolysis bullosa simplex with muscular dystrophy,226670|Epidermolysis bullosa simplex,Ogna type,131950|Epidermolysis bullosa simplex with pyloric atresia,612138|Muscular dystrophy,limb-girdle,type 2Q,613723|Epidermolysis bullosa simplex with nail dystrophy,616487];	RCV000078865.10 [other]; 								0		237	632			n/a	n/a	PLEC (inh=AR+AD pLI=0.02)
chr8	145001031	145001031	T	C	0.2308	13		15.0	0|2|1,6|2|2,3|4	PLEC	missense_variant	PLEC:NM_201380.3:missense_variant:MODERATE:exon30/32:c.4376A>G:p.His1459Arg,PLEC:NM_201384.2:missense_variant:MODERATE:exon30/32:c.3965A>G:p.His1322Arg,PLEC:NM_201383.2:missense_variant:MODERATE:exon30/32:c.3977A>G:p.His1326Arg,PLEC:NM_201382.3:missense_variant:MODERATE:exon30/32:c.3965A>G:p.His1322Arg,PLEC:NM_201381.2:missense_variant:MODERATE:exon30/32:c.3869A>G:p.His1290Arg,PLEC:NM_201379.2:missense_variant:MODERATE:exon30/32:c.3899A>G:p.His1300Arg,PLEC:NM_201378.3:missense_variant:MODERATE:exon30/32:c.3923A>G:p.His1308Arg,PLEC:NM_000445.4:missense_variant:MODERATE:exon31/33:c.4046A>G:p.His1349Arg						rs55895668	0.466653	0.41276773064422	0.4064140	COSM3763170, COSM150563, COSM3763172, COSM3763171, COSM150562, COSM3763173	601282 [PLEC (confirmed) Epidermolysis bullosa simplex with muscular dystrophy,226670|Epidermolysis bullosa simplex,Ogna type,131950|Epidermolysis bullosa simplex with pyloric atresia,612138|Muscular dystrophy,limb-girdle,type 2Q,613723|Epidermolysis bullosa simplex with nail dystrophy,616487];	RCV000117968.4 [other]; 	CM168220 [CLASS=DP MUT=ALT PHEN="Platelet volume association with" GENE=PLEC]; 	1.623000,1.623000	T,T	T,T,T,T,T,T,T,T,T,	B,B,B,B,B,B,B,B,	T,T,T,T,T,T,T,T,T,	1.76	0		254	677			n/a	n/a	PLEC (inh=AR+AD pLI=0.02)
chr8	145001509	145001509	T	C	0.2333	60		177.0	4|10|0,19|7|19,6|3	PLEC	splice_region_variant&intron_variant	PLEC:NM_201380.3:splice_region_variant&intron_variant:LOW:exon27/31:c.4168-6A>G:,PLEC:NM_201384.2:splice_region_variant&intron_variant:LOW:exon27/31:c.3757-6A>G:,PLEC:NM_201383.2:splice_region_variant&intron_variant:LOW:exon27/31:c.3769-6A>G:,PLEC:NM_201382.3:splice_region_variant&intron_variant:LOW:exon27/31:c.3757-6A>G:,PLEC:NM_201381.2:splice_region_variant&intron_variant:LOW:exon27/31:c.3661-6A>G:,PLEC:NM_201379.2:splice_region_variant&intron_variant:LOW:exon27/31:c.3691-6A>G:,PLEC:NM_201378.3:splice_region_variant&intron_variant:LOW:exon27/31:c.3715-6A>G:,PLEC:NM_000445.4:splice_region_variant&intron_variant:LOW:exon28/32:c.3838-6A>G:						rs11136333	0.230831	0.34372150359688	0.3336891		601282 [PLEC (confirmed) Epidermolysis bullosa simplex with muscular dystrophy,226670|Epidermolysis bullosa simplex,Ogna type,131950|Epidermolysis bullosa simplex with pyloric atresia,612138|Muscular dystrophy,limb-girdle,type 2Q,613723|Epidermolysis bullosa simplex with nail dystrophy,616487];	RCV000078862.9 [other]; 								1	cfDNA_HNSCC,	238	660			n/a	n/a	PLEC (inh=AR+AD pLI=0.02)
chr8	145001588	145001588	C	T	0.6250	8		100.0	2|1|2,1|0|2,6|4	PLEC	missense_variant	PLEC:NM_201380.3:missense_variant:MODERATE:exon27/32:c.4157G>A:p.Arg1386Gln,PLEC:NM_201384.2:missense_variant:MODERATE:exon27/32:c.3746G>A:p.Arg1249Gln,PLEC:NM_201383.2:missense_variant:MODERATE:exon27/32:c.3758G>A:p.Arg1253Gln,PLEC:NM_201382.3:missense_variant:MODERATE:exon27/32:c.3746G>A:p.Arg1249Gln,PLEC:NM_201381.2:missense_variant:MODERATE:exon27/32:c.3650G>A:p.Arg1217Gln,PLEC:NM_201379.2:missense_variant:MODERATE:exon27/32:c.3680G>A:p.Arg1227Gln,PLEC:NM_201378.3:missense_variant:MODERATE:exon27/32:c.3704G>A:p.Arg1235Gln,PLEC:NM_000445.4:missense_variant:MODERATE:exon28/33:c.3827G>A:p.Arg1276Gln						rs11136334	0.230831	0.34894882409299	0.3267311	COSM3750112, COSM1489106, COSM454197, COSM3750113, COSM454196, COSM3750111	601282 [PLEC (confirmed) Epidermolysis bullosa simplex with muscular dystrophy,226670|Epidermolysis bullosa simplex,Ogna type,131950|Epidermolysis bullosa simplex with pyloric atresia,612138|Muscular dystrophy,limb-girdle,type 2Q,613723|Epidermolysis bullosa simplex with nail dystrophy,616487];	RCV000078861.9 [other]; 		0.002000	T	T,T,T,T,T,T,T,T,T	B,B,B,B,B,B,B,B	T,T,T,T,T,T,T,T,T	17.68	0		241	654			n/a	n/a	PLEC (inh=AR+AD pLI=0.02)
chr8	145001784	145001784	A	G	0.6486	74		1202.0	18|2|28,21|0|5,7|3	PLEC	synonymous_variant	PLEC:NM_201380.3:synonymous_variant:LOW:exon27/32:c.3961T>C:p.Leu1321Leu,PLEC:NM_201384.2:synonymous_variant:LOW:exon27/32:c.3550T>C:p.Leu1184Leu,PLEC:NM_201383.2:synonymous_variant:LOW:exon27/32:c.3562T>C:p.Leu1188Leu,PLEC:NM_201382.3:synonymous_variant:LOW:exon27/32:c.3550T>C:p.Leu1184Leu,PLEC:NM_201381.2:synonymous_variant:LOW:exon27/32:c.3454T>C:p.Leu1152Leu,PLEC:NM_201379.2:synonymous_variant:LOW:exon27/32:c.3484T>C:p.Leu1162Leu,PLEC:NM_201378.3:synonymous_variant:LOW:exon27/32:c.3508T>C:p.Leu1170Leu,PLEC:NM_000445.4:synonymous_variant:LOW:exon28/33:c.3631T>C:p.Leu1211Leu						rs3135109	0.230831	0.3687074829932	0.2839991	COSM3750117, COSM3750119, COSM3750116, COSM3750118, COSM3750114, COSM3750115	601282 [PLEC (confirmed) Epidermolysis bullosa simplex with muscular dystrophy,226670|Epidermolysis bullosa simplex,Ogna type,131950|Epidermolysis bullosa simplex with pyloric atresia,612138|Muscular dystrophy,limb-girdle,type 2Q,613723|Epidermolysis bullosa simplex with nail dystrophy,616487];	RCV000078859.9 [other]; 								1	cfDNA_HNSCC,	237	643			n/a	n/a	PLEC (inh=AR+AD pLI=0.02)
chr8	145007187	145007187	G	A	0.4186	43		273.0	0|10|8,15|10|0,4|6	PLEC	missense_variant	PLEC:NM_201380.3:missense_variant:MODERATE:exon14/32:c.1922C>T:p.Ala641Val,PLEC:NM_201384.2:missense_variant:MODERATE:exon14/32:c.1511C>T:p.Ala504Val,PLEC:NM_201383.2:missense_variant:MODERATE:exon14/32:c.1523C>T:p.Ala508Val,PLEC:NM_201382.3:missense_variant:MODERATE:exon14/32:c.1511C>T:p.Ala504Val,PLEC:NM_201381.2:missense_variant:MODERATE:exon14/32:c.1415C>T:p.Ala472Val,PLEC:NM_201379.2:missense_variant:MODERATE:exon14/32:c.1445C>T:p.Ala482Val,PLEC:NM_201378.3:missense_variant:MODERATE:exon14/32:c.1469C>T:p.Ala490Val,PLEC:NM_000445.4:missense_variant:MODERATE:exon15/33:c.1592C>T:p.Ala531Val						rs11136336	0.23143	0.3668672253659	0.3004038	COSM3763174, COSM3763175, COSM3763179, COSM3763176, COSM3763178, COSM3763177	601282 [PLEC (confirmed) Epidermolysis bullosa simplex with muscular dystrophy,226670|Epidermolysis bullosa simplex,Ogna type,131950|Epidermolysis bullosa simplex with pyloric atresia,612138|Muscular dystrophy,limb-girdle,type 2Q,613723|Epidermolysis bullosa simplex with nail dystrophy,616487];	RCV000117955.4 [other]; 		1.952000	T	T,T,T,T,T,T,T,T,T,T	B,B,B,B,B,B,B,B	T,T,T,T,T,T,T,T,T,D	13.05	0		211	652			n/a	n/a	PLEC (inh=AR+AD pLI=0.02)
chr8	145008560	145008560	A	G	0.4741	135		1642.0	24|17|23,14|15|42,6|6	PLEC	synonymous_variant	PLEC:NM_201380.3:synonymous_variant:LOW:exon11/32:c.1506T>C:p.Asp502Asp,PLEC:NM_201384.2:synonymous_variant:LOW:exon11/32:c.1095T>C:p.Asp365Asp,PLEC:NM_201383.2:synonymous_variant:LOW:exon11/32:c.1107T>C:p.Asp369Asp,PLEC:NM_201382.3:synonymous_variant:LOW:exon11/32:c.1095T>C:p.Asp365Asp,PLEC:NM_201381.2:synonymous_variant:LOW:exon11/32:c.999T>C:p.Asp333Asp,PLEC:NM_201379.2:synonymous_variant:LOW:exon11/32:c.1029T>C:p.Asp343Asp,PLEC:NM_201378.3:synonymous_variant:LOW:exon11/32:c.1053T>C:p.Asp351Asp,PLEC:NM_000445.4:synonymous_variant:LOW:exon12/33:c.1176T>C:p.Asp392Asp						rs11783799	0.23143	0.33021685933676	0.3233807	COSM3763184, COSM3763185, COSM3763180, COSM3763183, COSM3763181, COSM3763182	601282 [PLEC (confirmed) Epidermolysis bullosa simplex with muscular dystrophy,226670|Epidermolysis bullosa simplex,Ogna type,131950|Epidermolysis bullosa simplex with pyloric atresia,612138|Muscular dystrophy,limb-girdle,type 2Q,613723|Epidermolysis bullosa simplex with nail dystrophy,616487];	RCV000117948.5 [other]; 								1	cfDNA_HNSCC,	211	657			n/a	n/a	PLEC (inh=AR+AD pLI=0.02)
chr8	145011204	145011204	A	G	0.4677	62		586.0	0|13|16,0|7|26,2|4	PLEC	synonymous_variant	PLEC:NM_201380.3:synonymous_variant:LOW:exon5/32:c.789T>C:p.Ala263Ala,PLEC:NM_201384.2:synonymous_variant:LOW:exon5/32:c.378T>C:p.Ala126Ala,PLEC:NM_201383.2:synonymous_variant:LOW:exon5/32:c.390T>C:p.Ala130Ala,PLEC:NM_201382.3:synonymous_variant:LOW:exon5/32:c.378T>C:p.Ala126Ala,PLEC:NM_201381.2:synonymous_variant:LOW:exon5/32:c.282T>C:p.Ala94Ala,PLEC:NM_201379.2:synonymous_variant:LOW:exon5/32:c.312T>C:p.Ala104Ala,PLEC:NM_201378.3:synonymous_variant:LOW:exon5/32:c.336T>C:p.Ala112Ala,PLEC:NM_000445.4:synonymous_variant:LOW:exon6/33:c.459T>C:p.Ala153Ala						rs6993938	0.232428	0.33028243114593	0.3189500	COSM150564, COSM150565, COSM3763188, COSM3763186, COSM3763187, COSM1489113	601282 [PLEC (confirmed) Epidermolysis bullosa simplex with muscular dystrophy,226670|Epidermolysis bullosa simplex,Ogna type,131950|Epidermolysis bullosa simplex with pyloric atresia,612138|Muscular dystrophy,limb-girdle,type 2Q,613723|Epidermolysis bullosa simplex with nail dystrophy,616487];	RCV000179315.2 [other]; RCV000117970.4 [other]; 								0		211	659			n/a	n/a	PLEC (inh=AR+AD pLI=0.02)
chr8	145024489	145024489	C	A	0.2857	21		53.0	0|6|0,4|1|10,7|7	PLEC	missense_variant,intron_variant	PLEC:NM_201380.3:missense_variant:MODERATE:exon1/32:c.386G>T:p.Arg129Leu,PLEC:NM_201379.2:intron_variant:MODIFIER:exon1/31:c.46+3405G>T:,PLEC:NM_201378.3:intron_variant:MODIFIER:exon1/31:c.71-11629G>T:,PLEC:NM_000445.4:intron_variant:MODIFIER:exon2/32:c.194-11629G>T:						rs782692739	0.0000	0.00010375596596804	0.0000450		601282 [PLEC (confirmed) Epidermolysis bullosa simplex with muscular dystrophy,226670|Epidermolysis bullosa simplex,Ogna type,131950|Epidermolysis bullosa simplex with pyloric atresia,612138|Muscular dystrophy,limb-girdle,type 2Q,613723|Epidermolysis bullosa simplex with nail dystrophy,616487];			1.378000	T	D	B	T	23.00	0		0	0			n/a	n/a	PLEC (inh=AR+AD pLI=0.02)
chr8	145737286	145737286	G	A	0.3023	43		244.0	6|4|3,12|18|0,2|2	RECQL4	splice_region_variant&intron_variant	RECQL4:NM_004260.3:splice_region_variant&intron_variant:LOW:exon20/21:c.3393+8C>T:			DNA-dependent ATPase. May modulate chromosome segregation			rs756627	0.400559	0.46696221594274	0.4516540	COSM3765393	603780 [RECQL4 (provisional) Rothmund-Thomson syndrome,268400|RAPADILINO syndrome,266280|Baller-Gerold syndrome,218600];	RCV000080895.5 [benign]; 								1	Leuk,	328	743			n/a	n/a	RECQL4 (inh=AR pLI=n/a)
chr8	145737636	145737636	A	G	1.0000	51		1589.0	7|0|44,0|0|0,6|9	RECQL4	synonymous_variant	RECQL4:NM_004260.3:synonymous_variant:LOW:exon19/22:c.3127T>C:p.Leu1043Leu			DNA-dependent ATPase. May modulate chromosome segregation			rs4925828	0.946086	0.97282553878223	0.9367412		603780 [RECQL4 (provisional) Rothmund-Thomson syndrome,268400|RAPADILINO syndrome,266280|Baller-Gerold syndrome,218600];	RCV000228280.1 [likely benign]; RCV000153817.2 [benign]; 								0		1509	10			n/a	n/a	RECQL4 (inh=AR pLI=n/a)
chr8	145738669	145738669	C	T	0.6383	94		1421.0	30|6|24,15|6|12,7|7	RECQL4	missense_variant	RECQL4:NM_004260.3:missense_variant:MODERATE:exon15/22:c.2395G>A:p.Val799Met			DNA-dependent ATPase. May modulate chromosome segregation			rs34293591	0.00579073	0.01804113297507	0.0151765		603780 [RECQL4 (provisional) Rothmund-Thomson syndrome,268400|RAPADILINO syndrome,266280|Baller-Gerold syndrome,218600];	RCV000121939.2 [benign]; RCV000229133.1 [benign]; 								0		0	45			n/a	n/a	RECQL4 (inh=AR pLI=n/a)
chr8	145741702	145741702	C	G	0.6250	24		320.0	14|1|0,8|0|1,4|3	RECQL4	missense_variant	RECQL4:NM_004260.3:missense_variant:MODERATE:exon5/22:c.801G>C:p.Glu267Asp			DNA-dependent ATPase. May modulate chromosome segregation			rs4244612	0.447684	0.43770694253038	0.4149604	COSM3763202	603780 [RECQL4 (provisional) Rothmund-Thomson syndrome,268400|RAPADILINO syndrome,266280|Baller-Gerold syndrome,218600];	RCV000080899.7 [benign]; 								0		252	723			n/a	n/a	RECQL4 (inh=AR pLI=n/a)
chr8	145741765	145741765	G	A	0.5000	22		231.0	8|3|0,10|0|1,5|3	RECQL4	synonymous_variant	RECQL4:NM_004260.3:synonymous_variant:LOW:exon5/22:c.738C>T:p.Ser246Ser			DNA-dependent ATPase. May modulate chromosome segregation			rs4244613	0.370008	0.43942754357165	0.4207609	COSM3763203	603780 [RECQL4 (provisional) Rothmund-Thomson syndrome,268400|RAPADILINO syndrome,266280|Baller-Gerold syndrome,218600];	RCV000080898.6 [benign]; 								1	Leuk,	275	720			n/a	n/a	RECQL4 (inh=AR pLI=n/a)
chr8	145742514	145742514	A	G	1.0000	56		1723.0	10|0|46,0|0|0,6|5	RECQL4	missense_variant	RECQL4:NM_004260.3:missense_variant:MODERATE:exon4/22:c.274T>C:p.Ser92Pro			DNA-dependent ATPase. May modulate chromosome segregation			rs2721190	0.943291	0.97332113793339	0.9436992		603780 [RECQL4 (provisional) Rothmund-Thomson syndrome,268400|RAPADILINO syndrome,266280|Baller-Gerold syndrome,218600];	RCV000229915.1 [benign]; RCV000121962.3 [benign]; 								0		1509	9			n/a	n/a	RECQL4 (inh=AR pLI=n/a)
chr8	145742879	145742879	T	C	0.3333	30		171.0	2|4|4,8|0|12,3|2	RECQL4	synonymous_variant	RECQL4:NM_004260.3:synonymous_variant:LOW:exon3/22:c.132A>G:p.Glu44Glu			DNA-dependent ATPase. May modulate chromosome segregation			rs2306386	0.57508	0.55522426453393	0.4677179		603780 [RECQL4 (provisional) Rothmund-Thomson syndrome,268400|RAPADILINO syndrome,266280|Baller-Gerold syndrome,218600];	RCV000080885.6 [benign]; 								1	Leuk,	394	750			n/a	n/a	RECQL4 (inh=AR pLI=n/a)
chr9	2191309	2191309	C	G	0.6190	21		236.0	5|8|0,3|5|0,4|6	SMARCA2	missense_variant	SMARCA2:NM_001289396.1:missense_variant:MODERATE:exon33/34:c.4638C>G:p.Asp1546Glu,SMARCA2:NM_001289397.1:missense_variant:MODERATE:exon32/33:c.4410C>G:p.Asp1470Glu,SMARCA2:NM_003070.4:missense_variant:MODERATE:exon33/34:c.4638C>G:p.Asp1546Glu,SMARCA2:NM_139045.3:missense_variant:MODERATE:exon32/33:c.4584C>G:p.Asp1528Glu,SMARCA2:NM_001289398.1:missense_variant:MODERATE:exon6/7:c.612C>G:p.Asp204Glu,SMARCA2:NM_001289399.1:missense_variant:MODERATE:exon7/8:c.696C>G:p.Asp232Glu,SMARCA2:NM_001289400.1:missense_variant:MODERATE:exon7/8:c.702C>G:p.Asp234Glu						rs2296212	0.223642	0.16837020673283	0.1625939		600014 [SMARCA2 (provisional) Nicolaides-Baraitser syndrome,601358];	RCV000114292.2 [likely benign]; RCV000298011.1 [benign]; 	CM093465 [CLASS=DFP MUT=ALT PHEN="Schizophrenia association with" GENE=SMARCA2]; 	0.094000	T	T,T,T,T,T,T,T,T,T,T,T	B,B,B,B	D,D,D,D,T,T,T,T,T,T	16.74	0		34	321			n/a	n/a	SMARCA2 (inh=AD pLI=1.00)
chr9	27202870	27202870	A	G	0.5000	16		135.0	6|2|0,4|4|0,3|4	TEK	synonymous_variant	TEK:NM_000459.4:synonymous_variant:LOW:exon13/23:c.1962A>G:p.Ser654Ser,TEK:NM_001290077.1:synonymous_variant:LOW:exon12/22:c.1833A>G:p.Ser611Ser,TEK:NM_001290078.1:synonymous_variant:LOW:exon11/21:c.1521A>G:p.Ser507Ser			Tyrosine-protein kinase that acts as cell-surface receptor for ANGPT1, ANGPT2 and ANGPT4 and regulates angiogenesis, endothelial cell survival, proliferation, migration, adhesion and cell spreading, reorganization of the actin cytoskeleton, but also maintenance of vascular quiescence. Has anti-inflammatory effects by preventing the leakage of proinflammatory plasma proteins and leukocytes from blood vessels. Required for normal angiogenesis and heart development during embryogenesis. Required for post- natal hematopoiesis. After birth, activates or inhibits angiogenesis, depending on the context. Inhibits angiogenesis and promotes vascular stability in quiescent vessels, where endothelial cells have tight contacts. In quiescent vessels, ANGPT1 oligomers recruit TEK to cell-cell contacts, forming complexes with TEK molecules from adjoining cells, and this leads to preferential activation of phosphatidylinositol 3-kinase and the AKT1 signaling cascades. In migrating endothelial cells that lack cell-cell adhesions, ANGT1 recruits TEK to contacts with the extracellular matrix, leading to the formation of focal adhesion complexes, activation of PTK2/FAK and of the downstream kinases MAPK1/ERK2 and MAPK3/ERK1, and ultimately to the stimulation of sprouting angiogenesis. ANGPT1 signaling triggers receptor dimerization and autophosphorylation at specific tyrosine residues that then serve as binding sites for scaffold proteins and effectors. Signaling is modulated by ANGPT2 that has lower affinity for TEK, can promote TEK autophosphorylation in the absence of ANGPT1, but inhibits ANGPT1-mediated signaling by competing for the same binding site. Signaling is also modulated by formation of heterodimers with TIE1, and by proteolytic processing that gives rise to a soluble TEK extracellular domain. The soluble extracellular domain modulates signaling by functioning as decoy receptor for angiopoietins. TEK phosphorylates DOK2, GRB7, GRB14, PIK3R1; SHC1 and TIE1			rs639225	0.414337	0.46488206108758	0.4590493	COSM3763867, COSM3763868	600221 [TEK (confirmed) Venous malformations,multiple cutaneous and mucosal,600195|Glaucoma 3,primary congenital,E,617272];	RCV000366679.1 [benign]; 								1	Leuk,	254	602			n/a	n/a	TEK (inh=AD pLI=1.00)
chr9	27205021	27205021	G	A	0.2500	32		70.0	0|0|8,2|0|22,2|3	TEK	synonymous_variant	TEK:NM_000459.4:synonymous_variant:LOW:exon14/23:c.2322G>A:p.Arg774Arg,TEK:NM_001290077.1:synonymous_variant:LOW:exon13/22:c.2193G>A:p.Arg731Arg,TEK:NM_001290078.1:synonymous_variant:LOW:exon12/21:c.1881G>A:p.Arg627Arg			Tyrosine-protein kinase that acts as cell-surface receptor for ANGPT1, ANGPT2 and ANGPT4 and regulates angiogenesis, endothelial cell survival, proliferation, migration, adhesion and cell spreading, reorganization of the actin cytoskeleton, but also maintenance of vascular quiescence. Has anti-inflammatory effects by preventing the leakage of proinflammatory plasma proteins and leukocytes from blood vessels. Required for normal angiogenesis and heart development during embryogenesis. Required for post- natal hematopoiesis. After birth, activates or inhibits angiogenesis, depending on the context. Inhibits angiogenesis and promotes vascular stability in quiescent vessels, where endothelial cells have tight contacts. In quiescent vessels, ANGPT1 oligomers recruit TEK to cell-cell contacts, forming complexes with TEK molecules from adjoining cells, and this leads to preferential activation of phosphatidylinositol 3-kinase and the AKT1 signaling cascades. In migrating endothelial cells that lack cell-cell adhesions, ANGT1 recruits TEK to contacts with the extracellular matrix, leading to the formation of focal adhesion complexes, activation of PTK2/FAK and of the downstream kinases MAPK1/ERK2 and MAPK3/ERK1, and ultimately to the stimulation of sprouting angiogenesis. ANGPT1 signaling triggers receptor dimerization and autophosphorylation at specific tyrosine residues that then serve as binding sites for scaffold proteins and effectors. Signaling is modulated by ANGPT2 that has lower affinity for TEK, can promote TEK autophosphorylation in the absence of ANGPT1, but inhibits ANGPT1-mediated signaling by competing for the same binding site. Signaling is also modulated by formation of heterodimers with TIE1, and by proteolytic processing that gives rise to a soluble TEK extracellular domain. The soluble extracellular domain modulates signaling by functioning as decoy receptor for angiopoietins. TEK phosphorylates DOK2, GRB7, GRB14, PIK3R1; SHC1 and TIE1			rs542913	0.150958	0.21137259429061	0.2112679		600221 [TEK (confirmed) Venous malformations,multiple cutaneous and mucosal,600195|Glaucoma 3,primary congenital,E,617272];	RCV000323672.1 [benign]; 								0		68	414			n/a	n/a	TEK (inh=AD pLI=1.00)
chr9	35074917	35074917	T	C	1.0000	72		2365.0	22|0|50,0|0|0,6|2	FANCG	splice_region_variant&intron_variant	FANCG:NM_004629.1:splice_region_variant&intron_variant:LOW:exon12/13:c.1636+7A>G:			DNA repair protein that may operate in a postreplication repair or a cell cycle checkpoint function. May be implicated in interstrand DNA cross-link repair and in the maintenance of normal chromosome stability. Candidate tumor suppressor gene	BRCA1-dependent Ub-ligase activity;Role of BRCA1,  BRCA2 and ATR in Cancer Susceptibility		rs587118	0.220248	0.39569121766354	0.3922536		602956 [FANCG (confirmed) Fanconi anemia,complementation group G,614082];	RCV000247570.1 [benign]; RCV000275986.1 [benign]; RCV000367549.1 [benign]; RCV000394450.1 [benign]; 								1	SomaticAndTreatment,	733	1454	1	[1] Ilnaz Sepahi 29-03-2016 batch import	n/a	n/a	FANCG (inh=n/a pLI=0.00)
chr9	35705759	35705759	G	A	0.3023	43		203.0	6|0|7,16|0|14,11|15	TLN1	synonymous_variant	TLN1:NM_006289.3:synonymous_variant:LOW:exon42/57:c.5601C>T:p.Thr1867Thr		Focal adhesion	Probably involved in connections of major cytoskeletal structures to the plasma membrane. High molecular weight cytoskeletal protein concentrated at regions of cell-substratum contact and, in lymphocytes, at cell-cell contacts (By similarity)	Apoptotic Signaling in Response to DNA Damage;Erk and PI-3 Kinase Are Necessary for Collagen Binding in Corneal Epithelia;Integrin Signaling Pathway;mCalpain and friends in Cell motility;Rho cell motility signaling pathway;uCalpain and friends in Cell spread		rs11541908	0.169129	0.22641571626343	0.2283543											1	Leuk,	52	303			n/a	n/a	TLN1 (inh=n/a pLI=1.00)
chr9	35707338	35707338	G	A	0.2364	55		99.0	2|1|10,28|1|13,7|4	TLN1	splice_region_variant&intron_variant	TLN1:NM_006289.3:splice_region_variant&intron_variant:LOW:exon36/56:c.4773+7C>T:		Focal adhesion	Probably involved in connections of major cytoskeletal structures to the plasma membrane. High molecular weight cytoskeletal protein concentrated at regions of cell-substratum contact and, in lymphocytes, at cell-cell contacts (By similarity)	Apoptotic Signaling in Response to DNA Damage;Erk and PI-3 Kinase Are Necessary for Collagen Binding in Corneal Epithelia;Integrin Signaling Pathway;mCalpain and friends in Cell motility;Rho cell motility signaling pathway;uCalpain and friends in Cell spread		rs55810625	0.201677	0.24967356990562	0.2496978											1	Leuk,	59	307			n/a	n/a	TLN1 (inh=n/a pLI=1.00)
chr9	35708425	35708425	T	C	0.5400	50		671.0	6|3|18,3|3|17,6|7	TLN1	synonymous_variant	TLN1:NM_006289.3:synonymous_variant:LOW:exon34/57:c.4383A>G:p.Leu1461Leu		Focal adhesion	Probably involved in connections of major cytoskeletal structures to the plasma membrane. High molecular weight cytoskeletal protein concentrated at regions of cell-substratum contact and, in lymphocytes, at cell-cell contacts (By similarity)	Apoptotic Signaling in Response to DNA Damage;Erk and PI-3 Kinase Are Necessary for Collagen Binding in Corneal Epithelia;Integrin Signaling Pathway;mCalpain and friends in Cell motility;Rho cell motility signaling pathway;uCalpain and friends in Cell spread		rs35461988	0.00798722	0.025873199801357	0.0248933	COSM3763914										0		1	41			n/a	n/a	TLN1 (inh=n/a pLI=1.00)
chr9	79253703	79253703	C	T	1.0000	24		727.0	8|16|0,0|0|0,5|6	PRUNE2	splice_region_variant&intron_variant,intron_variant	PRUNE2:NM_001308047.1:splice_region_variant&intron_variant:LOW:exon13/17:c.8734+3G>A:,PRUNE2:NM_001308048.1:splice_region_variant&intron_variant:LOW:exon13/17:c.8737+3G>A:,PRUNE2:NM_015225.2:intron_variant:MODIFIER:exon12/18:c.8729-499G>A:,PRUNE2:NM_001308049.1:intron_variant:MODIFIER:exon5/11:c.476-499G>A:,PRUNE2:NM_001308050.1:intron_variant:MODIFIER:exon4/10:c.521-499G>A:,PRUNE2:NM_001308051.1:intron_variant:MODIFIER:exon4/8:c.524-499G>A:,PRUNE2:NR_131751.1:intron_variant:MODIFIER:exon12/15:n.8841-1238G>A:						rs6560537	0.841054	0.0000	0.8197741											0		14	1			n/a	n/a	PRUNE2 (inh=n/a pLI=0.00)
chr9	79318376	79318390	GTGACAGCCTGCAAC	-	1.0000	8		188.0	0|8|0,0|0|0,1|1	PRUNE2	disruptive_inframe_deletion,non_coding_transcript_exon_variant	PRUNE2:NM_015225.2:disruptive_inframe_deletion:MODERATE:exon9/19:c.8139_8153delGTTGCAGGCTGTCAC:p.Leu2714_Thr2718del,PRUNE2:NM_001308047.1:disruptive_inframe_deletion:MODERATE:exon9/18:c.8139_8153delGTTGCAGGCTGTCAC:p.Leu2714_Thr2718del,PRUNE2:NM_001308048.1:disruptive_inframe_deletion:MODERATE:exon9/18:c.8139_8153delGTTGCAGGCTGTCAC:p.Leu2714_Thr2718del,PRUNE2:NR_131751.1:non_coding_transcript_exon_variant:MODIFIER:exon8/16:n.8060_8074delGTTGCAGGCTGTCAC:						rs376038487	0.784345	0.77823250197078	0.7130556	COSM1319577										1	I16R041,	511	298			n/a	n/a	PRUNE2 (inh=n/a pLI=0.00)
chr9	79318471	79318471	C	T	1.0000	58		1874.0	0|0|58,0|0|0,2|2	PRUNE2	synonymous_variant,non_coding_transcript_exon_variant	PRUNE2:NM_015225.2:synonymous_variant:LOW:exon9/19:c.8058G>A:p.Leu2686Leu,PRUNE2:NM_001308047.1:synonymous_variant:LOW:exon9/18:c.8058G>A:p.Leu2686Leu,PRUNE2:NM_001308048.1:synonymous_variant:LOW:exon9/18:c.8058G>A:p.Leu2686Leu,PRUNE2:NR_131751.1:non_coding_transcript_exon_variant:MODIFIER:exon8/16:n.7979G>A:						rs560094	0.784345	0.79483851644786	0.7610094					-0.007000	T				14.77	1	I16R041,	538	277			n/a	n/a	PRUNE2 (inh=n/a pLI=0.00)
chr9	79318677	79318677	T	C	1.0000	59		1819.0	28|28|3,0|0|0,6|4	PRUNE2	missense_variant,non_coding_transcript_exon_variant	PRUNE2:NM_015225.2:missense_variant:MODERATE:exon9/19:c.7852A>G:p.Ser2618Gly,PRUNE2:NM_001308047.1:missense_variant:MODERATE:exon9/18:c.7852A>G:p.Ser2618Gly,PRUNE2:NM_001308048.1:missense_variant:MODERATE:exon9/18:c.7852A>G:p.Ser2618Gly,PRUNE2:NR_131751.1:non_coding_transcript_exon_variant:MODIFIER:exon8/16:n.7773A>G:						rs561970	0.784545	0.79540116927894	0.7657488	COSM4164026				0.109000,0.109000	T,T	T,T,T,T	,B,B	T,T,T	0.00	1	I16R041,	539	276			n/a	n/a	PRUNE2 (inh=n/a pLI=0.00)
chr9	79318812	79318812	C	T	0.5676	37		520.0	0|3|18,0|10|6,2|3	PRUNE2	missense_variant,non_coding_transcript_exon_variant	PRUNE2:NM_015225.2:missense_variant:MODERATE:exon9/19:c.7717G>A:p.Ala2573Thr,PRUNE2:NM_001308047.1:missense_variant:MODERATE:exon9/18:c.7717G>A:p.Ala2573Thr,PRUNE2:NM_001308048.1:missense_variant:MODERATE:exon9/18:c.7717G>A:p.Ala2573Thr,PRUNE2:NR_131751.1:non_coding_transcript_exon_variant:MODIFIER:exon8/16:n.7638G>A:						rs56261747	0.0365415	0.025284775920845	0.0240122					0.306000,0.306000	T,T	T,T,T,	B,B,	T,T,	0.01	0		0	34			n/a	n/a	PRUNE2 (inh=n/a pLI=0.00)
chr9	79318824	79318824	T	C	0.5676	37		498.0	0|3|18,0|10|6,2|3	PRUNE2	missense_variant,non_coding_transcript_exon_variant	PRUNE2:NM_015225.2:missense_variant:MODERATE:exon9/19:c.7705A>G:p.Arg2569Gly,PRUNE2:NM_001308047.1:missense_variant:MODERATE:exon9/18:c.7705A>G:p.Arg2569Gly,PRUNE2:NM_001308048.1:missense_variant:MODERATE:exon9/18:c.7705A>G:p.Arg2569Gly,PRUNE2:NR_131751.1:non_coding_transcript_exon_variant:MODIFIER:exon8/16:n.7626A>G:						rs41288767	0.0365415	0.025291925879104	0.0240315					1.104000,1.104000	T,T	,T,T,T	,B,B	,T,T	2.95	0		0	34			n/a	n/a	PRUNE2 (inh=n/a pLI=0.00)
chr9	79318921	79318921	A	G	0.8485	33		682.0	12|16|0,2|3|0,2|4	PRUNE2	synonymous_variant,non_coding_transcript_exon_variant	PRUNE2:NM_015225.2:synonymous_variant:LOW:exon9/19:c.7608T>C:p.Cys2536Cys,PRUNE2:NM_001308047.1:synonymous_variant:LOW:exon9/18:c.7608T>C:p.Cys2536Cys,PRUNE2:NM_001308048.1:synonymous_variant:LOW:exon9/18:c.7608T>C:p.Cys2536Cys,PRUNE2:NR_131751.1:non_coding_transcript_exon_variant:MODIFIER:exon8/16:n.7529T>C:						rs620985	0.429113	0.55088410932016	0.5252598					-1.646000	T				0.21	1	I16R041,	342	379			n/a	n/a	PRUNE2 (inh=n/a pLI=0.00)
chr9	79318998	79318998	A	G	1.0000	10		255.0	0|10|0,0|0|0,0|5	PRUNE2	missense_variant,non_coding_transcript_exon_variant	PRUNE2:NM_015225.2:missense_variant:MODERATE:exon9/19:c.7531T>C:p.Ser2511Pro,PRUNE2:NM_001308047.1:missense_variant:MODERATE:exon9/18:c.7531T>C:p.Ser2511Pro,PRUNE2:NM_001308048.1:missense_variant:MODERATE:exon9/18:c.7531T>C:p.Ser2511Pro,PRUNE2:NR_131751.1:non_coding_transcript_exon_variant:MODIFIER:exon8/16:n.7452T>C:						rs620552	0.784345	0.795439662844	0.7599483					-0.256000,-0.256000	T,T	D,T,T,T	,B	T,T,T	13.12	1	I16R041,	540	273			n/a	n/a	PRUNE2 (inh=n/a pLI=0.00)
chr9	79320640	79320640	C	T	1.0000	41		1295.0	1|40|0,0|0|0,6|7	PRUNE2	missense_variant,non_coding_transcript_exon_variant	PRUNE2:NM_015225.2:missense_variant:MODERATE:exon8/19:c.6550G>A:p.Ala2184Thr,PRUNE2:NM_001308047.1:missense_variant:MODERATE:exon8/18:c.6550G>A:p.Ala2184Thr,PRUNE2:NM_001308048.1:missense_variant:MODERATE:exon8/18:c.6550G>A:p.Ala2184Thr,PRUNE2:NR_131751.1:non_coding_transcript_exon_variant:MODIFIER:exon7/16:n.6471G>A:						rs512110	0.796925	0.799140253434	0.7649450					-2.081000,-2.081000	T,T	T,T,T,	B,	T,T,	7.06	1	I16R041,	543	272			n/a	n/a	PRUNE2 (inh=n/a pLI=0.00)
chr9	79321871	79321871	C	T	1.0000	11		311.0	1|0|10,0|0|0,6|6	PRUNE2	synonymous_variant,non_coding_transcript_exon_variant	PRUNE2:NM_015225.2:synonymous_variant:LOW:exon8/19:c.5319G>A:p.Thr1773Thr,PRUNE2:NM_001308047.1:synonymous_variant:LOW:exon8/18:c.5319G>A:p.Thr1773Thr,PRUNE2:NM_001308048.1:synonymous_variant:LOW:exon8/18:c.5319G>A:p.Thr1773Thr,PRUNE2:NR_131751.1:non_coding_transcript_exon_variant:MODIFIER:exon7/16:n.5240G>A:						rs577993	0.516374	0.60326358994894	0.5916890					-0.645000	T				10.56	1	I16R041,	384	364			n/a	n/a	PRUNE2 (inh=n/a pLI=0.00)
chr9	79322068	79322068	G	T	0.6164	73		1137.0	6|4|35,0|5|23,5|6	PRUNE2	missense_variant,non_coding_transcript_exon_variant	PRUNE2:NM_015225.2:missense_variant:MODERATE:exon8/19:c.5122C>A:p.His1708Asn,PRUNE2:NM_001308047.1:missense_variant:MODERATE:exon8/18:c.5122C>A:p.His1708Asn,PRUNE2:NM_001308048.1:missense_variant:MODERATE:exon8/18:c.5122C>A:p.His1708Asn,PRUNE2:NR_131751.1:non_coding_transcript_exon_variant:MODIFIER:exon7/16:n.5043C>A:						rs683866	0.501597	0.58325151025978	0.5671430					0.848000,0.848000	T,T	T,T,T,	B,	T,T,	12.83	1	I16R041,	368	367			n/a	n/a	PRUNE2 (inh=n/a pLI=0.00)
chr9	79322294	79322294	A	G	0.4000	10		58.0	2|0|2,2|2|2,4|2	PRUNE2	synonymous_variant,non_coding_transcript_exon_variant	PRUNE2:NM_015225.2:synonymous_variant:LOW:exon8/19:c.4896T>C:p.Asp1632Asp,PRUNE2:NM_001308047.1:synonymous_variant:LOW:exon8/18:c.4896T>C:p.Asp1632Asp,PRUNE2:NM_001308048.1:synonymous_variant:LOW:exon8/18:c.4896T>C:p.Asp1632Asp,PRUNE2:NR_131751.1:non_coding_transcript_exon_variant:MODIFIER:exon7/16:n.4817T>C:						rs11145015	0.0365415	0.025395552436804	0.0251891					1.083000	T				0.32	0		0	34			n/a	n/a	PRUNE2 (inh=n/a pLI=0.00)
chr9	79322674	79322674	A	G	1.0000	21		641.0	17|4|0,0|0|0,6|5	PRUNE2	missense_variant,non_coding_transcript_exon_variant	PRUNE2:NM_015225.2:missense_variant:MODERATE:exon8/19:c.4516T>C:p.Cys1506Arg,PRUNE2:NM_001308047.1:missense_variant:MODERATE:exon8/18:c.4516T>C:p.Cys1506Arg,PRUNE2:NM_001308048.1:missense_variant:MODERATE:exon8/18:c.4516T>C:p.Cys1506Arg,PRUNE2:NR_131751.1:non_coding_transcript_exon_variant:MODIFIER:exon7/16:n.4437T>C:						rs680775	0.786342	0.79693808882907	0.7677552					1.031000,1.031000	T,T	T,T,T,	B,	T,T,	9.45	1	I16R041,	541	273			n/a	n/a	PRUNE2 (inh=n/a pLI=0.00)
chr9	79322720	79322720	A	G	1.0000	27		880.0	17|4|6,0|0|0,7|6	PRUNE2	synonymous_variant,non_coding_transcript_exon_variant	PRUNE2:NM_015225.2:synonymous_variant:LOW:exon8/19:c.4470T>C:p.Asp1490Asp,PRUNE2:NM_001308047.1:synonymous_variant:LOW:exon8/18:c.4470T>C:p.Asp1490Asp,PRUNE2:NM_001308048.1:synonymous_variant:LOW:exon8/18:c.4470T>C:p.Asp1490Asp,PRUNE2:NR_131751.1:non_coding_transcript_exon_variant:MODIFIER:exon7/16:n.4391T>C:						rs680729	0.777157	0.7949714480525	0.7590223					-0.933000	T				0.01	1	I16R041,	541	273			n/a	n/a	PRUNE2 (inh=n/a pLI=0.00)
chr9	79325558	79325558	G	C	0.3478	23		152.0	4|1|3,6|4|5,5|5	PRUNE2	synonymous_variant,non_coding_transcript_exon_variant	PRUNE2:NM_015225.2:synonymous_variant:LOW:exon8/19:c.1632C>G:p.Thr544Thr,PRUNE2:NM_001308047.1:synonymous_variant:LOW:exon8/18:c.1632C>G:p.Thr544Thr,PRUNE2:NM_001308048.1:synonymous_variant:LOW:exon8/18:c.1632C>G:p.Thr544Thr,PRUNE2:NR_131751.1:non_coding_transcript_exon_variant:MODIFIER:exon7/16:n.1553C>G:						rs600859	0.483027	0.57847507033183	0.5604100											1	I16R041,	366	366			n/a	n/a	PRUNE2 (inh=n/a pLI=0.00)
chr9	79325615	79325615	A	G	1.0000	34		1003.0	19|12|3,0|0|0,3|4	PRUNE2	synonymous_variant,non_coding_transcript_exon_variant	PRUNE2:NM_015225.2:synonymous_variant:LOW:exon8/19:c.1575T>C:p.Ser525Ser,PRUNE2:NM_001308047.1:synonymous_variant:LOW:exon8/18:c.1575T>C:p.Ser525Ser,PRUNE2:NM_001308048.1:synonymous_variant:LOW:exon8/18:c.1575T>C:p.Ser525Ser,PRUNE2:NR_131751.1:non_coding_transcript_exon_variant:MODIFIER:exon7/16:n.1496T>C:						rs611461	0.785343	0.79665932513997	0.7676715											1	I16R041,	541	272			n/a	n/a	PRUNE2 (inh=n/a pLI=0.00)
chr9	120476433	120476433	C	A	0.3000	10		9.0	0|0|3,2|0|5,4|5	TLR4	missense_variant	TLR4:NM_138554.4:missense_variant:MODERATE:exon3/3:c.2027C>A:p.Ala676Asp,TLR4:NM_003266.3:missense_variant:MODERATE:exon4/4:c.1907C>A:p.Ala636Asp,TLR4:NM_138557.2:missense_variant:MODERATE:exon2/2:c.1427C>A:p.Ala476Asp	Toll/interleukin-1_receptor_homology__TIR__domain__4_						0.0000	0.0000	0.0000					5.824000	T	D,D	D	T,T	33.00	0		0	0			n/a	n/a	TLR4 (inh=n/a pLI=0.00)
chr9	134020092	134020092	C	T	1.0000	13		352.0	7|0|6,0|0|0,5|3	NUP214	missense_variant	NUP214:NM_005085.3:missense_variant:MODERATE:exon12/36:c.1720C>T:p.Pro574Ser,NUP214:NM_001318324.1:missense_variant:MODERATE:exon12/36:c.1720C>T:p.Pro574Ser			May serve as a docking site in the receptor-mediated import of substrates across the nuclear pore complex			rs103612	0.641973	0.66405939939145	0.6514238		114350 [NUP214 (confirmed) Leukemia,acute myeloid,somatic,601626|Leukemia,T-cell acute lymphoblastic,somatic,613065];			-0.048000,-0.048000	T,T	,T,T,T,T,T,T	,B,B,B	,T,T,T	22.40	2	I16R041,Leuk,	412	350			n/a	n/a	NUP214 (inh=n/a pLI=0.99)
chr9	135263573	135263573	G	T	1.0000	22		653.0	12|10|0,0|0|0,3|3	TTF1	synonymous_variant,non_coding_transcript_exon_variant	TTF1:NM_007344.3:synonymous_variant:LOW:exon8/11:c.2265C>A:p.Ile755Ile,TTF1:NM_001205296.1:synonymous_variant:LOW:exon7/10:c.720C>A:p.Ile240Ile,TTF1:NR_134525.1:non_coding_transcript_exon_variant:MODIFIER:exon8/11:n.2327C>A:						rs556386	0.901757	0.96659857333487	0.9460335											0		819	37			n/a	n/a	TTF1 (inh=n/a pLI=0.00)
chr9	135273607	135273607	C	G	1.0000	22		648.0	20|2|0,0|0|0,3|4	TTF1	synonymous_variant,non_coding_transcript_exon_variant	TTF1:NM_007344.3:synonymous_variant:LOW:exon4/11:c.1698G>C:p.Leu566Leu,TTF1:NM_001205296.1:synonymous_variant:LOW:exon3/10:c.153G>C:p.Leu51Leu,TTF1:NR_134525.1:non_coding_transcript_exon_variant:MODIFIER:exon4/11:n.1767G>C:						rs504525	0.71865	0.79853673005306	0.7936002											0		588	228			n/a	n/a	TTF1 (inh=n/a pLI=0.00)
chr9	139391636	139391636	G	A	1.0000	38		1176.0	2|8|28,0|0|0,8|9	NOTCH1	synonymous_variant	NOTCH1:NM_017617.4:synonymous_variant:LOW:exon34/34:c.6555C>T:p.Asp2185Asp		Notch signaling pathway	Functions as a receptor for membrane-bound ligands Jagged1, Jagged2 and Delta1 to regulate cell-fate determination. Upon ligand activation through the released notch intracellular domain (NICD) it forms a transcriptional activator complex with RBPJ/RBPSUH and activates genes of the enhancer of split locus. Affects the implementation of differentiation, proliferation and apoptotic programs. May be important for normal lymphocyte function. In altered form, may contribute to transformation or progression in some T-cell neoplasms. Involved in the maturation of both CD4+ and CD8+ cells in the thymus. May be important for follicular differentiation and possibly cell fate selection within the follicle. During cerebellar development, may function as a receptor for neuronal DNER and may be involved in the differentiation of Bergmann glia. Represses neuronal and myogenic differentiation. May enhance HIF1A function by sequestering HIF1AN away from HIF1A (By similarity). Involved in angiogenesis; negatively regulates endothelial cell proliferation, migration and angiogenic sprouting	Presenilin action in Notch and Wnt signaling;Proteolysis and Signaling Pathway of Notch ;Segmentation Clock		rs2229974	0.695088	0.61872963074959	0.6073348	COSM3763781, COSM3763782	190198 [NOTCH1 (confirmed) Aortic valve disease 1,109730|Adams-Oliver syndrome 5,616028];	RCV000313125.1 [benign]; 								2	GT,cfDNA_HNSCC,	431	671			n/a	n/a	NOTCH1 (inh=AD pLI=1.00)
chr9	139412197	139412197	G	A	1.0000	32		995.0	10|19|3,0|0|0,7|8	NOTCH1	splice_region_variant&intron_variant	NOTCH1:NM_017617.4:splice_region_variant&intron_variant:LOW:exon8/33:c.1441+7C>T:		Notch signaling pathway	Functions as a receptor for membrane-bound ligands Jagged1, Jagged2 and Delta1 to regulate cell-fate determination. Upon ligand activation through the released notch intracellular domain (NICD) it forms a transcriptional activator complex with RBPJ/RBPSUH and activates genes of the enhancer of split locus. Affects the implementation of differentiation, proliferation and apoptotic programs. May be important for normal lymphocyte function. In altered form, may contribute to transformation or progression in some T-cell neoplasms. Involved in the maturation of both CD4+ and CD8+ cells in the thymus. May be important for follicular differentiation and possibly cell fate selection within the follicle. During cerebellar development, may function as a receptor for neuronal DNER and may be involved in the differentiation of Bergmann glia. Represses neuronal and myogenic differentiation. May enhance HIF1A function by sequestering HIF1AN away from HIF1A (By similarity). Involved in angiogenesis; negatively regulates endothelial cell proliferation, migration and angiogenic sprouting	Presenilin action in Notch and Wnt signaling;Proteolysis and Signaling Pathway of Notch ;Segmentation Clock		rs9411208	0.696286	0.57682287261039	0.5555355		190198 [NOTCH1 (confirmed) Aortic valve disease 1,109730|Adams-Oliver syndrome 5,616028];									1	GT,	336	637			n/a	n/a	NOTCH1 (inh=AD pLI=1.00)
chr9	139413908	139413908	C	T	1.0000	28		835.0	0|0|28,0|0|0,3|2	NOTCH1	synonymous_variant	NOTCH1:NM_017617.4:synonymous_variant:LOW:exon5/34:c.852G>A:p.Pro284Pro		Notch signaling pathway	Functions as a receptor for membrane-bound ligands Jagged1, Jagged2 and Delta1 to regulate cell-fate determination. Upon ligand activation through the released notch intracellular domain (NICD) it forms a transcriptional activator complex with RBPJ/RBPSUH and activates genes of the enhancer of split locus. Affects the implementation of differentiation, proliferation and apoptotic programs. May be important for normal lymphocyte function. In altered form, may contribute to transformation or progression in some T-cell neoplasms. Involved in the maturation of both CD4+ and CD8+ cells in the thymus. May be important for follicular differentiation and possibly cell fate selection within the follicle. During cerebellar development, may function as a receptor for neuronal DNER and may be involved in the differentiation of Bergmann glia. Represses neuronal and myogenic differentiation. May enhance HIF1A function by sequestering HIF1AN away from HIF1A (By similarity). Involved in angiogenesis; negatively regulates endothelial cell proliferation, migration and angiogenic sprouting	Presenilin action in Notch and Wnt signaling;Proteolysis and Signaling Pathway of Notch ;Segmentation Clock		rs2229975	0.122204	0.13699974830103	0.1311863		190198 [NOTCH1 (confirmed) Aortic valve disease 1,109730|Adams-Oliver syndrome 5,616028];									3	SomaticAndTreatment,TEST_SomaticAndTreatment,	42	313			n/a	n/a	NOTCH1 (inh=AD pLI=1.00)
chr9	139418260	139418260	A	G	1.0000	65		1962.0	26|36|3,0|0|0,3|4	NOTCH1	synonymous_variant	NOTCH1:NM_017617.4:synonymous_variant:LOW:exon3/34:c.312T>C:p.Asn104Asn		Notch signaling pathway	Functions as a receptor for membrane-bound ligands Jagged1, Jagged2 and Delta1 to regulate cell-fate determination. Upon ligand activation through the released notch intracellular domain (NICD) it forms a transcriptional activator complex with RBPJ/RBPSUH and activates genes of the enhancer of split locus. Affects the implementation of differentiation, proliferation and apoptotic programs. May be important for normal lymphocyte function. In altered form, may contribute to transformation or progression in some T-cell neoplasms. Involved in the maturation of both CD4+ and CD8+ cells in the thymus. May be important for follicular differentiation and possibly cell fate selection within the follicle. During cerebellar development, may function as a receptor for neuronal DNER and may be involved in the differentiation of Bergmann glia. Represses neuronal and myogenic differentiation. May enhance HIF1A function by sequestering HIF1AN away from HIF1A (By similarity). Involved in angiogenesis; negatively regulates endothelial cell proliferation, migration and angiogenic sprouting	Presenilin action in Notch and Wnt signaling;Proteolysis and Signaling Pathway of Notch ;Segmentation Clock		rs4489420	0.740016	0.5970491152757	0.5441339	COSM1756049, COSM1756050	190198 [NOTCH1 (confirmed) Aortic valve disease 1,109730|Adams-Oliver syndrome 5,616028];	RCV000367819.1 [benign]; 								1	GT,	375	624			n/a	n/a	NOTCH1 (inh=AD pLI=1.00)
chr10	3143643	3143643	A	C	1.0000	26		747.0	0|2|24,0|0|0,6|6	PFKP	synonymous_variant,5_prime_UTR_variant	PFKP:NM_002627.4:synonymous_variant:LOW:exon4/22:c.351A>C:p.Arg117Arg,PFKP:NM_001323068.1:synonymous_variant:LOW:exon4/21:c.351A>C:p.Arg117Arg,PFKP:NM_001323071.1:synonymous_variant:LOW:exon5/23:c.237A>C:p.Arg79Arg,PFKP:NM_001323067.1:synonymous_variant:LOW:exon4/22:c.270A>C:p.Arg90Arg,PFKP:NM_001242339.1:synonymous_variant:LOW:exon6/24:c.327A>C:p.Arg109Arg,PFKP:NM_001323072.1:synonymous_variant:LOW:exon5/23:c.237A>C:p.Arg79Arg,PFKP:NM_001323069.1:5_prime_UTR_variant:MODIFIER:exon4/22:c.-152A>C:						rs4881080	0.998602	0.999656157427	0.9279504	COSM4144639, COSM4144638										0		859	0			n/a	n/a	PFKP (inh=n/a pLI=0.00)
chr10	3150898	3150898	C	T	1.0000	96		3077.0	12|20|64,0|0|0,8|4	PFKP	synonymous_variant	PFKP:NM_002627.4:synonymous_variant:LOW:exon9/22:c.876C>T:p.Val292Val,PFKP:NM_001323068.1:synonymous_variant:LOW:exon9/21:c.876C>T:p.Val292Val,PFKP:NM_001323069.1:synonymous_variant:LOW:exon9/22:c.369C>T:p.Val123Val,PFKP:NM_001323071.1:synonymous_variant:LOW:exon10/23:c.762C>T:p.Val254Val,PFKP:NM_001323067.1:synonymous_variant:LOW:exon9/22:c.795C>T:p.Val265Val,PFKP:NM_001242339.1:synonymous_variant:LOW:exon11/24:c.852C>T:p.Val284Val,PFKP:NM_001323072.1:synonymous_variant:LOW:exon10/23:c.762C>T:p.Val254Val,PFKP:NM_001323070.1:synonymous_variant:LOW:exon4/16:c.228C>T:p.Val76Val,PFKP:NM_001323073.1:synonymous_variant:LOW:exon5/18:c.228C>T:p.Val76Val,PFKP:NM_001323074.1:synonymous_variant:LOW:exon4/17:c.228C>T:p.Val76Val						rs11251721	0.138179	0.17711668592177	0.1758669	COSM3751718, COSM3751717										1	I16R041,	33	255			n/a	n/a	PFKP (inh=n/a pLI=0.00)
chr10	3155620	3155620	A	G	0.6842	38		576.0	12|14|0,9|3|0,4|6	PFKP	synonymous_variant	PFKP:NM_002627.4:synonymous_variant:LOW:exon13/22:c.1281A>G:p.Ala427Ala,PFKP:NM_001323068.1:synonymous_variant:LOW:exon13/21:c.1281A>G:p.Ala427Ala,PFKP:NM_001323069.1:synonymous_variant:LOW:exon13/22:c.774A>G:p.Ala258Ala,PFKP:NM_001323071.1:synonymous_variant:LOW:exon14/23:c.1167A>G:p.Ala389Ala,PFKP:NM_001323067.1:synonymous_variant:LOW:exon13/22:c.1200A>G:p.Ala400Ala,PFKP:NM_001242339.1:synonymous_variant:LOW:exon15/24:c.1257A>G:p.Ala419Ala,PFKP:NM_001323072.1:synonymous_variant:LOW:exon14/23:c.1167A>G:p.Ala389Ala,PFKP:NM_001323070.1:synonymous_variant:LOW:exon8/16:c.633A>G:p.Ala211Ala,PFKP:NM_001323073.1:synonymous_variant:LOW:exon9/18:c.633A>G:p.Ala211Ala,PFKP:NM_001323074.1:synonymous_variant:LOW:exon8/17:c.633A>G:p.Ala211Ala						rs1052309	0.60623	0.61939315098579	0.6142864	COSM3751721, COSM3751722										0		316	417			n/a	n/a	PFKP (inh=n/a pLI=0.00)
chr10	3155698	3155698	C	T	0.2045	44		84.0	6|3|0,16|19|0,4|6	PFKP	synonymous_variant	PFKP:NM_002627.4:synonymous_variant:LOW:exon13/22:c.1359C>T:p.Phe453Phe,PFKP:NM_001323068.1:synonymous_variant:LOW:exon13/21:c.1359C>T:p.Phe453Phe,PFKP:NM_001323069.1:synonymous_variant:LOW:exon13/22:c.852C>T:p.Phe284Phe,PFKP:NM_001323071.1:synonymous_variant:LOW:exon14/23:c.1245C>T:p.Phe415Phe,PFKP:NM_001323067.1:synonymous_variant:LOW:exon13/22:c.1278C>T:p.Phe426Phe,PFKP:NM_001242339.1:synonymous_variant:LOW:exon15/24:c.1335C>T:p.Phe445Phe,PFKP:NM_001323072.1:synonymous_variant:LOW:exon14/23:c.1245C>T:p.Phe415Phe,PFKP:NM_001323070.1:synonymous_variant:LOW:exon8/16:c.711C>T:p.Phe237Phe,PFKP:NM_001323073.1:synonymous_variant:LOW:exon9/18:c.711C>T:p.Phe237Phe,PFKP:NM_001323074.1:synonymous_variant:LOW:exon8/17:c.711C>T:p.Phe237Phe						rs4881086	0.267572	0.27584225028314	0.2636138	COSM427477, COSM427478				-3.262000	T				9.68	0		60	361			n/a	n/a	PFKP (inh=n/a pLI=0.00)
chr10	3172121	3172121	C	T	1.0000	18		498.0	8|10|0,0|0|0,7|7	PFKP	synonymous_variant	PFKP:NM_002627.4:synonymous_variant:LOW:exon17/22:c.1794C>T:p.Ala598Ala,PFKP:NM_001323068.1:synonymous_variant:LOW:exon16/21:c.1641C>T:p.Ala547Ala,PFKP:NM_001323069.1:synonymous_variant:LOW:exon17/22:c.1287C>T:p.Ala429Ala,PFKP:NM_001323071.1:synonymous_variant:LOW:exon18/23:c.1680C>T:p.Ala560Ala,PFKP:NM_001323067.1:synonymous_variant:LOW:exon17/22:c.1713C>T:p.Ala571Ala,PFKP:NM_001242339.1:synonymous_variant:LOW:exon19/24:c.1770C>T:p.Ala590Ala,PFKP:NM_001323072.1:synonymous_variant:LOW:exon18/23:c.1680C>T:p.Ala560Ala,PFKP:NM_001323070.1:synonymous_variant:LOW:exon11/16:c.993C>T:p.Ala331Ala,PFKP:NM_001323073.1:synonymous_variant:LOW:exon13/18:c.1146C>T:p.Ala382Ala,PFKP:NM_001323074.1:synonymous_variant:LOW:exon12/17:c.1146C>T:p.Ala382Ala						rs1052333	0.41234	0.38458741353358	0.3718875	COSM427481, COSM427482				-4.635000	T				12.43	0		97	378			n/a	n/a	PFKP (inh=n/a pLI=0.00)
chr10	3172145	3172145	C	T	0.5263	19		218.0	4|6|0,5|4|0,6|6	PFKP	synonymous_variant,sequence_feature	PFKP:NM_002627.4:synonymous_variant:LOW:exon17/22:c.1818C>T:p.Phe606Phe,PFKP:NM_001323068.1:synonymous_variant:LOW:exon16/21:c.1665C>T:p.Phe555Phe,PFKP:NM_001323069.1:synonymous_variant:LOW:exon17/22:c.1311C>T:p.Phe437Phe,PFKP:NM_001323071.1:synonymous_variant:LOW:exon18/23:c.1704C>T:p.Phe568Phe,PFKP:NM_001323067.1:synonymous_variant:LOW:exon17/22:c.1737C>T:p.Phe579Phe,PFKP:NM_001242339.1:synonymous_variant:LOW:exon19/24:c.1794C>T:p.Phe598Phe,PFKP:NM_001323072.1:synonymous_variant:LOW:exon18/23:c.1704C>T:p.Phe568Phe,PFKP:NM_001323070.1:synonymous_variant:LOW:exon11/16:c.1017C>T:p.Phe339Phe,PFKP:NM_001323073.1:synonymous_variant:LOW:exon13/18:c.1170C>T:p.Phe390Phe,PFKP:NM_001323074.1:synonymous_variant:LOW:exon12/17:c.1170C>T:p.Phe390Phe,PFKP:NM_002627.4:sequence_feature:LOW:exon17/22:c.1818C>T:,PFKP:NM_001242339.1:sequence_feature:LOW:exon19/24:c.1794C>T:						rs1052337	0.1248	0.13365921054933	0.1273279	COSM1347583, COSM1347582										0		8	168			n/a	n/a	PFKP (inh=n/a pLI=0.00)
chr10	33190567	33190567	C	A	1.0000	9		228.0	5|3|1,0|0|0,4|6	ITGB1	splice_region_variant&intron_variant	ITGB1:NM_033668.2:splice_region_variant&intron_variant:LOW:exon15/15:c.*7-4G>T:,ITGB1:NM_133376.2:splice_region_variant&intron_variant:LOW:exon15/15:c.2332-4G>T:,ITGB1:NM_002211.3:splice_region_variant&intron_variant:LOW:exon15/15:c.2332-4G>T:						rs2153875	0.511182	0.67547334885026	0.6701178											0		473	301			n/a	n/a	ITGB1 (inh=n/a pLI=0.91)
chr10	33209266	33209266	G	T	1.0000	16		486.0	8|8|0,0|0|0,5|5	ITGB1	synonymous_variant	ITGB1:NM_033668.2:synonymous_variant:LOW:exon9/16:c.1176C>A:p.Gly392Gly,ITGB1:NM_133376.2:synonymous_variant:LOW:exon10/16:c.1176C>A:p.Gly392Gly,ITGB1:NM_002211.3:synonymous_variant:LOW:exon10/16:c.1176C>A:p.Gly392Gly						rs2230396	0.784545	0.85808850199492	0.8411424											0		659	192			n/a	n/a	ITGB1 (inh=n/a pLI=0.91)
chr10	33217098	33217098	G	A	0.3846	26		210.0	4|6|0,8|8|0,5|5	ITGB1	synonymous_variant,sequence_feature	ITGB1:NM_033668.2:synonymous_variant:LOW:exon4/16:c.471C>T:p.Asp157Asp,ITGB1:NM_133376.2:synonymous_variant:LOW:exon5/16:c.471C>T:p.Asp157Asp,ITGB1:NM_002211.3:synonymous_variant:LOW:exon5/16:c.471C>T:p.Asp157Asp,ITGB1:NM_033668.2:sequence_feature:LOW:exon4/16:c.471C>T:,ITGB1:NM_133376.2:sequence_feature:LOW:exon5/16:c.471C>T:						rs35057436	0.00599042	0.010621292023731	0.0100319	COSM3358742, COSM3358743, COSM3358741										0		0	28			n/a	n/a	ITGB1 (inh=n/a pLI=0.91)
chr10	43595968	43595968	A	G	0.3750	16		80.0	6|0|0,4|4|2,4|4	RET	synonymous_variant	RET:NM_020975.4:synonymous_variant:LOW:exon2/20:c.135A>G:p.Ala45Ala,RET:NM_020630.4:synonymous_variant:LOW:exon2/19:c.135A>G:p.Ala45Ala		Thyroid cancer	Receptor tyrosine-protein kinase involved in numerous cellular mechanisms including cell proliferation, neuronal navigation, cell migration, and cell differentiation upon binding with glial cell derived neurotrophic factor family ligands. Phosphorylates PTK2/FAK1. Regulates both cell death/survival balance and positional information. Required for the molecular mechanisms orchestration during intestine organogenesis; involved in the development of enteric nervous system and renal organogenesis during embryonic life, and promotes the formation of Peyer's patch-like structures, a major component of the gut- associated lymphoid tissue. Modulates cell adhesion via its cleavage by caspase in sympathetic neurons and mediates cell migration in an integrin (e.g. ITGB1 and ITGB3)-dependent manner. Involved in the development of the neural crest. Active in the absence of ligand, triggering apoptosis through a mechanism that requires receptor intracellular caspase cleavage. Acts as a dependence receptor; in the presence of the ligand GDNF in somatotrophs (within pituitary), promotes survival and down regulates growth hormone (GH) production, but triggers apoptosis in absence of GDNF. Regulates nociceptor survival and size. Triggers the differentiation of rapidly adapting (RA) mechanoreceptors. Mediator of several diseases such as neuroendocrine cancers; these diseases are characterized by aberrant integrins-regulated cell migration			rs1800858	0.753594	0.73652872878833	0.7262321	COSM4144677, COSM4144678	164761 [RET (confirmed) Multiple endocrine neoplasia IIA,171400|Medullary thyroid carcinoma,155240|Multiple endocrine neoplasia IIB,162300|Central hypoventilation syndrome,congenital,209880|Pheochromocytoma,171300|Hirschsprung disease,susceptibility to,1,142623];	RCV000014967.2 [other]; RCV000127776.1 [benign]; RCV000205827.1 [benign]; RCV000216697.1 [not provided]; RCV000153833.3 [benign]; 	CM020759 [CLASS=DP MUT=REF PHEN="Hirschsprung disease association with" GENE=RET]; 							1	Leuk,	1659	1175	1	[1] old entry - no details available	n/a	n/a	RET (inh=AR+AD pLI=1.00)
chr10	43596179	43596179	G	A	0.6364	22		294.0	6|4|4,3|1|4,7|5	RET	splice_region_variant&intron_variant	RET:NM_020975.4:splice_region_variant&intron_variant:LOW:exon2/19:c.337+9G>A:,RET:NM_020630.4:splice_region_variant&intron_variant:LOW:exon2/18:c.337+9G>A:		Thyroid cancer	Receptor tyrosine-protein kinase involved in numerous cellular mechanisms including cell proliferation, neuronal navigation, cell migration, and cell differentiation upon binding with glial cell derived neurotrophic factor family ligands. Phosphorylates PTK2/FAK1. Regulates both cell death/survival balance and positional information. Required for the molecular mechanisms orchestration during intestine organogenesis; involved in the development of enteric nervous system and renal organogenesis during embryonic life, and promotes the formation of Peyer's patch-like structures, a major component of the gut- associated lymphoid tissue. Modulates cell adhesion via its cleavage by caspase in sympathetic neurons and mediates cell migration in an integrin (e.g. ITGB1 and ITGB3)-dependent manner. Involved in the development of the neural crest. Active in the absence of ligand, triggering apoptosis through a mechanism that requires receptor intracellular caspase cleavage. Acts as a dependence receptor; in the presence of the ligand GDNF in somatotrophs (within pituitary), promotes survival and down regulates growth hormone (GH) production, but triggers apoptosis in absence of GDNF. Regulates nociceptor survival and size. Triggers the differentiation of rapidly adapting (RA) mechanoreceptors. Mediator of several diseases such as neuroendocrine cancers; these diseases are characterized by aberrant integrins-regulated cell migration			rs2435351	0.185503	0.28222521402927	0.2072101	COSM3747169, COSM3747170	164761 [RET (confirmed) Multiple endocrine neoplasia IIA,171400|Medullary thyroid carcinoma,155240|Multiple endocrine neoplasia IIB,162300|Central hypoventilation syndrome,congenital,209880|Pheochromocytoma,171300|Hirschsprung disease,susceptibility to,1,142623];	RCV000082056.5 [benign]; RCV000282670.1 [likely benign]; RCV000294618.1 [likely benign]; RCV000334351.1 [likely benign]; RCV000372689.1 [likely benign]; 	CS032424 [CLASS=DP MUT=ALT PHEN="Hirschsprung disease association with" GENE=RET]; 							3	GT,SomaticAndTreatment,cfDNA_HNSCC,	217	1230	1	[1] Ilnaz Sepahi 29-03-2016 batch import	n/a	n/a	RET (inh=AR+AD pLI=1.00)
chr10	43606687	43606687	A	G	0.4615	39		433.0	0|14|4,2|0|19,5|3	RET	synonymous_variant	RET:NM_020975.4:synonymous_variant:LOW:exon7/20:c.1296A>G:p.Ala432Ala,RET:NM_020630.4:synonymous_variant:LOW:exon7/19:c.1296A>G:p.Ala432Ala		Thyroid cancer	Receptor tyrosine-protein kinase involved in numerous cellular mechanisms including cell proliferation, neuronal navigation, cell migration, and cell differentiation upon binding with glial cell derived neurotrophic factor family ligands. Phosphorylates PTK2/FAK1. Regulates both cell death/survival balance and positional information. Required for the molecular mechanisms orchestration during intestine organogenesis; involved in the development of enteric nervous system and renal organogenesis during embryonic life, and promotes the formation of Peyer's patch-like structures, a major component of the gut- associated lymphoid tissue. Modulates cell adhesion via its cleavage by caspase in sympathetic neurons and mediates cell migration in an integrin (e.g. ITGB1 and ITGB3)-dependent manner. Involved in the development of the neural crest. Active in the absence of ligand, triggering apoptosis through a mechanism that requires receptor intracellular caspase cleavage. Acts as a dependence receptor; in the presence of the ligand GDNF in somatotrophs (within pituitary), promotes survival and down regulates growth hormone (GH) production, but triggers apoptosis in absence of GDNF. Regulates nociceptor survival and size. Triggers the differentiation of rapidly adapting (RA) mechanoreceptors. Mediator of several diseases such as neuroendocrine cancers; these diseases are characterized by aberrant integrins-regulated cell migration			rs1800860	0.77516	0.7060675490794	0.6998084		164761 [RET (confirmed) Multiple endocrine neoplasia IIA,171400|Medullary thyroid carcinoma,155240|Multiple endocrine neoplasia IIB,162300|Central hypoventilation syndrome,congenital,209880|Pheochromocytoma,171300|Hirschsprung disease,susceptibility to,1,142623];	RCV000082048.7 [benign]; RCV000131068.2 [benign]; RCV000265973.1 [benign]; RCV000285939.1 [benign]; RCV000321087.1 [benign]; RCV000380264.1 [benign]; 	CM033447 [CLASS=DP MUT=ALT PHEN="Hirschsprung disease association with" GENE=RET]; 							0		1473	1288	1	[1] Ilnaz Sepahi 29-03-2016 batch import	n/a	n/a	RET (inh=AR+AD pLI=1.00)
chr10	43613843	43613843	G	T	0.5556	63		760.0	3|12|20,2|13|13,7|9	RET	synonymous_variant	RET:NM_020975.4:synonymous_variant:LOW:exon13/20:c.2307G>T:p.Leu769Leu,RET:NM_020630.4:synonymous_variant:LOW:exon13/19:c.2307G>T:p.Leu769Leu		Thyroid cancer	Receptor tyrosine-protein kinase involved in numerous cellular mechanisms including cell proliferation, neuronal navigation, cell migration, and cell differentiation upon binding with glial cell derived neurotrophic factor family ligands. Phosphorylates PTK2/FAK1. Regulates both cell death/survival balance and positional information. Required for the molecular mechanisms orchestration during intestine organogenesis; involved in the development of enteric nervous system and renal organogenesis during embryonic life, and promotes the formation of Peyer's patch-like structures, a major component of the gut- associated lymphoid tissue. Modulates cell adhesion via its cleavage by caspase in sympathetic neurons and mediates cell migration in an integrin (e.g. ITGB1 and ITGB3)-dependent manner. Involved in the development of the neural crest. Active in the absence of ligand, triggering apoptosis through a mechanism that requires receptor intracellular caspase cleavage. Acts as a dependence receptor; in the presence of the ligand GDNF in somatotrophs (within pituitary), promotes survival and down regulates growth hormone (GH) production, but triggers apoptosis in absence of GDNF. Regulates nociceptor survival and size. Triggers the differentiation of rapidly adapting (RA) mechanoreceptors. Mediator of several diseases such as neuroendocrine cancers; these diseases are characterized by aberrant integrins-regulated cell migration			rs1800861	0.71246	0.74191013466565	0.7333316		164761 [RET (confirmed) Multiple endocrine neoplasia IIA,171400|Medullary thyroid carcinoma,155240|Multiple endocrine neoplasia IIB,162300|Central hypoventilation syndrome,congenital,209880|Pheochromocytoma,171300|Hirschsprung disease,susceptibility to,1,142623];	RCV000021844.1 [benign]; RCV000127779.1 [benign]; RCV000154625.1 [benign]; RCV000203706.1 [benign]; RCV000153835.3 [benign]; 	CM014825 [CLASS=DP MUT=REF PHEN="Hirschsprung disease association with" GENE=RET]; 							2	MIPs_Etablierung,cfDNA_HNSCC,	1729	1128	1	[1] Ilnaz Sepahi 29-03-2016 batch import	n/a	n/a	RET (inh=AR+AD pLI=1.00)
chr10	55566406	55566406	T	G	1.0000	51		1679.0	33|8|10,0|0|0,6|6	PCDH15	missense_variant	PCDH15:NM_001142771.1:missense_variant:MODERATE:exon35/35:c.4982A>C:p.Gln1661Pro,PCDH15:NM_001142772.1:missense_variant:MODERATE:exon34/34:c.4967A>C:p.Gln1656Pro						rs17704703	0.110224	0.2126914114514	0.2106312		605514 [PCDH15 (confirmed) Usher syndrome,type 1F,602083|Deafness,autosomal recessive 23,609533|Usher syndrome,type 1D/F digenic,601067];	RCV000222137.1 [benign]; 		1.590000	T	T,T,T	B,B	T,T	20.90	0		99	478			n/a	n/a	PCDH15 (inh=AR pLI=0.00)
chr10	56287569	56287569	T	C	0.4000	20		122.0	2|6|0,4|8|0,3|3	PCDH15,LOC105378311	splice_region_variant&intron_variant,intron_variant	PCDH15:NM_001142763.1:splice_region_variant&intron_variant:LOW:exon4/34:c.172+3A>G:,PCDH15:NM_001142771.1:splice_region_variant&intron_variant:LOW:exon4/34:c.172+3A>G:,PCDH15:NM_001142772.1:splice_region_variant&intron_variant:LOW:exon3/33:c.157+3A>G:,PCDH15:NM_001142769.1:splice_region_variant&intron_variant:LOW:exon4/35:c.172+3A>G:,PCDH15:NM_001142770.1:splice_region_variant&intron_variant:LOW:exon3/34:c.157+3A>G:,PCDH15:NM_001142764.1:splice_region_variant&intron_variant:LOW:exon3/33:c.157+3A>G:,PCDH15:NM_001142765.1:splice_region_variant&intron_variant:LOW:exon3/31:c.157+3A>G:,PCDH15:NM_001142766.1:splice_region_variant&intron_variant:LOW:exon3/31:c.157+3A>G:,PCDH15:NM_001142767.1:splice_region_variant&intron_variant:LOW:exon3/30:c.157+3A>G:,PCDH15:NM_033056.3:splice_region_variant&intron_variant:LOW:exon3/32:c.157+3A>G:,LOC105378311:NR_134503.1:intron_variant:MODIFIER:exon1/5:n.88-40756T>C:,PCDH15:NM_001142768.1:intron_variant:MODIFIER:exon2/32:c.91+136363A>G:,PCDH15:NM_001142773.1:intron_variant:MODIFIER:exon2/31:c.91+136363A>G:						rs41274636	0.0856629	0.079675604104601	0.0797729	COSM3998032, COSM3998031, COSM3998030, COSM3998028, COSM3998029	605514 [PCDH15 (confirmed) Usher syndrome,type 1F,602083|Deafness,autosomal recessive 23,609533|Usher syndrome,type 1D/F digenic,601067];	RCV000039703.7 [benign]; RCV000316372.1 [likely benign]; RCV000380306.1 [likely benign]; 								0		9	180			n/a	n/a	PCDH15 (inh=AR pLI=0.00), LOC105378311 (inh=n/a pLI=n/a)
chr10	89623861	89623861	T	-	1.0000	23		636.0	1|2|21,0|0|0,6|7	PTEN	splice_acceptor_variant&splice_donor_variant&intron_variant,5_prime_UTR_variant	PTEN:NM_001304717.2:splice_acceptor_variant&splice_donor_variant&intron_variant:HIGH:exon1/9:c.154+1delT:,PTEN:NM_000314.6:5_prime_UTR_variant:MODIFIER:exon1/9:c.-366delT:,PTEN:NM_001304718.1:5_prime_UTR_variant:MODIFIER:exon1/9:c.-1071delT:		Inositol phosphate metabolism;Phosphatidylinositol signaling system;p53 signaling pathway;Focal adhesion;Tight junction;Endometrial cancer;Glioma;Prostate cancer;Melanoma;Small cell lung cancer	Tumor suppressor. Acts as a dual-specificity protein phosphatase, dephosphorylating tyrosine-, serine- and threonine- phosphorylated proteins. Also acts as a lipid phosphatase, removing the phosphate in the D3 position of the inositol ring from phosphatidylinositol 3,4,5-trisphosphate, phosphatidylinositol 3,4-diphosphate, phosphatidylinositol 3- phosphate and inositol 1,3,4,5-tetrakisphosphate with order of substrate preference in vitro PtdIns(3,4,5)P3 > PtdIns(3,4)P2 > PtdIns3P > Ins(1,3,4,5)P4. The lipid phosphatase activity is critical for its tumor suppressor function. Antagonizes the PI3K- AKT/PKB signaling pathway by dephosphorylating phosphoinositides and thereby modulating cell cycle progression and cell survival. The unphosphorylated form cooperates with AIP1 to suppress AKT1 activation. Dephosphorylates tyrosine-phosphorylated focal adhesion kinase and inhibits cell migration and integrin-mediated cell spreading and focal adhesion formation. Plays a role as a key modulator of the AKT-mTOR signaling pathway controlling the tempo of the process of newborn neurons integration during adult neurogenesis, including correct neuron positioning, dendritic development and synapse formation. May be a negative regulator of insulin signaling and glucose metabolism in adipose tissue. The nuclear monoubiquitinated form possesses greater apoptotic potential, whereas the cytoplasmic nonubiquitinated form induces less tumor suppressive ability	CTCF: First Multivalent Nuclear Factor;mTOR Signaling Pathway;PTEN dependent cell cycle arrest and apoptosis;Regulation of eIF4e and p70 S6 Kinase;Signaling of Hepatocyte Growth Factor Receptor;Skeletal muscle hypertrophy is regulated via AKT/mTOR pathway		rs71022512	1	0.0000	0.4537494		601728 [PTEN (confirmed) Cowden syndrome 1,158350|Lhermitte-Duclos syndrome,158350|Bannayan-Riley-Ruvalcaba syndrome,153480|Meningioma,607174|Glioma susceptibility 2,613028|Macrocephaly/autism syndrome,605309|PTEN hamartoma tumor syndrome|VATER association with macrocephaly and ventriculomegaly,276950|Prostate cancer,somatic,176807|Malignant melanoma,somatic,155600|Endometrial carcinoma,somatic,608089|Squamous cell carcinoma,head and neck,somatic,275355];									0		212	7	1	[1] auto-classification 16.06.2016  	n/a	n/a	PTEN (inh=AD pLI=0.98)
chr10	108367020	108367020	C	T	0.3143	35		202.0	1|0|10,0|1|23,6|5	SORCS1	synonymous_variant	SORCS1:NM_001013031.2:synonymous_variant:LOW:exon23/27:c.3069G>A:p.Ala1023Ala,SORCS1:NM_001206570.1:synonymous_variant:LOW:exon23/26:c.3069G>A:p.Ala1023Ala,SORCS1:NM_001206572.1:synonymous_variant:LOW:exon23/27:c.3069G>A:p.Ala1023Ala,SORCS1:NM_052918.4:synonymous_variant:LOW:exon23/26:c.3069G>A:p.Ala1023Ala,SORCS1:NM_001206569.1:synonymous_variant:LOW:exon23/26:c.3069G>A:p.Ala1023Ala,SORCS1:NM_001206571.1:synonymous_variant:LOW:exon23/25:c.3069G>A:p.Ala1023Ala						rs7082289	0.237021	0.1470943608587	0.1415333	COSM3751521, COSM3751520				-2.984000	T				15.45	0		21	248			n/a	n/a	SORCS1 (inh=n/a pLI=0.97)
chr10	120828969	120828969	A	G	1.0000	75		2263.0	0|0|75,0|0|0,7|8	EIF3A	synonymous_variant	EIF3A:NM_003750.2:synonymous_variant:LOW:exon6/22:c.939T>C:p.Asp313Asp			Component of the eukaryotic translation initiation factor 3 (eIF-3) complex, which is required for several steps in the initiation of protein synthesis. The eIF-3 complex associates with the 40S ribosome and facilitates the recruitment of eIF-1, eIF-1A, eIF-2:GTP:methionyl-tRNAi and eIF-5 to form the 43S preinitiation complex (43S PIC). The eIF-3 complex stimulates mRNA recruitment to the 43S PIC and scanning of the mRNA for AUG recognition. The eIF-3 complex is also required for disassembly and recycling of post-termination ribosomal complexes and subsequently prevents premature joining of the 40S and 60S ribosomal subunits prior to initiation	Eukaryotic protein translation;Internal Ribosome Entry Pathway;mTOR Signaling Pathway		rs7908387	0.790535	0.9238149638239	0.9149089											0		795	61			n/a	n/a	EIF3A (inh=n/a pLI=1.00)
chr10	123298158	123298158	T	C	1.0000	24		768.0	24|0|0,0|0|0,4|3	FGFR2	synonymous_variant,non_coding_transcript_exon_variant	FGFR2:NM_022970.3:synonymous_variant:LOW:exon6/18:c.696A>G:p.Val232Val,FGFR2:NM_001144914.1:synonymous_variant:LOW:exon5/15:c.696A>G:p.Val232Val,FGFR2:NM_023029.2:synonymous_variant:LOW:exon4/16:c.429A>G:p.Val143Val,FGFR2:NM_001144916.1:synonymous_variant:LOW:exon3/15:c.351A>G:p.Val117Val,FGFR2:NM_001144915.1:synonymous_variant:LOW:exon5/17:c.429A>G:p.Val143Val,FGFR2:NM_000141.4:synonymous_variant:LOW:exon6/18:c.696A>G:p.Val232Val,FGFR2:NM_001144917.1:synonymous_variant:LOW:exon6/16:c.696A>G:p.Val232Val,FGFR2:NM_001144918.1:synonymous_variant:LOW:exon4/16:c.351A>G:p.Val117Val,FGFR2:NM_001320658.1:synonymous_variant:LOW:exon6/18:c.696A>G:p.Val232Val,FGFR2:NM_001144913.1:synonymous_variant:LOW:exon5/17:c.696A>G:p.Val232Val,FGFR2:NM_001144919.1:synonymous_variant:LOW:exon5/17:c.429A>G:p.Val143Val,FGFR2:NR_073009.1:non_coding_transcript_exon_variant:MODIFIER:exon4/17:n.998A>G:						rs1047100	0.795327	0.77968000790918	0.7744817		176943 [FGFR2 (confirmed) Crouzon syndrome,123500|Jackson-Weiss syndrome,123150|Beare-Stevenson cutis gyrata syndrome,123790|Pfeiffer syndrome,101600|Apert syndrome,101200|Saethre-Chotzen syndrome,101400|Craniosynostosis,nonspecific|Gastric cancer,somatic,613659|Craniofacial-skeletal-dermatologic dysplasia,101600|Antley-Bixler syndrome without genital anomalies or disordered steroidogenesis,207410|Scaphocephaly and Axenfeld-Rieger anomaly|LADD syndrome,149730|Scaphocephaly,maxillary retrusion,and mental retardation,609579|Bent bone dysplasia syndrome,614592];	RCV000250550.1 [benign]; RCV000264031.1 [benign]; RCV000268420.1 [benign]; RCV000270961.1 [benign]; RCV000308616.1 [benign]; RCV000316516.1 [benign]; RCV000321550.1 [benign]; RCV000363146.1 [benign]; RCV000365600.1 [benign]; RCV000378516.1 [benign]; 								0		930	479			n/a	n/a	FGFR2 (inh=AR+AD pLI=1.00)
chr10	123310871	123310871	A	G	0.5294	17		199.0	5|2|2,0|8|0,3|3	FGFR2	missense_variant,non_coding_transcript_exon_variant	FGFR2:NM_022970.3:missense_variant:MODERATE:exon5/18:c.557T>C:p.Met186Thr,FGFR2:NM_001144914.1:missense_variant:MODERATE:exon4/15:c.557T>C:p.Met186Thr,FGFR2:NM_023029.2:missense_variant:MODERATE:exon3/16:c.290T>C:p.Met97Thr,FGFR2:NM_001144916.1:missense_variant:MODERATE:exon2/15:c.212T>C:p.Met71Thr,FGFR2:NM_001144915.1:missense_variant:MODERATE:exon4/17:c.290T>C:p.Met97Thr,FGFR2:NM_000141.4:missense_variant:MODERATE:exon5/18:c.557T>C:p.Met186Thr,FGFR2:NM_001144917.1:missense_variant:MODERATE:exon5/16:c.557T>C:p.Met186Thr,FGFR2:NM_001144918.1:missense_variant:MODERATE:exon3/16:c.212T>C:p.Met71Thr,FGFR2:NM_001320658.1:missense_variant:MODERATE:exon5/18:c.557T>C:p.Met186Thr,FGFR2:NM_001144913.1:missense_variant:MODERATE:exon4/17:c.557T>C:p.Met186Thr,FGFR2:NM_001144919.1:missense_variant:MODERATE:exon4/17:c.290T>C:p.Met97Thr,FGFR2:NR_073009.1:non_coding_transcript_exon_variant:MODIFIER:exon3/17:n.859T>C:	Immunoglobulin_I-set__1_,Immunoglobulin_subtype_2__1_,Immunoglobulin-like__1_,Immunoglobulin-like_fold__1_					rs755793	0.125599	0.047321340318276	0.0456966		176943 [FGFR2 (confirmed) Crouzon syndrome,123500|Jackson-Weiss syndrome,123150|Beare-Stevenson cutis gyrata syndrome,123790|Pfeiffer syndrome,101600|Apert syndrome,101200|Saethre-Chotzen syndrome,101400|Craniosynostosis,nonspecific|Gastric cancer,somatic,613659|Craniofacial-skeletal-dermatologic dysplasia,101600|Antley-Bixler syndrome without genital anomalies or disordered steroidogenesis,207410|Scaphocephaly and Axenfeld-Rieger anomaly|LADD syndrome,149730|Scaphocephaly,maxillary retrusion,and mental retardation,609579|Bent bone dysplasia syndrome,614592];	RCV000121066.3 [benign]; RCV000390607.1 [benign]; 	CM071761 [CLASS=DM? MUT=ALT PHEN="Hypospadias" GENE=FGFR2]; 	1.098000	T	T,T,T,T,T,T,T,T,T,T,T,T,T,T,T	B,B,B,B,B,B,B,B,B,B,B,B	T,T,T,T,T,T,T,T,T,T,T,T,T,T	0.20	0		2	29	2	[2] Stefanie Beck-Woedl 19.12.2014	n/a	n/a	FGFR2 (inh=AR+AD pLI=1.00)
chr10	128926013	128926013	A	G	0.3125	32		177.0	4|4|2,14|8|0,5|7	DOCK1	synonymous_variant	DOCK1:NM_001290223.1:synonymous_variant:LOW:exon27/52:c.2832A>G:p.Arg944Arg,DOCK1:NM_001380.4:synonymous_variant:LOW:exon27/52:c.2769A>G:p.Arg923Arg		Focal adhesion;Regulation of actin cytoskeleton	Involved in cytoskeletal rearrangements required for phagocytosis of apoptotic cells and cell motility. Functions as a guanine nucleotide exchange factor (GEF), which activates Rac Rho small GTPases by exchanging bound GDP for free GTP. Its GEF activity may be enhanced by ELMO1	Signaling of Hepatocyte Growth Factor Receptor		rs1060561	0.74381	0.81915087463557	0.8062943											0		624	208			n/a	n/a	DOCK1 (inh=n/a pLI=0.37)
chr10	129242515	129242515	G	A	0.6316	38		496.0	18|6|0,4|8|2,5|6	DOCK1	synonymous_variant	DOCK1:NM_001290223.1:synonymous_variant:LOW:exon50/52:c.5385G>A:p.Arg1795Arg,DOCK1:NM_001380.4:synonymous_variant:LOW:exon50/52:c.5322G>A:p.Arg1774Arg		Focal adhesion;Regulation of actin cytoskeleton	Involved in cytoskeletal rearrangements required for phagocytosis of apoptotic cells and cell motility. Functions as a guanine nucleotide exchange factor (GEF), which activates Rac Rho small GTPases by exchanging bound GDP for free GTP. Its GEF activity may be enhanced by ELMO1	Signaling of Hepatocyte Growth Factor Receptor		rs11371	0.33746	0.35295934122491	0.3267955	COSM3751605										0		127	377			n/a	n/a	DOCK1 (inh=n/a pLI=0.37)
chr10	129245684	129245684	G	A	0.5340	103		1246.0	20|35|0,36|12|0,5|5	DOCK1	missense_variant,sequence_feature	DOCK1:NM_001290223.1:missense_variant:MODERATE:exon51/52:c.5440G>A:p.Ala1814Thr,DOCK1:NM_001380.4:missense_variant:MODERATE:exon51/52:c.5377G>A:p.Ala1793Thr,DOCK1:NM_001380.4:sequence_feature:LOW:exon51/52:c.5377G>A:		Focal adhesion;Regulation of actin cytoskeleton	Involved in cytoskeletal rearrangements required for phagocytosis of apoptotic cells and cell motility. Functions as a guanine nucleotide exchange factor (GEF), which activates Rac Rho small GTPases by exchanging bound GDP for free GTP. Its GEF activity may be enhanced by ELMO1	Signaling of Hepatocyte Growth Factor Receptor		rs869801	0.204673	0.25655944055944	0.2238528	COSM147088				-0.958000	T	T	B,B	T	3.82	0		66	338			n/a	n/a	DOCK1 (inh=n/a pLI=0.37)
chr10	129249662	129249662	G	A	1.0000	29		876.0	0|19|10,0|0|0,7|10	DOCK1	missense_variant	DOCK1:NM_001290223.1:missense_variant:MODERATE:exon52/52:c.5632G>A:p.Ala1878Thr,DOCK1:NM_001380.4:missense_variant:MODERATE:exon52/52:c.5569G>A:p.Ala1857Thr		Focal adhesion;Regulation of actin cytoskeleton	Involved in cytoskeletal rearrangements required for phagocytosis of apoptotic cells and cell motility. Functions as a guanine nucleotide exchange factor (GEF), which activates Rac Rho small GTPases by exchanging bound GDP for free GTP. Its GEF activity may be enhanced by ELMO1	Signaling of Hepatocyte Growth Factor Receptor		rs2229603	0.865016	0.94065225635192	0.8988965	COSM4144470				1.286000	T	T	B	T	14.54	0		773	83			n/a	n/a	DOCK1 (inh=n/a pLI=0.37)
chr11	534242	534242	A	G	0.4379	153		1368.0	16|37|14,7|69|10,7|6	HRAS	synonymous_variant,sequence_feature,5_prime_UTR_variant	HRAS:NM_001130442.2:synonymous_variant:LOW:exon2/5:c.81T>C:p.His27His,HRAS:NM_005343.3:synonymous_variant:LOW:exon2/6:c.81T>C:p.His27His,HRAS:NM_176795.4:synonymous_variant:LOW:exon2/6:c.81T>C:p.His27His,HRAS:NM_176795.4:sequence_feature:LOW:exon2/6:c.81T>C:,HRAS:NM_001318054.1:5_prime_UTR_variant:MODIFIER:exon2/7:c.-239T>C:		MAPK signaling pathway;ErbB signaling pathway;Axon guidance;VEGF signaling pathway;Focal adhesion;Tight junction;Gap junction;Natural killer cell mediated cytotoxicity;T cell receptor signaling pathway;B cell receptor signaling pathway;Fc epsilon RI signaling pathway;Long-term potentiation;Long-term depression;Regulation of actin cytoskeleton;Insulin signaling pathway;GnRH signaling pathway;Melanogenesis;Renal cell carcinoma;Endometrial cancer;Glioma;Prostate cancer;Thyroid cancer;Melanoma;Bladder cancer;Chronic myeloid leukemia;Acute myeloid leukemia;Non-small cell lung cancer	Ras proteins bind GDP/GTP and possess intrinsic GTPase activity	Angiotensin II mediated activation of JNK Pathway via Pyk2 dependent signaling;Aspirin Blocks Signaling Pathway Involved in Platelet Activation;BCR Signaling Pathway;Bioactive Peptide Induced Signaling Pathway;Cadmium induces DNA synthesis and proliferation in macrophages;Calcium Signaling by HBx of Hepatitis B virus;CCR3 signaling in Eosinophils;CXCR4 Signaling Pathway;EGF Signaling Pathway;EPO Signaling Pathway;Erk and PI-3 Kinase Are Necessary for Collagen Binding in Corneal Epithelia;Erk1/Erk2 Mapk Signaling pathway;Fc Epsilon Receptor I Signaling in Mast Cells;fMLP induced chemokine gene expression in HMC-1 cells;Growth Hormone Signaling Pathway;How Progesterone Initiates Oocyte Membrane;IGF-1 Signaling Pathway;IL 2 signaling pathway;IL 3 signaling pathway;IL 6 signaling pathway;IL-2 Receptor Beta Chain in T cell Activation;Influence of Ras and Rho proteins on G1 to S Transition;Inhibition of Cellular Proliferation by Gleevec;Inhibition of Matrix Metalloproteinases;Insulin Signaling Pathway;Integrin Signaling Pathway;Keratinocyte Differentiation;Links between Pyk2 and Map Kinases;MAPKinase Signaling Pathway;mCalpain and friends in Cell motility;METS affect on Macrophage Differentiation;Multiple antiapoptotic pathways from IGF-1R signaling lead to BAD phosphorylation;Nerve growth factor pathway (NGF);NFAT and Hypertrophy of the heart (Transcription in the broken heart);p38 MAPK Signaling Pathway ;PDGF Signaling Pathway;Phosphorylation of MEK1 by cdk5/p35 down regulates the MAP kinase pathway;Ras Signaling Pathway;Regulation of Splicing through Sam68;Regulation of transcriptional activity by PML;Role of EGF Receptor Transactivation by GPCRs in Cardiac Hypertrophy;Role of ERBB2 in Signal Transduction and Oncology;Role of Erk5 in Neuronal Survival;Role of MAL in Rho-Mediated Activation of SRF;Signaling of Hepatocyte Growth Factor Receptor;Signaling Pathway from G-Protein Families;Sprouty regulation of tyrosine kinase signals;T Cell Receptor Signaling Pathway;The IGF-1 Receptor and Longevity;TPO Signaling Pathway;Transcription factor CREB and its extracellular signals;Trefoil Factors Initiate  Mucosal Healing;Trka Receptor Signaling Pathway;VEGF, Hypoxia, and Angiogenesis		rs12628	0.297125	0.31352060733924	0.3116126	COSM3752426, COSM249860	190020 [HRAS (confirmed) Bladder cancer,somatic,109800|Costello syndrome,218040|Thyroid carcinoma,follicular,somatic,188470|Congenital myopathy with excess of muscle spindles,218040|Nevus sebaceous or woolly hair nevus,somatic,162900|Schimmelpenning-Feuerstein-Mims syndrome,somatic mosaic,163200|Spitz nevus or nevus spilus,somatic,137550];	RCV000038468.7 [benign]; RCV000149841.1 [benign]; 	CM035804 [CLASS=DP MUT=ALT PHEN="Bladder cancer association with" GENE=HRAS]; 							0		173	646			n/a	n/a	HRAS (inh=AD pLI=0.01)
chr11	1016756	1016756	G	A	0.3824	34		193.0	0|13|0,0|21|0,2|4	MUC6	synonymous_variant	MUC6:NM_005961.2:synonymous_variant:LOW:exon31/33:c.6045C>T:p.Ser2015Ser						rs537530758	0.00259585	0.24085494254257	0.0000836											0		0	21			n/a	n/a	MUC6 (inh=n/a pLI=0.00)
chr11	1016776	1016776	C	T	0.2059	68		40.0	0|14|0,0|54|0,2|3	MUC6	missense_variant	MUC6:NM_005961.2:missense_variant:MODERATE:exon31/33:c.6025G>A:p.Val2009Ile						rs33988517	0.0000	0.465321383209	0.0251248					-3.169000	T	T	B	T	0.01	0		1	855			n/a	n/a	MUC6 (inh=n/a pLI=0.00)
chr11	1016869	1016869	A	T	0.2037	54		86.0	2|9|0,4|37|0,3|3	MUC6	missense_variant	MUC6:NM_005961.2:missense_variant:MODERATE:exon31/33:c.5932T>A:p.Phe1978Ile						rs35469308	0.0299521	0.49248676587053	0.0179802					-5.070000	T	T	B	T	0.01	0		0	868			n/a	n/a	MUC6 (inh=n/a pLI=0.00)
chr11	1016894	1016894	G	A	0.4211	19		112.0	2|6|0,4|7|0,2|2	MUC6	synonymous_variant	MUC6:NM_005961.2:synonymous_variant:LOW:exon31/33:c.5907C>T:p.His1969His						rs34281988	0.0000	0.38511624792863	0.0139739											0		0	846			n/a	n/a	MUC6 (inh=n/a pLI=0.00)
chr11	1016910	1016910	G	A	0.2778	18		28.0	0|5|0,6|7|0,2|2	MUC6	missense_variant	MUC6:NM_005961.2:missense_variant:MODERATE:exon31/33:c.5891C>T:p.Thr1964Ile						rs113559934	0.0000	0.4023448250555	0.0026623	COSM3931188, COSM3931189				0.014000	T	D	B	T	23.30	0		0	585			n/a	n/a	MUC6 (inh=n/a pLI=0.00)
chr11	1016978	1016978	T	G	0.2473	93		128.0	2|22|0,0|14|48,6|4	MUC6	missense_variant	MUC6:NM_005961.2:missense_variant:MODERATE:exon31/33:c.5823A>C:p.Lys1941Asn						rs76461263	0.000599042	0.40066443767702	0.0007074	COSM4145043, COSM4145044				-5.739000	T	T	B	T	0.00	0		0	829			n/a	n/a	MUC6 (inh=n/a pLI=0.00)
chr11	1016991	1016991	T	G	0.2174	92		27.0	2|22|0,0|14|48,6|4	MUC6	missense_variant	MUC6:NM_005961.2:missense_variant:MODERATE:exon31/33:c.5810A>C:p.Asn1937Thr						rs74788171	0.000399361	0.4515853914994	0.0027330	COSM3773545, COSM3773544				0.460000	T	T	B	T	0.00	0		0	830			n/a	n/a	MUC6 (inh=n/a pLI=0.00)
chr11	1017029	1017029	T	G	0.6818	88		1489.0	15|8|38,9|9|10,4|6	MUC6	synonymous_variant	MUC6:NM_005961.2:synonymous_variant:LOW:exon31/33:c.5772A>C:p.Ser1924Ser						rs35621365	0.0000	0.50005194715243	0.0188420											0		1	868			n/a	n/a	MUC6 (inh=n/a pLI=0.00)
chr11	1017084	1017084	G	A	0.3936	188		1592.0	30|16|28,18|18|78,3|5	MUC6	missense_variant	MUC6:NM_005961.2:missense_variant:MODERATE:exon31/33:c.5717C>T:p.Pro1906Leu						rs34649796	0.0000	0.4962147520489	0.0092216	COSM4145050, COSM4145049				-2.032000	T	T	B	T	0.04	0		0	752			n/a	n/a	MUC6 (inh=n/a pLI=0.00)
chr11	1017110	1017110	C	T	0.1818	187		224.0	2|0|32,45|33|74,3|5	MUC6	synonymous_variant	MUC6:NM_005961.2:synonymous_variant:LOW:exon31/33:c.5691G>A:p.Pro1897Pro						rs36130410	0.00119808	0.47167886608086	0.0015498	COSM3931194, COSM237784										0		0	514			n/a	n/a	MUC6 (inh=n/a pLI=0.00)
chr11	1017112	1017112	G	C	0.1818	187		224.0	2|0|32,46|33|74,3|5	MUC6	missense_variant	MUC6:NM_005961.2:missense_variant:MODERATE:exon31/33:c.5689C>G:p.Pro1897Ala						rs77753732	0.0000	0.47332306148775	0.0015755					-3.717000	T	T	B	T	0.00	0		0	485			n/a	n/a	MUC6 (inh=n/a pLI=0.00)
chr11	1017113	1017113	T	C	0.1818	187		224.0	2|0|32,45|33|74,3|5	MUC6	synonymous_variant	MUC6:NM_005961.2:synonymous_variant:LOW:exon31/33:c.5688A>G:p.Thr1896Thr						rs74202058	0.0000	0.49427471028134	0.0019807											0		3	861			n/a	n/a	MUC6 (inh=n/a pLI=0.00)
chr11	1017173	1017173	G	A	0.3509	114		825.0	0|0|40,0|0|74,1|1	MUC6	synonymous_variant	MUC6:NM_005961.2:synonymous_variant:LOW:exon31/33:c.5628C>T:p.Thr1876Thr						rs61869004	0.0000	0.49584729324634	0.0148163	COSM4145058, COSM4145057										0		0	812			n/a	n/a	MUC6 (inh=n/a pLI=0.00)
chr11	1017183	1017183	G	T	0.2982	114		593.0	0|0|34,0|0|80,1|1	MUC6	missense_variant	MUC6:NM_005961.2:missense_variant:MODERATE:exon31/33:c.5618C>A:p.Pro1873Gln						rs34844844	0.000399361	0.48641973074696	0.0062828	COSM1350278, COSM1350279				0.775000	T	D	D	T	15.80	0		0	670			n/a	n/a	MUC6 (inh=n/a pLI=0.00)
chr11	1017325	1017325	A	C	0.5694	72		1070.0	19|22|0,18|35|0,4|5	MUC6	missense_variant	MUC6:NM_005961.2:missense_variant:MODERATE:exon31/33:c.5476T>G:p.Tyr1826Asp						rs55903826	0.0000	0.49850328060008	0.0155109	COSM1317402, COSM1317403				-4.881000	T	D	D	T	8.22	0		0	725			n/a	n/a	MUC6 (inh=n/a pLI=0.00)
chr11	1017746	1017746	T	G	0.1440	125		58.0	0|38|0,0|70|19,2|4	MUC6	missense_variant	MUC6:NM_005961.2:missense_variant:MODERATE:exon31/33:c.5055A>C:p.Leu1685Phe						rs78848170	0.0000	0.40790796259068	0.0005144	COSM4145083, COSM4145084					T	T	B	T	0.14	0		1	863			n/a	n/a	MUC6 (inh=n/a pLI=0.00)
chr11	1017783	1017783	A	G	0.3095	126		675.0	0|41|0,0|74|0,1|3	MUC6	missense_variant	MUC6:NM_005961.2:missense_variant:MODERATE:exon31/33:c.5018T>C:p.Leu1673Pro						rs36101709	0.28734	0.39568544915335	0.0147391					-7.641000	T	T	B	T	0.00	0		0	860			n/a	n/a	MUC6 (inh=n/a pLI=0.00)
chr11	1017789	1017789	A	C	0.1905	126		247.0	0|24|0,0|104|0,1|3	MUC6	missense_variant	MUC6:NM_005961.2:missense_variant:MODERATE:exon31/33:c.5012T>G:p.Met1671Arg						rs78819924	0.0000	0.494464979092	0.0051510	COSM4145088, COSM4145087				-3.155000	T	D	B	T	4.51	0		0	328			n/a	n/a	MUC6 (inh=n/a pLI=0.00)
chr11	1017858	1017858	A	G	0.5000	24		72.0	0|12|0,0|12|0,1|2	MUC6	missense_variant	MUC6:NM_005961.2:missense_variant:MODERATE:exon31/33:c.4943T>C:p.Met1648Thr						rs79583615	0.0000	0.46308925951185	0.0004373					-2.699000	T	T	B	T	0.00	0		1	854			n/a	n/a	MUC6 (inh=n/a pLI=0.00)
chr11	1017892	1017892	C	T	0.3000	20		21.0	0|6|0,0|11|0,1|2	MUC6	missense_variant	MUC6:NM_005961.2:missense_variant:MODERATE:exon31/33:c.4909G>A:p.Ala1637Thr						rs75500881	0.0000	0.0000	0.0000					-2.466000	T	T	B	T	3.65	0		0	0			n/a	n/a	MUC6 (inh=n/a pLI=0.00)
chr11	1017893	1017893	A	G	0.3000	20		11.0	0|6|0,0|14|0,1|2	MUC6	synonymous_variant	MUC6:NM_005961.2:synonymous_variant:LOW:exon31/33:c.4908T>C:p.His1636His						rs76078620	0.375	0.47687236871261	0.0123084	COSM3769165, COSM3769166										0		0	667			n/a	n/a	MUC6 (inh=n/a pLI=0.00)
chr11	1017894	1017894	T	C	0.3000	20		11.0	0|6|0,0|14|0,1|2	MUC6	missense_variant	MUC6:NM_005961.2:missense_variant:MODERATE:exon31/33:c.4907A>G:p.His1636Arg							0.0000	0.0000	0.0000064					-0.048000	T	D	D	T	0.01	0		0	0			n/a	n/a	MUC6 (inh=n/a pLI=0.00)
chr11	1017898	1017898	T	G	0.3000	20		11.0	0|6|0,0|14|0,1|2	MUC6	missense_variant	MUC6:NM_005961.2:missense_variant:MODERATE:exon31/33:c.4903A>C:p.Thr1635Pro						rs781135233	0.0000	0.014953377302706	0.0013504					-0.102000	T	D	D	T	14.50	0		0	0			n/a	n/a	MUC6 (inh=n/a pLI=0.00)
chr11	1017935	1017935	A	G	0.4500	20		49.0	0|9|0,0|11|0,2|2	MUC6	synonymous_variant	MUC6:NM_005961.2:synonymous_variant:LOW:exon31/33:c.4866T>C:p.Ser1622Ser						rs138784536	0.0000	0.47390465859097	0.0002058	COSM4145098, COSM4145099										0		0	799			n/a	n/a	MUC6 (inh=n/a pLI=0.00)
chr11	1017958	1017958	G	A	0.3000	20		21.0	0|6|0,0|14|0,2|2	MUC6	missense_variant	MUC6:NM_005961.2:missense_variant:MODERATE:exon31/33:c.4843C>T:p.His1615Tyr						rs775485176	0.0000	4.9691910157026E-5	0.0000965	COSM3927671, COSM3927672				0.009000	T	D	P	T	0.00	0		0	1			n/a	n/a	MUC6 (inh=n/a pLI=0.00)
chr11	1017968	1017968	T	A	0.3000	20		17.0	0|6|0,0|14|0,2|2	MUC6	synonymous_variant	MUC6:NM_005961.2:synonymous_variant:LOW:exon31/33:c.4833A>T:p.Thr1611Thr						rs61869009	0.0000	0.46285728756901	0.0012797											0		0	687			n/a	n/a	MUC6 (inh=n/a pLI=0.00)
chr11	1017988	1017988	G	T	0.4375	16		40.0	3|4|0,8|1|0,2|2	MUC6	missense_variant	MUC6:NM_005961.2:missense_variant:MODERATE:exon31/33:c.4813C>A:p.Pro1605Thr						rs112579249	0.0000	0.027256409255863	0.0000386					0.017000	T	D	D	T	0.11	0		0	608			n/a	n/a	MUC6 (inh=n/a pLI=0.00)
chr11	1018024	1018024	C	G	0.5833	24		239.0	6|8|0,8|2|0,2|2	MUC6	missense_variant	MUC6:NM_005961.2:missense_variant:MODERATE:exon31/33:c.4777G>C:p.Ala1593Pro						rs766179928	0.0000	0.26701063745126	0.0000064					-0.442000	T	T	B	T	10.61	0		0	551			n/a	n/a	MUC6 (inh=n/a pLI=0.00)
chr11	1018025	1018025	C	A	0.5833	24		239.0	6|8|0,8|2|0,2|2	MUC6	synonymous_variant	MUC6:NM_005961.2:synonymous_variant:LOW:exon31/33:c.4776G>T:p.Thr1592Thr						rs10751677	0.0000	0.3457541784972	0.0172407	COSM4145108, COSM4145109										0		7	856			n/a	n/a	MUC6 (inh=n/a pLI=0.00)
chr11	1018031	1018031	G	A	0.5833	24		269.0	6|8|0,8|2|0,2|2	MUC6	synonymous_variant	MUC6:NM_005961.2:synonymous_variant:LOW:exon31/33:c.4770C>T:p.Pro1590Pro						rs10751678	0.0000	0.32059340849456	0.0162311	COSM4145110, COSM4145111										0		0	867			n/a	n/a	MUC6 (inh=n/a pLI=0.00)
chr11	1018042	1018042	A	G	0.5833	24		278.0	6|8|0,8|2|0,2|2	MUC6	missense_variant	MUC6:NM_005961.2:missense_variant:MODERATE:exon31/33:c.4759T>C:p.Ser1587Pro						rs200364398	0.0000	0.30669546436285	0.0000322					-0.512000	T	D	D	T	0.29	0		0	810			n/a	n/a	MUC6 (inh=n/a pLI=0.00)
chr11	1018048	1018048	A	G	0.5833	24		311.0	6|8|0,8|2|0,2|2	MUC6	missense_variant	MUC6:NM_005961.2:missense_variant:MODERATE:exon31/33:c.4753T>C:p.Phe1585Leu						rs12787400	0.0000	0.35370249579457	0.0000129	COSM3773555, COSM3773556				-4.590000	T	T	B	T	0.00	0		0	839			n/a	n/a	MUC6 (inh=n/a pLI=0.00)
chr11	1018059	1018059	C	T	0.5833	24		263.0	6|8|0,8|2|0,2|2	MUC6	missense_variant	MUC6:NM_005961.2:missense_variant:MODERATE:exon31/33:c.4742G>A:p.Gly1581Glu						rs78336072	0.0000	0.37182135479735	0.0019421	COSM3773557, COSM3773558				-1.459000	T	T	B	T	0.03	0		0	821			n/a	n/a	MUC6 (inh=n/a pLI=0.00)
chr11	1018374	1018374	T	A	1.0000	47		1410.0	4|0|43,0|0|0,8|8	MUC6	missense_variant	MUC6:NM_005961.2:missense_variant:MODERATE:exon31/33:c.4427A>T:p.Asn1476Ile						rs7396383	0.705272	0.75593943519333	0.6746964					-0.797000	T	T	B	T	6.26	0		351	522			n/a	n/a	MUC6 (inh=n/a pLI=0.00)
chr11	1018385	1018385	T	A	0.3492	63		385.0	6|16|0,13|28|0,8|8	MUC6	synonymous_variant	MUC6:NM_005961.2:synonymous_variant:LOW:exon31/33:c.4416A>T:p.Thr1472Thr						rs7396380	0.0000	0.19112192006289	0.0008874	COSM4145169, COSM4145168										0		0	866			n/a	n/a	MUC6 (inh=n/a pLI=0.00)
chr11	1018390	1018390	C	A	0.3492	63		372.0	6|16|0,13|28|0,7|7	MUC6	missense_variant	MUC6:NM_005961.2:missense_variant:MODERATE:exon31/33:c.4411G>T:p.Ala1471Ser						rs111785507	0.0000	0.00097601068474855	0.0009389	COSM3773568, COSM3773567				-3.219000	T	T	B	T	0.00	0		0	718			n/a	n/a	MUC6 (inh=n/a pLI=0.00)
chr11	1018399	1018399	C	G	0.2821	78		300.0	6|16|0,13|28|15,7|7	MUC6	missense_variant	MUC6:NM_005961.2:missense_variant:MODERATE:exon31/33:c.4402G>C:p.Ala1468Pro						rs61742414	0.0000	4.1422275242735E-5	0.0000386					-0.687000	T	T	B	T	0.00	0		0	122			n/a	n/a	MUC6 (inh=n/a pLI=0.00)
chr11	1018406	1018406	A	T	0.2821	78		306.0	6|16|0,13|28|15,7|7	MUC6	synonymous_variant	MUC6:NM_005961.2:synonymous_variant:LOW:exon31/33:c.4395T>A:p.Pro1465Pro						rs760409699	0.0000	4.1405810063268E-5	0.0000386											0		0	78			n/a	n/a	MUC6 (inh=n/a pLI=0.00)
chr11	1019375	1019375	C	T	1.0000	18		486.0	2|6|10,0|0|0,5|5	MUC6	synonymous_variant	MUC6:NM_005961.2:synonymous_variant:LOW:exon30/33:c.3930G>A:p.Ala1310Ala						rs9704308	0.923323	0.915607473534	0.8844724	COSM4145181, COSM4145182										0		1153	127			n/a	n/a	MUC6 (inh=n/a pLI=0.00)
chr11	1027811	1027811	C	T	1.0000	30		823.0	2|2|26,0|0|0,5|5	MUC6	missense_variant	MUC6:NM_005961.2:missense_variant:MODERATE:exon16/33:c.1855G>A:p.Val619Met	Uncharacterised_domain__cysteine-rich__2_					rs7481521	0.396965	0.5056585115734	0.4669012	COSM428299, COSM428298				0.415000	T	T	P	T	14.39	0		342	587			n/a	n/a	MUC6 (inh=n/a pLI=0.00)
chr11	1029320	1029320	C	T	0.5294	102		1240.0	8|4|42,8|6|34,8|9	MUC6	missense_variant	MUC6:NM_005961.2:missense_variant:MODERATE:exon10/33:c.1183G>A:p.Gly395Arg	von_Willebrand_factor__type_D_domain__1_					rs11604757	0.0423323	0.10262759333606	0.0773999	COSM4145189, COSM4145188				1.681000	T	D	B	T	18.46	0		12	232			n/a	n/a	MUC6 (inh=n/a pLI=0.00)
chr11	1246941	1246941	A	G	0.4167	72		618.0	8|17|5,6|28|7,5|6	MUC5B	missense_variant	MUC5B:NM_002458.2:missense_variant:MODERATE:exon2/49:c.101A>G:p.Glu34Gly						rs2672785	0.327476	0.32505879278808	0.2471319		600770 [MUC5B (provisional) Pulmonary fibrosis,idiopathic,susceptibility to,178500];	RCV000151032.1 [benign]; 		-0.925000	T	T,T,T	B,B,B	T,T	3.82	1	I16R041,	72	454			n/a	n/a	MUC5B (inh=n/a pLI=1.00)
chr11	1247458	1247458	C	T	0.4853	68		678.0	4|6|23,11|8|15,6|7	MUC5B	missense_variant	MUC5B:NM_002458.2:missense_variant:MODERATE:exon3/49:c.151C>T:p.Arg51Trp						rs2075853	0.190495	0.13791851919064	0.0716573	COSM428624, COSM1475159	600770 [MUC5B (provisional) Pulmonary fibrosis,idiopathic,susceptibility to,178500];	RCV000151033.1 [benign]; 		-0.998000	T	T,T,T,T	B,B,B	T,T	9.93	2	I16R041,Leuk,	8	197			n/a	n/a	MUC5B (inh=n/a pLI=1.00)
chr11	1250488	1250488	C	T	0.3333	45		289.0	2|11|2,10|20|0,6|9	MUC5B	synonymous_variant	MUC5B:NM_002458.2:synonymous_variant:LOW:exon9/49:c.1065C>T:p.Cys355Cys						rs2075859	0.392772	0.43954727405987	0.3433545	COSM1475165, COSM428637	600770 [MUC5B (provisional) Pulmonary fibrosis,idiopathic,susceptibility to,178500];	RCV000155554.1 [benign]; 								2	I16R041,Leuk,	169	596			n/a	n/a	MUC5B (inh=n/a pLI=1.00)
chr11	1253942	1253942	T	C	0.3704	27		184.0	10|0|0,17|0|0,6|5	MUC5B	synonymous_variant	MUC5B:NM_002458.2:synonymous_variant:LOW:exon17/49:c.2007T>C:p.Tyr669Tyr						rs908229	0.544928	0.64398314490491	0.0722297	COSM3722637, COSM3722636	600770 [MUC5B (provisional) Pulmonary fibrosis,idiopathic,susceptibility to,178500];	RCV000151039.1 [benign]; 								0		337	955			n/a	n/a	MUC5B (inh=n/a pLI=1.00)
chr11	1255773	1255773	C	T	0.5316	79		1047.0	0|24|18,8|10|19,4|5	MUC5B	synonymous_variant	MUC5B:NM_002458.2:synonymous_variant:LOW:exon21/49:c.2493C>T:p.Cys831Cys						rs7116614	0.339457	0.37978670839167	0.2529838	COSM428646, COSM1475177	600770 [MUC5B (provisional) Pulmonary fibrosis,idiopathic,susceptibility to,178500];	RCV000151040.1 [benign]; 								2	I16R041,Leuk,	130	520			n/a	n/a	MUC5B (inh=n/a pLI=1.00)
chr11	1263687	1263687	C	T	0.2000	30		18.0	2|3|1,1|12|11,6|8	MUC5B	synonymous_variant	MUC5B:NM_002458.2:synonymous_variant:LOW:exon31/49:c.5577C>T:p.Asn1859Asn						rs55933911	0.014377	0.04004942940552	0.0387578		600770 [MUC5B (provisional) Pulmonary fibrosis,idiopathic,susceptibility to,178500];									0		1	56			n/a	n/a	MUC5B (inh=n/a pLI=1.00)
chr11	1264362	1264362	A	G	0.8571	14		191.0	3|0|9,0|0|2,5|3	MUC5B	synonymous_variant	MUC5B:NM_002458.2:synonymous_variant:LOW:exon31/49:c.6252A>G:p.Thr2084Thr						rs11605113	0.34385	0.34300175734056	0.0218644	COSM4145496, COSM4145497	600770 [MUC5B (provisional) Pulmonary fibrosis,idiopathic,susceptibility to,178500];									1	I16R041,	85	323			n/a	n/a	MUC5B (inh=n/a pLI=1.00)
chr11	1264823	1264823	T	C	1.0000	240		6806.0	158|33|49,0|0|0,9|9	MUC5B	missense_variant	MUC5B:NM_002458.2:missense_variant:MODERATE:exon31/49:c.6713T>C:p.Leu2238Pro						rs4963031	0.796925	0.74042035435105	0.0686413	COSM1600234, COSM1600233	600770 [MUC5B (provisional) Pulmonary fibrosis,idiopathic,susceptibility to,178500];			-2.462000	T	T,T,T,T	B,B	T,T	0.05	0		315	262			n/a	n/a	MUC5B (inh=n/a pLI=1.00)
chr11	1264965	1264965	G	A	0.7308	26		158.0	13|6|0,6|1|0,3|2	MUC5B	synonymous_variant	MUC5B:NM_002458.2:synonymous_variant:LOW:exon31/49:c.6855G>A:p.Thr2285Thr						rs4963051	0.111621	0.14904485049834	0.1284790	COSM3752230, COSM3752229	600770 [MUC5B (provisional) Pulmonary fibrosis,idiopathic,susceptibility to,178500];									0		16	155			n/a	n/a	MUC5B (inh=n/a pLI=1.00)
chr11	1265422	1265422	G	A	0.6667	63		961.0	1|1|42,2|2|18,7|7	MUC5B	missense_variant	MUC5B:NM_002458.2:missense_variant:MODERATE:exon31/49:c.7312G>A:p.Glu2438Lys						rs199749553	0.0712859	0.09260755048288	0.0838371		600770 [MUC5B (provisional) Pulmonary fibrosis,idiopathic,susceptibility to,178500];			-0.291000	T	T,T,T,T	B,B	T,T	6.61	0		21	177			n/a	n/a	MUC5B (inh=n/a pLI=1.00)
chr11	1266599	1266599	C	T	0.3333	18		13.0	6|0|0,10|2|0,5|5	MUC5B	missense_variant	MUC5B:NM_002458.2:missense_variant:MODERATE:exon31/49:c.8489C>T:p.Pro2830Leu						rs139960671	0.0828674	0.16803207704032	0.1334564	COSM3752231, COSM3752232	600770 [MUC5B (provisional) Pulmonary fibrosis,idiopathic,susceptibility to,178500];			-0.797000	T	T,T,T,D	B,B	T,T	6.73	0		34	134			n/a	n/a	MUC5B (inh=n/a pLI=1.00)
chr11	1267562	1267562	C	T	0.4545	11		70.0	0|0|5,0|6|0,3|4	MUC5B	missense_variant	MUC5B:NM_002458.2:missense_variant:MODERATE:exon31/49:c.9452C>T:p.Thr3151Met						rs60268710	0.340655	0.32093987215342	0.2723788		600770 [MUC5B (provisional) Pulmonary fibrosis,idiopathic,susceptibility to,178500];			-1.828000	T	D,D,D,D	B,B	T,T	0.69	2	I16R041,Leuk,	81	365			n/a	n/a	MUC5B (inh=n/a pLI=1.00)
chr11	1268064	1268064	C	T	0.3725	51		72.0	6|0|19,32|0|20,5|3	MUC5B	synonymous_variant	MUC5B:NM_002458.2:synonymous_variant:LOW:exon31/49:c.9954C>T:p.Ala3318Ala						rs200948102	0.326677	0.28077765372724	0.2353509	COSM1475220, COSM1475219	600770 [MUC5B (provisional) Pulmonary fibrosis,idiopathic,susceptibility to,178500];			-0.998000	T				4.60	1	I16R041,	68	349			n/a	n/a	MUC5B (inh=n/a pLI=1.00)
chr11	1268513	1268513	G	C	0.6119	67		1053.0	32|8|1,38|46|0,5|4	MUC5B	missense_variant	MUC5B:NM_002458.2:missense_variant:MODERATE:exon31/49:c.10403G>C:p.Arg3468Pro						rs2943529	0.49401	0.49949521293601	0.4332300	COSM4145508, COSM4145509	600770 [MUC5B (provisional) Pulmonary fibrosis,idiopathic,susceptibility to,178500];			-2.554000	T	T,T,T,T	B,B	T,T	5.91	1	I16R041,	201	387			n/a	n/a	MUC5B (inh=n/a pLI=1.00)
chr11	1268608	1268608	A	G	1.0000	56		756.0	17|0|42,0|0|0,4|4	MUC5B	missense_variant	MUC5B:NM_002458.2:missense_variant:MODERATE:exon31/49:c.10498A>G:p.Ser3500Gly						rs2943527	0.655152	0.66780526573888	0.5435873	COSM3765547, COSM3765546	600770 [MUC5B (provisional) Pulmonary fibrosis,idiopathic,susceptibility to,178500];			-0.717000	T	T,T,T,T	B,B	T,T	0.01	0		296	259			n/a	n/a	MUC5B (inh=n/a pLI=1.00)
chr11	1268682	1268682	T	C	0.5307	179		1916.0	73|0|25,82|0|2,4|3	MUC5B	synonymous_variant	MUC5B:NM_002458.2:synonymous_variant:LOW:exon31/49:c.10572T>C:p.Ser3524Ser						rs2943518	0.113419	0.15408294715005	0.1324082	COSM4145510, COSM4145511	600770 [MUC5B (provisional) Pulmonary fibrosis,idiopathic,susceptibility to,178500];									1	cfDNA_HNSCC,	21	146			n/a	n/a	MUC5B (inh=n/a pLI=1.00)
chr11	1269672	1269672	T	C	0.4190	210		583.0	134|20|16,68|10|23,8|7	MUC5B	synonymous_variant	MUC5B:NM_002458.2:synonymous_variant:LOW:exon31/49:c.11562T>C:p.Ser3854Ser						rs4963057	0.522963	0.49918251954289	0.4121823	COSM4145516	600770 [MUC5B (provisional) Pulmonary fibrosis,idiopathic,susceptibility to,178500];									1	I16R041,	219	399			n/a	n/a	MUC5B (inh=n/a pLI=1.00)
chr11	1269835	1269835	G	A	0.3125	64		50.0	0|0|20,22|0|22,4|5	MUC5B	missense_variant	MUC5B:NM_002458.2:missense_variant:MODERATE:exon31/49:c.11725G>A:p.Val3909Ile						rs2943521	0.461462	0.45700945809087	0.3916234	COSM3765549, COSM3765548	600770 [MUC5B (provisional) Pulmonary fibrosis,idiopathic,susceptibility to,178500];			0.108000	T	T,T,T,T	B,B	T,T	0.02	1	I16R041,	181	408			n/a	n/a	MUC5B (inh=n/a pLI=1.00)
chr11	1271321	1271321	C	G	0.5714	14		142.0	7|1|6,6|0|2,7|6	MUC5B	missense_variant	MUC5B:NM_002458.2:missense_variant:MODERATE:exon31/49:c.13211C>G:p.Ala4404Gly						rs2943517	0.451877	0.45987618072916	0.3961506	COSM3765550, COSM3765551	600770 [MUC5B (provisional) Pulmonary fibrosis,idiopathic,susceptibility to,178500];			-0.172000	T	T,T,T,T,T	B,P	T,T	0.04	1	I16R041,	165	457			n/a	n/a	MUC5B (inh=n/a pLI=1.00)
chr11	1271429	1271429	C	T	0.5870	46		483.0	24|2|1,18|1|0,5|4	MUC5B	missense_variant	MUC5B:NM_002458.2:missense_variant:MODERATE:exon31/49:c.13319C>T:p.Pro4440Leu						rs2943516	0.467053	0.47496218983197	0.4057066		600770 [MUC5B (provisional) Pulmonary fibrosis,idiopathic,susceptibility to,178500];			0.119000	T	T,T,T,T,T	B,B	T,T	7.90	1	I16R041,	169	444			n/a	n/a	MUC5B (inh=n/a pLI=1.00)
chr11	1271508	1271508	G	A	0.7059	17		94.0	63|8|2,189|32|0,5|4	MUC5B	synonymous_variant	MUC5B:NM_002458.2:synonymous_variant:LOW:exon31/49:c.13398G>A:p.Thr4466Thr						rs12418291	0.339058	0.32073254662347	0.0184047	COSM4145524, COSM4145523	600770 [MUC5B (provisional) Pulmonary fibrosis,idiopathic,susceptibility to,178500];									2	I16R041,Leuk,	82	366			n/a	n/a	MUC5B (inh=n/a pLI=1.00)
chr11	1272858	1272858	C	T	0.6176	68		1047.0	8|4|30,8|4|14,9|9	MUC5B	synonymous_variant	MUC5B:NM_002458.2:synonymous_variant:LOW:exon31/49:c.14748C>T:p.Phe4916Phe						rs4963059	0.338858	0.31905682582381	0.3160176		600770 [MUC5B (provisional) Pulmonary fibrosis,idiopathic,susceptibility to,178500];									2	I16R041,Leuk,	85	363			n/a	n/a	MUC5B (inh=n/a pLI=1.00)
chr11	5080359	5080359	G	A	1.0000	52		1573.0	25|18|9,0|0|0,13|14	OR52E2	missense_variant	OR52E2:NM_001005164.2:missense_variant:MODERATE:exon1/1:c.499C>T:p.Arg167Trp	GPCR__rhodopsin-like_superfamily__1_	Olfactory transduction	Odorant receptor (Potential)			rs11035396	0.0758786	0.106129010762	0.1052192	COSM1354287				-1.363000	T	D	B	T	14.02	0		9	157			n/a	n/a	OR52E2 (inh=n/a pLI=0.00)
chr11	6048056	6048056	T	C	0.6000	10		98.0	0|6|0,0|4|0,6|8	OR56A1	synonymous_variant	OR56A1:NM_001001917.2:synonymous_variant:LOW:exon1/1:c.879A>G:p.Ala293Ala		Olfactory transduction	Odorant receptor (Potential)			rs11040335	0.269968	0.32967458890666	0.3246605											0		97	380			n/a	n/a	OR56A1 (inh=n/a pLI=0.26)
chr11	6636106	6636106	T	A	0.4909	55		574.0	14|13|0,14|14|0,3|4	TPP1	synonymous_variant	TPP1:NM_000391.3:synonymous_variant:LOW:exon12/13:c.1542A>T:p.Gly514Gly			Lysosomal serine protease with tripeptidyl-peptidase I activity. May act as a non-specific lysosomal peptidase which generates tripeptides from the breakdown products produced by lysosomal proteinases. Requires substrates with an unsubstituted N-terminus (By similarity)			rs1128396	0.23123	0.19326553821304	0.1859952	COSM3752668	607998 [TPP1 (confirmed) Ceroid lipofuscinosis,neuronal,2,204500|Spinocerebellar ataxia,autosomal recessive 7,609270];	RCV000118652.3 [other]; RCV000395501.1 [benign]; 								1	I16R041,	75	662			n/a	n/a	TPP1 (inh=AR pLI=0.03)
chr11	55541098	55541098	G	A	1.0000	10		293.0	6|4|0,0|0|0,3|3	OR5D13	missense_variant	OR5D13:NM_001001967.1:missense_variant:MODERATE:exon1/1:c.185G>A:p.Cys62Tyr	GPCR__rhodopsin-like_superfamily__1_	Olfactory transduction	Odorant receptor (Potential)			rs297118	0.971246	0.99180598146866	0.9602325					2.949000	T	T	B	T	0.28	0		857	2			n/a	n/a	OR5D13 (inh=n/a pLI=0.00)
chr11	60182970	60182970	A	T	0.5000	8		69.0	2|2|0,4|0|0,5|3	MS4A14	missense_variant,non_coding_transcript_exon_variant	MS4A14:NM_001261828.1:missense_variant:MODERATE:exon6/6:c.628A>T:p.Asn210Tyr,MS4A14:NM_001079692.2:missense_variant:MODERATE:exon4/4:c.478A>T:p.Asn160Tyr,MS4A14:NM_001261827.1:missense_variant:MODERATE:exon5/5:c.577A>T:p.Asn193Tyr,MS4A14:NM_032597.4:missense_variant:MODERATE:exon5/5:c.529A>T:p.Asn177Tyr,MS4A14:NR_049731.1:non_coding_transcript_exon_variant:MODIFIER:exon6/6:n.1263A>T:,MS4A14:NR_049732.1:non_coding_transcript_exon_variant:MODIFIER:exon6/6:n.1215A>T:,MS4A14:NR_049733.1:non_coding_transcript_exon_variant:MODIFIER:exon5/5:n.1164A>T:,MS4A14:NR_049734.1:non_coding_transcript_exon_variant:MODIFIER:exon7/7:n.1314A>T:			May be involved in signal transduction as a component of a multimeric receptor complex (By similarity)			rs7131283	0.577875	0.6490020306077	0.6446394	COSM3752533				0.397000	T	D,D,D,T	D,D	T,T,T,T	18.30	0		416	366			n/a	n/a	MS4A14 (inh=n/a pLI=0.00)
chr11	60184191	60184191	G	A	0.3333	18		103.0	2|2|2,6|2|4,3|4	MS4A14	missense_variant,non_coding_transcript_exon_variant	MS4A14:NM_001261828.1:missense_variant:MODERATE:exon6/6:c.1849G>A:p.Gly617Arg,MS4A14:NM_001079692.2:missense_variant:MODERATE:exon4/4:c.1699G>A:p.Gly567Arg,MS4A14:NM_001261827.1:missense_variant:MODERATE:exon5/5:c.1798G>A:p.Gly600Arg,MS4A14:NM_032597.4:missense_variant:MODERATE:exon5/5:c.1750G>A:p.Gly584Arg,MS4A14:NR_049731.1:non_coding_transcript_exon_variant:MODIFIER:exon6/6:n.2484G>A:,MS4A14:NR_049732.1:non_coding_transcript_exon_variant:MODIFIER:exon6/6:n.2436G>A:,MS4A14:NR_049733.1:non_coding_transcript_exon_variant:MODIFIER:exon5/5:n.2385G>A:,MS4A14:NR_049734.1:non_coding_transcript_exon_variant:MODIFIER:exon7/7:n.2535G>A:			May be involved in signal transduction as a component of a multimeric receptor complex (By similarity)			rs3825020	0.498203	0.57290002662407	0.5686606	COSM3752534				-0.859000	T	T,T,T,T	B,B	T,T,T,T	2.54	0		335	394			n/a	n/a	MS4A14 (inh=n/a pLI=0.00)
chr11	69462910	69462910	G	A	1.0000	76		2264.0	38|4|34,0|0|0,5|4	CCND1	splice_region_variant&synonymous_variant,sequence_feature	CCND1:NM_053056.2:splice_region_variant&synonymous_variant:LOW:exon4/5:c.723G>A:p.Pro241Pro,CCND1:NM_053056.2:sequence_feature:LOW:exon4/5:c.723G>A:		Cell cycle;p53 signaling pathway;Wnt signaling pathway;Focal adhesion;Jak-STAT signaling pathway;Colorectal cancer;Pancreatic cancer;Endometrial cancer;Glioma;Prostate cancer;Thyroid cancer;Melanoma;Bladder cancer;Chronic myeloid leukemia;Acute myeloid leukemia;Small cell lung cancer;Non-small cell lung cancer	Regulatory component of the cyclin D1-CDK4 (DC) complex that phosphorylates and inhibits members of the retinoblastoma (RB) protein family including RB1 and regulates the cell-cycle during G(1)/S transition. Phosphorylation of RB1 allows dissociation of the transcription factor E2F from the RB/E2F complex and the subsequent transcription of E2F target genes which are responsible for the progression through the G(1) phase. Hypophosphorylates RB1 in early G(1) phase. Cyclin D-CDK4 complexes are major integrators of various mitogenenic and antimitogenic signals. Also substrate for SMAD3, phosphorylating SMAD3 in a cell-cycle-dependent manner and repressing its transcriptional activity. Component of the ternary complex, cyclin D1/CDK4/CDKN1B, required for nuclear translocation and activity of the cyclin D-CDK4 complex	BTG family proteins and cell cycle regulation;Cell Cycle: G1/S Check Point ;Cyclins and Cell Cycle Regulation;Inactivation of Gsk3 by AKT causes accumulation of b-catenin in Alveolar Macrophages;Influence of Ras and Rho proteins on G1 to S Transition;p53 Signaling Pathway;WNT Signaling Pathway		rs9344	0.413538	0.455128735138	0.4431011	COSM1179751, COSM4146233	168461 [CCND1 (confirmed) Colorectal cancer,susceptibility to,114500|von Hippel-Lindau syndrome,modifier of,193300|Multiple myeloma,susceptibility to,254500];	RCV000014762.4 [other]; RCV000087019.4 [other]; 	CS004528 [CLASS=DFP MUT=ALT PHEN="HNPCC early onset association with" GENE=CCND1]; 							0		315	659			n/a	n/a	CCND1 (inh=n/a pLI=0.24)
chr11	70002012	70002012	C	T	0.4375	112		997.0	48|1|0,25|36|0,3|3	ANO1	splice_region_variant&intron_variant,intron_variant	ANO1:NM_018043.5:splice_region_variant&intron_variant:LOW:exon14/25:c.1426-5C>T:,ANO1:NR_030691.1:intron_variant:MODIFIER:exon13/24:n.1567-1041C>T:			Calcium-activated chloride channel (CaCC) which plays a role in transepithelial anion transport and smooth muscle contraction. Required for the normal functioning of the interstitial cells of Cajal (ICCs) which generate electrical pacemaker activity in gastrointestinal smooth muscles. Acts as a major contributor to basal and stimulated chloride conductance in airway epithelial cells and plays an important role in tracheal cartilage development			rs11235438	0.0585064	0.12655581947743	0.0385971											0		22	194			n/a	n/a	ANO1 (inh=n/a pLI=0.99)
chr11	70007311	70007311	A	G	1.0000	66		1989.0	10|0|56,0|0|0,7|8	ANO1	synonymous_variant,sequence_feature,non_coding_transcript_exon_variant	ANO1:NM_018043.5:synonymous_variant:LOW:exon17/26:c.1623A>G:p.Arg541Arg,ANO1:NM_018043.5:sequence_feature:LOW:exon17/26:c.1623A>G:,ANO1:NR_030691.1:non_coding_transcript_exon_variant:MODIFIER:exon15/25:n.1686A>G:			Calcium-activated chloride channel (CaCC) which plays a role in transepithelial anion transport and smooth muscle contraction. Required for the normal functioning of the interstitial cells of Cajal (ICCs) which generate electrical pacemaker activity in gastrointestinal smooth muscles. Acts as a major contributor to basal and stimulated chloride conductance in airway epithelial cells and plays an important role in tracheal cartilage development			rs2276066	0.603235	0.65600936006373	0.6453789	COSM4146241, COSM4146240, COSM4146239										0		369	393			n/a	n/a	ANO1 (inh=n/a pLI=0.99)
chr11	70007392	70007392	A	G	1.0000	43		1350.0	26|16|1,0|0|0,6|6	ANO1	synonymous_variant,non_coding_transcript_exon_variant	ANO1:NM_018043.5:synonymous_variant:LOW:exon17/26:c.1704A>G:p.Ala568Ala,ANO1:NR_030691.1:non_coding_transcript_exon_variant:MODIFIER:exon15/25:n.1767A>G:			Calcium-activated chloride channel (CaCC) which plays a role in transepithelial anion transport and smooth muscle contraction. Required for the normal functioning of the interstitial cells of Cajal (ICCs) which generate electrical pacemaker activity in gastrointestinal smooth muscles. Acts as a major contributor to basal and stimulated chloride conductance in airway epithelial cells and plays an important role in tracheal cartilage development			rs2276067	0.658147	0.6743446654192	0.6642016											0		387	385			n/a	n/a	ANO1 (inh=n/a pLI=0.99)
chr11	70034096	70034096	G	A	0.4615	39		403.0	0|18|0,6|9|6,5|5	ANO1	missense_variant,non_coding_transcript_exon_variant	ANO1:NM_018043.5:missense_variant:MODERATE:exon26/26:c.2947G>A:p.Gly983Arg,ANO1:NR_030691.1:non_coding_transcript_exon_variant:MODIFIER:exon24/25:n.3010G>A:			Calcium-activated chloride channel (CaCC) which plays a role in transepithelial anion transport and smooth muscle contraction. Required for the normal functioning of the interstitial cells of Cajal (ICCs) which generate electrical pacemaker activity in gastrointestinal smooth muscles. Acts as a major contributor to basal and stimulated chloride conductance in airway epithelial cells and plays an important role in tracheal cartilage development			rs3740722	0.0854633	0.16289178677648	0.0769434					3.167000	T	D,D,D,D,D,D,D	B,B	T,T,T,T,T	22.90	0		29	204			n/a	n/a	ANO1 (inh=n/a pLI=0.99)
chr11	71941212	71941212	A	G	0.5854	41		579.0	10|14|0,12|2|3,5|4	INPPL1	synonymous_variant	INPPL1:NM_001567.3:synonymous_variant:LOW:exon9/28:c.987A>G:p.Ser329Ser						rs2276048	0.36222	0.25018020887466	0.2407334	COSM4146291	600829 [INPPL1 (provisional) Opsismodysplasia,258480];									0		48	280			n/a	n/a	INPPL1 (inh=AR pLI=0.01)
chr11	71945564	71945564	A	C	0.3611	36		8.0	10|2|1,16|2|5,4|2	INPPL1	splice_region_variant&intron_variant	INPPL1:NM_001567.3:splice_region_variant&intron_variant:LOW:exon20/27:c.2327-7A>C:						rs753148652	0.0000	5.7907711652686E-5	0.0000064		600829 [INPPL1 (provisional) Opsismodysplasia,258480];									0		0	4			n/a	n/a	INPPL1 (inh=AR pLI=0.01)
chr11	132177633	132177633	A	C	0.9583	24		601.0	6|8|9,0|1|0,5|8	NTM	synonymous_variant	NTM:NM_001144058.1:synonymous_variant:LOW:exon4/8:c.577A>C:p.Arg193Arg,NTM:NM_001048209.1:synonymous_variant:LOW:exon5/8:c.577A>C:p.Arg193Arg,NTM:NM_001144059.1:synonymous_variant:LOW:exon4/6:c.577A>C:p.Arg193Arg,NTM:NM_016522.2:synonymous_variant:LOW:exon4/7:c.577A>C:p.Arg193Arg						rs2305271	0.880591	0.84631799232125	0.8407115											0		585	253			n/a	n/a	NTM (inh=n/a pLI=0.53)
chr12	7638020	7638020	G	A	0.3818	55		431.0	11|10|0,23|11|0,3|3	CD163	splice_region_variant&intron_variant	CD163:NM_004244.5:splice_region_variant&intron_variant:LOW:exon10/16:c.2459-8C>T:,CD163:NM_203416.3:splice_region_variant&intron_variant:LOW:exon10/16:c.2459-8C>T:						rs10743939	0.478235	0.67137126974352	0.6617193											0		475	273			n/a	n/a	CD163 (inh=n/a pLI=0.02)
chr12	7649484	7649484	T	C	1.0000	45		1361.0	2|6|37,0|0|0,2|2	CD163	missense_variant	CD163:NM_004244.5:missense_variant:MODERATE:exon5/17:c.1024A>G:p.Ile342Val,CD163:NM_203416.3:missense_variant:MODERATE:exon5/17:c.1024A>G:p.Ile342Val	Speract/scavenger_receptor__2_,Speract/scavenger_receptor-related__2_					rs4883263	0.76258	0.88702390766694	0.8725435					-0.207000	T	T,T,T,T	B,B,B	T,T,T,T	0.05	0		776	78			n/a	n/a	CD163 (inh=n/a pLI=0.02)
chr12	7655137	7655137	A	G	0.4545	11		93.0	1|4|0,2|4|0,2|4	CD163	synonymous_variant	CD163:NM_004244.5:synonymous_variant:LOW:exon2/17:c.70T>C:p.Leu24Leu,CD163:NM_203416.3:synonymous_variant:LOW:exon2/17:c.70T>C:p.Leu24Leu						rs3210140	0.462061	0.66757885172846	0.6113605											0		371	306			n/a	n/a	CD163 (inh=n/a pLI=0.02)
chr12	11992168	11992168	G	A	1.0000	24		743.0	15|9|0,0|0|0,7|6	ETV6	synonymous_variant	ETV6:NM_001987.4:synonymous_variant:LOW:exon3/8:c.258G>A:p.Thr86Thr			Transcriptional repressor; binds to the DNA sequence 5'- CCGGAAGT-3'			rs11611479	0.212859	0.15193420250202	0.1478419	COSM3752958	600618 [ETV6 (confirmed) Leukemia,acute myeloid,somatic,601626|Thrombocytopenia 5,616216];									0		30	204			n/a	n/a	ETV6 (inh=AD pLI=1.00)
chr12	25362777	25362777	A	G	0.5455	22		270.0	2|10|0,0|10|0,2|1	KRAS	synonymous_variant,3_prime_UTR_variant	KRAS:NM_004985.4:synonymous_variant:LOW:exon5/5:c.519T>C:p.Asp173Asp,KRAS:NM_033360.3:3_prime_UTR_variant:MODIFIER:exon6/6:c.*73T>C:		MAPK signaling pathway;ErbB signaling pathway;Axon guidance;VEGF signaling pathway;Tight junction;Gap junction;Natural killer cell mediated cytotoxicity;T cell receptor signaling pathway;B cell receptor signaling pathway;Fc epsilon RI signaling pathway;Long-term potentiation;Long-term depression;Regulation of actin cytoskeleton;Insulin signaling pathway;GnRH signaling pathway;Melanogenesis;Colorectal cancer;Renal cell carcinoma;Pancreatic cancer;Endometrial cancer;Glioma;Prostate cancer;Thyroid cancer;Melanoma;Bladder cancer;Chronic myeloid leukemia;Acute myeloid leukemia;Non-small cell lung cancer	Ras proteins bind GDP/GTP and possess intrinsic GTPase activity	Telomeres, Telomerase, Cellular Aging, and  Immortality		rs1137282	0.175519	0.19689865362717	0.1941493	COSM3753105	190070 [KRAS (confirmed) Lung cancer,somatic,211980|Bladder cancer,somatic,109800|Pancreatic carcinoma,somatic,260350|Gastric cancer,somatic,137215|Leukemia,acute myeloid,601626|Noonan syndrome 3,609942|Cardiofaciocutaneous syndrome 2,615278|Breast cancer,somatic,114480|Schimmelpenning-Feuerstein-Mims syndrome,somatic mosaic,163200|RAS-associated autoimmune leukoproliferative disorder,614470];	RCV000038277.9 [benign]; RCV000339718.1 [likely benign]; RCV000378737.1 [likely benign]; 								0		83	523			n/a	n/a	KRAS (inh=AD pLI=0.00)
chr12	40619082	40619082	G	A	1.0000	15		469.0	14|1|0,0|0|0,4|5	LRRK2	missense_variant&splice_region_variant	LRRK2:NM_198578.3:missense_variant&splice_region_variant:MODERATE:exon1/51:c.149G>A:p.Arg50His						rs2256408	0.969249	0.99111650004949	0.9371720		609007 [LRRK2 (confirmed) Parkinson disease 8,607060];	RCV000032408.1 [uncertain significance]; 		0.204000	T	T,T	B	T,T	13.86	0		2161	1			n/a	n/a	LRRK2 (inh=AD pLI=0.00)
chr12	40631791	40631791	T	C	1.0000	12		339.0	4|8|0,0|0|0,3|2	LRRK2	synonymous_variant	LRRK2:NM_198578.3:synonymous_variant:LOW:exon5/51:c.457T>C:p.Leu153Leu						rs10878245	0.452875	0.52626194287223	0.5239286	COSM1128598, COSM1128599	609007 [LRRK2 (confirmed) Parkinson disease 8,607060];	RCV000032466.2 [other]; 								0		740	1041	1	[1] old entry - no details available	n/a	n/a	LRRK2 (inh=AD pLI=0.00)
chr12	40758652	40758652	T	C	1.0000	9		270.0	2|6|1,0|0|0,2|2	LRRK2	missense_variant	LRRK2:NM_198578.3:missense_variant:MODERATE:exon49/51:c.7190T>C:p.Met2397Thr	WD40_repeat-like-containing_domain__1_					rs3761863	0.551717	0.62397573873524	0.6097271	COSM3753219, COSM3753218	609007 [LRRK2 (confirmed) Parkinson disease 8,607060];	RCV000032513.1 [uncertain significance]; RCV000375193.1 [benign]; 	CM1413562 [CLASS=DP MUT=ALT PHEN="Multiple system atrophy reduced risk" GENE=LRRK2]; 	0.377000	T	T	B	T	0.01	0		931	975			n/a	n/a	LRRK2 (inh=AD pLI=0.00)
chr12	52913517	52913517	G	A	0.6364	22		249.0	0|0|14,0|0|8,3|3	KRT5	splice_region_variant&intron_variant	KRT5:NM_000424.3:splice_region_variant&intron_variant:LOW:exon1/8:c.555+9C>T:		Cell Communication				rs638907	0.101837	0.19743669999835	0.1951976		148040 [KRT5 (confirmed) Epidermolysis bullosa simplex,Dowling-Meara type,131760|Epidermolysis bullosa simplex,Koebner type,131900|Epidermolysis bullosa simplex,Weber-Cockayne type,131800|Epidermolysis bullosa simplex-MP,131960|Dowling-Degos disease 1,179850|Epidermylysis bullosa simplex-MCR,609352|Epidermolysis bullosa simplex,recessive 1,601001];	RCV000056621.1 [not provided]; RCV000253381.1 [benign]; RCV000283337.1 [benign]; 								0		87	454			n/a	n/a	KRT5 (inh=AR+AD pLI=0.47)
chr12	57589784	57589784	A	C	1.0000	51		1520.0	4|0|47,0|0|0,6|4	LRP1	missense_variant&splice_region_variant	LRP1:NM_002332.2:missense_variant&splice_region_variant:MODERATE:exon54/89:c.8699A>C:p.Gln2900Pro		Alzheimer's disease	Endocytic receptor involved in endocytosis and in phagocytosis of apoptotic cells. Required for early embryonic development. Involved in cellular lipid homeostasis. Involved in the plasma clearance of chylomicron remnants and activated LRPAP1 (alpha 2-macroglobulin), as well as the local metabolism of complexes between plasminogen activators and their endogenous inhibitors. May modulate cellular events, such as APP metabolism, kinase-dependent intracellular signaling, neuronal calcium signaling as well as neurotransmission			rs7397167	0.989816	0.99695998413905	0.9331271		107770 [LRP1 (confirmed) Keratosis pilaris atrophicans,604093];			3.699000	T	T	B	D	16.31	0		1280	1			n/a	n/a	LRP1 (inh=n/a pLI=1.00)
chr12	57589865	57589865	C	T	1.0000	12		301.0	0|0|12,0|0|0,2|5	LRP1	splice_region_variant&intron_variant	LRP1:NM_002332.2:splice_region_variant&intron_variant:LOW:exon54/88:c.8702-5C>T:		Alzheimer's disease	Endocytic receptor involved in endocytosis and in phagocytosis of apoptotic cells. Required for early embryonic development. Involved in cellular lipid homeostasis. Involved in the plasma clearance of chylomicron remnants and activated LRPAP1 (alpha 2-macroglobulin), as well as the local metabolism of complexes between plasminogen activators and their endogenous inhibitors. May modulate cellular events, such as APP metabolism, kinase-dependent intracellular signaling, neuronal calcium signaling as well as neurotransmission			rs1800189	0.504393	0.61602352198541	0.6086339		107770 [LRP1 (confirmed) Keratosis pilaris atrophicans,604093];									1	cfDNA_HNSCC,	626	513			n/a	n/a	LRP1 (inh=n/a pLI=1.00)
chr12	57590869	57590869	T	C	1.0000	11		298.0	3|0|8,0|0|0,3|3	LRP1	synonymous_variant	LRP1:NM_002332.2:synonymous_variant:LOW:exon56/89:c.8997T>C:p.Thr2999Thr		Alzheimer's disease	Endocytic receptor involved in endocytosis and in phagocytosis of apoptotic cells. Required for early embryonic development. Involved in cellular lipid homeostasis. Involved in the plasma clearance of chylomicron remnants and activated LRPAP1 (alpha 2-macroglobulin), as well as the local metabolism of complexes between plasminogen activators and their endogenous inhibitors. May modulate cellular events, such as APP metabolism, kinase-dependent intracellular signaling, neuronal calcium signaling as well as neurotransmission			rs7308698	0.984625	0.9954108787714	0.9411076	COSM4147319	107770 [LRP1 (confirmed) Keratosis pilaris atrophicans,604093];									0		1278	4			n/a	n/a	LRP1 (inh=n/a pLI=1.00)
chr12	57593101	57593101	G	A	1.0000	88		2709.0	38|40|10,0|0|0,3|4	LRP1	synonymous_variant	LRP1:NM_002332.2:synonymous_variant:LOW:exon61/89:c.9783G>A:p.Thr3261Thr		Alzheimer's disease	Endocytic receptor involved in endocytosis and in phagocytosis of apoptotic cells. Required for early embryonic development. Involved in cellular lipid homeostasis. Involved in the plasma clearance of chylomicron remnants and activated LRPAP1 (alpha 2-macroglobulin), as well as the local metabolism of complexes between plasminogen activators and their endogenous inhibitors. May modulate cellular events, such as APP metabolism, kinase-dependent intracellular signaling, neuronal calcium signaling as well as neurotransmission			rs1140648	0.533347	0.62188267484218	0.6162285	COSM3998893	107770 [LRP1 (confirmed) Keratosis pilaris atrophicans,604093];									1	cfDNA_HNSCC,	627	509			n/a	n/a	LRP1 (inh=n/a pLI=1.00)
chr12	57593116	57593116	G	A	0.6118	85		1218.0	25|24|3,10|16|6,3|4	LRP1	synonymous_variant	LRP1:NM_002332.2:synonymous_variant:LOW:exon61/89:c.9798G>A:p.Thr3266Thr		Alzheimer's disease	Endocytic receptor involved in endocytosis and in phagocytosis of apoptotic cells. Required for early embryonic development. Involved in cellular lipid homeostasis. Involved in the plasma clearance of chylomicron remnants and activated LRPAP1 (alpha 2-macroglobulin), as well as the local metabolism of complexes between plasminogen activators and their endogenous inhibitors. May modulate cellular events, such as APP metabolism, kinase-dependent intracellular signaling, neuronal calcium signaling as well as neurotransmission			rs371123820	0.0000	5.7661575973245E-5	0.0000514		107770 [LRP1 (confirmed) Keratosis pilaris atrophicans,604093];									0		0	2			n/a	n/a	LRP1 (inh=n/a pLI=1.00)
chr12	124829156	124829156	C	T	0.4737	19		159.0	0|2|7,2|5|3,4|4	NCOR2	synonymous_variant	NCOR2:NM_006312.5:synonymous_variant:LOW:exon34/49:c.4701G>A:p.Pro1567Pro,NCOR2:NM_001077261.3:synonymous_variant:LOW:exon33/48:c.4671G>A:p.Pro1557Pro,NCOR2:NM_001206654.1:synonymous_variant:LOW:exon33/48:c.4671G>A:p.Pro1557Pro						rs193097789	0.00219649	0.0041152263374486	0.0008296											0		0	12			n/a	n/a	NCOR2 (inh=n/a pLI=1.00)
chr12	124829234	124829234	C	T	1.0000	21		640.0	0|0|21,0|0|0,4|6	NCOR2	synonymous_variant	NCOR2:NM_006312.5:synonymous_variant:LOW:exon34/49:c.4623G>A:p.Leu1541Leu,NCOR2:NM_001077261.3:synonymous_variant:LOW:exon33/48:c.4593G>A:p.Leu1531Leu,NCOR2:NM_001206654.1:synonymous_variant:LOW:exon33/48:c.4593G>A:p.Leu1531Leu						rs1263992	0.582268	0.70045385779123	0.2552667	COSM3749203, COSM3749202										0		449	328			n/a	n/a	NCOR2 (inh=n/a pLI=1.00)
chr12	124829255	124829255	A	G	1.0000	47		1487.0	16|14|17,0|0|0,6|7	NCOR2	synonymous_variant	NCOR2:NM_006312.5:synonymous_variant:LOW:exon34/49:c.4602T>C:p.Gly1534Gly,NCOR2:NM_001077261.3:synonymous_variant:LOW:exon33/48:c.4572T>C:p.Gly1524Gly,NCOR2:NM_001206654.1:synonymous_variant:LOW:exon33/48:c.4572T>C:p.Gly1524Gly						rs1244085	0.539936	0.6406333870102	0.2535755	COSM3749204, COSM3749205										0		434	332			n/a	n/a	NCOR2 (inh=n/a pLI=1.00)
chr12	124856660	124856660	T	A	1.0000	134		4015.0	38|6|90,0|0|0,12|8	NCOR2	synonymous_variant	NCOR2:NM_006312.5:synonymous_variant:LOW:exon22/49:c.2715A>T:p.Thr905Thr,NCOR2:NM_001077261.3:synonymous_variant:LOW:exon21/48:c.2661A>T:p.Thr887Thr,NCOR2:NM_001206654.1:synonymous_variant:LOW:exon21/48:c.2661A>T:p.Thr887Thr						rs3741513	0.385184	0.53579221930512	0.5006752	COSM4146802, COSM4146803										0		270	432			n/a	n/a	NCOR2 (inh=n/a pLI=1.00)
chr12	124887058	124887058	-	GCT	0.7083	24		257.0	0|0|0,0|18|6,3|4	NCOR2	conservative_inframe_insertion	NCOR2:NM_006312.5:conservative_inframe_insertion:MODERATE:exon16/49:c.1529_1531dupAGC:p.Gln510dup,NCOR2:NM_001077261.3:conservative_inframe_insertion:MODERATE:exon16/48:c.1526_1528dupAGC:p.Gln509dup,NCOR2:NM_001206654.1:conservative_inframe_insertion:MODERATE:exon16/48:c.1526_1528dupAGC:p.Gln509dup						rs35831183;rs372331070;rs750745134;rs879061669	0.30651	0.30894851443422	0.2566042	COSM1476308, COSM1476307										0		297	174			n/a	n/a	NCOR2 (inh=n/a pLI=1.00)
chr13	28636084	28636084	G	A	1.0000	12		353.0	0|0|12,0|0|0,3|5	FLT3	synonymous_variant,non_coding_transcript_exon_variant	FLT3:NM_004119.2:synonymous_variant:LOW:exon3/24:c.288C>T:p.Asp96Asp,FLT3:NR_130706.1:non_coding_transcript_exon_variant:MODIFIER:exon3/25:n.370C>T:						rs7338903	0.958067	0.98274413547707	0.9515061		136351 [FLT3 (confirmed) Leukemia,acute myeloid,reduced survival in,somatic,601626|Leukemia,acute myeloid,somatic,601626|Leukemia,acute lymphoblastic,somatic,613065];									0		1297	41			n/a	n/a	FLT3 (inh=n/a pLI=0.61)
chr13	32906729	32906729	A	C	1.0000	11		341.0	0|11|0,0|0|0,1|3	BRCA2	missense_variant	BRCA2:NM_000059.3:missense_variant:MODERATE:exon10/27:c.1114A>C:p.Asn372His		Homologous recombination;Pancreatic cancer	Involved in double-strand break repair and/or homologous recombination. Binds RAD51 and potentiates recombinational DNA repair by promoting assembly of RAD51 onto single-stranded DNA (ssDNA). Acts by targeting RAD51 to ssDNA over double-stranded DNA, enabling RAD51 to displace replication protein-A (RPA) from ssDNA and stabilizing RAD51-ssDNA filaments by blocking ATP hydrolysis. May participate in S phase checkpoint activation. Binds selectively to ssDNA, and to ssDNA in tailed duplexes and replication fork structures. In concert with NPM1, regulates centrosome duplication	Role of BRCA1,  BRCA2 and ATR in Cancer Susceptibility		rs144848	0.249401	0.27792958399576	0.2665784	COSM147663, COSM3753646	600185 [BRCA2 (confirmed) Breast-ovarian cancer,familial,2,612555|Fanconi anemia,complementation group D1,605724|Prostate cancer,176807|Breast cancer,male,susceptibility to,114480|Wilms tumor,194070|Medulloblastoma,155255|Glioblastoma 3,613029|Pancreatic cancer 2,613347];	RCV000112880.1 [not provided]; RCV000009916.7 [benign]; RCV000034427.1 [benign]; RCV000120303.6 [benign]; RCV000130720.3 [benign]; RCV000207052.1 [uncertain significance]; RCV000260146.1 [benign]; RCV000320173.1 [benign]; 	CM002750 [CLASS=DFP MUT=ALT PHEN="Breast cancer association with" GENE=BRCA2]; 	0.757000	T	T,T,T		T,T	0.01	1	I16R041,	278	1335	1	[1] old entry - no details available	n/a	n/a	BRCA2 (inh=AR+AD pLI=0.00)
chr13	32929387	32929387	T	C	1.0000	8		249.0	7|1|0,0|0|0,5|4	BRCA2	missense_variant	BRCA2:NM_000059.3:missense_variant:MODERATE:exon14/27:c.7397T>C:p.Val2466Ala		Homologous recombination;Pancreatic cancer	Involved in double-strand break repair and/or homologous recombination. Binds RAD51 and potentiates recombinational DNA repair by promoting assembly of RAD51 onto single-stranded DNA (ssDNA). Acts by targeting RAD51 to ssDNA over double-stranded DNA, enabling RAD51 to displace replication protein-A (RPA) from ssDNA and stabilizing RAD51-ssDNA filaments by blocking ATP hydrolysis. May participate in S phase checkpoint activation. Binds selectively to ssDNA, and to ssDNA in tailed duplexes and replication fork structures. In concert with NPM1, regulates centrosome duplication	Role of BRCA1,  BRCA2 and ATR in Cancer Susceptibility		rs169547	0.975839	0.99371826155774	0.9638144		600185 [BRCA2 (confirmed) Breast-ovarian cancer,familial,2,612555|Fanconi anemia,complementation group D1,605724|Prostate cancer,176807|Breast cancer,male,susceptibility to,114480|Wilms tumor,194070|Medulloblastoma,155255|Glioblastoma 3,613029|Pancreatic cancer 2,613347];	RCV000045197.4 [benign]; RCV000113751.2 [benign]; RCV000168597.1 [benign]; RCV000203672.1 [benign]; RCV000120357.6 [benign]; RCV000207137.1 [uncertain significance]; 	CM960194 [CLASS=DM? MUT=REF PHEN="Breast cancer" GENE=BRCA2]; 	2.353000	T	T,T		T,T	0.37	0		3385	11	2	[2] old entry - no details available	n/a	n/a	BRCA2 (inh=AR+AD pLI=0.00)
chr14	42360633	42360633	T	C	0.6364	33		465.0	0|0|21,0|0|12,5|6	LRFN5	synonymous_variant,intron_variant	LRFN5:NM_152447.3:synonymous_variant:LOW:exon4/6:c.1566T>C:p.Ser522Ser,LRFN5:NM_001330106.1:intron_variant:MODIFIER:exon3/4:c.1385+3420T>C:			Cell adhesion molecule that mediates homophilic cell- cell adhesion in a Ca(2+)-independent manner. Promotes neurite outgrowth in hippocampal neurons			rs6572117	0.705272	0.69752038882939	0.6730116											1	I16R041,	693	493			n/a	n/a	LRFN5 (inh=n/a pLI=0.71)
chr14	64496763	64496763	T	C	0.5556	18		210.0	10|0|0,8|0|0,5|5	SYNE2	synonymous_variant	SYNE2:NM_182914.2:synonymous_variant:LOW:exon44/116:c.6865T>C:p.Leu2289Leu,SYNE2:NM_015180.4:synonymous_variant:LOW:exon44/115:c.6865T>C:p.Leu2289Leu						rs11850509	0.0880591	0.057707681033908	0.0563201		608442 [SYNE2 (provisional) Emery-Dreifuss muscular dystrophy 5,autosomal dominant,612999];	RCV000118545.1 [benign]; RCV000270285.1 [benign]; 								1	Leuk,	5	127			n/a	n/a	SYNE2 (inh=AD pLI=0.00)
chr14	64498037	64498037	G	A	1.0000	18		493.0	0|18|0,0|0|0,8|7	SYNE2	missense_variant	SYNE2:NM_182914.2:missense_variant:MODERATE:exon45/116:c.7183G>A:p.Ala2395Thr,SYNE2:NM_015180.4:missense_variant:MODERATE:exon45/115:c.7183G>A:p.Ala2395Thr						rs4027405	0.83726	0.89238305941846	0.8824789		608442 [SYNE2 (provisional) Emery-Dreifuss muscular dystrophy 5,autosomal dominant,612999];	RCV000118551.1 [benign]; RCV000393202.1 [benign]; 		1.817000	T	T,T,T,T	B,B	T,T,T	22.90	0		1223	288			n/a	n/a	SYNE2 (inh=AD pLI=0.00)
chr14	64519035	64519035	A	G	1.0000	8		245.0	6|1|1,0|0|0,5|5	SYNE2	missense_variant	SYNE2:NM_182914.2:missense_variant:MODERATE:exon48/116:c.8404A>G:p.Ser2802Gly,SYNE2:NM_015180.4:missense_variant:MODERATE:exon48/115:c.8404A>G:p.Ser2802Gly						rs1890908	0.861821	0.90675635375592	0.8970123		608442 [SYNE2 (provisional) Emery-Dreifuss muscular dystrophy 5,autosomal dominant,612999];	RCV000118553.1 [benign]; RCV000280345.1 [benign]; 		-1.609000	T	T,T,T,T	B,B	T,T,T	0.01	0		1290	220			n/a	n/a	SYNE2 (inh=AD pLI=0.00)
chr14	64580297	64580297	T	C	0.7429	35		696.0	6|20|0,5|2|2,4|5	SYNE2	splice_region_variant&intron_variant	SYNE2:NM_182914.2:splice_region_variant&intron_variant:LOW:exon66/115:c.12840+8T>C:,SYNE2:NM_015180.4:splice_region_variant&intron_variant:LOW:exon66/114:c.12840+8T>C:						rs145218296	0.00738818	0.032314805508091	0.0187584		608442 [SYNE2 (provisional) Emery-Dreifuss muscular dystrophy 5,autosomal dominant,612999];	RCV000118508.2 [benign]; RCV000398086.1 [benign]; 								0		2	63			n/a	n/a	SYNE2 (inh=AD pLI=0.00)
chr14	64637147	64637147	C	A	0.4286	35		313.0	5|4|6,3|4|13,5|6	SYNE2	synonymous_variant	SYNE2:NM_182914.2:synonymous_variant:LOW:exon94/116:c.17202C>A:p.Leu5734Leu,SYNE2:NM_015180.4:synonymous_variant:LOW:exon94/115:c.17202C>A:p.Leu5734Leu						rs7161192	0.365815	0.35103823188664	0.3293227		608442 [SYNE2 (provisional) Emery-Dreifuss muscular dystrophy 5,autosomal dominant,612999];	RCV000118525.1 [benign]; RCV000390655.1 [benign]; 								0		155	665			n/a	n/a	SYNE2 (inh=AD pLI=0.00)
chr14	64681193	64681193	C	T	0.4074	54		418.0	0|8|14,0|4|28,2|6	SYNE2	splice_region_variant&intron_variant	SYNE2:NM_182914.2:splice_region_variant&intron_variant:LOW:exon106/115:c.19333+5C>T:,SYNE2:NM_015180.4:splice_region_variant&intron_variant:LOW:exon106/114:c.19333+5C>T:,SYNE2:NM_182913.2:splice_region_variant&intron_variant:LOW:exon1/10:c.235+5C>T:						rs1152590	0.583267	0.47015605527965	0.4347219		608442 [SYNE2 (provisional) Emery-Dreifuss muscular dystrophy 5,autosomal dominant,612999];	RCV000118529.2 [benign]; RCV000372153.1 [benign]; 								1	Leuk,	276	657			n/a	n/a	SYNE2 (inh=AD pLI=0.00)
chr14	95906321	95906321	G	A	0.7222	18		295.0	0|12|1,0|4|1,7|8	SYNE3	missense_variant	SYNE3:NM_152592.3:missense_variant:MODERATE:exon11/17:c.2003C>T:p.Thr668Met						rs9671369	0.41254	0.41627606538914	0.4098287	COSM1477881, COSM433555, COSM1477882				0.891000	T	T,T,T	P,D	T,T,T	13.72	0		124	384			n/a	n/a	SYNE3 (inh=n/a pLI=0.00)
chr14	95910933	95910933	T	C	0.4624	93		945.0	34|9|0,37|12|0,7|4	SYNE3	synonymous_variant	SYNE3:NM_152592.3:synonymous_variant:LOW:exon9/17:c.1665A>G:p.Ala555Ala						rs9919918	0.28155	0.23967148248516	0.2337882	COSM147840										0		53	241			n/a	n/a	SYNE3 (inh=n/a pLI=0.00)
chr14	95918625	95918625	T	C	0.4667	15		141.0	0|1|6,0|0|8,5|3	SYNE3	synonymous_variant	SYNE3:NM_152592.3:synonymous_variant:LOW:exon6/17:c.1233A>G:p.Pro411Pro						rs4905318	0.460863	0.45866935483871	0.4525286	COSM4148330, COSM4148329, COSM4148331										0		154	403			n/a	n/a	SYNE3 (inh=n/a pLI=0.00)
chr14	95921741	95921741	C	T	0.4286	14		105.0	0|6|0,0|8|0,3|4	SYNE3	synonymous_variant	SYNE3:NM_152592.3:synonymous_variant:LOW:exon5/17:c.1110G>A:p.Glu370Glu						rs4905324	0.455272	0.5222460658083	0.5045401	COSM1477888, COSM1477887, COSM433558										2	Leuk,	247	400			n/a	n/a	SYNE3 (inh=n/a pLI=0.00)
chr14	95923670	95923670	A	C	0.6757	37		643.0	0|0|25,0|0|12,4|4	SYNE3	synonymous_variant	SYNE3:NM_152592.3:synonymous_variant:LOW:exon4/17:c.633T>G:p.Arg211Arg						rs2024863	0.624002	0.57202527667036	0.5562558											2	Leuk,	266	399			n/a	n/a	SYNE3 (inh=n/a pLI=0.00)
chr14	105239894	105239894	C	T	0.6000	10		124.0	0|0|6,0|4|0,4|3	AKT1	synonymous_variant	AKT1:NM_001014431.1:synonymous_variant:LOW:exon9/14:c.726G>A:p.Glu242Glu,AKT1:NM_005163.2:synonymous_variant:LOW:exon9/14:c.726G>A:p.Glu242Glu,AKT1:NM_001014432.1:synonymous_variant:LOW:exon10/15:c.726G>A:p.Glu242Glu						rs1130233	0.322484	0.31413316324431	0.2734078	COSM3765730	164730 [AKT1 (confirmed) Breast cancer,somatic,114480|Colorectal cancer,somatic,114500|Ovarian cancer,somatic,167000|Schizophrenia,susceptibility to,181500|Proteus syndrome,somatic,176920|Cowden syndrome 6,615109];		CM081515 [CLASS=DFP MUT=ALT PHEN="Schizophrenia familial association with" GENE=AKT1]; 							1	SomaticAndTreatment,	177	993			n/a	n/a	AKT1 (inh=AD pLI=0.98)
chr15	22368862	22368862	G	A	1.0000	13		406.0	0|1|12,0|0|0,4|4	OR4M2,LOC101927079,LOC727924	missense_variant,intron_variant,non_coding_transcript_exon_variant	OR4M2:NM_001004719.2:missense_variant:MODERATE:exon1/1:c.287G>A:p.Gly96Glu,LOC101927079:NR_110480.1:intron_variant:MODIFIER:exon7/8:n.824-13602G>A:,LOC101927079:NR_110481.1:intron_variant:MODIFIER:exon5/6:n.556-13602G>A:,LOC727924:NR_015416.1:non_coding_transcript_exon_variant:MODIFIER:exon10/11:n.1319G>A:	GPCR__rhodopsin-like_superfamily__1_	Olfactory transduction	Odorant receptor (Potential)			rs1835183	0.0000	0.62772952751364	0.0445069					0.394000	T	D	P	T	23.90	0		228	546			n/a	n/a	OR4M2 (inh=n/a pLI=n/a), LOC101927079 (inh=n/a pLI=n/a), LOC727924 (inh=n/a pLI=n/a)
chr15	27018797	27018797	G	A	1.0000	10		275.0	0|0|10,0|0|0,5|5	GABRB3	synonymous_variant	GABRB3:NM_021912.4:synonymous_variant:LOW:exon1/9:c.75C>T:p.Pro25Pro						rs20318	0.198083	0.29825308904985	0.1443050	COSM433657	137192 [GABRB3 (confirmed) Epilepsy,childhood absence,susceptibility to,5,612269|Epileptic encephalopathy,early infantile,43,617113];									1	Leuk,	46	358			n/a	n/a	GABRB3 (inh=AD pLI=1.00)
chr15	28386626	28386626	C	T	1.0000	30		890.0	0|6|24,0|0|0,5|5	HERC2	synonymous_variant	HERC2:NM_004667.5:synonymous_variant:LOW:exon78/93:c.11967G>A:p.Gln3989Gln		Ubiquitin mediated proteolysis	E3 ubiquitin-protein ligase that regulates ubiquitin- dependent retention of repair proteins on damaged chromosomes. Recruited to sites of DNA damage in response to ionizing radiation (IR) and facilitates the assembly of UBE2N and RNF8 promoting DNA damage-induced formation of 'Lys-63'-linked ubiquitin chains. Acts as a mediator of binding specificity between UBE2N and RNF8. Involved in the maintenance of RNF168 levels. E3 ubiquitin-protein ligase that promotes the ubiquitination and proteasomal degradation of XPA which influences the circadian oscillation of DNA excision repair activity			rs11636232	0.0856629	0.25423058544382	0.2563985		605837 [HERC2 (confirmed) Skin/hair/eye pigmentation 1,blue/nonblue eyes,227220|Skin/hair/eye pigmentation 1,blond/brown hair,227220|Mental retardation,autosomal recessive 38,615516];									0		112	435			n/a	n/a	HERC2 (inh=AR pLI=1.00)
chr15	28419695	28419695	T	C	0.3611	72		490.0	2|24|0,12|34|0,4|5	HERC2	synonymous_variant	HERC2:NM_004667.5:synonymous_variant:LOW:exon65/93:c.9903A>G:p.Thr3301Thr		Ubiquitin mediated proteolysis	E3 ubiquitin-protein ligase that regulates ubiquitin- dependent retention of repair proteins on damaged chromosomes. Recruited to sites of DNA damage in response to ionizing radiation (IR) and facilitates the assembly of UBE2N and RNF8 promoting DNA damage-induced formation of 'Lys-63'-linked ubiquitin chains. Acts as a mediator of binding specificity between UBE2N and RNF8. Involved in the maintenance of RNF168 levels. E3 ubiquitin-protein ligase that promotes the ubiquitination and proteasomal degradation of XPA which influences the circadian oscillation of DNA excision repair activity			rs149592795	0.0670927	0.12246313202247	0.0988592	COSM307015	605837 [HERC2 (confirmed) Skin/hair/eye pigmentation 1,blue/nonblue eyes,227220|Skin/hair/eye pigmentation 1,blond/brown hair,227220|Mental retardation,autosomal recessive 38,615516];									1	Leuk,	0	422			n/a	n/a	HERC2 (inh=AR pLI=1.00)
chr15	28419746	28419746	G	A	0.1875	48		6.0	0|9|0,15|24|10,4|6	HERC2	synonymous_variant	HERC2:NM_004667.5:synonymous_variant:LOW:exon65/93:c.9852C>T:p.Asn3284Asn		Ubiquitin mediated proteolysis	E3 ubiquitin-protein ligase that regulates ubiquitin- dependent retention of repair proteins on damaged chromosomes. Recruited to sites of DNA damage in response to ionizing radiation (IR) and facilitates the assembly of UBE2N and RNF8 promoting DNA damage-induced formation of 'Lys-63'-linked ubiquitin chains. Acts as a mediator of binding specificity between UBE2N and RNF8. Involved in the maintenance of RNF168 levels. E3 ubiquitin-protein ligase that promotes the ubiquitination and proteasomal degradation of XPA which influences the circadian oscillation of DNA excision repair activity			rs139335991	0.0000	0.13836025280899	0.1041002		605837 [HERC2 (confirmed) Skin/hair/eye pigmentation 1,blue/nonblue eyes,227220|Skin/hair/eye pigmentation 1,blond/brown hair,227220|Mental retardation,autosomal recessive 38,615516];									0		1	330			n/a	n/a	HERC2 (inh=AR pLI=1.00)
chr15	28502279	28502279	A	G	1.0000	50		1489.0	0|0|50,0|0|0,4|5	HERC2	synonymous_variant	HERC2:NM_004667.5:synonymous_variant:LOW:exon17/93:c.2445T>C:p.Gly815Gly		Ubiquitin mediated proteolysis	E3 ubiquitin-protein ligase that regulates ubiquitin- dependent retention of repair proteins on damaged chromosomes. Recruited to sites of DNA damage in response to ionizing radiation (IR) and facilitates the assembly of UBE2N and RNF8 promoting DNA damage-induced formation of 'Lys-63'-linked ubiquitin chains. Acts as a mediator of binding specificity between UBE2N and RNF8. Involved in the maintenance of RNF168 levels. E3 ubiquitin-protein ligase that promotes the ubiquitination and proteasomal degradation of XPA which influences the circadian oscillation of DNA excision repair activity			rs11631797	0.442492	0.68756604147405	0.6734618		605837 [HERC2 (confirmed) Skin/hair/eye pigmentation 1,blue/nonblue eyes,227220|Skin/hair/eye pigmentation 1,blond/brown hair,227220|Mental retardation,autosomal recessive 38,615516];									0		765	383			n/a	n/a	HERC2 (inh=AR pLI=1.00)
chr15	28517436	28517436	T	C	0.3333	30		162.0	0|0|10,10|0|10,5|5	HERC2	synonymous_variant	HERC2:NM_004667.5:synonymous_variant:LOW:exon9/93:c.1008A>G:p.Pro336Pro		Ubiquitin mediated proteolysis	E3 ubiquitin-protein ligase that regulates ubiquitin- dependent retention of repair proteins on damaged chromosomes. Recruited to sites of DNA damage in response to ionizing radiation (IR) and facilitates the assembly of UBE2N and RNF8 promoting DNA damage-induced formation of 'Lys-63'-linked ubiquitin chains. Acts as a mediator of binding specificity between UBE2N and RNF8. Involved in the maintenance of RNF168 levels. E3 ubiquitin-protein ligase that promotes the ubiquitination and proteasomal degradation of XPA which influences the circadian oscillation of DNA excision repair activity			rs75181529	0.0000	0.49306766293068	0.0207840		605837 [HERC2 (confirmed) Skin/hair/eye pigmentation 1,blue/nonblue eyes,227220|Skin/hair/eye pigmentation 1,blond/brown hair,227220|Mental retardation,autosomal recessive 38,615516];									0		1	1255			n/a	n/a	HERC2 (inh=AR pLI=1.00)
chr15	39880277	39880277	G	A	0.5000	10		62.0	1|4|0,2|3|0,6|6	THBS1	synonymous_variant	THBS1:NM_003246.3:synonymous_variant:LOW:exon9/22:c.1329G>A:p.Pro443Pro		Cell Communication;p53 signaling pathway;TGF-beta signaling pathway;Focal adhesion;ECM-receptor interaction;Bladder cancer	Adhesive glycoprotein that mediates cell-to-cell and cell-to-matrix interactions. Binds heparin. May play a role in dentinogenesis and/or maintenance of dentin and dental pulp (By similarity). Ligand for CD36 mediating antiangiogenic properties	TSP-1 Induced Apoptosis in Microvascular Endothelial Cell 		rs35275624	0.0361422	0.078352673567614	0.0775286											0		21	196			n/a	n/a	THBS1 (inh=n/a pLI=1.00)
chr15	39881216	39881216	G	T	0.2400	25		54.0	6|0|0,9|10|0,6|3	THBS1	missense_variant	THBS1:NM_003246.3:missense_variant:MODERATE:exon11/22:c.1702G>T:p.Gly568Cys	Epidermal_growth_factor-like__1_,Epidermal_growth_factor-like__type_3__1_,	Cell Communication;p53 signaling pathway;TGF-beta signaling pathway;Focal adhesion;ECM-receptor interaction;Bladder cancer	Adhesive glycoprotein that mediates cell-to-cell and cell-to-matrix interactions. Binds heparin. May play a role in dentinogenesis and/or maintenance of dentin and dental pulp (By similarity). Ligand for CD36 mediating antiangiogenic properties	TSP-1 Induced Apoptosis in Microvascular Endothelial Cell 			0.0000	0.0000	0.0000					9.869000,9.869000	D,D	D,	D,D,	D,	33.00	0		0	0			n/a	n/a	THBS1 (inh=n/a pLI=1.00)
chr15	39882178	39882178	A	G	0.5556	27		349.0	0|5|10,0|9|2,4|6	THBS1	missense_variant	THBS1:NM_003246.3:missense_variant:MODERATE:exon13/22:c.2099A>G:p.Asn700Ser		Cell Communication;p53 signaling pathway;TGF-beta signaling pathway;Focal adhesion;ECM-receptor interaction;Bladder cancer	Adhesive glycoprotein that mediates cell-to-cell and cell-to-matrix interactions. Binds heparin. May play a role in dentinogenesis and/or maintenance of dentin and dental pulp (By similarity). Ligand for CD36 mediating antiangiogenic properties	TSP-1 Induced Apoptosis in Microvascular Endothelial Cell 		rs2228262	0.0401358	0.092586547877345	0.0805317	COSM433760			CM043345 [CLASS=DFP MUT=ALT PHEN="Coronary artery disease association with" GENE=THBS1]; 	9.339000	T	D	P,D	D	26.40	0		21	203			n/a	n/a	THBS1 (inh=n/a pLI=1.00)
chr15	39885301	39885301	T	C	0.4000	30		258.0	4|8|0,5|13|0,2|3	THBS1	synonymous_variant	THBS1:NM_003246.3:synonymous_variant:LOW:exon18/22:c.2868T>C:p.Asp956Asp		Cell Communication;p53 signaling pathway;TGF-beta signaling pathway;Focal adhesion;ECM-receptor interaction;Bladder cancer	Adhesive glycoprotein that mediates cell-to-cell and cell-to-matrix interactions. Binds heparin. May play a role in dentinogenesis and/or maintenance of dentin and dental pulp (By similarity). Ligand for CD36 mediating antiangiogenic properties	TSP-1 Induced Apoptosis in Microvascular Endothelial Cell 		rs2228263	0.114617	0.13290910031559	0.1301831											0		43	314			n/a	n/a	THBS1 (inh=n/a pLI=1.00)
chr15	89858602	89858602	T	C	1.0000	18		548.0	0|0|18,0|0|0,3|2	FANCI	synonymous_variant	FANCI:NM_001113378.1:synonymous_variant:LOW:exon37/38:c.3906T>C:p.Gly1302Gly,FANCI:NM_018193.2:synonymous_variant:LOW:exon36/37:c.3726T>C:p.Gly1242Gly			Plays an essential role in the repair of DNA double- strand breaks by homologous recombination and in the repair of interstrand DNA cross-links (ICLs) by promoting FANCD2 monoubiquitination by FANCL and participating in recruitment to DNA repair sites. Required for maintenance of chromosomal stability. Specifically binds branched DNA: binds both single- stranded DNA (ssDNA) and double-stranded DNA (dsDNA). Participates in S phase and G2 phase checkpoint activation upon DNA damage			rs1138465	0.41234	0.41226074484396	0.4031793	COSM3754561, COSM3754560	611360 [FANCI (provisional) Fanconi anemia,complementation group I,609053];	RCV000251297.1 [benign]; RCV000329693.1 [likely benign]; RCV000348737.1 [benign]; 								0		272	770			n/a	n/a	FANCI (inh=AR pLI=0.00)
chr15	90226947	90226947	C	A	1.0000	61		1951.0	29|28|4,0|0|0,8|7	PEX11A	synonymous_variant,5_prime_UTR_premature_start_codon_gain_variant,5_prime_UTR_variant	PEX11A:NM_003847.2:synonymous_variant:LOW:exon3/3:c.405G>T:p.Leu135Leu,PEX11A:NM_001271572.1:synonymous_variant:LOW:exon3/3:c.312G>T:p.Leu104Leu,PEX11A:NM_001271573.1:5_prime_UTR_premature_start_codon_gain_variant:LOW:exon2/2:c.-31G>T:,PEX11A:NM_001271573.1:5_prime_UTR_variant:MODIFIER:exon2/2:c.-31G>T:						rs7169981	0.505192	0.62058309710594	0.6167108	COSM3999679										0		379	374			n/a	n/a	PEX11A (inh=n/a pLI=0.00)
chr15	91354505	91354505	C	T	0.4638	69		745.0	12|8|12,7|14|16,9|8	BLM	synonymous_variant	BLM:NM_000057.3:synonymous_variant:LOW:exon21/22:c.3945C>T:p.Leu1315Leu,BLM:NM_001287246.1:synonymous_variant:LOW:exon22/23:c.3945C>T:p.Leu1315Leu,BLM:NM_001287247.1:synonymous_variant:LOW:exon19/20:c.3552C>T:p.Leu1184Leu,BLM:NM_001287248.1:synonymous_variant:LOW:exon21/22:c.2820C>T:p.Leu940Leu		Homologous recombination	Participates in DNA replication and repair. Exhibits a magnesium-dependent ATP-dependent DNA-helicase activity that unwinds single- and double-stranded DNA in a 3'-5' direction. Involved in 5'-end resection of DNA during double-strand break (DSB) repair: unwinds DNA and recruits DNA2 which mediates the cleavage of 5'-ssDNA			rs1063147	0.132788	0.15567786694791	0.1555587		604610 [BLM (confirmed) Bloom syndrome,210900];	RCV000078061.8 [other]; RCV000320678.1 [likely benign]; 								0		105	882	1	[1] Ilnaz Sepahi 29-03-2016 batch import	n/a	n/a	BLM (inh=AR pLI=0.00)
chr15	99456369	99456369	G	A	0.4500	40		422.0	8|4|6,8|8|6,5|3	IGF1R	synonymous_variant	IGF1R:NM_000875.4:synonymous_variant:LOW:exon8/21:c.1686G>A:p.Val562Val,IGF1R:NM_001291858.1:synonymous_variant:LOW:exon8/21:c.1686G>A:p.Val562Val						rs2228531	0.00439297	0.0085434173669468	0.0087072		147370 [IGF1R (confirmed) Insulin-like growth factor I,resistance to,270450];	RCV000312821.1 [uncertain significance]; 								0		1	32			n/a	n/a	IGF1R (inh=AR+AD pLI=0.55)
chr16	2155469	2155469	G	A	0.6286	35		474.0	12|4|6,2|7|4,4|6	PKD1	missense_variant	PKD1:NM_001009944.2:missense_variant:MODERATE:exon21/46:c.7870C>T:p.Arg2624Trp,PKD1:NM_000296.3:missense_variant:MODERATE:exon21/46:c.7870C>T:p.Arg2624Trp	Egg_jelly_receptor__REJ-like__1_,Polycystin_cation_channel__1_		Involved in renal tubulogenesis. Involved in fluid-flow mechanosensation by the primary cilium in renal epithelium (By similarity). Acts as a regulator of cilium length, together with PKD2 (By similarity). The dynamic control of cilium length is essential in the regulation of mechanotransductive signaling. The cilium length response creates a negative feedback loop whereby fluid shear-mediated deflection of the primary cilium, which decreases intracellular cAMP, leads to cilium shortening and thus decreases flow-induced signaling (By similarity). May be an ion- channel regulator. Involved in adhesive protein-protein and protein-carbohydrate interactions			rs766658912	0.0000	3.6218761318363E-5	0.0000064		601313 [PKD1 (confirmed) Polycystic kidney disease,adult type I,173900];			4.347000	T	D,D,D	B,B	T,T	28.00	0		0	1			n/a	n/a	PKD1 (inh=AD pLI=1.00)
chr16	3639139	3639139	A	G	1.0000	61		1854.0	4|6|51,0|0|0,6|6	SLX4	synonymous_variant	SLX4:NM_032444.2:synonymous_variant:LOW:exon12/15:c.4500T>C:p.Asn1500Asn			Regulatory subunit that interacts with and increases the activity of different structure-specific endonucleases. Has several distinct roles in protecting genome stability by resolving diverse forms of deleterious DNA structures originating from replication and recombination intermediates and from DNA damage. Component of the SLX1-SLX4 structure-specific endonuclease that resolves DNA secondary structures generated during DNA repair and recombination. Has endonuclease activity towards branched DNA substrates, introducing single-strand cuts in duplex DNA close to junctions with ss-DNA. Has a preference for 5'-flap structures, and promotes symmetrical cleavage of static and migrating Holliday junctions (HJs). Resolves HJs by generating two pairs of ligatable, nicked duplex products. Interacts with the structure- specific ERCC4-ERCC1 endonuclease and promotes the cleavage of bubble structures. Interacts with the structure-specific MUS81- EME1 endonuclease and promotes the cleavage of 3'-flap and replication fork-like structures. SLX4 is required for recovery from alkylation-induced DNA damage and is involved in the resolution of DNA double-strand breaks			rs3810812	0.739617	0.61158581935377	0.5994637		613278 [SLX4 (provisional) Fanconi anemia,complementation group P,613951];	RCV000252099.1 [benign]; RCV000341995.1 [benign]; 								0		776	1327	1	[1] Ilnaz Sepahi 29-03-2016 batch import	n/a	n/a	SLX4 (inh=AR pLI=0.00)
chr16	3640274	3640274	G	A	0.7500	32		598.0	14|2|8,2|3|3,4|5	SLX4	missense_variant	SLX4:NM_032444.2:missense_variant:MODERATE:exon12/15:c.3365C>T:p.Pro1122Leu			Regulatory subunit that interacts with and increases the activity of different structure-specific endonucleases. Has several distinct roles in protecting genome stability by resolving diverse forms of deleterious DNA structures originating from replication and recombination intermediates and from DNA damage. Component of the SLX1-SLX4 structure-specific endonuclease that resolves DNA secondary structures generated during DNA repair and recombination. Has endonuclease activity towards branched DNA substrates, introducing single-strand cuts in duplex DNA close to junctions with ss-DNA. Has a preference for 5'-flap structures, and promotes symmetrical cleavage of static and migrating Holliday junctions (HJs). Resolves HJs by generating two pairs of ligatable, nicked duplex products. Interacts with the structure- specific ERCC4-ERCC1 endonuclease and promotes the cleavage of bubble structures. Interacts with the structure-specific MUS81- EME1 endonuclease and promotes the cleavage of 3'-flap and replication fork-like structures. SLX4 is required for recovery from alkylation-induced DNA damage and is involved in the resolution of DNA double-strand breaks			rs714181	0.239617	0.13472565496787	0.1300738		613278 [SLX4 (provisional) Fanconi anemia,complementation group P,613951];	RCV000245084.1 [benign]; RCV000323962.1 [benign]; 		0.088000	T	T	B	T	9.45	0		23	433	1	[1] Ilnaz Sepahi 29-03-2016 batch import	n/a	n/a	SLX4 (inh=AR pLI=0.00)
chr16	3640784	3640784	G	A	0.3636	11		47.0	4|0|0,5|2|0,3|3	SLX4	missense_variant	SLX4:NM_032444.2:missense_variant:MODERATE:exon12/15:c.2855C>T:p.Ala952Val			Regulatory subunit that interacts with and increases the activity of different structure-specific endonucleases. Has several distinct roles in protecting genome stability by resolving diverse forms of deleterious DNA structures originating from replication and recombination intermediates and from DNA damage. Component of the SLX1-SLX4 structure-specific endonuclease that resolves DNA secondary structures generated during DNA repair and recombination. Has endonuclease activity towards branched DNA substrates, introducing single-strand cuts in duplex DNA close to junctions with ss-DNA. Has a preference for 5'-flap structures, and promotes symmetrical cleavage of static and migrating Holliday junctions (HJs). Resolves HJs by generating two pairs of ligatable, nicked duplex products. Interacts with the structure- specific ERCC4-ERCC1 endonuclease and promotes the cleavage of bubble structures. Interacts with the structure-specific MUS81- EME1 endonuclease and promotes the cleavage of 3'-flap and replication fork-like structures. SLX4 is required for recovery from alkylation-induced DNA damage and is involved in the resolution of DNA double-strand breaks			rs78637028	0.0411342	0.058394824790708	0.0542301	COSM3754891	613278 [SLX4 (provisional) Fanconi anemia,complementation group P,613951];	RCV000243947.1 [benign]; RCV000345444.1 [likely benign]; 		-0.216000	T	D	B	T	21.40	0		7	292	1	[1] Ilnaz Sepahi 29-03-2016 batch import	n/a	n/a	SLX4 (inh=AR pLI=0.00)
chr16	3640785	3640785	C	T	0.3636	11		47.0	4|0|0,5|2|0,3|3	SLX4	missense_variant	SLX4:NM_032444.2:missense_variant:MODERATE:exon12/15:c.2854G>A:p.Ala952Thr			Regulatory subunit that interacts with and increases the activity of different structure-specific endonucleases. Has several distinct roles in protecting genome stability by resolving diverse forms of deleterious DNA structures originating from replication and recombination intermediates and from DNA damage. Component of the SLX1-SLX4 structure-specific endonuclease that resolves DNA secondary structures generated during DNA repair and recombination. Has endonuclease activity towards branched DNA substrates, introducing single-strand cuts in duplex DNA close to junctions with ss-DNA. Has a preference for 5'-flap structures, and promotes symmetrical cleavage of static and migrating Holliday junctions (HJs). Resolves HJs by generating two pairs of ligatable, nicked duplex products. Interacts with the structure- specific ERCC4-ERCC1 endonuclease and promotes the cleavage of bubble structures. Interacts with the structure-specific MUS81- EME1 endonuclease and promotes the cleavage of 3'-flap and replication fork-like structures. SLX4 is required for recovery from alkylation-induced DNA damage and is involved in the resolution of DNA double-strand breaks			rs59939128	0.0670927	0.067246141885969	0.0623264	COSM3754892	613278 [SLX4 (provisional) Fanconi anemia,complementation group P,613951];	RCV000253587.1 [benign]; RCV000400447.1 [likely benign]; 		-0.014000	T	T	B	T	10.20	0		7	295	1	[1] Ilnaz Sepahi 29-03-2016 batch import	n/a	n/a	SLX4 (inh=AR pLI=0.00)
chr16	3647692	3647692	A	C	0.3830	47		358.0	7|5|6,2|3|24,5|6	SLX4	missense_variant	SLX4:NM_032444.2:missense_variant:MODERATE:exon7/15:c.1371T>G:p.Asn457Lys			Regulatory subunit that interacts with and increases the activity of different structure-specific endonucleases. Has several distinct roles in protecting genome stability by resolving diverse forms of deleterious DNA structures originating from replication and recombination intermediates and from DNA damage. Component of the SLX1-SLX4 structure-specific endonuclease that resolves DNA secondary structures generated during DNA repair and recombination. Has endonuclease activity towards branched DNA substrates, introducing single-strand cuts in duplex DNA close to junctions with ss-DNA. Has a preference for 5'-flap structures, and promotes symmetrical cleavage of static and migrating Holliday junctions (HJs). Resolves HJs by generating two pairs of ligatable, nicked duplex products. Interacts with the structure- specific ERCC4-ERCC1 endonuclease and promotes the cleavage of bubble structures. Interacts with the structure-specific MUS81- EME1 endonuclease and promotes the cleavage of 3'-flap and replication fork-like structures. SLX4 is required for recovery from alkylation-induced DNA damage and is involved in the resolution of DNA double-strand breaks			rs74319927	0.0549121	0.06277829467668	0.0602814		613278 [SLX4 (provisional) Fanconi anemia,complementation group P,613951];	RCV000250221.1 [benign]; RCV000299919.1 [likely benign]; 		0.674000	T	T	B	T	12.02	0		7	295	1	[1] Ilnaz Sepahi 29-03-2016 batch import	n/a	n/a	SLX4 (inh=AR pLI=0.00)
chr16	3650970	3650970	G	A	0.3864	44		321.0	4|13|0,17|10|0,3|4	SLX4	splice_region_variant&intron_variant	SLX4:NM_032444.2:splice_region_variant&intron_variant:LOW:exon5/14:c.1163+10C>T:			Regulatory subunit that interacts with and increases the activity of different structure-specific endonucleases. Has several distinct roles in protecting genome stability by resolving diverse forms of deleterious DNA structures originating from replication and recombination intermediates and from DNA damage. Component of the SLX1-SLX4 structure-specific endonuclease that resolves DNA secondary structures generated during DNA repair and recombination. Has endonuclease activity towards branched DNA substrates, introducing single-strand cuts in duplex DNA close to junctions with ss-DNA. Has a preference for 5'-flap structures, and promotes symmetrical cleavage of static and migrating Holliday junctions (HJs). Resolves HJs by generating two pairs of ligatable, nicked duplex products. Interacts with the structure- specific ERCC4-ERCC1 endonuclease and promotes the cleavage of bubble structures. Interacts with the structure-specific MUS81- EME1 endonuclease and promotes the cleavage of 3'-flap and replication fork-like structures. SLX4 is required for recovery from alkylation-induced DNA damage and is involved in the resolution of DNA double-strand breaks			rs80116508	0.0589058	0.064447747580359	0.0608730		613278 [SLX4 (provisional) Fanconi anemia,complementation group P,613951];	RCV000253660.1 [benign]; RCV000370750.1 [likely benign]; 								0		8	290	1	[1] Ilnaz Sepahi 29-03-2016 batch import	n/a	n/a	SLX4 (inh=AR pLI=0.00)
chr16	3650987	3650987	T	C	0.3721	43		347.0	4|13|0,17|10|0,3|4	SLX4	missense_variant	SLX4:NM_032444.2:missense_variant:MODERATE:exon5/15:c.1156A>G:p.Met386Val			Regulatory subunit that interacts with and increases the activity of different structure-specific endonucleases. Has several distinct roles in protecting genome stability by resolving diverse forms of deleterious DNA structures originating from replication and recombination intermediates and from DNA damage. Component of the SLX1-SLX4 structure-specific endonuclease that resolves DNA secondary structures generated during DNA repair and recombination. Has endonuclease activity towards branched DNA substrates, introducing single-strand cuts in duplex DNA close to junctions with ss-DNA. Has a preference for 5'-flap structures, and promotes symmetrical cleavage of static and migrating Holliday junctions (HJs). Resolves HJs by generating two pairs of ligatable, nicked duplex products. Interacts with the structure- specific ERCC4-ERCC1 endonuclease and promotes the cleavage of bubble structures. Interacts with the structure-specific MUS81- EME1 endonuclease and promotes the cleavage of 3'-flap and replication fork-like structures. SLX4 is required for recovery from alkylation-induced DNA damage and is involved in the resolution of DNA double-strand breaks			rs113490934	0.0545128	0.062787392358498	0.0581014		613278 [SLX4 (provisional) Fanconi anemia,complementation group P,613951];	RCV000250315.1 [benign]; RCV000268958.1 [likely benign]; 		0.435000	T	T	B	T	0.00	0		7	292	1	[1] Ilnaz Sepahi 29-03-2016 batch import	n/a	n/a	SLX4 (inh=AR pLI=0.00)
chr16	3650991	3650991	T	C	0.3721	43		347.0	4|12|0,17|10|0,3|4	SLX4	synonymous_variant	SLX4:NM_032444.2:synonymous_variant:LOW:exon5/15:c.1152A>G:p.Pro384Pro			Regulatory subunit that interacts with and increases the activity of different structure-specific endonucleases. Has several distinct roles in protecting genome stability by resolving diverse forms of deleterious DNA structures originating from replication and recombination intermediates and from DNA damage. Component of the SLX1-SLX4 structure-specific endonuclease that resolves DNA secondary structures generated during DNA repair and recombination. Has endonuclease activity towards branched DNA substrates, introducing single-strand cuts in duplex DNA close to junctions with ss-DNA. Has a preference for 5'-flap structures, and promotes symmetrical cleavage of static and migrating Holliday junctions (HJs). Resolves HJs by generating two pairs of ligatable, nicked duplex products. Interacts with the structure- specific ERCC4-ERCC1 endonuclease and promotes the cleavage of bubble structures. Interacts with the structure-specific MUS81- EME1 endonuclease and promotes the cleavage of 3'-flap and replication fork-like structures. SLX4 is required for recovery from alkylation-induced DNA damage and is involved in the resolution of DNA double-strand breaks			rs112511042	0.0547125	0.062716926979042	0.0598956		613278 [SLX4 (provisional) Fanconi anemia,complementation group P,613951];	RCV000253747.1 [benign]; RCV000383495.1 [likely benign]; 								0		7	291	1	[1] Ilnaz Sepahi 29-03-2016 batch import	n/a	n/a	SLX4 (inh=AR pLI=0.00)
chr16	3656625	3656625	G	A	0.4043	47		396.0	0|18|1,0|28|0,3|8	SLX4	missense_variant	SLX4:NM_032444.2:missense_variant:MODERATE:exon3/15:c.610C>T:p.Arg204Cys			Regulatory subunit that interacts with and increases the activity of different structure-specific endonucleases. Has several distinct roles in protecting genome stability by resolving diverse forms of deleterious DNA structures originating from replication and recombination intermediates and from DNA damage. Component of the SLX1-SLX4 structure-specific endonuclease that resolves DNA secondary structures generated during DNA repair and recombination. Has endonuclease activity towards branched DNA substrates, introducing single-strand cuts in duplex DNA close to junctions with ss-DNA. Has a preference for 5'-flap structures, and promotes symmetrical cleavage of static and migrating Holliday junctions (HJs). Resolves HJs by generating two pairs of ligatable, nicked duplex products. Interacts with the structure- specific ERCC4-ERCC1 endonuclease and promotes the cleavage of bubble structures. Interacts with the structure-specific MUS81- EME1 endonuclease and promotes the cleavage of 3'-flap and replication fork-like structures. SLX4 is required for recovery from alkylation-induced DNA damage and is involved in the resolution of DNA double-strand breaks			rs79842542	0.0597045	0.06419024703769	0.0622749		613278 [SLX4 (provisional) Fanconi anemia,complementation group P,613951];	RCV000251559.1 [benign]; RCV000336802.1 [likely benign]; 		2.460000	T	D	D	T	24.90	0		7	294	1	[1] Ilnaz Sepahi 29-03-2016 batch import	n/a	n/a	SLX4 (inh=AR pLI=0.00)
chr16	3656680	3656680	G	A	0.4167	48		415.0	0|18|2,0|28|0,1|6	SLX4	synonymous_variant	SLX4:NM_032444.2:synonymous_variant:LOW:exon3/15:c.555C>T:p.Asp185Asp			Regulatory subunit that interacts with and increases the activity of different structure-specific endonucleases. Has several distinct roles in protecting genome stability by resolving diverse forms of deleterious DNA structures originating from replication and recombination intermediates and from DNA damage. Component of the SLX1-SLX4 structure-specific endonuclease that resolves DNA secondary structures generated during DNA repair and recombination. Has endonuclease activity towards branched DNA substrates, introducing single-strand cuts in duplex DNA close to junctions with ss-DNA. Has a preference for 5'-flap structures, and promotes symmetrical cleavage of static and migrating Holliday junctions (HJs). Resolves HJs by generating two pairs of ligatable, nicked duplex products. Interacts with the structure- specific ERCC4-ERCC1 endonuclease and promotes the cleavage of bubble structures. Interacts with the structure-specific MUS81- EME1 endonuclease and promotes the cleavage of 3'-flap and replication fork-like structures. SLX4 is required for recovery from alkylation-induced DNA damage and is involved in the resolution of DNA double-strand breaks			rs74640850	0.0419329	0.058558260927021	0.0565516		613278 [SLX4 (provisional) Fanconi anemia,complementation group P,613951];	RCV000248623.1 [benign]; RCV000311234.1 [likely benign]; 								0		7	292	1	[1] Ilnaz Sepahi 29-03-2016 batch import	n/a	n/a	SLX4 (inh=AR pLI=0.00)
chr16	15811023	15811023	C	T	1.0000	54		1648.0	0|6|48,0|0|0,3|4	MYH11,NDE1	synonymous_variant,intron_variant	MYH11:NM_001040114.1:synonymous_variant:LOW:exon39/42:c.5499G>A:p.Leu1833Leu,MYH11:NM_001040113.1:synonymous_variant:LOW:exon39/43:c.5499G>A:p.Leu1833Leu,MYH11:NM_002474.2:synonymous_variant:LOW:exon38/41:c.5478G>A:p.Leu1826Leu,MYH11:NM_022844.2:synonymous_variant:LOW:exon38/42:c.5478G>A:p.Leu1826Leu,NDE1:NM_001143979.1:intron_variant:MODIFIER:exon9/9:c.948-7025C>T:,NDE1:NM_017668.2:intron_variant:MODIFIER:exon8/8:c.948-7025C>T:			Required for centrosome duplication and formation and function of the mitotic spindle. Essential for the development of the cerebral cortex. May regulate the production of neurons by controlling the orientation of the mitotic spindle during division of cortical neuronal progenitors of the proliferative ventricular zone of the brain. Orientation of the division plane perpendicular to the layers of the cortex gives rise to two proliferative neuronal progenitors whereas parallel orientation of the division plane yields one proliferative neuronal progenitor and a post- mitotic neuron. A premature shift towards a neuronal fate within the progenitor population may result in an overall reduction in the final number of neurons and an increase in the number of neurons in the deeper layers of the cortex			rs1050163	0.396166	0.48178805217076	0.4748238		609449 [NDE1 (provisional) Lissencephaly 4 (with microcephaly),614019|Microhydranencephaly,605013]:160745 [MYH11 (confirmed) Aortic aneurysm,familial thoracic 4,132900];	RCV000146506.3 [other]; RCV000253101.2 [other]; RCV000344115.1 [benign]; 								0		379	636			n/a	n/a	MYH11 (inh=AD pLI=1.00), NDE1 (inh=AR pLI=0.05)
chr16	15814717	15814717	C	T	0.5909	22		305.0	0|3|10,3|2|4,4|5	MYH11,NDE1	synonymous_variant,intron_variant	MYH11:NM_001040114.1:synonymous_variant:LOW:exon34/42:c.4791G>A:p.Lys1597Lys,MYH11:NM_001040113.1:synonymous_variant:LOW:exon34/43:c.4791G>A:p.Lys1597Lys,MYH11:NM_002474.2:synonymous_variant:LOW:exon33/41:c.4770G>A:p.Lys1590Lys,MYH11:NM_022844.2:synonymous_variant:LOW:exon33/42:c.4770G>A:p.Lys1590Lys,NDE1:NM_001143979.1:intron_variant:MODIFIER:exon9/9:c.948-3331C>T:,NDE1:NM_017668.2:intron_variant:MODIFIER:exon8/8:c.948-3331C>T:			Required for centrosome duplication and formation and function of the mitotic spindle. Essential for the development of the cerebral cortex. May regulate the production of neurons by controlling the orientation of the mitotic spindle during division of cortical neuronal progenitors of the proliferative ventricular zone of the brain. Orientation of the division plane perpendicular to the layers of the cortex gives rise to two proliferative neuronal progenitors whereas parallel orientation of the division plane yields one proliferative neuronal progenitor and a post- mitotic neuron. A premature shift towards a neuronal fate within the progenitor population may result in an overall reduction in the final number of neurons and an increase in the number of neurons in the deeper layers of the cortex			rs11648119	0.00479233	0.01426735642031	0.0141411		609449 [NDE1 (provisional) Lissencephaly 4 (with microcephaly),614019|Microhydranencephaly,605013]:160745 [MYH11 (confirmed) Aortic aneurysm,familial thoracic 4,132900];	RCV000030299.1 [benign]; RCV000126956.3 [benign]; RCV000230875.1 [benign]; RCV000252040.2 [other]; RCV000279480.1 [likely benign]; 								0		0	32			n/a	n/a	MYH11 (inh=AD pLI=1.00), NDE1 (inh=AR pLI=0.05)
chr16	15818141	15818141	A	C	1.0000	28		892.0	9|19|0,0|0|0,3|7	MYH11,NDE1	synonymous_variant,3_prime_UTR_variant	MYH11:NM_001040114.1:synonymous_variant:LOW:exon32/42:c.4263T>G:p.Ala1421Ala,MYH11:NM_001040113.1:synonymous_variant:LOW:exon32/43:c.4263T>G:p.Ala1421Ala,MYH11:NM_002474.2:synonymous_variant:LOW:exon31/41:c.4242T>G:p.Ala1414Ala,MYH11:NM_022844.2:synonymous_variant:LOW:exon31/42:c.4242T>G:p.Ala1414Ala,NDE1:NM_001143979.1:3_prime_UTR_variant:MODIFIER:exon10/10:c.*33A>C:,NDE1:NM_017668.2:3_prime_UTR_variant:MODIFIER:exon9/9:c.*33A>C:			Required for centrosome duplication and formation and function of the mitotic spindle. Essential for the development of the cerebral cortex. May regulate the production of neurons by controlling the orientation of the mitotic spindle during division of cortical neuronal progenitors of the proliferative ventricular zone of the brain. Orientation of the division plane perpendicular to the layers of the cortex gives rise to two proliferative neuronal progenitors whereas parallel orientation of the division plane yields one proliferative neuronal progenitor and a post- mitotic neuron. A premature shift towards a neuronal fate within the progenitor population may result in an overall reduction in the final number of neurons and an increase in the number of neurons in the deeper layers of the cortex			rs2075511	0.410144	0.50093930754907	0.4937043		609449 [NDE1 (provisional) Lissencephaly 4 (with microcephaly),614019|Microhydranencephaly,605013]:160745 [MYH11 (confirmed) Aortic aneurysm,familial thoracic 4,132900];	RCV000126950.4 [benign]; RCV000250056.2 [other]; RCV000316233.1 [benign]; 								1	Leuk,	424	584			n/a	n/a	MYH11 (inh=AD pLI=1.00), NDE1 (inh=AR pLI=0.05)
chr16	15917197	15917197	G	A	0.6104	77		1179.0	18|9|20,14|6|10,7|7	MYH11	synonymous_variant	MYH11:NM_001040114.1:synonymous_variant:LOW:exon3/42:c.417C>T:p.Val139Val,MYH11:NM_001040113.1:synonymous_variant:LOW:exon3/43:c.417C>T:p.Val139Val,MYH11:NM_002474.2:synonymous_variant:LOW:exon3/41:c.417C>T:p.Val139Val,MYH11:NM_022844.2:synonymous_variant:LOW:exon3/42:c.417C>T:p.Val139Val						rs1050111	0.0752796	0.099123587361207	0.0974444		160745 [MYH11 (confirmed) Aortic aneurysm,familial thoracic 4,132900];	RCV000126976.4 [benign]; RCV000242321.2 [other]; 								0		17	271			n/a	n/a	MYH11 (inh=AD pLI=1.00)
chr16	65016087	65016087	A	C	0.5664	143		2049.0	7|46|28,20|8|34,7|8	CDH11	missense_variant	CDH11:NM_001797.3:missense_variant:MODERATE:exon8/13:c.1117T>G:p.Ser373Ala,CDH11:NM_001308392.1:missense_variant:MODERATE:exon8/14:c.1117T>G:p.Ser373Ala	Cadherin__4_,Cadherin-like__1_					rs35213	0.745407	0.80425398708317	0.7852403					-0.184000	T	T,T,T	B,B	T,T	0.12	0		586	230			n/a	n/a	CDH11 (inh=n/a pLI=1.00)
chr16	65022114	65022114	C	T	0.3103	29		153.0	4|0|5,6|12|2,6|4	CDH11	synonymous_variant	CDH11:NM_001797.3:synonymous_variant:LOW:exon7/13:c.945G>A:p.Ser315Ser,CDH11:NM_001308392.1:synonymous_variant:LOW:exon7/14:c.945G>A:p.Ser315Ser						rs28216	0.223642	0.33063132895735	0.3214773	COSM3754969, COSM3754970										1	Leuk,	124	395			n/a	n/a	CDH11 (inh=n/a pLI=1.00)
chr16	65038674	65038674	G	A	0.5000	10		86.0	0|2|3,0|5|0,5|10	CDH11	synonymous_variant	CDH11:NM_001797.3:synonymous_variant:LOW:exon3/13:c.99C>T:p.Pro33Pro,CDH11:NM_001308392.1:synonymous_variant:LOW:exon3/14:c.99C>T:p.Pro33Pro						rs35182	0.0625	0.12203575763234	0.0894704	COSM3754974, COSM3754973										1	Leuk,	15	147			n/a	n/a	CDH11 (inh=n/a pLI=1.00)
chr16	66420885	66420885	C	T	1.0000	32		1026.0	4|8|20,0|0|0,7|7	CDH5	synonymous_variant	CDH5:NM_001795.4:synonymous_variant:LOW:exon3/12:c.384C>T:p.Gly128Gly		Cell adhesion molecules (CAMs);Leukocyte transendothelial migration	Cadherins are calcium-dependent cell adhesion proteins. They preferentially interact with themselves in a homophilic manner in connecting cells; cadherins may thus contribute to the sorting of heterogeneous cell types. This cadherin may play a important role in endothelial cell biology through control of the cohesion and organization of the intercellular junctions. It associates with alpha-catenin forming a link to the cytoskeleton. Acts in concert with KRIT1 to establish and maintain correct endothelial cell polarity and vascular lumen. These effects are mediated by recruitment and activation of the Par polarity complex and RAP1B. Required for activation of PRKCZ and for the localization of phosphorylated PRKCZ, PARD3, TIAM1 and RAP1B to the cell junction			rs1130844	0.622204	0.5835217800373	0.5778758											1	SomaticAndTreatment,	352	678			n/a	n/a	CDH5 (inh=n/a pLI=0.15)
chr16	66432381	66432381	T	C	0.3684	19		123.0	4|0|3,4|4|4,5|6	CDH5	missense_variant	CDH5:NM_001795.4:missense_variant:MODERATE:exon10/12:c.1508T>C:p.Ile503Thr	Cadherin__4_,Cadherin-like__1_	Cell adhesion molecules (CAMs);Leukocyte transendothelial migration	Cadherins are calcium-dependent cell adhesion proteins. They preferentially interact with themselves in a homophilic manner in connecting cells; cadherins may thus contribute to the sorting of heterogeneous cell types. This cadherin may play a important role in endothelial cell biology through control of the cohesion and organization of the intercellular junctions. It associates with alpha-catenin forming a link to the cytoskeleton. Acts in concert with KRIT1 to establish and maintain correct endothelial cell polarity and vascular lumen. These effects are mediated by recruitment and activation of the Par polarity complex and RAP1B. Required for activation of PRKCZ and for the localization of phosphorylated PRKCZ, PARD3, TIAM1 and RAP1B to the cell junction			rs16956504	0.0435304	0.08564765216818	0.0841265					-0.467000	T	T,T,T	B	T	11.26	2	I16R041,SomaticAndTreatment,	17	245			n/a	n/a	CDH5 (inh=n/a pLI=0.15)
chr16	66432423	66432423	T	C	1.0000	19		619.0	8|4|7,0|0|0,5|10	CDH5	missense_variant	CDH5:NM_001795.4:missense_variant:MODERATE:exon10/12:c.1550T>C:p.Ile517Thr	Cadherin__4_,Cadherin-like__1_	Cell adhesion molecules (CAMs);Leukocyte transendothelial migration	Cadherins are calcium-dependent cell adhesion proteins. They preferentially interact with themselves in a homophilic manner in connecting cells; cadherins may thus contribute to the sorting of heterogeneous cell types. This cadherin may play a important role in endothelial cell biology through control of the cohesion and organization of the intercellular junctions. It associates with alpha-catenin forming a link to the cytoskeleton. Acts in concert with KRIT1 to establish and maintain correct endothelial cell polarity and vascular lumen. These effects are mediated by recruitment and activation of the Par polarity complex and RAP1B. Required for activation of PRKCZ and for the localization of phosphorylated PRKCZ, PARD3, TIAM1 and RAP1B to the cell junction			rs1049970	0.744409	0.72082549737702	0.6461763	COSM1128913			CM1212658 [CLASS=DP MUT=ALT PHEN="Haemorrhagic fever with renal syndrome reduced severity association with" GENE=CDH5]; 	1.933000	T	T,T,T	B	T	11.08	1	Leuk,	678	564			n/a	n/a	CDH5 (inh=n/a pLI=0.15)
chr16	66432424	66432424	C	T	1.0000	19		619.0	8|4|7,0|0|0,5|10	CDH5	synonymous_variant	CDH5:NM_001795.4:synonymous_variant:LOW:exon10/12:c.1551C>T:p.Ile517Ile		Cell adhesion molecules (CAMs);Leukocyte transendothelial migration	Cadherins are calcium-dependent cell adhesion proteins. They preferentially interact with themselves in a homophilic manner in connecting cells; cadherins may thus contribute to the sorting of heterogeneous cell types. This cadherin may play a important role in endothelial cell biology through control of the cohesion and organization of the intercellular junctions. It associates with alpha-catenin forming a link to the cytoskeleton. Acts in concert with KRIT1 to establish and maintain correct endothelial cell polarity and vascular lumen. These effects are mediated by recruitment and activation of the Par polarity complex and RAP1B. Required for activation of PRKCZ and for the localization of phosphorylated PRKCZ, PARD3, TIAM1 and RAP1B to the cell junction			rs3826229	0.415136	0.38965431895058	0.3569233	COSM1378765										3	I16R041,Leuk,SomaticAndTreatment,	174	645			n/a	n/a	CDH5 (inh=n/a pLI=0.15)
chr16	68771372	68771372	C	T	1.0000	34		1021.0	0|1|33,0|0|0,5|6	CDH1	splice_region_variant&intron_variant	CDH1:NM_004360.4:splice_region_variant&intron_variant:LOW:exon1/15:c.48+6C>T:,CDH1:NM_001317184.1:splice_region_variant&intron_variant:LOW:exon1/14:c.48+6C>T:,CDH1:NM_001317185.1:splice_region_variant&intron_variant:LOW:exon1/15:c.-1568+6C>T:,CDH1:NM_001317186.1:splice_region_variant&intron_variant:LOW:exon1/14:c.-1772+6C>T:						rs3743674	0.763379	0.8111438028687	0.5522816		192090 [CDH1 (confirmed) Endometrial carcinoma,somatic,608089|Ovarian carcinoma,somatic,167000|Breast cancer,lobular,114480|Gastric cancer,familial diffuse,with or without cleft lip and/or palate,137215|Prostate cancer,susceptibility to,176807];	RCV000132163.3 [benign]; RCV000173339.2 [benign]; RCV000274668.1 [benign]; 								0		2400	659	1	[1] Ilnaz Sepahi 29-03-2016 batch import	n/a	n/a	CDH1 (inh=AD pLI=0.34)
chr16	68857441	68857441	T	C	0.6471	34		497.0	2|20|0,0|12|0,4|7	CDH1	synonymous_variant	CDH1:NM_004360.4:synonymous_variant:LOW:exon13/16:c.2076T>C:p.Ala692Ala,CDH1:NM_001317184.1:synonymous_variant:LOW:exon12/15:c.1893T>C:p.Ala631Ala,CDH1:NM_001317185.1:synonymous_variant:LOW:exon13/16:c.528T>C:p.Ala176Ala,CDH1:NM_001317186.1:synonymous_variant:LOW:exon12/15:c.111T>C:p.Ala37Ala						rs1801552	0.71865	0.65480761308396	0.6414433	COSM3755010	192090 [CDH1 (confirmed) Endometrial carcinoma,somatic,608089|Ovarian carcinoma,somatic,167000|Breast cancer,lobular,114480|Gastric cancer,familial diffuse,with or without cleft lip and/or palate,137215|Prostate cancer,susceptibility to,176807];	RCV000132164.2 [benign]; RCV000246442.1 [benign]; RCV000293455.1 [benign]; 	CM1414917 [CLASS=DP MUT=ALT PHEN="Gastric cancer early-onset diffuse association with" GENE=CDH1]; 							4	SomaticAndTreatment,TEST_SomaticAndTreatment,	1264	1515	1	[1] Ilnaz Sepahi 29-03-2016 batch import	n/a	n/a	CDH1 (inh=AD pLI=0.34)
chr16	69419394	69419394	G	A	0.5000	12		111.0	2|0|4,1|1|4,6|6	TERF2	splice_region_variant&intron_variant	TERF2:NM_005652.4:splice_region_variant&intron_variant:LOW:exon1/9:c.380-5C>T:			Binds the telomeric double-stranded 5'-TTAGGG-3' repeat and plays a central role in telomere maintenance and protection against end-to-end fusion of chromosomes. In addition to its telomeric DNA-binding role, required to recruit a number of factors and enzymes required for telomere protection, including the shelterin complex, TERF2IP/RAP1 and DCLRE1B/Apollo. Component of the shelterin complex (telosome) that is involved in the regulation of telomere length and protection. Shelterin associates with arrays of double-stranded 5'-TTAGGG-3' repeats added by telomerase and protects chromosome ends; without its protective activity, telomeres are no longer hidden from the DNA damage surveillance and chromosome ends are inappropriately processed by DNA repair pathways. Together with DCLRE1B/Apollo, plays a key role in telomeric loop (T loop) formation by generating 3' single- stranded overhang at the leading end telomeres: T loops have been proposed to protect chromosome ends from degradation and repair. Required both to recruit DCLRE1B/Apollo to telomeres and activate the exonuclease activity of DCLRE1B/Apollo. Preferentially binds to positive supercoiled DNA. Together with DCLRE1B/Apollo, required to control the amount of DNA topoisomerase (TOP1, TOP2A and TOP2B) needed for telomere replication during fork passage and prevent aberrant telomere topology. Recruits TERF2IP/RAP1 to telomeres, thereby participating in to repressing homology- directed repair (HDR), which can affect telomere length			rs34415214	0.0397364	0.052755671007131	0.0520565											0		0	67			n/a	n/a	TERF2 (inh=n/a pLI=0.93)
chr16	89836323	89836323	C	T	0.2500	36		72.0	0|1|8,0|0|27,7|6	FANCA	missense_variant	FANCA:NM_000135.2:missense_variant:MODERATE:exon26/43:c.2426G>A:p.Gly809Asp,FANCA:NM_001286167.1:missense_variant:MODERATE:exon26/43:c.2426G>A:p.Gly809Asp		Tyrosine metabolism;Styrene degradation	DNA repair protein that may operate in a postreplication repair or a cell cycle checkpoint function. May be involved in interstrand DNA cross-link repair and in the maintenance of normal chromosome stability			rs7195066	0.666733	0.46899070715102	0.4484772	COSM435949	607139 [FANCA (confirmed) Fanconi anemia,complementation group A,227650];	RCV000120927.2 [benign]; RCV000292806.1 [benign]; 	CM137288 [CLASS=R MUT=ALT PHEN="Fanconi anaemia A" GENE=FANCA]; 	0.305000	T	T	B,B	D	3.27	5	GT,Leuk,SomaticAndTreatment,TEST_SomaticAndTreatment,	395	1359	2	[2] old entry - no details available	n/a	n/a	FANCA (inh=AR pLI=0.00)
chr16	89838078	89838078	A	G	0.5778	45		603.0	2|14|10,2|10|7,2|2	FANCA	splice_region_variant&intron_variant	FANCA:NM_000135.2:splice_region_variant&intron_variant:LOW:exon23/42:c.2151+8T>C:,FANCA:NM_001286167.1:splice_region_variant&intron_variant:LOW:exon23/42:c.2151+8T>C:		Tyrosine metabolism;Styrene degradation	DNA repair protein that may operate in a postreplication repair or a cell cycle checkpoint function. May be involved in interstrand DNA cross-link repair and in the maintenance of normal chromosome stability			rs1800340	0.559904	0.43148450244698	0.4235775		607139 [FANCA (confirmed) Fanconi anemia,complementation group A,227650];	RCV000244957.1 [benign]; RCV000398159.1 [benign]; 								4	GT,SomaticAndTreatment,TEST_SomaticAndTreatment,	330	1354	1	[1] Ilnaz Sepahi 29-03-2016 batch import	n/a	n/a	FANCA (inh=AR pLI=0.00)
chr16	89866043	89866043	T	C	0.6364	44		645.0	0|16|12,0|10|6,2|5	FANCA	missense_variant	FANCA:NM_000135.2:missense_variant:MODERATE:exon9/43:c.796A>G:p.Thr266Ala,FANCA:NM_001286167.1:missense_variant:MODERATE:exon9/43:c.796A>G:p.Thr266Ala,FANCA:NM_001018112.1:missense_variant:MODERATE:exon9/11:c.796A>G:p.Thr266Ala		Tyrosine metabolism;Styrene degradation	DNA repair protein that may operate in a postreplication repair or a cell cycle checkpoint function. May be involved in interstrand DNA cross-link repair and in the maintenance of normal chromosome stability			rs7190823	0.690495	0.51659908350641	0.4991640		607139 [FANCA (confirmed) Fanconi anemia,complementation group A,227650];	RCV000120967.2 [benign]; RCV000308742.1 [benign]; 	CM137879 [CLASS=DP MUT=ALT PHEN="Breast cancer association with" GENE=FANCA]; 	0.402000	T	T,T,T,T	B,B,B,B,B,B	T,T,T,T	0.00	4	GT,SomaticAndTreatment,TEST_SomaticAndTreatment,	530	1460	1	[1] Ilnaz Sepahi 29-03-2016 batch import	n/a	n/a	FANCA (inh=AR pLI=0.00)
chr17	8416901	8416901	C	T	1.0000	20		638.0	8|0|12,0|0|0,5|4	MYH10	synonymous_variant	MYH10:NM_001256012.1:synonymous_variant:LOW:exon23/43:c.2700G>A:p.Thr900Thr,MYH10:NM_001256095.1:synonymous_variant:LOW:exon22/42:c.2634G>A:p.Thr878Thr,MYH10:NM_005964.3:synonymous_variant:LOW:exon21/41:c.2607G>A:p.Thr869Thr		Tight junction;Regulation of actin cytoskeleton	Cellular myosin that appears to play a role in cytokinesis, cell shape, and specialized functions such as secretion and capping. Involved with LARP6 in the stabilization of type I collagen mRNAs for CO1A1 and CO1A2			rs11374	0.423323	0.40309240983904	0.3957905	COSM1130107										0		125	406			n/a	n/a	MYH10 (inh=n/a pLI=1.00)
chr17	8424270	8424270	G	A	1.0000	24		750.0	16|8|0,0|0|0,4|3	MYH10	synonymous_variant	MYH10:NM_001256012.1:synonymous_variant:LOW:exon19/43:c.2199C>T:p.Asn733Asn,MYH10:NM_001256095.1:synonymous_variant:LOW:exon18/42:c.2133C>T:p.Asn711Asn,MYH10:NM_005964.3:synonymous_variant:LOW:exon17/41:c.2106C>T:p.Asn702Asn		Tight junction;Regulation of actin cytoskeleton	Cellular myosin that appears to play a role in cytokinesis, cell shape, and specialized functions such as secretion and capping. Involved with LARP6 in the stabilization of type I collagen mRNAs for CO1A1 and CO1A2			rs8067456	0.979433	0.99231238258462	0.9290951											0		856	2			n/a	n/a	MYH10 (inh=n/a pLI=1.00)
chr17	10415840	10415840	A	G	1.0000	47		1492.0	34|3|10,0|0|0,6|4	MYH1,MYHAS	synonymous_variant,intron_variant	MYH1:NM_005963.3:synonymous_variant:LOW:exon12/40:c.1032T>C:p.Phe344Phe,MYHAS:NR_125367.1:intron_variant:MODIFIER:exon2/10:n.168-55014A>G:		Tight junction	Muscle contraction			rs2007027	0.88139	0.92882445011945	0.9064461											0		728	125			n/a	n/a	MYH1 (inh=n/a pLI=0.00), MYHAS (inh=n/a pLI=n/a)
chr17	15973844	15973844	A	T	0.9259	27		632.0	2|12|11,0|0|2,6|5	NCOR1	splice_region_variant&intron_variant	NCOR1:NM_006311.3:splice_region_variant&intron_variant:LOW:exon30/45:c.4153-5T>A:,NCOR1:NM_001190440.1:splice_region_variant&intron_variant:LOW:exon29/44:c.4201-5T>A:						rs12942295	0.351637	0.45773520732256	0.4498984	COSM3765997										0		258	376			n/a	n/a	NCOR1 (inh=n/a pLI=1.00)
chr17	37879588	37879588	A	G	0.4203	138		1357.0	2|52|4,0|79|1,7|8	ERBB2	missense_variant,non_coding_transcript_exon_variant	ERBB2:NM_004448.3:missense_variant:MODERATE:exon17/27:c.1963A>G:p.Ile655Val,ERBB2:NM_001005862.2:missense_variant:MODERATE:exon20/30:c.1873A>G:p.Ile625Val,ERBB2:NM_001289936.1:missense_variant:MODERATE:exon21/31:c.1918A>G:p.Ile640Val,ERBB2:NM_001289937.1:missense_variant:MODERATE:exon17/26:c.1963A>G:p.Ile655Val,ERBB2:NR_110535.1:non_coding_transcript_exon_variant:MODIFIER:exon17/27:n.2287A>G:	Cytochrome_c1__transmembrane_anchor__C-terminal__1_	ErbB signaling pathway;Calcium signaling pathway;Focal adhesion;Adherens junction;Pancreatic cancer;Endometrial cancer;Prostate cancer;Bladder cancer;Non-small cell lung cancer	Protein tyrosine kinase that is part of several cell surface receptor complexes, but that apparently needs a coreceptor for ligand binding. Essential component of a neuregulin-receptor complex, although neuregulins do not interact with it alone. GP30 is a potential ligand for this receptor. Regulates outgrowth and stabilization of peripheral microtubules (MTs). Upon ERBB2 activation, the MEMO1-RHOA-DIAPH1 signaling pathway elicits the phosphorylation and thus the inhibition of GSK3B at cell membrane. This prevents the phosphorylation of APC and CLASP2, allowing its association with the cell membrane. In turn, membrane-bound APC allows the localization of MACF1 to the cell membrane, which is required for microtubule capture and stabilization			rs1136201	0.121406	0.19635734300313	0.1941043	COSM4000121	164870 [ERBB2 (confirmed) Adenocarcinoma of lung,somatic,211980|Glioblastoma,somatic,137800|Gastric cancer,somatic,613659|Ovarian cancer,somatic,];	RCV000014887.2 [benign]; RCV000120744.1 [not provided]; 	CM004332 [CLASS=DP MUT=ALT PHEN="Breast cancer increased risk association with" GENE=ERBB2]; 	4.008000	T	T,T,T,T,T	B,B,B	T,T,T,T,T	13.70	2	I16R041,Leuk,	71	427			n/a	n/a	ERBB2 (inh=AR+AD pLI=1.00)
chr17	39742807	39742807	C	T	0.6667	42		611.0	28|0|0,14|0|0,5|2	KRT14	missense_variant	KRT14:NM_000526.4:missense_variant:MODERATE:exon1/8:c.280G>A:p.Ala94Thr		Cell Communication	The nonhelical tail domain is involved in promoting KRT5-KRT14 filaments to self-organize into large bundles and enhances the mechanical properties involved in resilience of keratin intermediate filaments in vitro			rs3826550	0.290735	0.35245339224152	0.3401520	COSM3755538	173325 [JUP (confirmed) Naxos disease,601214|Arrhythmogenic right ventricular dysplasia 12,611528]:148066 [KRT14 (confirmed) Epidermolysis bullosa simplex,Dowling-Meara type,131760|Epidermolysis bullosa simplex,Koebner type,131900|Epidermolysis bullosa simplex,recessive 1,601001|Naegeli-Franceschetti-Jadassohn syndrome,161000|Dermatopathia pigmentosa reticularis,125595|Epidermolysis bullosa simplex,Weber-Cockayne type,131800];	RCV000056702.1 [not provided]; RCV000248897.1 [benign]; 	CM147717 [CLASS=R MUT=ALT PHEN="Epidermolysis bullosa Koebner" GENE=KRT14]; 	0.065000	T	T	B	D	11.89	0		268	595			n/a	n/a	KRT14 (inh=AR+AD pLI=0.07)
chr17	39742856	39742856	G	A	0.3636	22		111.0	0|0|8,0|0|14,4|4	KRT14	synonymous_variant	KRT14:NM_000526.4:synonymous_variant:LOW:exon1/8:c.231C>T:p.Ser77Ser		Cell Communication	The nonhelical tail domain is involved in promoting KRT5-KRT14 filaments to self-organize into large bundles and enhances the mechanical properties involved in resilience of keratin intermediate filaments in vitro			rs6503639	0.152356	0.25575520929716	0.2308236	COSM3766094	173325 [JUP (confirmed) Naxos disease,601214|Arrhythmogenic right ventricular dysplasia 12,611528]:148066 [KRT14 (confirmed) Epidermolysis bullosa simplex,Dowling-Meara type,131760|Epidermolysis bullosa simplex,Koebner type,131900|Epidermolysis bullosa simplex,recessive 1,601001|Naegeli-Franceschetti-Jadassohn syndrome,161000|Dermatopathia pigmentosa reticularis,125595|Epidermolysis bullosa simplex,Weber-Cockayne type,131800];	RCV000056700.1 [not provided]; RCV000244313.1 [benign]; 								0		119	536			n/a	n/a	KRT14 (inh=AR+AD pLI=0.07)
chr17	39742894	39742894	G	A	0.6364	22		438.0	0|0|14,0|0|8,4|4	KRT14	synonymous_variant	KRT14:NM_000526.4:synonymous_variant:LOW:exon1/8:c.193C>T:p.Leu65Leu		Cell Communication	The nonhelical tail domain is involved in promoting KRT5-KRT14 filaments to self-organize into large bundles and enhances the mechanical properties involved in resilience of keratin intermediate filaments in vitro			rs3826551	0.680711	0.59771824244255	0.5225460	COSM329474	173325 [JUP (confirmed) Naxos disease,601214|Arrhythmogenic right ventricular dysplasia 12,611528]:148066 [KRT14 (confirmed) Epidermolysis bullosa simplex,Dowling-Meara type,131760|Epidermolysis bullosa simplex,Koebner type,131900|Epidermolysis bullosa simplex,recessive 1,601001|Naegeli-Franceschetti-Jadassohn syndrome,161000|Dermatopathia pigmentosa reticularis,125595|Epidermolysis bullosa simplex,Weber-Cockayne type,131800];	RCV000056698.1 [not provided]; RCV000249438.1 [benign]; 								0		411	577			n/a	n/a	KRT14 (inh=AR+AD pLI=0.07)
chr17	39742898	39742898	G	A	0.6364	22		438.0	0|0|14,0|0|8,4|4	KRT14	synonymous_variant	KRT14:NM_000526.4:synonymous_variant:LOW:exon1/8:c.189C>T:p.Cys63Cys		Cell Communication	The nonhelical tail domain is involved in promoting KRT5-KRT14 filaments to self-organize into large bundles and enhances the mechanical properties involved in resilience of keratin intermediate filaments in vitro			rs11551758	0.680711	0.59113112683775	0.5056590	COSM329475	173325 [JUP (confirmed) Naxos disease,601214|Arrhythmogenic right ventricular dysplasia 12,611528]:148066 [KRT14 (confirmed) Epidermolysis bullosa simplex,Dowling-Meara type,131760|Epidermolysis bullosa simplex,Koebner type,131900|Epidermolysis bullosa simplex,recessive 1,601001|Naegeli-Franceschetti-Jadassohn syndrome,161000|Dermatopathia pigmentosa reticularis,125595|Epidermolysis bullosa simplex,Weber-Cockayne type,131800];	RCV000056697.1 [not provided]; RCV000244483.1 [benign]; 								0		411	569			n/a	n/a	KRT14 (inh=AR+AD pLI=0.07)
chr17	39742899	39742899	C	T	0.6364	22		438.0	0|0|22,0|0|0,4|4	KRT14	missense_variant	KRT14:NM_000526.4:missense_variant:MODERATE:exon1/8:c.188G>A:p.Cys63Tyr		Cell Communication	The nonhelical tail domain is involved in promoting KRT5-KRT14 filaments to self-organize into large bundles and enhances the mechanical properties involved in resilience of keratin intermediate filaments in vitro			rs6503640	0.992612	0.99708503175656	0.8606339		173325 [JUP (confirmed) Naxos disease,601214|Arrhythmogenic right ventricular dysplasia 12,611528]:148066 [KRT14 (confirmed) Epidermolysis bullosa simplex,Dowling-Meara type,131760|Epidermolysis bullosa simplex,Koebner type,131900|Epidermolysis bullosa simplex,recessive 1,601001|Naegeli-Franceschetti-Jadassohn syndrome,161000|Dermatopathia pigmentosa reticularis,125595|Epidermolysis bullosa simplex,Weber-Cockayne type,131800];	RCV000056696.1 [not provided]; 		-1.774000	T	T	B	D	6.15	0		1280	8			n/a	n/a	KRT14 (inh=AR+AD pLI=0.07)
chr17	59763347	59763347	A	G	0.4000	10		62.0	0|4|0,2|4|0,2|4	BRIP1	missense_variant	BRIP1:NM_032043.2:missense_variant:MODERATE:exon19/20:c.2755T>C:p.Ser919Pro			DNA-dependent ATPase and 5' to 3' DNA helicase required for the maintenance of chromosomal stability. Acts late in the Fanconi anemia pathway, after FANCD2 ubiquitination. Involved in the repair of DNA double-strand breaks by homologous recombination in a manner that depends on its association with BRCA1			rs4986764	0.627796	0.59722382403822	0.5828210		605882 [BRIP1 (confirmed) Breast cancer,early-onset,114480|Fanconi anemia,complementation group J,609054];	RCV000120400.2 [benign]; RCV000132148.2 [benign]; RCV000286073.1 [likely benign]; RCV000377937.1 [likely benign]; RCV000410195.1 [benign]; RCV000412161.1 [benign]; 	CM046104 [CLASS=DP MUT=REF PHEN="Breast cancer association with" GENE=BRIP1]; 	0.136000	T	T	B	T	0.20	4	TEST_SomaticAndTreatment,	1143	1543	1	[1] Ilnaz Sepahi 29-03-2016 batch import	n/a	n/a	BRIP1 (inh=AR+AD pLI=0.00)
chr17	63533768	63533768	G	A	1.0000	10		264.0	0|0|10,0|0|0,4|5	AXIN2	synonymous_variant	AXIN2:NM_004655.3:synonymous_variant:LOW:exon6/11:c.1386C>T:p.Pro462Pro		Wnt signaling pathway;Colorectal cancer;Endometrial cancer;Basal cell carcinoma	Inhibitor of the Wnt signaling pathway. Down-regulates beta-catenin. Probably facilitate the phosphorylation of beta- catenin and APC by GSK3B (By similarity)			rs1133683	0.446086	0.62363629985618	0.5217551	COSM3749411	604025 [AXIN2 (confirmed) Oligodontia-colorectal cancer syndrome,608615|Colorectal cancer,somatic,114500];	RCV000253379.1 [benign]; RCV000302412.1 [benign]; 								0		487	594			n/a	n/a	AXIN2 (inh=AD pLI=0.12)
chr17	63533789	63533789	T	C	1.0000	22		643.0	0|0|22,0|0|0,4|5	AXIN2	synonymous_variant	AXIN2:NM_004655.3:synonymous_variant:LOW:exon6/11:c.1365A>G:p.Pro455Pro		Wnt signaling pathway;Colorectal cancer;Endometrial cancer;Basal cell carcinoma	Inhibitor of the Wnt signaling pathway. Down-regulates beta-catenin. Probably facilitate the phosphorylation of beta- catenin and APC by GSK3B (By similarity)			rs9915936	0.909744	0.9143986157875	0.7999280	COSM3755754	604025 [AXIN2 (confirmed) Oligodontia-colorectal cancer syndrome,608615|Colorectal cancer,somatic,114500];	RCV000250428.1 [benign]; RCV000305836.1 [benign]; 								0		1068	217			n/a	n/a	AXIN2 (inh=AD pLI=0.12)
chr17	63554591	63554591	G	A	1.0000	26		769.0	18|6|2,0|0|0,3|3	AXIN2	missense_variant	AXIN2:NM_004655.3:missense_variant:MODERATE:exon2/11:c.148C>T:p.Pro50Ser		Wnt signaling pathway;Colorectal cancer;Endometrial cancer;Basal cell carcinoma	Inhibitor of the Wnt signaling pathway. Down-regulates beta-catenin. Probably facilitate the phosphorylation of beta- catenin and APC by GSK3B (By similarity)			rs2240308	0.33766	0.47373191446507	0.4638595	COSM4000258	604025 [AXIN2 (confirmed) Oligodontia-colorectal cancer syndrome,608615|Colorectal cancer,somatic,114500];	RCV000245378.1 [benign]; RCV000291911.1 [benign]; 	CM066739 [CLASS=DP MUT=REF PHEN="Lung cancer association with" GENE=AXIN2]; 	0.923000	T	T,T,T	B	T,T,T	0.02	0		278	615			n/a	n/a	AXIN2 (inh=AD pLI=0.12)
chr17	80788220	80788220	G	C	0.3803	71		640.0	4|17|6,17|7|20,5|4	ZNF750,TBCD	missense_variant,intron_variant	ZNF750:NM_024702.2:missense_variant:MODERATE:exon3/3:c.1970C>G:p.Ala657Gly,TBCD:NM_005993.4:intron_variant:MODIFIER:exon13/38:c.1318+15410G>C:			Transcription factor involved in epidermis differentiation. Required for terminal epidermal differentiation: acts downstream of p63/TP63 and activates expression of late epidermal differentiation genes. Specifically binds to the promoter of KLF4 and promotes its expression			rs61729341	0.0000	0.00040435048109455	0.0003280		604649 [TBCD (confirmed) Encephalopathy,progressive,early-onset,with brain atrophy and thin corpus callosum,617193]:610226 [ZNF750 (confirmed) Seborrhea-like dermatitis with psoriasiform elements,610227];			-0.056000	T	T,T	B	T	0.82	0		0	4			n/a	n/a	ZNF750 (inh=AD pLI=0.87), TBCD (inh=n/a pLI=0.00)
chr17	80789468	80789468	G	A	0.5263	19		167.0	0|4|6,0|0|9,8|8	ZNF750,TBCD	missense_variant,intron_variant	ZNF750:NM_024702.2:missense_variant:MODERATE:exon2/3:c.863C>T:p.Pro288Leu,TBCD:NM_005993.4:intron_variant:MODIFIER:exon13/38:c.1318+16658G>A:			Transcription factor involved in epidermis differentiation. Required for terminal epidermal differentiation: acts downstream of p63/TP63 and activates expression of late epidermal differentiation genes. Specifically binds to the promoter of KLF4 and promotes its expression			rs35653278	0.0205671	0.070308381655245	0.0688793		604649 [TBCD (confirmed) Encephalopathy,progressive,early-onset,with brain atrophy and thin corpus callosum,617193]:610226 [ZNF750 (confirmed) Seborrhea-like dermatitis with psoriasiform elements,610227];			5.112000	T	D	P	T	23.60	0		10	171			n/a	n/a	ZNF750 (inh=AD pLI=0.87), TBCD (inh=n/a pLI=0.00)
chr17	80789628	80789628	T	C	1.0000	29		929.0	2|11|16,0|0|0,5|5	ZNF750,TBCD	missense_variant,intron_variant	ZNF750:NM_024702.2:missense_variant:MODERATE:exon2/3:c.703A>G:p.Met235Val,TBCD:NM_005993.4:intron_variant:MODIFIER:exon13/38:c.1318+16818T>C:			Transcription factor involved in epidermis differentiation. Required for terminal epidermal differentiation: acts downstream of p63/TP63 and activates expression of late epidermal differentiation genes. Specifically binds to the promoter of KLF4 and promotes its expression			rs8074277	0.124601	0.16929951850142	0.1620087	COSM1178452	604649 [TBCD (confirmed) Encephalopathy,progressive,early-onset,with brain atrophy and thin corpus callosum,617193]:610226 [ZNF750 (confirmed) Seborrhea-like dermatitis with psoriasiform elements,610227];			-1.308000	T	T	B	T	0.00	0		45	311			n/a	n/a	ZNF750 (inh=AD pLI=0.87), TBCD (inh=n/a pLI=0.00)
chr18	5410574	5410574	A	G	1.0000	12		326.0	0|6|6,0|0|0,2|3	EPB41L3	synonymous_variant	EPB41L3:NM_012307.3:synonymous_variant:LOW:exon14/23:c.2112T>C:p.Thr704Thr,EPB41L3:NM_001281533.1:synonymous_variant:LOW:exon13/21:c.1605T>C:p.Thr535Thr,EPB41L3:NM_001281534.1:synonymous_variant:LOW:exon13/20:c.1605T>C:p.Thr535Thr,EPB41L3:NM_001281535.1:synonymous_variant:LOW:exon15/22:c.1278T>C:p.Thr426Thr		Tight junction	Tumor suppressor that inhibits cell proliferation and promotes apoptosis. Modulates the activity of protein arginine N- methyltransferases, including PRMT3 and PRMT5			rs3817466	0.711661	0.85309193394205	0.8408916											0		679	160			n/a	n/a	EPB41L3 (inh=n/a pLI=0.03)
chr18	6942205	6942205	G	T	0.2000	20		6.0	4|0|0,6|6|4,4|3	LAMA1	missense_variant	LAMA1:NM_005559.3:missense_variant:MODERATE:exon63/63:c.9101C>A:p.Thr3034Asn	Concanavalin_A-like_lectin/glucanase__1_,Concanavalin_A-like_lectin/glucanase__subgroup__1_,Laminin_G_domain__2_,Laminin_G__subdomain_1__1_	Cell Communication;Focal adhesion;ECM-receptor interaction;Prion disease;Small cell lung cancer	Binding to cells via a high affinity receptor, laminin is thought to mediate the attachment, migration and organization of cells into tissues during embryonic development by interacting with other extracellular matrix components				0.0000	0.0000	0.0000		150320 [LAMA1 (provisional) Poretti-Boltshauser syndrome,615960];			1.590000	T	T	P,P	T	18.76	1	cfDNA_HNSCC,	0	0			n/a	n/a	LAMA1 (inh=AR pLI=0.00)
chr18	6980523	6980523	T	C	1.0000	9		270.0	6|3|0,0|0|0,6|5	LAMA1	missense_variant	LAMA1:NM_005559.3:missense_variant:MODERATE:exon42/63:c.6004A>G:p.Lys2002Glu		Cell Communication;Focal adhesion;ECM-receptor interaction;Prion disease;Small cell lung cancer	Binding to cells via a high affinity receptor, laminin is thought to mediate the attachment, migration and organization of cells into tissues during embryonic development by interacting with other extracellular matrix components			rs607230	0.69369	0.72778043589447	0.7198143		150320 [LAMA1 (provisional) Poretti-Boltshauser syndrome,615960];			1.467000	T	T	B	T	17.60	0		745	563			n/a	n/a	LAMA1 (inh=AR pLI=0.00)
chr18	6985270	6985270	C	T	1.0000	58		1758.0	8|10|40,0|0|0,6|4	LAMA1	missense_variant	LAMA1:NM_005559.3:missense_variant:MODERATE:exon39/63:c.5626G>A:p.Ala1876Thr		Cell Communication;Focal adhesion;ECM-receptor interaction;Prion disease;Small cell lung cancer	Binding to cells via a high affinity receptor, laminin is thought to mediate the attachment, migration and organization of cells into tissues during embryonic development by interacting with other extracellular matrix components			rs11664063	0.135583	0.19413509060956	0.1934998	COSM148380	150320 [LAMA1 (provisional) Poretti-Boltshauser syndrome,615960];			0.065000	T	T	B	T	11.36	1	Leuk,	84	525			n/a	n/a	LAMA1 (inh=AR pLI=0.00)
chr18	6986259	6986259	G	A	1.0000	26		719.0	4|22|0,0|0|0,3|6	LAMA1	synonymous_variant	LAMA1:NM_005559.3:synonymous_variant:LOW:exon37/63:c.5256C>T:p.His1752His		Cell Communication;Focal adhesion;ECM-receptor interaction;Prion disease;Small cell lung cancer	Binding to cells via a high affinity receptor, laminin is thought to mediate the attachment, migration and organization of cells into tissues during embryonic development by interacting with other extracellular matrix components			rs62081531	0.13778	0.19749262779855	0.1989659	COSM148381	150320 [LAMA1 (provisional) Poretti-Boltshauser syndrome,615960];									1	Leuk,	89	539			n/a	n/a	LAMA1 (inh=AR pLI=0.00)
chr18	6997818	6997818	A	C	1.0000	26		794.0	10|16|0,0|0|0,3|2	LAMA1	missense_variant	LAMA1:NM_005559.3:missense_variant:MODERATE:exon33/63:c.4729T>G:p.Ser1577Ala	Laminin_I__1_	Cell Communication;Focal adhesion;ECM-receptor interaction;Prion disease;Small cell lung cancer	Binding to cells via a high affinity receptor, laminin is thought to mediate the attachment, migration and organization of cells into tissues during embryonic development by interacting with other extracellular matrix components			rs12961939	0.149561	0.20250255362615	0.2034481	COSM3756202	150320 [LAMA1 (provisional) Poretti-Boltshauser syndrome,615960];			4.299000	T	D	B	T	9.18	0		88	562			n/a	n/a	LAMA1 (inh=AR pLI=0.00)
chr18	6999628	6999628	T	C	1.0000	16		459.0	9|7|0,0|0|0,6|4	LAMA1	synonymous_variant	LAMA1:NM_005559.3:synonymous_variant:LOW:exon32/63:c.4479A>G:p.Ser1493Ser		Cell Communication;Focal adhesion;ECM-receptor interaction;Prion disease;Small cell lung cancer	Binding to cells via a high affinity receptor, laminin is thought to mediate the attachment, migration and organization of cells into tissues during embryonic development by interacting with other extracellular matrix components			rs625106	0.466254	0.45073827012442	0.4079959	COSM3756203	150320 [LAMA1 (provisional) Poretti-Boltshauser syndrome,615960];									1	Leuk,	276	683			n/a	n/a	LAMA1 (inh=AR pLI=0.00)
chr18	7008591	7008591	T	C	0.3333	12		59.0	2|2|0,8|0|0,4|4	LAMA1	missense_variant	LAMA1:NM_005559.3:missense_variant:MODERATE:exon28/63:c.4018A>G:p.Met1340Val	Laminin_B_type_IV__2_,Laminin_B__subgroup__1_	Cell Communication;Focal adhesion;ECM-receptor interaction;Prion disease;Small cell lung cancer	Binding to cells via a high affinity receptor, laminin is thought to mediate the attachment, migration and organization of cells into tissues during embryonic development by interacting with other extracellular matrix components			rs662471	0.187101	0.23843656796348	0.2342705		150320 [LAMA1 (provisional) Poretti-Boltshauser syndrome,615960];			-0.035000	T	D	B	T	9.36	1	Leuk,	116	557			n/a	n/a	LAMA1 (inh=AR pLI=0.00)
chr18	7012123	7012123	A	G	0.2632	57		241.0	11|4|0,24|16|2,7|6	LAMA1	synonymous_variant	LAMA1:NM_005559.3:synonymous_variant:LOW:exon24/63:c.3378T>C:p.Gly1126Gly		Cell Communication;Focal adhesion;ECM-receptor interaction;Prion disease;Small cell lung cancer	Binding to cells via a high affinity receptor, laminin is thought to mediate the attachment, migration and organization of cells into tissues during embryonic development by interacting with other extracellular matrix components			rs9946794	0.420128	0.3773915977729	0.3682413	COSM438362	150320 [LAMA1 (provisional) Poretti-Boltshauser syndrome,615960];									0		202	660			n/a	n/a	LAMA1 (inh=AR pLI=0.00)
chr18	7015714	7015714	T	C	0.9744	39		1204.0	33|4|1,1|0|0,4|2	LAMA1	splice_region_variant&intron_variant	LAMA1:NM_005559.3:splice_region_variant&intron_variant:LOW:exon22/62:c.3126+7A>G:		Cell Communication;Focal adhesion;ECM-receptor interaction;Prion disease;Small cell lung cancer	Binding to cells via a high affinity receptor, laminin is thought to mediate the attachment, migration and organization of cells into tissues during embryonic development by interacting with other extracellular matrix components			rs603258	0.241414	0.23711544168563	0.2299298		150320 [LAMA1 (provisional) Poretti-Boltshauser syndrome,615960];									0		101	518			n/a	n/a	LAMA1 (inh=AR pLI=0.00)
chr18	7017322	7017322	A	G	1.0000	17		525.0	12|5|0,0|0|0,6|4	LAMA1	synonymous_variant	LAMA1:NM_005559.3:synonymous_variant:LOW:exon20/63:c.2763T>C:p.Cys921Cys		Cell Communication;Focal adhesion;ECM-receptor interaction;Prion disease;Small cell lung cancer	Binding to cells via a high affinity receptor, laminin is thought to mediate the attachment, migration and organization of cells into tissues during embryonic development by interacting with other extracellular matrix components			rs539713	0.547524	0.51942616565282	0.5089837	COSM4131076	150320 [LAMA1 (provisional) Poretti-Boltshauser syndrome,615960];									0		446	688			n/a	n/a	LAMA1 (inh=AR pLI=0.00)
chr18	7037641	7037641	G	A	0.3636	22		133.0	4|4|0,4|10|0,3|2	LAMA1	missense_variant	LAMA1:NM_005559.3:missense_variant:MODERATE:exon12/63:c.1673C>T:p.Ala558Val	Laminin_B_type_IV__1_	Cell Communication;Focal adhesion;ECM-receptor interaction;Prion disease;Small cell lung cancer	Binding to cells via a high affinity receptor, laminin is thought to mediate the attachment, migration and organization of cells into tissues during embryonic development by interacting with other extracellular matrix components			rs143997842	0.00179712	0.0036738661262953	0.0040063		150320 [LAMA1 (provisional) Poretti-Boltshauser syndrome,615960];			-1.078000	T	T	B	T	5.58	0		0	4			n/a	n/a	LAMA1 (inh=AR pLI=0.00)
chr18	14848820	14848820	C	T	0.5714	28		334.0	2|2|12,10|2|2,4|6	ANKRD30B	missense_variant	ANKRD30B:NM_001145029.1:missense_variant:MODERATE:exon34/36:c.2930C>T:p.Thr977Met						rs4090319	0.400759	0.63184612518629	0.4485672	COSM1136029				2.178000	T	T,T,T	B,B	T	0.02	0		170	449			n/a	n/a	ANKRD30B (inh=n/a pLI=0.00)
chr18	14848821	14848821	G	A	0.4286	28		146.0	10|0|2,2|4|12,4|6	ANKRD30B	synonymous_variant	ANKRD30B:NM_001145029.1:synonymous_variant:LOW:exon34/36:c.2931G>A:p.Thr977Thr						rs28555630	0.469649	0.32048372454935	0.2845715	COSM3756090										0		191	446			n/a	n/a	ANKRD30B (inh=n/a pLI=0.00)
chr18	21413869	21413869	T	C	0.7143	42		711.0	10|6|14,0|4|8,3|3	LAMA3	synonymous_variant	LAMA3:NM_198129.2:synonymous_variant:LOW:exon24/75:c.2901T>C:p.Ala967Ala,LAMA3:NM_001127717.2:synonymous_variant:LOW:exon24/74:c.2901T>C:p.Ala967Ala						rs9962023	0.624401	0.6631309618442	0.6568513	COSM4130939	600805 [LAMA3 (provisional) Epidermolysis bullosa,junctional,Herlitz type,226700|Epidermolysis bullosa,generalized atrophic benign,226650|Laryngoonychocutaneous syndrome,245660];									0		692	605			n/a	n/a	LAMA3 (inh=AR pLI=0.00)
chr18	21441717	21441717	C	T	0.7333	15		213.0	3|2|6,0|0|4,5|6	LAMA3	synonymous_variant	LAMA3:NM_198129.2:synonymous_variant:LOW:exon35/75:c.4530C>T:p.Pro1510Pro,LAMA3:NM_001127717.2:synonymous_variant:LOW:exon35/74:c.4530C>T:p.Pro1510Pro						rs12965685	0.340655	0.49954209348077	0.4879939		600805 [LAMA3 (provisional) Epidermolysis bullosa,junctional,Herlitz type,226700|Epidermolysis bullosa,generalized atrophic benign,226650|Laryngoonychocutaneous syndrome,245660];									0		476	672			n/a	n/a	LAMA3 (inh=AR pLI=0.00)
chr18	21481233	21481233	C	G	0.4494	89		723.0	6|34|0,12|35|0,4|4	LAMA3	synonymous_variant	LAMA3:NM_198129.2:synonymous_variant:LOW:exon48/75:c.6147C>G:p.Ala2049Ala,LAMA3:NM_001127717.2:synonymous_variant:LOW:exon47/74:c.5979C>G:p.Ala1993Ala,LAMA3:NM_000227.4:synonymous_variant:LOW:exon11/38:c.1320C>G:p.Ala440Ala,LAMA3:NM_001127718.2:synonymous_variant:LOW:exon10/37:c.1152C>G:p.Ala384Ala						rs1154226	0.168331	0.23427449945575	0.2339361	COSM1179775, COSM1179776	600805 [LAMA3 (provisional) Epidermolysis bullosa,junctional,Herlitz type,226700|Epidermolysis bullosa,generalized atrophic benign,226650|Laryngoonychocutaneous syndrome,245660];	RCV000241986.1 [benign]; RCV000350792.1 [benign]; RCV000386499.1 [benign]; 								0		86	548			n/a	n/a	LAMA3 (inh=AR pLI=0.00)
chr18	21511089	21511089	A	G	1.0000	36		1091.0	6|4|26,0|0|0,3|3	LAMA3	missense_variant	LAMA3:NM_198129.2:missense_variant:MODERATE:exon65/75:c.8500A>G:p.Ser2834Gly,LAMA3:NM_001127717.2:missense_variant:MODERATE:exon64/74:c.8332A>G:p.Ser2778Gly,LAMA3:NM_000227.4:missense_variant:MODERATE:exon28/38:c.3673A>G:p.Ser1225Gly,LAMA3:NM_001127718.2:missense_variant:MODERATE:exon27/37:c.3505A>G:p.Ser1169Gly	Concanavalin_A-like_lectin/glucanase__1_,Concanavalin_A-like_lectin/glucanase__subgroup__1_,Laminin_G_domain__2_,Laminin_G__subdomain_2__1_					rs1154233	1	0.99998352689235	0.9419051		600805 [LAMA3 (provisional) Epidermolysis bullosa,junctional,Herlitz type,226700|Epidermolysis bullosa,generalized atrophic benign,226650|Laryngoonychocutaneous syndrome,245660];	RCV000242248.1 [benign]; RCV000270352.1 [benign]; RCV000383453.1 [benign]; 		-1.256000	T	T,T,T	B,B,B,B	T,T,T	0.00	0		1429	0			n/a	n/a	LAMA3 (inh=AR pLI=0.00)
chr18	21511172	21511172	G	C	1.0000	19		602.0	1|16|2,0|0|0,4|4	LAMA3	splice_region_variant&intron_variant	LAMA3:NM_198129.2:splice_region_variant&intron_variant:LOW:exon65/74:c.8576+7G>C:,LAMA3:NM_001127717.2:splice_region_variant&intron_variant:LOW:exon64/73:c.8408+7G>C:,LAMA3:NM_000227.4:splice_region_variant&intron_variant:LOW:exon28/37:c.3749+7G>C:,LAMA3:NM_001127718.2:splice_region_variant&intron_variant:LOW:exon27/36:c.3581+7G>C:						rs1258107	0.948882	0.97316088639921	0.9304519		600805 [LAMA3 (provisional) Epidermolysis bullosa,junctional,Herlitz type,226700|Epidermolysis bullosa,generalized atrophic benign,226650|Laryngoonychocutaneous syndrome,245660];	RCV000247245.1 [benign]; RCV000325474.1 [benign]; RCV000389378.1 [benign]; RCV000296169.1 [uncertain significance]; RCV000348726.1 [uncertain significance]; 								0		1367	59			n/a	n/a	LAMA3 (inh=AR pLI=0.00)
chr18	21513768	21513768	C	T	0.4737	19		176.0	3|5|1,6|2|2,4|3	LAMA3	synonymous_variant	LAMA3:NM_198129.2:synonymous_variant:LOW:exon67/75:c.8731C>T:p.Leu2911Leu,LAMA3:NM_001127717.2:synonymous_variant:LOW:exon66/74:c.8563C>T:p.Leu2855Leu,LAMA3:NM_000227.4:synonymous_variant:LOW:exon30/38:c.3904C>T:p.Leu1302Leu,LAMA3:NM_001127718.2:synonymous_variant:LOW:exon29/37:c.3736C>T:p.Leu1246Leu						rs1131521	0.148363	0.18603058850704	0.1849792	COSM3756099, COSM3756100	600805 [LAMA3 (provisional) Epidermolysis bullosa,junctional,Herlitz type,226700|Epidermolysis bullosa,generalized atrophic benign,226650|Laryngoonychocutaneous syndrome,245660];	RCV000252202.1 [benign]; RCV000309977.1 [benign]; RCV000362299.1 [benign]; 								0		58	453			n/a	n/a	LAMA3 (inh=AR pLI=0.00)
chr18	21529722	21529722	G	A	0.4000	10		47.0	2|2|0,3|3|0,4|3	LAMA3	splice_region_variant&intron_variant	LAMA3:NM_198129.2:splice_region_variant&intron_variant:LOW:exon70/74:c.9352-7G>A:,LAMA3:NM_001127717.2:splice_region_variant&intron_variant:LOW:exon69/73:c.9184-7G>A:,LAMA3:NM_000227.4:splice_region_variant&intron_variant:LOW:exon33/37:c.4525-7G>A:,LAMA3:NM_001127718.2:splice_region_variant&intron_variant:LOW:exon32/36:c.4357-7G>A:						rs2241643	0.359026	0.53772713781618	0.5302114		600805 [LAMA3 (provisional) Epidermolysis bullosa,junctional,Herlitz type,226700|Epidermolysis bullosa,generalized atrophic benign,226650|Laryngoonychocutaneous syndrome,245660];	RCV000247590.1 [benign]; RCV000290820.1 [benign]; RCV000348031.1 [benign]; 								0		561	636			n/a	n/a	LAMA3 (inh=AR pLI=0.00)
chr18	31324051	31324051	C	T	0.3333	48		329.0	16|0|0,17|2|13,5|5	ASXL3	synonymous_variant	ASXL3:NM_030632.2:synonymous_variant:LOW:exon12/12:c.4239C>T:p.Val1413Val			Putative Polycomb group (PcG) protein. PcG proteins act by forming multiprotein complexes, which are required to maintain the transcriptionally repressive state of homeotic genes throughout development. PcG proteins are not required to initiate repression, but to maintain it during later stages of development. They probably act via methylation of histones, rendering chromatin heritably changed in its expressibility (By similarity)			rs149577667	0.00399361	0.0069411082580966	0.0071124		615115 [ASXL3 (provisional) Bainbridge-Ropers syndrome,615485];									0		0	19			n/a	n/a	ASXL3 (inh=AD pLI=1.00)
chr18	31324934	31324934	A	G	0.5385	26		290.0	8|6|0,4|8|0,6|5	ASXL3	missense_variant	ASXL3:NM_030632.2:missense_variant:MODERATE:exon12/12:c.5122A>G:p.Met1708Val			Putative Polycomb group (PcG) protein. PcG proteins act by forming multiprotein complexes, which are required to maintain the transcriptionally repressive state of homeotic genes throughout development. PcG proteins are not required to initiate repression, but to maintain it during later stages of development. They probably act via methylation of histones, rendering chromatin heritably changed in its expressibility (By similarity)			rs7232237	0.679113	0.58628520280462	0.5772713		615115 [ASXL3 (provisional) Bainbridge-Ropers syndrome,615485];			-1.434000	T	T	B	T	0.00	0		244	494			n/a	n/a	ASXL3 (inh=AD pLI=1.00)
chr18	42456653	42456653	G	A	1.0000	21		620.0	4|16|1,0|0|0,4|5	SETBP1	missense_variant,intron_variant	SETBP1:NM_001130110.1:missense_variant:MODERATE:exon4/4:c.664G>A:p.Ala222Thr,SETBP1:NM_015559.2:intron_variant:MODIFIER:exon3/5:c.540+7405G>A:						rs663651	0.493011	0.50726812341742	0.1671147		611060 [SETBP1 (confirmed) Schinzel-Giedion midface retraction syndrome,269150|Mental retardation,autosomal dominant 29,616078];	RCV000147471.1 [likely benign]; 		-0.969000	T	D	B		2.67	0		425	675			n/a	n/a	SETBP1 (inh=AD pLI=1.00)
chr18	42456670	42456670	-	TCTT	1.0000	21		566.0	0|0|0,4|16|1,4|5	SETBP1	frameshift_variant,intron_variant	SETBP1:NM_001130110.1:frameshift_variant:HIGH:exon4/4:c.681_682insTCTT:p.Thr228fs,SETBP1:NM_015559.2:intron_variant:MODIFIER:exon3/5:c.540+7422_540+7423insTCTT:						rs3085861	0.49381	0.51457669659234	0.0840428	COSM1480329	611060 [SETBP1 (confirmed) Schinzel-Giedion midface retraction syndrome,269150|Mental retardation,autosomal dominant 29,616078];	RCV000326176.1 [benign]; 								0		424	673	1	[1] auto-classification 16.06.2016  [2] old entry - no details available	n/a	n/a	SETBP1 (inh=AD pLI=1.00)
chr18	42529996	42529996	G	C	0.3750	40		288.0	10|5|0,18|7|0,6|5	SETBP1	missense_variant	SETBP1:NM_015559.2:missense_variant:MODERATE:exon4/6:c.691G>C:p.Val231Leu						rs11082414	0.156749	0.19341284676846	0.1879823		611060 [SETBP1 (confirmed) Schinzel-Giedion midface retraction syndrome,269150|Mental retardation,autosomal dominant 29,616078];	RCV000147472.1 [benign]; RCV000291334.1 [benign]; 		-0.123000	T	D	B	T	0.01	0		71	407			n/a	n/a	SETBP1 (inh=AD pLI=1.00)
chr18	42533130	42533130	A	G	1.0000	17		481.0	14|1|2,0|0|0,6|5	SETBP1	synonymous_variant	SETBP1:NM_015559.2:synonymous_variant:LOW:exon4/6:c.3825A>G:p.Ser1275Ser						rs8096662	0.906949	0.87747945476748	0.8514186		611060 [SETBP1 (confirmed) Schinzel-Giedion midface retraction syndrome,269150|Mental retardation,autosomal dominant 29,616078];	RCV000147461.1 [uncertain significance]; RCV000147462.1 [benign]; RCV000324790.1 [benign]; RCV000147463.1 [uncertain significance]; 								0		1054	302			n/a	n/a	SETBP1 (inh=AD pLI=1.00)
chr18	47800179	47800179	G	C	0.3077	13		49.0	4|0|0,5|0|4,7|6	MBD1	missense_variant	MBD1:NM_001323942.1:missense_variant:MODERATE:exon13/17:c.1276C>G:p.Pro426Ala,MBD1:NM_001204139.1:missense_variant:MODERATE:exon12/17:c.1201C>G:p.Pro401Ala,MBD1:NM_001204141.1:missense_variant:MODERATE:exon11/15:c.1051C>G:p.Pro351Ala,MBD1:NM_001323951.1:missense_variant:MODERATE:exon12/16:c.1201C>G:p.Pro401Ala,MBD1:NM_001323953.1:missense_variant:MODERATE:exon11/14:c.625C>G:p.Pro209Ala,MBD1:NM_001204143.1:missense_variant:MODERATE:exon11/14:c.1033C>G:p.Pro345Ala,MBD1:NM_001204136.1:missense_variant:MODERATE:exon12/16:c.1201C>G:p.Pro401Ala,MBD1:NM_001204142.1:missense_variant:MODERATE:exon12/14:c.1201C>G:p.Pro401Ala,MBD1:NM_001204151.2:missense_variant:MODERATE:exon11/15:c.1132C>G:p.Pro378Ala,MBD1:NM_001323947.1:missense_variant:MODERATE:exon13/17:c.1276C>G:p.Pro426Ala,MBD1:NM_001323949.1:missense_variant:MODERATE:exon13/18:c.769C>G:p.Pro257Ala,MBD1:NM_001323950.1:missense_variant:MODERATE:exon12/17:c.1198C>G:p.Pro400Ala,MBD1:NM_001323952.1:missense_variant:MODERATE:exon11/16:c.958C>G:p.Pro320Ala,MBD1:NM_001323954.1:missense_variant:MODERATE:exon10/14:c.964C>G:p.Pro322Ala,MBD1:NM_002384.2:missense_variant:MODERATE:exon11/15:c.1033C>G:p.Pro345Ala,MBD1:NM_015844.2:missense_variant:MODERATE:exon11/16:c.1033C>G:p.Pro345Ala,MBD1:NM_015845.3:missense_variant:MODERATE:exon11/14:c.1132C>G:p.Pro378Ala,MBD1:NM_015846.3:missense_variant:MODERATE:exon12/17:c.1201C>G:p.Pro401Ala,MBD1:NM_015847.3:missense_variant:MODERATE:exon11/16:c.1054C>G:p.Pro352Ala,MBD1:NM_001204137.1:missense_variant:MODERATE:exon13/17:c.1276C>G:p.Pro426Ala,MBD1:NM_001204138.1:missense_variant:MODERATE:exon13/17:c.1273C>G:p.Pro425Ala,MBD1:NM_001204140.1:missense_variant:MODERATE:exon12/16:c.1108C>G:p.Pro370Ala						rs125555	0.177716	0.19266450202107	0.1888762				CM106261 [CLASS=DM? MUT=ALT PHEN="Autism" GENE=MBD1]; 	0.249000	T	D,T,D,D,T,T,T,D,D,D,D,T,D	B,B,B,B,B,B,B,B,B,B,B,B	D,D,D,D,D,D,D,D,D,D,D,D,D	13.00	1	Leuk,	55	395	2	[2] old entry - no details available	n/a	n/a	MBD1 (inh=n/a pLI=0.96)
chr18	49867224	49867224	T	C	1.0000	13		324.0	9|4|0,0|0|0,2|2	DCC	missense_variant	DCC:NM_005215.3:missense_variant:MODERATE:exon1/29:c.67T>C:p.Phe23Leu	Immunoglobulin-like__1_	Axon guidance;Colorectal cancer	Receptor for netrin required for axon guidance. Mediates axon attraction of neuronal growth cones in the developing nervous system upon ligand binding. Its association with UNC5 proteins may trigger signaling for axon repulsion. It also acts as a dependence receptor required for apoptosis induction when not associated with netrin ligand. Implicated as a tumor suppressor gene			rs9951523	0.995807	0.98624518169538	0.9166388		120470 [DCC (confirmed) Mirror movements 1,157600|Colorectal cancer,somatic,114500|Esophageal carcinoma,somatic 133239];			1.107000	T	T	B	T	15.79	0		1236	42			n/a	n/a	DCC (inh=AD pLI=1.00)
chr18	50432602	50432602	C	G	0.5833	24		324.0	14|0|0,10|0|0,4|3	DCC	missense_variant	DCC:NM_005215.3:missense_variant:MODERATE:exon3/29:c.601C>G:p.Arg201Gly	Immunoglobulin_I-set__1_,Immunoglobulin_subtype_2__1_,Immunoglobulin-like__1_,Immunoglobulin-like_fold__1_	Axon guidance;Colorectal cancer	Receptor for netrin required for axon guidance. Mediates axon attraction of neuronal growth cones in the developing nervous system upon ligand binding. Its association with UNC5 proteins may trigger signaling for axon repulsion. It also acts as a dependence receptor required for apoptosis induction when not associated with netrin ligand. Implicated as a tumor suppressor gene			rs2229080	0.477436	0.44474511751076	0.4358473		120470 [DCC (confirmed) Mirror movements 1,157600|Colorectal cancer,somatic,114500|Esophageal carcinoma,somatic 133239];		CM973390 [CLASS=DP MUT=ALT PHEN="Colorectal cancer risk association with" GENE=DCC]; 	-0.023000	T	T,T,T	B,P	T,T	20.90	0		228	593			n/a	n/a	DCC (inh=AD pLI=1.00)
chr18	67345034	67345034	T	C	1.0000	19		593.0	0|1|18,0|0|0,4|4	DOK6	synonymous_variant	DOK6:NM_152721.5:synonymous_variant:LOW:exon4/8:c.354T>C:p.Asp118Asp			DOK proteins are enzymatically inert adaptor or scaffolding proteins. They provide a docking platform for the assembly of multimolecular signaling complexes. DOK6 promotes Ret- mediated neurite growth. May have a role in brain development and/or maintenance			rs8099030	0.793131	0.80328274089089	0.7984875	COSM4131074										0		569	251			n/a	n/a	DOK6 (inh=n/a pLI=0.46)
chr19	1222012	1222012	G	C	0.4000	10		41.0	0|4|0,5|1|0,4|5	STK11	splice_region_variant&intron_variant,sequence_feature	STK11:NM_000455.4:splice_region_variant&intron_variant:LOW:exon7/9:c.920+7G>C:,STK11:NM_000455.4:sequence_feature:LOW::c.920+7G>C:						rs2075607	0.170527	0.24283820605346	0.1328004		602216 [STK11 (confirmed) Peutz-Jeghers syndrome,175200|Melanoma,malignant,somatic|Pancreatic cancer,260350|Testicular tumor,somatic,273300];	RCV000198532.2 [likely benign]; RCV000078914.6 [benign]; RCV000129163.1 [benign]; RCV000288977.1 [benign]; RCV000123067.3 [likely benign]; 								4	GT,TEST_SomaticAndTreatment,	106	918	1	[1] Ilnaz Sepahi 29-03-2016 batch import	n/a	n/a	STK11 (inh=AD pLI=0.98)
chr19	10600418	10600418	G	A	0.4750	80		936.0	25|6|7,22|15|5,5|5	KEAP1	synonymous_variant	KEAP1:NM_012289.3:synonymous_variant:LOW:exon4/6:c.1437C>T:p.Asp479Asp,KEAP1:NM_203500.1:synonymous_variant:LOW:exon4/6:c.1437C>T:p.Asp479Asp		Ubiquitin mediated proteolysis	Acts as a substrate adapter protein for the E3 ubiquitin ligase complex formed by CUL3 and RBX1 and targets NFE2L2/NRF2 for ubiquitination and degradation by the proteasome, thus resulting in the suppression of its transcriptional activity and the repression of antioxidant response element-mediated detoxifying enzyme gene expression. Retains NFE2L2/NRF2 and may also retain BPTF in the cytosol. Targets PGAM5 for ubiquitination and degradation by the proteasome	Oxidative Stress Induced Gene Expression Via Nrf2		rs35074907	0.00958466	0.018735884205147	0.0180381											0		1	32			n/a	n/a	KEAP1 (inh=n/a pLI=0.25)
chr19	10600442	10600442	G	C	0.4722	36		317.0	10|1|6,10|0|9,5|5	KEAP1	synonymous_variant,sequence_feature	KEAP1:NM_012289.3:synonymous_variant:LOW:exon4/6:c.1413C>G:p.Leu471Leu,KEAP1:NM_203500.1:synonymous_variant:LOW:exon4/6:c.1413C>G:p.Leu471Leu,KEAP1:NM_012289.3:sequence_feature:LOW:exon4/6:c.1413C>G:,KEAP1:NM_012289.3:sequence_feature:LOW:exon4/6:c.1413C>G:		Ubiquitin mediated proteolysis	Acts as a substrate adapter protein for the E3 ubiquitin ligase complex formed by CUL3 and RBX1 and targets NFE2L2/NRF2 for ubiquitination and degradation by the proteasome, thus resulting in the suppression of its transcriptional activity and the repression of antioxidant response element-mediated detoxifying enzyme gene expression. Retains NFE2L2/NRF2 and may also retain BPTF in the cytosol. Targets PGAM5 for ubiquitination and degradation by the proteasome	Oxidative Stress Induced Gene Expression Via Nrf2		rs1048290	0.508187	0.42030087617788	0.4138736	COSM148507										0		174	414			n/a	n/a	KEAP1 (inh=n/a pLI=0.25)
chr19	11118687	11118687	G	A	0.2500	16		36.0	0|4|0,0|12|0,2|5	SMARCA4	missense_variant	SMARCA4:NM_001128849.1:missense_variant:MODERATE:exon14/36:c.2111G>A:p.Arg704Gln,SMARCA4:NM_001128844.1:missense_variant:MODERATE:exon15/36:c.2111G>A:p.Arg704Gln,SMARCA4:NM_003072.3:missense_variant:MODERATE:exon14/35:c.2111G>A:p.Arg704Gln,SMARCA4:NM_001128845.1:missense_variant:MODERATE:exon13/33:c.2111G>A:p.Arg704Gln,SMARCA4:NM_001128846.1:missense_variant:MODERATE:exon13/33:c.2111G>A:p.Arg704Gln,SMARCA4:NM_001128847.1:missense_variant:MODERATE:exon13/33:c.2111G>A:p.Arg704Gln,SMARCA4:NM_001128848.1:missense_variant:MODERATE:exon13/33:c.2111G>A:p.Arg704Gln							0.0000	0.0000	0.0000		603254 [SMARCA4 (provisional) Rhabdoid tumor predisposition syndrome 2,613325|Coffin-Siris syndrome 4,614609];			2.260000	T	D,D,D,D,D,D,D,D	B,B,B,B,B,B,B	D,D,D,D,D,D,D	24.00	1	cfDNA_HNSCC,	0	0			n/a	n/a	SMARCA4 (inh=AD pLI=1.00)
chr19	11170839	11170839	T	C	0.7000	60		903.0	0|0|42,0|0|18,7|4	SMARCA4	synonymous_variant	SMARCA4:NM_001128849.1:synonymous_variant:LOW:exon35/36:c.4983T>C:p.Asp1661Asp,SMARCA4:NM_001128844.1:synonymous_variant:LOW:exon35/36:c.4887T>C:p.Asp1629Asp,SMARCA4:NM_003072.3:synonymous_variant:LOW:exon34/35:c.4887T>C:p.Asp1629Asp,SMARCA4:NM_001128845.1:synonymous_variant:LOW:exon32/33:c.4797T>C:p.Asp1599Asp,SMARCA4:NM_001128846.1:synonymous_variant:LOW:exon32/33:c.4794T>C:p.Asp1598Asp,SMARCA4:NM_001128847.1:synonymous_variant:LOW:exon32/33:c.4788T>C:p.Asp1596Asp,SMARCA4:NM_001128848.1:synonymous_variant:LOW:exon32/33:c.4785T>C:p.Asp1595Asp						rs7275	0.2498	0.30903155603917	0.1108396	COSM1390290, COSM1390291	603254 [SMARCA4 (provisional) Rhabdoid tumor predisposition syndrome 2,613325|Coffin-Siris syndrome 4,614609];	RCV000114308.2 [benign]; RCV000287003.1 [benign]; 								3	SomaticAndTreatment,TEST_SomaticAndTreatment,	223	1030			n/a	n/a	SMARCA4 (inh=AD pLI=1.00)
chr19	14554394	14554394	G	A	0.6522	23		278.0	1|14|0,8|0|0,3|4	PKN1	synonymous_variant	PKN1:NM_213560.1:synonymous_variant:LOW:exon3/22:c.453G>A:p.Ala151Ala,PKN1:NM_002741.3:synonymous_variant:LOW:exon3/22:c.435G>A:p.Ala145Ala						rs55814382	0.00159744	0.0060544124214215	0.0058005											0		0	6			n/a	n/a	PKN1 (inh=n/a pLI=0.85)
chr19	14561722	14561722	A	G	1.0000	12		344.0	0|12|0,0|0|0,3|6	PKN1	synonymous_variant	PKN1:NM_213560.1:synonymous_variant:LOW:exon6/22:c.789A>G:p.Leu263Leu,PKN1:NM_002741.3:synonymous_variant:LOW:exon6/22:c.771A>G:p.Leu257Leu						rs8107892	0.996406	0.99400683315401	0.9257511	COSM4131281, COSM4131280										0		815	18			n/a	n/a	PKN1 (inh=n/a pLI=0.85)
chr19	14574959	14574959	G	A	0.6667	51		820.0	4|0|30,6|0|11,4|3	PKN1	synonymous_variant	PKN1:NM_213560.1:synonymous_variant:LOW:exon12/22:c.1743G>A:p.Ser581Ser,PKN1:NM_002741.3:synonymous_variant:LOW:exon12/22:c.1725G>A:p.Ser575Ser						rs2230538	0.0597045	0.062102946325847	0.0599792											0		1	69			n/a	n/a	PKN1 (inh=n/a pLI=0.85)
chr19	14580328	14580328	A	G	0.5556	54		733.0	0|0|30,0|0|24,3|3	PKN1	missense_variant&splice_region_variant	PKN1:NM_213560.1:missense_variant&splice_region_variant:MODERATE:exon16/22:c.2170A>G:p.Ile724Val,PKN1:NM_002741.3:missense_variant&splice_region_variant:MODERATE:exon16/22:c.2152A>G:p.Ile718Val	Serine/threonine-protein_kinase-like_domain__1_,Serine/threonine-protein_kinase__catalytic__domain__1_,Protein_kinase-like_domain__1_,Protein_kinase__catalytic_domain__1_					rs2230539	0.189497	0.10936772433979	0.1050970					-0.587000	T	T,T	B,B	T,T	0.00	0		4	104			n/a	n/a	PKN1 (inh=n/a pLI=0.85)
chr19	15273381	15273381	A	G	1.0000	34		974.0	16|6|12,0|0|0,3|2	NOTCH3	splice_region_variant&intron_variant	NOTCH3:NM_000435.2:splice_region_variant&intron_variant:LOW:exon31/32:c.5816-8T>C:		Notch signaling pathway	Functions as a receptor for membrane-bound ligands Jagged1, Jagged2 and Delta1 to regulate cell-fate determination. Upon ligand activation through the released notch intracellular domain (NICD) it forms a transcriptional activator complex with RBPJ/RBPSUH and activates genes of the enhancer of split locus. Affects the implementation of differentiation, proliferation and apoptotic programs (By similarity)			rs4809030	0.86901	0.87451224574512	0.8661192		600276 [NOTCH3 (confirmed) Cerebral arteriopathy with subcortical infarcts and leukoencephalopathy 1,125310|Myofibromatosis,infantile 2,615293|Lateral meningocele syndrome,130720];	RCV000241820.1 [benign]; RCV000277327.1 [benign]; 								0		1167	269			n/a	n/a	NOTCH3 (inh=AD pLI=0.21)
chr19	15278057	15278057	A	G	1.0000	23		711.0	4|19|0,0|0|0,9|4	NOTCH3	splice_region_variant&intron_variant	NOTCH3:NM_000435.2:splice_region_variant&intron_variant:LOW:exon29/32:c.5362+3T>C:		Notch signaling pathway	Functions as a receptor for membrane-bound ligands Jagged1, Jagged2 and Delta1 to regulate cell-fate determination. Upon ligand activation through the released notch intracellular domain (NICD) it forms a transcriptional activator complex with RBPJ/RBPSUH and activates genes of the enhancer of split locus. Affects the implementation of differentiation, proliferation and apoptotic programs (By similarity)			rs1548555	0.870008	0.8740686403798	0.8677848		600276 [NOTCH3 (confirmed) Cerebral arteriopathy with subcortical infarcts and leukoencephalopathy 1,125310|Myofibromatosis,infantile 2,615293|Lateral meningocele syndrome,130720];	RCV000246404.1 [benign]; RCV000288178.1 [benign]; 								0		1167	270			n/a	n/a	NOTCH3 (inh=AD pLI=0.21)
chr19	15285052	15285052	T	C	1.0000	58		1872.0	24|20|14,0|0|0,5|5	NOTCH3	synonymous_variant,sequence_feature	NOTCH3:NM_000435.2:synonymous_variant:LOW:exon25/33:c.4563A>G:p.Pro1521Pro,NOTCH3:NM_000435.2:sequence_feature:LOW:exon25/33:c.4563A>G:		Notch signaling pathway	Functions as a receptor for membrane-bound ligands Jagged1, Jagged2 and Delta1 to regulate cell-fate determination. Upon ligand activation through the released notch intracellular domain (NICD) it forms a transcriptional activator complex with RBPJ/RBPSUH and activates genes of the enhancer of split locus. Affects the implementation of differentiation, proliferation and apoptotic programs (By similarity)			rs1044006	0.871805	0.88124292506226	0.8145835	COSM438775, COSM1480700	600276 [NOTCH3 (confirmed) Cerebral arteriopathy with subcortical infarcts and leukoencephalopathy 1,125310|Myofibromatosis,infantile 2,615293|Lateral meningocele syndrome,130720];	RCV000249034.1 [benign]; RCV000315021.1 [benign]; 								0		1165	268			n/a	n/a	NOTCH3 (inh=AD pLI=0.21)
chr19	15292437	15292437	T	C	1.0000	37		1116.0	6|1|30,0|0|0,6|5	NOTCH3	synonymous_variant	NOTCH3:NM_000435.2:synonymous_variant:LOW:exon17/33:c.2742A>G:p.Pro914Pro		Notch signaling pathway	Functions as a receptor for membrane-bound ligands Jagged1, Jagged2 and Delta1 to regulate cell-fate determination. Upon ligand activation through the released notch intracellular domain (NICD) it forms a transcriptional activator complex with RBPJ/RBPSUH and activates genes of the enhancer of split locus. Affects the implementation of differentiation, proliferation and apoptotic programs (By similarity)			rs1043997	0.739018	0.80192763632615	0.4975499	COSM4131310, COSM4131309	600276 [NOTCH3 (confirmed) Cerebral arteriopathy with subcortical infarcts and leukoencephalopathy 1,125310|Myofibromatosis,infantile 2,615293|Lateral meningocele syndrome,130720];	RCV000246643.1 [benign]; RCV000304759.1 [benign]; 								0		1052	366			n/a	n/a	NOTCH3 (inh=AD pLI=0.21)
chr19	15295134	15295134	G	A	0.6296	54		828.0	2|22|10,6|10|4,6|7	NOTCH3	synonymous_variant	NOTCH3:NM_000435.2:synonymous_variant:LOW:exon16/33:c.2538C>T:p.Cys846Cys		Notch signaling pathway	Functions as a receptor for membrane-bound ligands Jagged1, Jagged2 and Delta1 to regulate cell-fate determination. Upon ligand activation through the released notch intracellular domain (NICD) it forms a transcriptional activator complex with RBPJ/RBPSUH and activates genes of the enhancer of split locus. Affects the implementation of differentiation, proliferation and apoptotic programs (By similarity)			rs1043996	0.519968	0.64274030994944	0.6382280	COSM4131311, COSM4131312	600276 [NOTCH3 (confirmed) Cerebral arteriopathy with subcortical infarcts and leukoencephalopathy 1,125310|Myofibromatosis,infantile 2,615293|Lateral meningocele syndrome,130720];	RCV000241854.1 [benign]; RCV000269025.1 [benign]; 								2	GT,SomaticAndTreatment,	703	611			n/a	n/a	NOTCH3 (inh=AD pLI=0.21)
chr19	15302844	15302844	T	C	0.9737	38		1031.0	2|16|19,0|0|0,4|4	NOTCH3	synonymous_variant	NOTCH3:NM_000435.2:synonymous_variant:LOW:exon4/33:c.606A>G:p.Ala202Ala		Notch signaling pathway	Functions as a receptor for membrane-bound ligands Jagged1, Jagged2 and Delta1 to regulate cell-fate determination. Upon ligand activation through the released notch intracellular domain (NICD) it forms a transcriptional activator complex with RBPJ/RBPSUH and activates genes of the enhancer of split locus. Affects the implementation of differentiation, proliferation and apoptotic programs (By similarity)			rs1043994	0.855831	0.85812237163611	0.8277986		600276 [NOTCH3 (confirmed) Cerebral arteriopathy with subcortical infarcts and leukoencephalopathy 1,125310|Myofibromatosis,infantile 2,615293|Lateral meningocele syndrome,130720];	RCV000242339.1 [benign]; RCV000374496.1 [benign]; 								0		1102	332			n/a	n/a	NOTCH3 (inh=AD pLI=0.21)
chr19	15303225	15303225	G	A	0.3774	106		865.0	4|14|22,6|16|44,5|6	NOTCH3	synonymous_variant	NOTCH3:NM_000435.2:synonymous_variant:LOW:exon3/33:c.303C>T:p.Thr101Thr		Notch signaling pathway	Functions as a receptor for membrane-bound ligands Jagged1, Jagged2 and Delta1 to regulate cell-fate determination. Upon ligand activation through the released notch intracellular domain (NICD) it forms a transcriptional activator complex with RBPJ/RBPSUH and activates genes of the enhancer of split locus. Affects the implementation of differentiation, proliferation and apoptotic programs (By similarity)			rs3815188	0.224042	0.18219456119553	0.1737769		600276 [NOTCH3 (confirmed) Cerebral arteriopathy with subcortical infarcts and leukoencephalopathy 1,125310|Myofibromatosis,infantile 2,615293|Lateral meningocele syndrome,130720];	RCV000251392.1 [benign]; RCV000373577.1 [benign]; 								0		35	372			n/a	n/a	NOTCH3 (inh=AD pLI=0.21)
chr19	17948732	17948732	T	C	0.3056	72		446.0	16|6|0,38|12|0,2|1	JAK3	splice_region_variant&intron_variant	JAK3:NM_000215.3:splice_region_variant&intron_variant:LOW:exon12/23:c.1701+9A>G:						rs3212752	0.11222	0.084995799219149	0.0794513		600173 [JAK3 (provisional) SCID,autosomal recessive,T-negative/B-positive type,600802];	RCV000125433.1 [benign]; RCV000306012.1 [benign]; 								3	TEST_SomaticAndTreatment,	19	191			n/a	n/a	JAK3 (inh=AR pLI=1.00)
chr19	20727463	20727463	T	C	0.5000	44		467.0	1|21|0,14|22|0,3|7	ZNF737	missense_variant	ZNF737:NM_001159293.1:missense_variant:MODERATE:exon4/4:c.1546A>G:p.Lys516Glu						rs10411329	0.417732	0.42457874131181	0.3969480					-2.106000	T	D	B	T	23.40	0		129	374			n/a	n/a	ZNF737 (inh=n/a pLI=0.00)
chr19	20727997	20727997	C	A	0.2500	16		34.0	0|4|0,0|12|0,0|1	ZNF737	stop_gained	ZNF737:NM_001159293.1:stop_gained:HIGH:exon4/4:c.1012G>T:p.Glu338*							0.0000	0.0000	0.0000					3.664000					35.00	1	cfDNA_HNSCC,	0	0			n/a	n/a	ZNF737 (inh=n/a pLI=0.00)
chr19	40748535	40748535	C	G	0.4082	49		421.0	4|12|4,10|12|7,3|8	AKT2	missense_variant	AKT2:NM_001626.5:missense_variant:MODERATE:exon5/14:c.347G>C:p.Gly116Ala,AKT2:NM_001243027.2:missense_variant:MODERATE:exon5/14:c.161G>C:p.Gly54Ala,AKT2:NM_001243028.2:missense_variant:MODERATE:exon4/13:c.161G>C:p.Gly54Ala						rs141209878	0.000199681	0.00026427934326583	0.0002958		164731 [AKT2 (provisional) Diabetes mellitus,type II,125853|Hypoinsulinemic hypoglycemia with hemihypertrophy,240900];			2.999000	T	T,T,T,T,T,T,T,T,T	B,B,B,B	T,T,T,T,T,T,T	10.10	0		0	2			n/a	n/a	AKT2 (inh=AR+AD pLI=1.00)
chr19	55144186	55144186	C	T	1.0000	13		357.0	4|8|1,0|0|0,5|5	LILRB1	synonymous_variant,non_coding_transcript_exon_variant	LILRB1:NM_001081637.2:synonymous_variant:LOW:exon6/15:c.933C>T:p.Ser311Ser,LILRB1:NM_006669.6:synonymous_variant:LOW:exon7/16:c.933C>T:p.Ser311Ser,LILRB1:NM_001081638.3:synonymous_variant:LOW:exon6/15:c.933C>T:p.Ser311Ser,LILRB1:NM_001081639.3:synonymous_variant:LOW:exon6/15:c.933C>T:p.Ser311Ser,LILRB1:NM_001278399.2:synonymous_variant:LOW:exon6/9:c.933C>T:p.Ser311Ser,LILRB1:NM_001278398.2:synonymous_variant:LOW:exon6/14:c.933C>T:p.Ser311Ser,LILRB1:NR_103518.2:non_coding_transcript_exon_variant:MODIFIER:exon6/14:n.1098C>T:			Receptor for class I MHC antigens. Recognizes a broad spectrum of HLA-A, HLA-B, HLA-C and HLA-G alleles. Receptor for H301/UL18, a human cytomegalovirus class I MHC homolog. Ligand binding results in inhibitory signals and down-regulation of the immune response. Engagement of LILRB1 present on natural killer cells or T-cells by class I MHC molecules protects the target cells from lysis. Interaction with HLA-B or HLA-E leads to inhibition of the signal triggered by FCER1A and inhibits serotonin release. Inhibits FCGR1A-mediated phosphorylation of cellular proteins and mobilization of intracellular calcium ions			rs272423	0.59365	0.60900330210931	0.5536128	COSM3757198										0		376	355			n/a	n/a	LILRB1 (inh=n/a pLI=0.00)
chr19	55418054	55418054	A	C	0.4839	31		346.0	2|1|12,4|0|12,3|6	NCR1	missense_variant,intron_variant	NCR1:NM_004829.6:missense_variant:MODERATE:exon3/7:c.244A>C:p.Lys82Gln,NCR1:NM_001145457.2:missense_variant:MODERATE:exon3/7:c.244A>C:p.Lys82Gln,NCR1:NM_001145458.2:missense_variant:MODERATE:exon3/6:c.244A>C:p.Lys82Gln,NCR1:NM_001242356.2:intron_variant:MODIFIER:exon2/5:c.70+362A>C:,NCR1:NM_001242357.2:intron_variant:MODIFIER:exon2/4:c.70+362A>C:	Immunoglobulin-like_fold__1_	Natural killer cell mediated cytotoxicity	Cytotoxicity-activating receptor that may contribute to the increased efficiency of activated natural killer (NK) cells to mediate tumor cell lysis			rs2278428	0.176717	0.13276089828269	0.1309613					-0.952000	T	T,T,T	B,B,B	T,T,T	0.01	1	Leuk,	19	156			n/a	n/a	NCR1 (inh=n/a pLI=0.00)
chr19	55420801	55420801	C	A	0.6111	72		1056.0	33|11|0,20|7|1,8|5	NCR1	synonymous_variant	NCR1:NM_004829.6:synonymous_variant:LOW:exon4/7:c.553C>A:p.Arg185Arg,NCR1:NM_001145457.2:synonymous_variant:LOW:exon4/7:c.553C>A:p.Arg185Arg,NCR1:NM_001145458.2:synonymous_variant:LOW:exon4/6:c.553C>A:p.Arg185Arg,NCR1:NM_001242356.2:synonymous_variant:LOW:exon3/6:c.268C>A:p.Arg90Arg,NCR1:NM_001242357.2:synonymous_variant:LOW:exon3/5:c.268C>A:p.Arg90Arg		Natural killer cell mediated cytotoxicity	Cytotoxicity-activating receptor that may contribute to the increased efficiency of activated natural killer (NK) cells to mediate tumor cell lysis			rs3765013	0.483227	0.33902531666474	0.3320300	COSM3757210										1	Leuk,	87	342			n/a	n/a	NCR1 (inh=n/a pLI=0.00)
chr19	57326970	57326970	T	C	0.4194	31		270.0	5|4|4,5|7|6,4|4	PEG3,ZIM2	missense_variant,intron_variant	PEG3:NM_001146184.1:missense_variant:MODERATE:exon9/9:c.2840A>G:p.Asn947Ser,PEG3:NM_001146186.1:missense_variant:MODERATE:exon7/7:c.2840A>G:p.Asn947Ser,PEG3:NM_001146185.1:missense_variant:MODERATE:exon9/9:c.2462A>G:p.Asn821Ser,PEG3:NM_001146187.1:missense_variant:MODERATE:exon9/9:c.2468A>G:p.Asn823Ser,PEG3:NM_006210.2:missense_variant:MODERATE:exon10/10:c.2840A>G:p.Asn947Ser,ZIM2:NM_001146326.1:intron_variant:MODIFIER:exon8/11:c.397+2998A>G:,ZIM2:NM_001146327.1:intron_variant:MODIFIER:exon8/11:c.397+2998A>G:,ZIM2:NM_015363.4:intron_variant:MODIFIER:exon7/10:c.397+2998A>G:			Induces apoptosis in cooperation with SIAH1A. Acts as a mediator between p53/TP53 and BAX in a neuronal death pathway that is activated by DNA damage. Acts synergistically with TRAF2 and inhibits TNF induced apoptosis through activation of NF-kappa-B (By similarity). Possesses a tumor suppressing activity in glioma cells.,May be involved in transcriptional regulation			rs35851866	0.0159744	0.022015687825456	0.0221602					-0.293000	T	T,T	B,B,B	T,T	0.01	0		0	42			n/a	n/a	PEG3 (inh=n/a pLI=0.00), ZIM2 (inh=n/a pLI=0.47)
chr19	57327503	57327503	A	G	1.0000	26		812.0	1|0|25,0|0|0,4|3	PEG3,ZIM2	synonymous_variant,intron_variant	PEG3:NM_001146184.1:synonymous_variant:LOW:exon9/9:c.2307T>C:p.Tyr769Tyr,PEG3:NM_001146186.1:synonymous_variant:LOW:exon7/7:c.2307T>C:p.Tyr769Tyr,PEG3:NM_001146185.1:synonymous_variant:LOW:exon9/9:c.1929T>C:p.Tyr643Tyr,PEG3:NM_001146187.1:synonymous_variant:LOW:exon9/9:c.1935T>C:p.Tyr645Tyr,PEG3:NM_006210.2:synonymous_variant:LOW:exon10/10:c.2307T>C:p.Tyr769Tyr,ZIM2:NM_001146326.1:intron_variant:MODIFIER:exon8/11:c.397+2465T>C:,ZIM2:NM_001146327.1:intron_variant:MODIFIER:exon8/11:c.397+2465T>C:,ZIM2:NM_015363.4:intron_variant:MODIFIER:exon7/10:c.397+2465T>C:			Induces apoptosis in cooperation with SIAH1A. Acts as a mediator between p53/TP53 and BAX in a neuronal death pathway that is activated by DNA damage. Acts synergistically with TRAF2 and inhibits TNF induced apoptosis through activation of NF-kappa-B (By similarity). Possesses a tumor suppressing activity in glioma cells.,May be involved in transcriptional regulation			rs33931963	0.200879	0.23487506205527	0.2217949	COSM4000998, COSM4000999										1	Leuk,	41	296			n/a	n/a	PEG3 (inh=n/a pLI=0.00), ZIM2 (inh=n/a pLI=0.47)
chr20	8769180	8769180	C	T	1.0000	11		321.0	0|1|10,0|0|0,6|5	PLCB1	splice_region_variant&intron_variant	PLCB1:NM_015192.3:splice_region_variant&intron_variant:LOW:exon28/31:c.3188+8C>T:,PLCB1:NM_182734.2:splice_region_variant&intron_variant:LOW:exon28/32:c.3188+8C>T:		Inositol phosphate metabolism;Calcium signaling pathway;Phosphatidylinositol signaling system;Wnt signaling pathway;Gap junction;Long-term potentiation;Long-term depression;GnRH signaling pathway;Melanogenesis	The production of the second messenger molecules diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3) is mediated by activated phosphatidylinositol-specific phospholipase C enzymes	Activation of PKC through G protein coupled receptor;Aspirin Blocks Signaling Pathway Involved in Platelet Activation;Cadmium induces DNA synthesis and proliferation in macrophages;CCR3 signaling in Eosinophils;Eicosanoid Metabolism;fMLP induced chemokine gene expression in HMC-1 cells;G-Protein Signaling Through Tubby Proteins;Phospholipase C Signaling Pathway;Phospholipids as signalling intermediaries;PKC-catalyzed phosphorylation of inhibitory phosphoprotein of myosin phosphatase;Regulation of ck1/cdk5 by type 1 glutamate receptors;b-arrestins in GPCR Desensitization;Thrombin signaling and protease-activated receptors		rs2327089	0.896965	0.94078914257914	0.9186452		607120 [PLCB1 (confirmed) Epileptic encephalopathy,early infantile,12,613722];	RCV000117932.5 [benign]; RCV000398026.1 [benign]; 								0		1154	121			n/a	n/a	PLCB1 (inh=AR pLI=0.98)
chr20	36030939	36030939	G	C	1.0000	16		425.0	0|2|14,0|0|0,4|5	SRC	synonymous_variant	SRC:NM_005417.4:synonymous_variant:LOW:exon12/14:c.1218G>C:p.Ala406Ala,SRC:NM_198291.2:synonymous_variant:LOW:exon12/14:c.1218G>C:p.Ala406Ala		ErbB signaling pathway;VEGF signaling pathway;Focal adhesion;Adherens junction;Tight junction;Gap junction;GnRH signaling pathway;Epithelial cell signaling in Helicobacter pylori infection	Non-receptor protein tyrosine kinase which is activated following engagement of many different classes of cellular receptors including immune response receptors, integrins and other adhesion receptors, receptor protein tyrosine kinases, G protein- coupled receptors as well as cytokine receptors. Participates in signaling pathways that control a diverse spectrum of biological activities including gene transcription, immune response, cell adhesion, cell cycle progression, apoptosis, migration, and transformation. Due to functional redundancy between members of the SRC kinase family, identification of the specific role of each SRC kinase is very difficult. SRC appears to be one of the primary kinases activated following engagement of receptors and plays a role in the activation of other protein tyrosine kinase (PTK) families. Receptor clustering or dimerization leads to recruitment of SRC to the receptor complexes where it phosphorylates the tyrosine residues within the receptor cytoplasmic domains. Plays an important role in the regulation of cytoskeletal organization through phosphorylation of specific substrates such as AFAP1. Phosphorylation of AFAP1 allows the SRC SH2 domain to bind AFAP1 and to localize to actin filaments. Cytoskeletal reorganization is also controlled through the phosphorylation of cortactin (CTTN). When cells adhere via focal adhesions to the extracellular matrix, signals are transmitted by integrins into the cell resulting in tyrosine phosphorylation of a number of focal adhesion proteins, including PTK2/FAK1 and paxillin (PXN). In addition to phosphorylating focal adhesion proteins, SRC is also active at the sites of cell-cell contact adherens junctions and phosphorylates substrates such as beta-catenin (CTNNB1), delta-catenin (CTNND1), and plakoglobin (JUP). Another type of cell-cell junction, the gap junction, is also a target for SRC, which phosphorylates connexin- 43 (GJA1). SRC is implicated in regulation of pre-mRNA-processing and phosphorylates RNA-binding proteins such as KHDRBS1. Also plays a role in PDGF-mediated tyrosine phosphorylation of both STAT1 and STAT3, leading to increased DNA binding activity of these transcription factors. Involved in the RAS pathway through phosphorylation of RASA1 and RASGRF1. Plays a role in EGF-mediated calcium-activated chloride channel activation. Required for epidermal growth factor receptor (EGFR) internalization through phosphorylation of clathrin heavy chain (CLTC and CLTCL1) at 'Tyr- 1477'. Involved in beta-arrestin (ARRB1 and ARRB2) desensitization through phosphorylation and activation of ADRBK1, leading to beta- arrestin phosphorylation and internalization. Has a critical role in the stimulation of the CDK20/MAPK3 mitogen-activated protein kinase cascade by epidermal growth factor. Might be involved not only in mediating the transduction of mitogenic signals at the level of the plasma membrane but also in controlling progression through the cell cycle via interaction with regulatory proteins in the nucleus. Plays an important role in osteoclastic bone resorption in conjunction with PTK2B/PYK2. Both the formation of a SRC-PTK2B/PYK2 complex and SRC kinase activity are necessary for this function. Recruited to activated integrins by PTK2B/PYK2, thereby phosphorylating CBL, which in turn induces the activation and recruitment of phosphatidylinositol 3-kinase to the cell membrane in a signaling pathway that is critical for osteoclast function. Promotes energy production in osteoclasts by activating mitochondrial cytochrome C oxidase. Phosphorylates DDR2 on tyrosine residues, thereby promoting its subsequent autophosphorylation. Phosphorylates RUNX3 and COX2 on tyrosine residues, TNK2 on 'Tyr-284' and CBL on 'Tyr-731'. Enhances DDX58/RIG-I-elicited antiviral signaling. Phosphorylates PDPK1 at 'Tyr-9', 'Tyr-373' and 'Tyr-376'. Phosphorylates BCAR1 at 'Tyr- 128'	Activation of Src by Protein-tyrosine phosphatase alpha;Agrin in Postsynaptic Differentiation;Angiotensin II mediated activation of JNK Pathway via Pyk2 dependent signaling;Aspirin Blocks Signaling Pathway Involved in Platelet Activation;Calcium Signaling by HBx of Hepatitis B virus;CBL mediated ligand-induced downregulation of EGF receptors;Cell to Cell Adhesion Signaling;Erk and PI-3 Kinase Are Necessary for Collagen Binding in Corneal Epithelia;Erk1/Erk2 Mapk Signaling pathway;Gamma-aminobutyric Acid Receptor Life Cycle;How Progesterone Initiates Oocyte Membrane;Integrin Signaling Pathway;Links between Pyk2 and Map Kinases;Pelp1 Modulation of Estrogen Receptor Activity;Phospholipids as signalling intermediaries;Regulation of Splicing through Sam68;Rho cell motility signaling pathway;Role of nicotinic acetylcholine receptors in the regulation of apoptosis;Signaling of Hepatocyte Growth Factor Receptor;Sprouty regulation of tyrosine kinase signals;uCalpain and friends in Cell spread		rs1885257	1	1	0.9361303		190090 [SRC (confirmed) Colon cancer,advanced,somatic,114500|Thrombocytopenia 6,616937];									0		1338	0			n/a	n/a	SRC (inh=n/a pLI=0.99)
chr20	36979265	36979265	T	C	0.5000	40		440.0	6|12|2,4|6|10,6|7	LBP	synonymous_variant	LBP:NM_004139.4:synonymous_variant:LOW:exon3/15:c.291T>C:p.Pro97Pro		Toll-like receptor signaling pathway	Binds to the lipid A moiety of bacterial lipopolysaccharides (LPS), a glycolipid present in the outer membrane of all Gram-negative bacteria, and acts as an affinity enhancer for CD14, facilitating its association with LPS	Inactivation of Gsk3 by AKT causes accumulation of b-catenin in Alveolar Macrophages		rs2232582	0.213259	0.17113318701629	0.1662401	COSM4001902										0		53	371			n/a	n/a	LBP (inh=n/a pLI=0.00)
chr20	36989381	36989381	G	A	0.3333	63		441.0	14|7|0,16|26|0,8|6	LBP	synonymous_variant	LBP:NM_004139.4:synonymous_variant:LOW:exon6/15:c.612G>A:p.Ser204Ser		Toll-like receptor signaling pathway	Binds to the lipid A moiety of bacterial lipopolysaccharides (LPS), a glycolipid present in the outer membrane of all Gram-negative bacteria, and acts as an affinity enhancer for CD14, facilitating its association with LPS	Inactivation of Gsk3 by AKT causes accumulation of b-catenin in Alveolar Macrophages		rs2232596	0.649361	0.55529103580078	0.5546803											0		344	647			n/a	n/a	LBP (inh=n/a pLI=0.00)
chr20	37001761	37001761	T	C	0.5294	17		178.0	1|8|0,2|6|0,3|5	LBP	missense_variant	LBP:NM_004139.4:missense_variant:MODERATE:exon13/15:c.1306T>C:p.Phe436Leu	Lipid-binding_serum_glycoprotein__C-terminal__2_,Bactericidal_permeability-increasing_protein__alpha/beta_domain__1_	Toll-like receptor signaling pathway	Binds to the lipid A moiety of bacterial lipopolysaccharides (LPS), a glycolipid present in the outer membrane of all Gram-negative bacteria, and acts as an affinity enhancer for CD14, facilitating its association with LPS	Inactivation of Gsk3 by AKT causes accumulation of b-catenin in Alveolar Macrophages		rs2232618	0.125599	0.096465062623599	0.0936117				CM121221 [CLASS=DFP MUT=ALT PHEN="Sepsis and multiple organ dysfunction in major trauma association with" GENE=LBP]; 	-0.516000	T	T,T	B	T	0.01	0		20	224			n/a	n/a	LBP (inh=n/a pLI=0.00)
chr20	40743829	40743829	A	G	1.0000	11		313.0	1|10|0,0|0|0,3|5	PTPRT	splice_region_variant&intron_variant	PTPRT:NM_133170.3:splice_region_variant&intron_variant:LOW:exon23/31:c.3156+10T>C:,PTPRT:NM_007050.5:splice_region_variant&intron_variant:LOW:exon22/30:c.3099+10T>C:			May be involved in both signal transduction and cellular adhesion in the CNS			rs2076248	0.55651	0.53083941605839	0.5195043											0		334	640			n/a	n/a	PTPRT (inh=n/a pLI=1.00)
chr20	41306600	41306600	A	G	0.7778	18		300.0	6|0|8,3|1|0,3|2	PTPRT	synonymous_variant	PTPRT:NM_133170.3:synonymous_variant:LOW:exon7/32:c.1059T>C:p.Asp353Asp,PTPRT:NM_007050.5:synonymous_variant:LOW:exon7/31:c.1059T>C:p.Asp353Asp			May be involved in both signal transduction and cellular adhesion in the CNS			rs2425516	0.384784	0.37847486829462	0.3716818	COSM3758576, COSM3758577										0		184	560			n/a	n/a	PTPRT (inh=n/a pLI=1.00)
chr20	41818289	41818289	C	G	1.0000	19		616.0	9|0|10,0|0|0,6|4	PTPRT	missense_variant	PTPRT:NM_133170.3:missense_variant:MODERATE:exon1/32:c.85G>C:p.Ala29Pro,PTPRT:NM_007050.5:missense_variant:MODERATE:exon1/31:c.85G>C:p.Ala29Pro	Concanavalin_A-like_lectin/glucanase__1_,MAM_domain__1_		May be involved in both signal transduction and cellular adhesion in the CNS			rs2867655	0.711062	0.92112879884226	0.1856672					1.472000	T	D,D,D,D,D,D,D	B,B	T,T,T,T,T,T,T	23.10	0		754	246			n/a	n/a	PTPRT (inh=n/a pLI=1.00)
chr20	60885142	60885142	C	A	0.6452	31		389.0	0|0|20,0|0|11,4|4	LAMA5	splice_region_variant&intron_variant	LAMA5:NM_005560.4:splice_region_variant&intron_variant:LOW:exon77/79:c.10735-5G>T:		Cell Communication;Focal adhesion;ECM-receptor interaction;Small cell lung cancer	Binding to cells via a high affinity receptor, laminin is thought to mediate the attachment, migration and organization of cells into tissues during embryonic development by interacting with other extracellular matrix components			rs2379129	0.354633	0.41283617735627	0.3893533											1	I16R041,	245	595			n/a	n/a	LAMA5 (inh=n/a pLI=0.94)
chr20	60887581	60887581	G	A	1.0000	28		840.0	0|20|8,0|0|0,3|5	LAMA5	missense_variant	LAMA5:NM_005560.4:missense_variant:MODERATE:exon68/80:c.9235C>T:p.Arg3079Trp	Concanavalin_A-like_lectin/glucanase__1_,Concanavalin_A-like_lectin/glucanase__subgroup__1_,Laminin_G_domain__2_,Laminin_G__subdomain_2__1_	Cell Communication;Focal adhesion;ECM-receptor interaction;Small cell lung cancer	Binding to cells via a high affinity receptor, laminin is thought to mediate the attachment, migration and organization of cells into tissues during embryonic development by interacting with other extracellular matrix components			rs944895	0.677117	0.68112985208506	0.6547420	COSM444167			CM088367 [CLASS=DP MUT=ALT PHEN="Body composition in African American women association with" GENE=LAMA5]; 	-0.605000	T	D	P	T	26.00	0		563	551			n/a	n/a	LAMA5 (inh=n/a pLI=0.94)
chr20	60892526	60892526	A	G	1.0000	25		718.0	3|1|21,0|0|0,5|6	LAMA5	synonymous_variant	LAMA5:NM_005560.4:synonymous_variant:LOW:exon55/80:c.7386T>C:p.Asp2462Asp		Cell Communication;Focal adhesion;ECM-receptor interaction;Small cell lung cancer	Binding to cells via a high affinity receptor, laminin is thought to mediate the attachment, migration and organization of cells into tissues during embryonic development by interacting with other extracellular matrix components			rs2427281	0.999201	0.99976975665049	0.9208573											0		1279	1			n/a	n/a	LAMA5 (inh=n/a pLI=0.94)
chr20	60897071	60897071	A	G	1.0000	73		2300.0	16|52|5,0|0|0,5|8	LAMA5	splice_region_variant&intron_variant	LAMA5:NM_005560.4:splice_region_variant&intron_variant:LOW:exon48/79:c.6496+4T>C:		Cell Communication;Focal adhesion;ECM-receptor interaction;Small cell lung cancer	Binding to cells via a high affinity receptor, laminin is thought to mediate the attachment, migration and organization of cells into tissues during embryonic development by interacting with other extracellular matrix components			rs2274936	0.822284	0.87436451124751	0.8502418											0		1059	204			n/a	n/a	LAMA5 (inh=n/a pLI=0.94)
chr20	60897104	60897104	C	T	0.5000	34		409.0	8|4|5,4|13|0,6|6	LAMA5	missense_variant	LAMA5:NM_005560.4:missense_variant:MODERATE:exon48/80:c.6467G>A:p.Gly2156Glu	EGF-like__laminin__2_	Cell Communication;Focal adhesion;ECM-receptor interaction;Small cell lung cancer	Binding to cells via a high affinity receptor, laminin is thought to mediate the attachment, migration and organization of cells into tissues during embryonic development by interacting with other extracellular matrix components			rs141208202	0.0163738	0.030002933006677	0.0257035	COSM3758694				0.871000	T	D	B	T	8.08	1	I16R041,	4	92			n/a	n/a	LAMA5 (inh=n/a pLI=0.94)
chr20	60897487	60897487	C	T	1.0000	41		1218.0	27|14|0,0|0|0,3|3	LAMA5	missense_variant	LAMA5:NM_005560.4:missense_variant:MODERATE:exon47/80:c.6184G>A:p.Asp2062Asn	EGF-like__laminin__4_	Cell Communication;Focal adhesion;ECM-receptor interaction;Small cell lung cancer	Binding to cells via a high affinity receptor, laminin is thought to mediate the attachment, migration and organization of cells into tissues during embryonic development by interacting with other extracellular matrix components			rs2274934	0.477835	0.58871219650717	0.5057233	COSM4134724				0.835000	T	T	B	T	17.01	0		461	554			n/a	n/a	LAMA5 (inh=n/a pLI=0.94)
chr20	60898505	60898505	C	T	1.0000	79		2415.0	14|29|36,0|0|0,2|4	LAMA5	splice_region_variant&intron_variant	LAMA5:NM_005560.4:splice_region_variant&intron_variant:LOW:exon45/79:c.6064+7G>A:		Cell Communication;Focal adhesion;ECM-receptor interaction;Small cell lung cancer	Binding to cells via a high affinity receptor, laminin is thought to mediate the attachment, migration and organization of cells into tissues during embryonic development by interacting with other extracellular matrix components			rs2379128	0.623403	0.68669985775249	0.3539330											0		577	538			n/a	n/a	LAMA5 (inh=n/a pLI=0.94)
chr20	60899206	60899206	C	T	1.0000	52		1634.0	1|3|48,0|0|0,5|6	LAMA5	missense_variant	LAMA5:NM_005560.4:missense_variant:MODERATE:exon43/80:c.5698G>A:p.Val1900Met	EGF-like__laminin__4_	Cell Communication;Focal adhesion;ECM-receptor interaction;Small cell lung cancer	Binding to cells via a high affinity receptor, laminin is thought to mediate the attachment, migration and organization of cells into tissues during embryonic development by interacting with other extracellular matrix components			rs2427283	0.66274	0.68480904264429	0.6696484	COSM149203				0.486000	T	T	B	T	21.70	0		624	500			n/a	n/a	LAMA5 (inh=n/a pLI=0.94)
chr20	60900481	60900481	A	G	1.0000	20		593.0	2|0|18,0|0|0,5|2	LAMA5	missense_variant	LAMA5:NM_005560.4:missense_variant:MODERATE:exon41/80:c.5420T>C:p.Phe1807Ser	Laminin_B_type_IV__2_,Laminin_B__subgroup__1_	Cell Communication;Focal adhesion;ECM-receptor interaction;Small cell lung cancer	Binding to cells via a high affinity receptor, laminin is thought to mediate the attachment, migration and organization of cells into tissues during embryonic development by interacting with other extracellular matrix components			rs2427284	0.89397	0.9185399379767	0.8965171					4.754000	T	T	B	T	10.13	0		1135	140			n/a	n/a	LAMA5 (inh=n/a pLI=0.94)
chr20	60900579	60900579	C	A	1.0000	103		2925.0	55|14|34,0|0|0,6|3	LAMA5	synonymous_variant	LAMA5:NM_005560.4:synonymous_variant:LOW:exon41/80:c.5322G>T:p.Thr1774Thr		Cell Communication;Focal adhesion;ECM-receptor interaction;Small cell lung cancer	Binding to cells via a high affinity receptor, laminin is thought to mediate the attachment, migration and organization of cells into tissues during embryonic development by interacting with other extracellular matrix components			rs2427285	0.89397	0.91864378401005	0.8887746											0		1135	140			n/a	n/a	LAMA5 (inh=n/a pLI=0.94)
chr20	60904853	60904853	T	C	1.0000	19		558.0	2|1|16,0|0|0,5|4	LAMA5	missense_variant	LAMA5:NM_005560.4:missense_variant:MODERATE:exon32/80:c.4099A>G:p.Lys1367Glu		Cell Communication;Focal adhesion;ECM-receptor interaction;Small cell lung cancer	Binding to cells via a high affinity receptor, laminin is thought to mediate the attachment, migration and organization of cells into tissues during embryonic development by interacting with other extracellular matrix components			rs2427286	0.908746	0.92265112766469	0.8889032	COSM4134726				2.971000	T	T	B	T	13.12	0		1134	138			n/a	n/a	LAMA5 (inh=n/a pLI=0.94)
chr20	60905878	60905878	A	G	1.0000	83		2621.0	18|12|53,0|0|0,7|9	LAMA5	missense_variant	LAMA5:NM_005560.4:missense_variant:MODERATE:exon30/80:c.3773T>C:p.Met1258Thr		Cell Communication;Focal adhesion;ECM-receptor interaction;Small cell lung cancer	Binding to cells via a high affinity receptor, laminin is thought to mediate the attachment, migration and organization of cells into tissues during embryonic development by interacting with other extracellular matrix components			rs3810548	0.756589	0.85096284241931	0.6995189	COSM3758701			CM099893 [CLASS=DP MUT=ALT PHEN="Schizophrenia association with" GENE=LAMA5]; 	1.193000	T	T	B	T	0.00	0		1048	216			n/a	n/a	LAMA5 (inh=n/a pLI=0.94)
chr20	60907446	60907446	T	C	1.0000	13		330.0	0|1|12,0|0|0,4|4	LAMA5	synonymous_variant	LAMA5:NM_005560.4:synonymous_variant:LOW:exon28/80:c.3534A>G:p.Glu1178Glu		Cell Communication;Focal adhesion;ECM-receptor interaction;Small cell lung cancer	Binding to cells via a high affinity receptor, laminin is thought to mediate the attachment, migration and organization of cells into tissues during embryonic development by interacting with other extracellular matrix components			rs2151513	0.731629	0.85695992017296	0.8386794	COSM1412945										0		1063	203			n/a	n/a	LAMA5 (inh=n/a pLI=0.94)
chr20	60909060	60909060	A	G	1.0000	44		1355.0	0|0|44,0|0|0,5|6	LAMA5	synonymous_variant	LAMA5:NM_005560.4:synonymous_variant:LOW:exon23/80:c.2775T>C:p.Pro925Pro		Cell Communication;Focal adhesion;ECM-receptor interaction;Small cell lung cancer	Binding to cells via a high affinity receptor, laminin is thought to mediate the attachment, migration and organization of cells into tissues during embryonic development by interacting with other extracellular matrix components			rs13038331	0.756589	0.85864609794257	0.8285703	COSM4134729										0		1043	221			n/a	n/a	LAMA5 (inh=n/a pLI=0.94)
chr20	60910124	60910124	T	G	0.6176	68		1029.0	10|16|16,2|6|18,10|11	LAMA5	missense_variant	LAMA5:NM_005560.4:missense_variant:MODERATE:exon20/80:c.2435A>C:p.Lys812Thr	EGF-like__laminin__4_	Cell Communication;Focal adhesion;ECM-receptor interaction;Small cell lung cancer	Binding to cells via a high affinity receptor, laminin is thought to mediate the attachment, migration and organization of cells into tissues during embryonic development by interacting with other extracellular matrix components			rs79319629	0.0113818	0.021966911764706	0.0210477	COSM444172				0.808000	T	D	D	T	23.10	0		0	51			n/a	n/a	LAMA5 (inh=n/a pLI=0.94)
chr20	60912683	60912683	T	C	1.0000	72		2356.0	0|38|34,0|0|0,7|6	LAMA5	synonymous_variant	LAMA5:NM_005560.4:synonymous_variant:LOW:exon16/80:c.2127A>G:p.Thr709Thr		Cell Communication;Focal adhesion;ECM-receptor interaction;Small cell lung cancer	Binding to cells via a high affinity receptor, laminin is thought to mediate the attachment, migration and organization of cells into tissues during embryonic development by interacting with other extracellular matrix components			rs2427289	0.740815	0.85867785685974	0.8043780	COSM1412953										0		1039	226			n/a	n/a	LAMA5 (inh=n/a pLI=0.94)
chr20	60920887	60920887	G	A	1.0000	14		402.0	6|8|0,0|0|0,5|6	LAMA5	synonymous_variant	LAMA5:NM_005560.4:synonymous_variant:LOW:exon11/80:c.1464C>T:p.Ala488Ala		Cell Communication;Focal adhesion;ECM-receptor interaction;Small cell lung cancer	Binding to cells via a high affinity receptor, laminin is thought to mediate the attachment, migration and organization of cells into tissues during embryonic development by interacting with other extracellular matrix components			rs11204472	0.522564	0.60297020818378	0.4130698											0		587	539			n/a	n/a	LAMA5 (inh=n/a pLI=0.94)
chr20	60921643	60921643	T	C	0.9848	66		1899.0	5|42|18,0|0|0,5|4	LAMA5	missense_variant	LAMA5:NM_005560.4:missense_variant:MODERATE:exon9/80:c.1201A>G:p.Thr401Ala	EGF-like__laminin__4_	Cell Communication;Focal adhesion;ECM-receptor interaction;Small cell lung cancer	Binding to cells via a high affinity receptor, laminin is thought to mediate the attachment, migration and organization of cells into tissues during embryonic development by interacting with other extracellular matrix components			rs4925229	0.859425	0.94365249244213	0.8636241	COSM4134732				1.064000	T	T,T,T	B	T,T,T	19.20	0		1186	91			n/a	n/a	LAMA5 (inh=n/a pLI=0.94)
chr20	60927349	60927349	C	T	1.0000	47		1034.0	13|23|11,0|0|0,6|5	LAMA5	synonymous_variant	LAMA5:NM_005560.4:synonymous_variant:LOW:exon4/80:c.636G>A:p.Ala212Ala		Cell Communication;Focal adhesion;ECM-receptor interaction;Small cell lung cancer	Binding to cells via a high affinity receptor, laminin is thought to mediate the attachment, migration and organization of cells into tissues during embryonic development by interacting with other extracellular matrix components			rs483876	0.751198	0.86046025454485	0.8345251	COSM444175										0		1042	219			n/a	n/a	LAMA5 (inh=n/a pLI=0.94)
chr20	60927412	60927412	G	A	0.9920	125		3772.0	21|39|64,1|0|0,8|8	LAMA5	synonymous_variant	LAMA5:NM_005560.4:synonymous_variant:LOW:exon4/80:c.573C>T:p.Ser191Ser		Cell Communication;Focal adhesion;ECM-receptor interaction;Small cell lung cancer	Binding to cells via a high affinity receptor, laminin is thought to mediate the attachment, migration and organization of cells into tissues during embryonic development by interacting with other extracellular matrix components			rs624313	0.51897	0.63601630592369	0.6221576	COSM444176										0		574	542			n/a	n/a	LAMA5 (inh=n/a pLI=0.94)
chr20	60937597	60937597	A	G	1.0000	64		1823.0	5|7|52,0|0|0,6|7	LAMA5	synonymous_variant	LAMA5:NM_005560.4:synonymous_variant:LOW:exon2/80:c.309T>C:p.Cys103Cys		Cell Communication;Focal adhesion;ECM-receptor interaction;Small cell lung cancer	Binding to cells via a high affinity receptor, laminin is thought to mediate the attachment, migration and organization of cells into tissues during embryonic development by interacting with other extracellular matrix components			rs477859	0.829673	0.81616138984161	0.7986033	COSM3758705										0		796	413			n/a	n/a	LAMA5 (inh=n/a pLI=0.94)
chr22	36684331	36684331	C	T	0.5588	34		462.0	13|0|6,8|0|7,6|5	MYH9	synonymous_variant	MYH9:NM_002473.5:synonymous_variant:LOW:exon34/41:c.4899G>A:p.Arg1633Arg		Tight junction;Regulation of actin cytoskeleton	Cellular myosin that appears to play a role in cytokinesis, cell shape, and specialized functions such as secretion and capping			rs5756130	0.096246	0.070157939857557	0.0679790		160775 [MYH9 (confirmed) May-Hegglin anomaly,155100|Fechtner syndrome,153640|Sebastian syndrome,605249|Deafness,autosomal dominant 17,603622|Epstein syndrome,153650|Macrothrombocytopenia and progressive sensorineural deafness,600208];	RCV000037564.3 [benign]; RCV000280212.1 [benign]; RCV000335221.1 [benign]; 								1	I16R041,	4	133			n/a	n/a	MYH9 (inh=AD pLI=1.00)
chr22	36691607	36691607	A	C	1.0000	20		599.0	6|8|6,0|0|0,2|4	MYH9	synonymous_variant	MYH9:NM_002473.5:synonymous_variant:LOW:exon26/41:c.3429T>G:p.Ala1143Ala		Tight junction;Regulation of actin cytoskeleton	Cellular myosin that appears to play a role in cytokinesis, cell shape, and specialized functions such as secretion and capping			rs710181	0.982628	0.9765609530724	0.9548243		160775 [MYH9 (confirmed) May-Hegglin anomaly,155100|Fechtner syndrome,153640|Sebastian syndrome,605249|Deafness,autosomal dominant 17,603622|Epstein syndrome,153650|Macrothrombocytopenia and progressive sensorineural deafness,600208];	RCV000037556.3 [benign]; RCV000351776.1 [benign]; RCV000404023.1 [benign]; 								0		1224	56			n/a	n/a	MYH9 (inh=AD pLI=1.00)
chr22	36708084	36708084	C	T	1.0000	20		576.0	0|0|20,0|0|0,2|2	MYH9	splice_region_variant&intron_variant	MYH9:NM_002473.5:splice_region_variant&intron_variant:LOW:exon14/40:c.1728+10G>A:		Tight junction;Regulation of actin cytoskeleton	Cellular myosin that appears to play a role in cytokinesis, cell shape, and specialized functions such as secretion and capping			rs2413396	0.760783	0.87138549750383	0.8567047		160775 [MYH9 (confirmed) May-Hegglin anomaly,155100|Fechtner syndrome,153640|Sebastian syndrome,605249|Deafness,autosomal dominant 17,603622|Epstein syndrome,153650|Macrothrombocytopenia and progressive sensorineural deafness,600208];	RCV000037548.3 [benign]; RCV000326334.1 [benign]; RCV000378689.1 [benign]; 								0		1029	224			n/a	n/a	MYH9 (inh=AD pLI=1.00)
chr22	36708256	36708256	C	T	0.4805	77		819.0	12|13|12,0|2|38,4|4	MYH9	synonymous_variant	MYH9:NM_002473.5:synonymous_variant:LOW:exon14/41:c.1566G>A:p.Pro522Pro		Tight junction;Regulation of actin cytoskeleton	Cellular myosin that appears to play a role in cytokinesis, cell shape, and specialized functions such as secretion and capping			rs145517108	0.000798722	0.00016564518800729	0.0001543	COSM4103836	160775 [MYH9 (confirmed) May-Hegglin anomaly,155100|Fechtner syndrome,153640|Sebastian syndrome,605249|Deafness,autosomal dominant 17,603622|Epstein syndrome,153650|Macrothrombocytopenia and progressive sensorineural deafness,600208];	RCV000311142.1 [uncertain significance]; 								0		0	2			n/a	n/a	MYH9 (inh=AD pLI=1.00)
chr22	36710183	36710183	T	C	1.0000	16		491.0	6|6|4,0|0|0,4|4	MYH9	splice_region_variant&intron_variant	MYH9:NM_002473.5:splice_region_variant&intron_variant:LOW:exon13/40:c.1554+7A>G:		Tight junction;Regulation of actin cytoskeleton	Cellular myosin that appears to play a role in cytokinesis, cell shape, and specialized functions such as secretion and capping			rs3752462	0.39357	0.56141653058868	0.5564166		160775 [MYH9 (confirmed) May-Hegglin anomaly,155100|Fechtner syndrome,153640|Sebastian syndrome,605249|Deafness,autosomal dominant 17,603622|Epstein syndrome,153650|Macrothrombocytopenia and progressive sensorineural deafness,600208];	RCV000037547.3 [benign]; RCV000334868.1 [benign]; RCV000392730.1 [benign]; 								0		515	563			n/a	n/a	MYH9 (inh=AD pLI=1.00)
chr22	41537234	41537234	G	T	1.0000	28		857.0	16|10|2,0|0|0,5|7	EP300	splice_region_variant&intron_variant	EP300:NM_001429.3:splice_region_variant&intron_variant:LOW:exon10/30:c.2053+8G>T:		Neurodegenerative Diseases;Cell cycle;Wnt signaling pathway;Notch signaling pathway;TGF-beta signaling pathway;Adherens junction;Jak-STAT signaling pathway;Long-term potentiation;Melanogenesis;Huntington's disease;Renal cell carcinoma;Prostate cancer	Functions as histone acetyltransferase and regulates transcription via chromatin remodeling. Acetylates all four core histones in nucleosomes. Histone acetylation gives an epigenetic tag for transcriptional activation. Mediates cAMP-gene regulation by binding specifically to phosphorylated CREB protein. Also functions as acetyltransferase for nonhistone targets. Acetylates 'Lys-131' of ALX1 and acts as its coactivator in the presence of CREBBP. Acetylates SIRT2 and is proposed to indirectly increase the transcriptional activity of TP53 through acetylation and subsequent attenuation of SIRT2 deacetylase function. Acetylates HDAC1 leading to its inactivation and modulation of transcription. Acts as a TFAP2A-mediated transcriptional coactivator in presence of CITED2. Plays a role as a coactivator of NEUROD1-dependent transcription of the secretin and p21 genes and controls terminal differentiation of cells in the intestinal epithelium. Promotes cardiac myocyte enlargement. Can also mediate transcriptional repression. Binds to and may be involved in the transforming capacity of the adenovirus E1A protein. In case of HIV-1 infection, it is recruited by the viral protein Tat. Regulates Tat's transactivating activity and may help inducing chromatin remodeling of proviral genes. Acetylates FOXO1 and enhances its transcriptional activity	Acetylation and Deacetylation of RelA in The Nucleus;Cell Cycle: G2/M Checkpoint;Control of Gene Expression by Vitamin D Receptor;Hypoxia and p53 in the Cardiovascular system;Hypoxia-Inducible Factor in the Cardiovascular System;IL-7 Signal Transduction;Mechanism of Gene Regulation by Peroxisome Proliferators via PPARa(alpha);Melanocyte Development and Pigmentation Pathway;Multi-step Regulation of Transcription by Pitx2;NFkB activation by Nontypeable Hemophilus influenzae;Pelp1 Modulation of Estrogen Receptor Activity;Role of ERBB2 in Signal Transduction and Oncology;Role of MEF2D in T-cell Apoptosis;Role of PPAR-gamma Coactivators in Obesity and Thermogenesis;TGF beta signaling pathway;Transcription Regulation by Methyltransferase of CARM1		rs6002267	0.961661	0.98917574179943	0.9335966		602700 [EP300 (provisional) Rubinstein-Taybi syndrome 2,613684|Colorectal cancer,somatic,114500];	RCV000079669.6 [benign]; RCV000390092.1 [benign]; 								0		1313	6			n/a	n/a	EP300 (inh=AD pLI=1.00)
chr22	41551039	41551039	T	A	1.0000	9		264.0	0|2|7,0|0|0,3|2	EP300	synonymous_variant	EP300:NM_001429.3:synonymous_variant:LOW:exon17/31:c.3183T>A:p.Thr1061Thr		Neurodegenerative Diseases;Cell cycle;Wnt signaling pathway;Notch signaling pathway;TGF-beta signaling pathway;Adherens junction;Jak-STAT signaling pathway;Long-term potentiation;Melanogenesis;Huntington's disease;Renal cell carcinoma;Prostate cancer	Functions as histone acetyltransferase and regulates transcription via chromatin remodeling. Acetylates all four core histones in nucleosomes. Histone acetylation gives an epigenetic tag for transcriptional activation. Mediates cAMP-gene regulation by binding specifically to phosphorylated CREB protein. Also functions as acetyltransferase for nonhistone targets. Acetylates 'Lys-131' of ALX1 and acts as its coactivator in the presence of CREBBP. Acetylates SIRT2 and is proposed to indirectly increase the transcriptional activity of TP53 through acetylation and subsequent attenuation of SIRT2 deacetylase function. Acetylates HDAC1 leading to its inactivation and modulation of transcription. Acts as a TFAP2A-mediated transcriptional coactivator in presence of CITED2. Plays a role as a coactivator of NEUROD1-dependent transcription of the secretin and p21 genes and controls terminal differentiation of cells in the intestinal epithelium. Promotes cardiac myocyte enlargement. Can also mediate transcriptional repression. Binds to and may be involved in the transforming capacity of the adenovirus E1A protein. In case of HIV-1 infection, it is recruited by the viral protein Tat. Regulates Tat's transactivating activity and may help inducing chromatin remodeling of proviral genes. Acetylates FOXO1 and enhances its transcriptional activity	Acetylation and Deacetylation of RelA in The Nucleus;Cell Cycle: G2/M Checkpoint;Control of Gene Expression by Vitamin D Receptor;Hypoxia and p53 in the Cardiovascular system;Hypoxia-Inducible Factor in the Cardiovascular System;IL-7 Signal Transduction;Mechanism of Gene Regulation by Peroxisome Proliferators via PPARa(alpha);Melanocyte Development and Pigmentation Pathway;Multi-step Regulation of Transcription by Pitx2;NFkB activation by Nontypeable Hemophilus influenzae;Pelp1 Modulation of Estrogen Receptor Activity;Role of ERBB2 in Signal Transduction and Oncology;Role of MEF2D in T-cell Apoptosis;Role of PPAR-gamma Coactivators in Obesity and Thermogenesis;TGF beta signaling pathway;Transcription Regulation by Methyltransferase of CARM1		rs20552	0.673922	0.65724829892746	0.6365238		602700 [EP300 (provisional) Rubinstein-Taybi syndrome 2,613684|Colorectal cancer,somatic,114500];	RCV000079675.6 [benign]; RCV000305645.1 [benign]; 								1	GT,	508	628			n/a	n/a	EP300 (inh=AD pLI=1.00)
chr22	41574383	41574383	A	C	0.3721	43		292.0	2|2|12,3|1|23,6|7	EP300	missense_variant	EP300:NM_001429.3:missense_variant:MODERATE:exon31/31:c.6668A>C:p.Gln2223Pro		Neurodegenerative Diseases;Cell cycle;Wnt signaling pathway;Notch signaling pathway;TGF-beta signaling pathway;Adherens junction;Jak-STAT signaling pathway;Long-term potentiation;Melanogenesis;Huntington's disease;Renal cell carcinoma;Prostate cancer	Functions as histone acetyltransferase and regulates transcription via chromatin remodeling. Acetylates all four core histones in nucleosomes. Histone acetylation gives an epigenetic tag for transcriptional activation. Mediates cAMP-gene regulation by binding specifically to phosphorylated CREB protein. Also functions as acetyltransferase for nonhistone targets. Acetylates 'Lys-131' of ALX1 and acts as its coactivator in the presence of CREBBP. Acetylates SIRT2 and is proposed to indirectly increase the transcriptional activity of TP53 through acetylation and subsequent attenuation of SIRT2 deacetylase function. Acetylates HDAC1 leading to its inactivation and modulation of transcription. Acts as a TFAP2A-mediated transcriptional coactivator in presence of CITED2. Plays a role as a coactivator of NEUROD1-dependent transcription of the secretin and p21 genes and controls terminal differentiation of cells in the intestinal epithelium. Promotes cardiac myocyte enlargement. Can also mediate transcriptional repression. Binds to and may be involved in the transforming capacity of the adenovirus E1A protein. In case of HIV-1 infection, it is recruited by the viral protein Tat. Regulates Tat's transactivating activity and may help inducing chromatin remodeling of proviral genes. Acetylates FOXO1 and enhances its transcriptional activity	Acetylation and Deacetylation of RelA in The Nucleus;Cell Cycle: G2/M Checkpoint;Control of Gene Expression by Vitamin D Receptor;Hypoxia and p53 in the Cardiovascular system;Hypoxia-Inducible Factor in the Cardiovascular System;IL-7 Signal Transduction;Mechanism of Gene Regulation by Peroxisome Proliferators via PPARa(alpha);Melanocyte Development and Pigmentation Pathway;Multi-step Regulation of Transcription by Pitx2;NFkB activation by Nontypeable Hemophilus influenzae;Pelp1 Modulation of Estrogen Receptor Activity;Role of ERBB2 in Signal Transduction and Oncology;Role of MEF2D in T-cell Apoptosis;Role of PPAR-gamma Coactivators in Obesity and Thermogenesis;TGF beta signaling pathway;Transcription Regulation by Methyltransferase of CARM1		rs1046088	0.0113818	0.024090227051627	0.0235428		602700 [EP300 (provisional) Rubinstein-Taybi syndrome 2,613684|Colorectal cancer,somatic,114500];	RCV000079681.6 [benign]; RCV000343626.1 [likely benign]; 		4.250000	T	T	B	D	8.03	0		1	72			n/a	n/a	EP300 (inh=AD pLI=1.00)
chrX	32503194	32503194	T	C	1.0000	12		367.0	6|0|6,0|0|0,5|5	DMD	missense_variant	DMD:NM_004006.2:missense_variant:MODERATE:exon21/79:c.2645A>G:p.Asp882Gly,DMD:NM_004010.3:missense_variant:MODERATE:exon21/79:c.2276A>G:p.Asp759Gly,DMD:NM_004009.3:missense_variant:MODERATE:exon21/79:c.2633A>G:p.Asp878Gly,DMD:NM_000109.3:missense_variant:MODERATE:exon21/79:c.2621A>G:p.Asp874Gly						rs228406	0.748344	0.72107095963921	0.6671082	COSM4156808, COSM4156807, COSM4156809	300377 [DMD (confirmed) Duchenne muscular dystrophy,310200|Becker muscular dystrophy,300376|Cardiomyopathy,dilated,3B,302045];	RCV000124736.2 [benign]; RCV000206108.1 [benign]; RCV000152984.3 [benign]; 		0.899000	T	T,T,T,T,T	B,B,B	T,T	8.37	0		1018	273	1	[1] Peter Bauer 16.12.2014	n/a	n/a	DMD (inh=XLR pLI=1.00)
chrX	32591931	32591931	T	C	1.0000	12		350.0	4|8|0,0|0|0,3|2	DMD	synonymous_variant	DMD:NM_004006.2:synonymous_variant:LOW:exon14/79:c.1635A>G:p.Arg545Arg,DMD:NM_004010.3:synonymous_variant:LOW:exon14/79:c.1266A>G:p.Arg422Arg,DMD:NM_004009.3:synonymous_variant:LOW:exon14/79:c.1623A>G:p.Arg541Arg,DMD:NM_000109.3:synonymous_variant:LOW:exon14/79:c.1611A>G:p.Arg537Arg						rs5927083	0.110464	0.11653518421724	0.1056179		300377 [DMD (confirmed) Duchenne muscular dystrophy,310200|Becker muscular dystrophy,300376|Cardiomyopathy,dilated,3B,302045];	RCV000080462.7 [benign]; RCV000246678.1 [benign]; RCV000381508.1 [likely benign]; 	CS081890 [CLASS=DM? MUT=ALT PHEN="Muscular dystrophy Becker" GENE=DMD]; 							0		156	150	2	[2] old entry - no details available	n/a	n/a	DMD (inh=XLR pLI=1.00)
chrX	53563589	53563589	A	G	1.0000	11		297.0	5|0|6,0|0|0,7|4	HUWE1	synonymous_variant	HUWE1:NM_031407.6:synonymous_variant:LOW:exon79/84:c.12177T>C:p.Gly4059Gly						rs426298	0.994967	0.99734200319416	0.9080474		300697 [HUWE1 (provisional) Mental retardation,X-linked syndromic,Turner type,300706];	RCV000082281.7 [other]; 		-0.388000	T				11.76	0		1614	0	1	[1] Peter Bauer 07.08.2014	n/a	n/a	HUWE1 (inh=XLR+XLD pLI=1.00)
chrX	53641647	53641647	T	C	1.0000	10		287.0	1|5|4,0|0|0,9|9	HUWE1	synonymous_variant	HUWE1:NM_031407.6:synonymous_variant:LOW:exon23/84:c.2109A>G:p.Ser703Ser						rs6638360	0.389669	0.48954896758565	0.4558982		300697 [HUWE1 (provisional) Mental retardation,X-linked syndromic,Turner type,300706];	RCV000117252.2 [likely benign]; 								1	I16R041,	733	273			n/a	n/a	HUWE1 (inh=XLR+XLD pLI=1.00)
chrX	66765159	66765170	GCAGCAGCAGCA	-	0.8000	10		188.0	0|0|9,0|1|0,7|8	AR	disruptive_inframe_deletion,sequence_feature	AR:NM_000044.3:disruptive_inframe_deletion:MODERATE:exon1/8:c.228_239delGCAGCAGCAGCA:p.Gln77_Gln80del,AR:NM_000044.3:sequence_feature:LOW:exon1/8:c.171_182delGCAGCAGCAGCA:,AR:NM_000044.3:sequence_feature:LOW:exon1/8:c.171_182delGCAGCAGCAGCA:						rs781380725	0.0000	0.0085389392413562	0.0106556		313700 [AR (confirmed) Androgen insensitivity,300068|Spinal and bulbar muscular atrophy of Kennedy,313200|Androgen insensitivity,partial,with or without breast cancer,312300|Prostate cancer,susceptibility to,176807|Hypospadias 1,X-linked,300633];									0		48	13			n/a	n/a	AR (inh=n/a pLI=0.99)
